TY - JOUR TI - Complement Overactivation and Consumption Predicts In-Hospital Mortality in SARS-CoV-2 Infection. AU - Sinkovits, György AU - Mező, Blanka AU - Réti, Marienn AU - Müller, Veronika AU - Iványi, Zsolt AU - Gál, János AU - Gopcsa, László AU - Reményi, Péter AU - Szathmáry, Beáta AU - Lakatos, Botond AU - Szlávik, János AU - Bobek, Ilona AU - Prohászka, Zita Z. AU - Förhécz, Zsolt AU - Csuka, Dorottya AU - Hurler, Lisa AU - Kajdácsi, Erika AU - Cervenak, László AU - Kiszel, Petra AU - Masszi, Tamás AU - Vályi-Nagy, István AU - Prohászka, Zoltán T2 - Frontiers in immunology AB - OBJECTIVES: Uncontrolled thromboinflammation plays an important role in the pathogenesis of coronavirus disease (COVID-19) caused by SARS-CoV-2 virus. Complement was implicated as key contributor to this process, therefore we hypothesized that markers of the complement profile, indicative for the activation state of the system, may be related to the severity and mortality of COVID-19. METHODS: In this prospective cohort study samples of 102 hospitalized and 26 outpatients with PCR-confirmed COVID-19 were analyzed. Primary outcome was in-hospital, COVID-19 related mortality, and secondary outcome was COVID-19 severity as assessed by the WHO ordinal scale. Complement activity of alternative and classical pathways, its factors, regulators, and activation products were measured by hemolytic titration, turbidimetry, or enzyme-immunoassays. Clinical covariates and markers of inflammation were extracted from hospital records. RESULTS: Increased complement activation was characteristic for hospitalized COVID-19 patients. Complement activation was significantly associated with markers of inflammation, such as interleukin-6, C-reactive protein, and ferritin. Twenty-five patients died during hospital stay due to COVID-19 related illness. Patients with uncontrolled complement activation leading to consumption of C3 and decrease of complement activity were more likely to die, than those who had complement activation without consumption. Cox models identified anaphylatoxin C3a, and C3 overactivation and consumption (ratio of C3a/C3) as predictors of in-hospital mortality [HR of 3.63 (1.55-8.45, 95% CI) and 6.1 (2.1-17.8), respectively]. CONCLUSION: Increased complement activation is associated with advanced disease severity of COVID-19. Patients with SARS-CoV-2 infection are more likely to die when the disease is accompanied by overactivation and consumption of C3. These results may provide observational evidence and further support to studies on complement inhibitory drugs for the treatment of COVID-19. DA - 2021/// PY - 2021 DO - 10.3389/fimmu.2021.663187 VL - 12 SP - 663187 J2 - Front Immunol LA - eng SN - 1664-3224 KW - Adult KW - Female KW - Humans KW - Male KW - Middle Aged KW - Aged KW - *complement activation and consumption KW - *complement system KW - *coronavirus disease (COVID-19) KW - *Hospital Mortality KW - *mortality KW - *SARS-CoV-2 infection KW - *severity KW - Complement Activation/*immunology KW - Complement C3a/*immunology KW - COVID-19/*immunology/*mortality KW - Disease-Free Survival KW - Predictive Value of Tests KW - SARS-CoV-2/*immunology KW - Survival Rate ER - TY - JOUR TI - Cardiovascular RNA markers and artificial intelligence may improve COVID-19 outcome: a position paper from the EU-CardioRNA COST Action CA17129 AU - Badimon, Lina AU - Robinson, Emma L. AU - Jusic, Amela AU - Carpusca, Irina AU - de Windt, Leon J. AU - Emanueli, Costanza AU - Ferdinandy, Péter AU - Gu, Wei AU - Gyöngyösi, Mariann AU - Hackl, Matthias AU - Karaduzovic-Hadziabdic, Kanita AU - Lustrek, Mitja AU - Martelli, Fabio AU - Nham, Eric AU - Potočnjak, Ines AU - Satagopam, Venkata AU - Schneider, Reinhard AU - Thum, Thomas AU - Devaux, Yvan T2 - Cardiovascular research AB - The coronavirus disease 2019 (COVID-19) pandemic has been as unprecedented as unexpected, affecting more than 105 million people worldwide as of February 8th, 2020 and causing more than 2.3 million deaths according the World Health Organization. Not only affecting the lungs and provoking acute respiratory distress, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is able to infect multiple cell types including cardiac and vascular cells. Hence a significant proportion of infected patients develop cardiac events such as arrhythmias and heart failure. Patients with cardiovascular comorbidities are at highest risk of cardiac death. To face the pandemic and limit its burden, health authorities have launched several fast track calls for research projects aiming to develop rapid strategies to combat the disease, as well as longer-term projects to prepare for the future. Biomarkers have the possibility to aid in clinical decision making and tailoring healthcare in order to improve patient quality of life. The biomarker potential of circulating RNAs has been recognized in several disease conditions, including cardiovascular disease. RNA biomarkers may be useful in the current COVID-19 situation. The discovery, validation and marketing of novel biomarkers, including RNA biomarkers, require multi-centre studies by large and interdisciplinary collaborative networks, involving both the academia and the industry. Here, members of the EU-CardioRNA COST Action CA17129 summarize the current knowledge about the strain that COVID-19 places on the cardiovascular system and discuss how RNA biomarkers can aid to limit this burden. They present the benefits and challenges of the discovery of novel RNA biomarkers, the need for networking efforts and the added value of artificial intelligence to achieve reliable advances. DA - 2021/07/07/ PY - 2021 DO - 10.1093/cvr/cvab094 VL - 117 IS - 8 SP - 1823 EP - 1840 J2 - Cardiovasc Res LA - eng SN - 1755-3245 0008-6363 L1 - https://academic.oup.com/cardiovascres/article-pdf/117/8/1823/38878642/cvab094.pdf KW - artificial intelligence KW - biomarkers KW - genomics KW - RNAs ER - TY - JOUR TI - [Diagnosis and treatment of paediatric multisystem inflammatory syndrome]. AU - Constantin, Tamás AU - Andrási, Noémi AU - Ponyi, Andrea AU - Goschler, Ádám AU - Ablonczy, László AU - Kincs, Judit AU - Csóka, Monika AU - Egyed, Bálint AU - Horváth, Zsuzsanna AU - Kalocsai, Krisztina AU - Káposzta, Rita AU - Kardics, Kinga AU - Kemény, Viktória AU - Mosdósi, Bernadett AU - Pék, Tamás AU - Szabó, Zsófia AU - Tóth, Attila AU - Tory, Kálmán AU - Tölgyesi, Andrea AU - Ónozó, Beáta AU - Vágó, Hajnalka AU - Vilmányi, Csaba AU - Peter, Weiser AU - Szekanecz, Zoltán AU - Kovács, Gábor AU - Szabó, Attila T2 - Orvosi hetilap AB - Összefoglaló. A SARS-CoV-2-fertőzés ritka gyermekkori szövődménye a sokszervi gyulladás, angol terminológiával paediatric inflammatory multisystem syndrome (PIMS). Két vagy több szerv érintettségével járó, súlyos tünetekkel induló betegségről van szó, amelynek tünetei átfedést mutatnak a Kawasaki-betegséggel, a toxikus sokk szindrómával és a makrofágaktivációs szindrómával. A PIMS-betegek intenzív terápiás osztályon vagy intenzív terápiás háttérrel rendelkező intézményben kezelendők, ahol biztosítottak a kardiológiai ellátás feltételei is. A szükséges immunterápia a klinikai prezentációtól függ. A jelen közleményben a szerzők a releváns nemzetközi irodalom áttekintését követően ajánlást tesznek a PIMS diagnosztikai és terápiás algoritmusára. Orv Hetil. 2021; 162(17): 652-667. Summary. Pediatric inflammatory multisystem syndrome (PIMS) is a rare complication of SARS-CoV-2 infection in children. PIMS is a severe condition, involving two or more organ systems. The symptoms overlap with Kawasaki disease, toxic shock syndrome and macrophage activation syndrome. PIMS patients should be treated in an intensive care unit or in an institution with an intensive care background, where cardiological care is also provided. The required specific immunotherapy depends on the clinical presentation. In this paper, after reviewing the relevant international literature, the authors make a recommendation for the diagnostic and therapeutic algorithm for PIMS. Orv Hetil. 2021; 162(17): 652-667. DA - 2021/04/10/ PY - 2021 DO - 10.1556/650.2021.32231 VL - 162 IS - 17 SP - 652 EP - 667 J2 - Orv Hetil LA - hun SN - 1788-6120 0030-6002 KW - Child KW - Humans KW - *COVID-19/complications/diagnosis/therapy/virology KW - *diagnosis KW - *diagnosztika KW - *multiple organ inflammation KW - *paediatric inflammatory multisystem syndrome (PIMS) KW - *PIMS KW - *sokszervi gyulladás KW - *Systemic Inflammatory Response Syndrome/diagnosis/therapy/virology KW - *terápia KW - *treatment KW - Algorithms KW - Critical Care ER - TY - JOUR TI - [Antiviral and anti-inflammatory therapies in COVID-19]. AU - Szekanecz, Zoltán AU - Bogos, Krisztina AU - Constantin, Tamás AU - Fülesdi, Béla AU - Müller, Veronika AU - Rákóczi, Éva AU - Várkonyi, István AU - Vályi-Nagy, István T2 - Orvosi hetilap AB - Összefoglaló. Az új típusú koronavírus-fertőzés (COVID-19) nagy terhet ró az egészségügyi ellátórendszerre és a társadalomra. A betegségnek három nagy szakasza van, melyek alapvetően meghatározzák a kezelést. Az I-IIA fázisban az antivirális, míg a IIB-III. fázisban a gyulladásgátló kezelés áll előtérben, melyhez intenzív terápiás, szupportív kezelés csatlakozik. A jelen ajánlás kizárólag a gyógyszeres kezelésre vonatkozik, és a rendelkezésre álló bizonyítékok alapján foglalja össze a terápiás lehetőségeket. Emellett egy javasolt kezelési algoritmust is tartalmaz. Orv Hetil. 2021; 162(17): 643-651. Summary. The novel coronavirus infection (COVID-19) places a heavy burden on the health care system and our society. There are three major stages in the disease that fundamentally determine treatment approaches. Phases I-IIA require primarily antiviral treatment. In phases IIB-III, anti-inflammatory treatment is needed accompanied by intensive and supportive care. This recommendation applies only to pharmacotherapy and summarizes the therapeutic options based on the available evidence. It also includes a proposed treatment algorithm. Orv Hetil. 2021; 162(17): 643-651. DA - 2021/04/10/ PY - 2021 DO - 10.1556/650.2021.32230 VL - 162 IS - 17 SP - 643 EP - 651 J2 - Orv Hetil LA - hun SN - 1788-6120 0030-6002 KW - Humans KW - *Anti-Inflammatory Agents/therapeutic use KW - *Antiviral Agents/therapeutic use KW - *antiviral treatment KW - *antivirális kezelés KW - *citokingátló kezelés KW - *citokinvihar KW - *coronavirus KW - *corticosteroid KW - *COVID-19/drug therapy/epidemiology KW - *cytokine inhibition treatment KW - *cytokine storm KW - *interleukin-6 inhibition KW - *interleukin-6-gátlás KW - *intravénás immunglobulin KW - *intravenous immunoglobulin KW - *Janus kinase inhibition KW - *Janus-kináz-gátlás KW - *koronavírus KW - *kortikoszteroid KW - *novel coronavirus infection (COVID-19) KW - *új típusú koronavírus-fertőzés (COVID–19) ER - TY - JOUR TI - Management of anaphylaxis due to COVID-19 vaccines in the elderly. AU - Bousquet, Jean AU - Agache, Ioana AU - Blain, Hubert AU - Jutel, Marek AU - Ventura, Maria Teresa AU - Worm, Margitta AU - Del Giacco, Stefano AU - Benetos, Athanasios AU - Bilo, M. Beatrice AU - Czarlewski, Wienczyslawa AU - Abdul Latiff, Amir Hamzah AU - Al-Ahmad, Mona AU - Angier, Elizabeth AU - Annesi-Maesano, Isabella AU - Atanaskovic-Markovic, Marina AU - Bachert, Claus AU - Barbaud, Annick AU - Bedbrook, Anna AU - Bennoor, Kazi S. AU - Berghea, Elena Camelia AU - Bindslev-Jensen, Carsten AU - Bonini, Sergio AU - Bosnic-Anticevich, Sinthia AU - Brockow, Knut AU - Brussino, Luisa AU - Camargos, Paulo AU - Canonica, G. Walter AU - Cardona, Victoria AU - Carreiro-Martins, Pedro AU - Carriazo, Ana AU - Casale, Thomas AU - Caubet, Jean-Christoph AU - Cecchi, Lorenzo AU - Cherubini, Antonio AU - Christoff, George AU - Chu, Derek K. AU - Cruz, Alvaro A. AU - Dokic, Dejan AU - El-Gamal, Yehia AU - Ebisawa, Motohiro AU - Eberlein, Bernadette AU - Farrell, John AU - Fernandez-Rivas, Montserrat AU - Fokkens, Wytske J. AU - Fonseca, Joao A. AU - Gao, Yadong AU - Gavazzi, Gaëtan AU - Gawlik, Radolslaw AU - Gelincik, Asli AU - Gemicioğlu, Bilun AU - Gotua, Maia AU - Guérin, Olivier AU - Haahtela, Tari AU - Hoffmann-Sommergruber, Karin AU - Hoffmann, Hans Jürgen AU - Hofmann, Maja AU - Hrubisko, Martin AU - lenaIllario, Madda AU - Irani, Carla AU - Ispayeva, Zhanat AU - Ivancevich, Juan Carlos AU - Julge, Kaja AU - Kaidashev, Igor AU - Khaitov, Musa AU - Knol, Edward AU - Kraxner, Helga AU - Kuna, Piotr AU - Kvedariene, Violeta AU - Lauerma, Antti AU - Le, Lan Tt AU - Le Moing, Vincent AU - Levin, Michael AU - Louis, Renaud AU - Lourenco, Olga AU - Mahler, Vera AU - Martin, Finbarr C. AU - Matucci, Andrea AU - Milenkovic, Branislava AU - Miot, Stéphanie AU - Montella, Emma AU - Morais-Almeida, Mario AU - Mortz, Charlotte G. AU - Mullol, Joaquim AU - Namazova-Baranova, Leyla AU - Neffen, Hugo AU - Nekam, Kristof AU - Niedoszytko, Marek AU - Odemyr, Mikaëla AU - O'Hehir, Robyn E. AU - Okamoto, Yoshitaka AU - Ollert, Markus AU - Palomares, Oscar AU - Papadopoulos, Nikolaos G. AU - Panzner, Petr AU - Passalacqua, Gianni AU - Patella, Vincenzo AU - Petrovic, Mirko AU - Pfaar, Oliver AU - Pham-Thi, Nhân AU - Plavec, Davor AU - Popov, Todor A. AU - Recto, Marysia T. AU - Regateiro, Frederico S. AU - Reynes, Jacques AU - Roller-Winsberger, Regina E. AU - Rolland, Yves AU - Romano, Antonino AU - Rondon, Carmen AU - Rottem, Menachem AU - Rouadi, Philip W. AU - Salles, Nathalie AU - Samolinski, Boleslaw AU - Santos, Alexandra F. AU - Serpa, Faradiba Sarquis AU - Sastre, Joaquin AU - Schols, Jos M. G. A. AU - Scichilone, Nicola AU - Sediva, Anna AU - Shamji, Mohamed H. AU - Sheikh, Aziz AU - Skypala, Isabel AU - Smolinska, Sylwia AU - Sokolowska, Milena AU - Sousa-Pinto, Bernardo AU - Sova, Milan AU - Stelmach, Rafael AU - Sturm, Gunter AU - Suppli Ulrik, Charlotte AU - Todo-Bom, Ana Maria AU - Toppila-Salmi, Sanna AU - Tsiligianni, Ioanna AU - Torres, Maria AU - Untersmayr, Eva AU - Urrutia Pereira, Marilyn AU - Valiulis, Arunas AU - Vitte, Joana AU - Vultaggio, Alessandra AU - Wallace, Dana AU - Walusiak-Skorupa, Jolanta AU - Wang, De-Yun AU - Waserman, Susan AU - Yorgancioglu, Arzu AU - Yusuf, Osman M. AU - Zernotti, Mario AU - Zidarn, Mihaela AU - Chivato, Tomas AU - Akdis, Cezmi A. AU - Zuberbier, Torsten AU - Klimek, Ludger T2 - Allergy AB - Older adults, especially men and/or those with diabetes, hypertension and/or obesity, are prone to severe COVID-19. In some countries, older adults, particularly those residing in nursing homes, have been prioritised to receive COVID-19 vaccines due to high risk of death. In very rare instances,the COVID-19 vaccines can induce anaphylaxis, and the management of anaphylaxis in older people should be considered carefully. An ARIA-EAACI-EuGMS (Allergic Rhinitis and its Impact on Asthma, European Academy of Allergy and Clinical Immunology, and European Geriatric Medicine Society)Working Group has proposed some recommendations for older adults receiving the COVID-19 vaccines. Anaphylaxis to COVID-19 vaccines is extremely rare (from 1 per 100,000 to 5 per million injections). Symptoms are similar in younger and older adults but they tend to be more severe in the older patients. Adrenaline is the mainstay treatment and should be readily available. A flowchart is proposed to manage anaphylaxis in the older patients. DA - 2021/10//undefined PY - 2021 DO - 10.1111/all.14838 VL - 76 IS - 10 SP - 2952 EP - 2964 J2 - Allergy LA - eng SN - 1398-9995 0105-4538 KW - adrenaline KW - anaphylaxis KW - COVID-19 vaccines KW - older (adults/people) ER - TY - JOUR TI - Quantitative Burden of COVID-19 Pneumonia on Chest CT Predicts Adverse Outcomes: A Post-Hoc Analysis of a Prospective International Registry. AU - Grodecki, Kajetan AU - Lin, Andrew AU - Cadet, Sebastien AU - McElhinney, Priscilla A. AU - Razipour, Aryabod AU - Chan, Cato AU - Pressman, Barry AU - Julien, Peter AU - Maurovich-Horvat, Pal AU - Gaibazzi, Nicola AU - Thakur, Udit AU - Mancini, Elisabetta AU - Agalbato, Cecilia AU - Menè, Roberto AU - Parati, Gianfranco AU - Cernigliaro, Franco AU - Nerlekar, Nitesh AU - Torlasco, Camilla AU - Pontone, Gianluca AU - Slomka, Piotr J. AU - Dey, Damini T2 - Radiology. Cardiothoracic imaging AB - PURPOSE: To examine the independent and incremental value of CT-derived quantitative burden and attenuation of COVID-19 pneumonia for the prediction of clinical deterioration or death. METHODS: This was a retrospective analysis of a prospective international registry of consecutive patients with laboratory-confirmed COVID-19 and chest CT imaging, admitted to four centers between January 10 and May 6, 2020. Total burden (expressed as a percentage) and mean attenuation of ground glass opacities (GGO) and consolidation were quantified from CT using semi-automated research software. The primary outcome was clinical deterioration (intensive care unit admission, invasive mechanical ventilation, or vasopressor therapy) or in-hospital death. Logistic regression was performed to assess the predictive value of clinical and CT parameters for the primary outcome. RESULTS: The final population comprised 120 patients (mean age 64 ± 16 years, 78 men), of whom 39 (32.5%) experienced clinical deterioration or death. In multivariable regression of clinical and CT parameters, consolidation burden (odds ratio [OR], 3.4; 95% confidence interval [CI]: 1.7, 6.9 per doubling; P = .001) and increasing GGO attenuation (OR, 3.2; 95% CI: 1.3, 8.3 per standard deviation, P = .02) were independent predictors of deterioration or death; as was C-reactive protein (OR, 2.1; 95% CI: 1.3, 3.4 per doubling; P = .004), history of heart failure (OR 1.3; 95% CI: 1.1, 1.6, P = .01), and chronic lung disease (OR, 1.3; 95% CI: 1.0, 1.6; P = .02). Quantitative CT measures added incremental predictive value beyond a model with only clinical parameters (area under the curve, 0.93 vs 0.82, P = .006). The optimal prognostic cutoffs for burden of COVID-19 pneumonia as determined by Youden's index were consolidation of greater than or equal to 1.8% and GGO of greater than or equal to 13.5%. CONCLUSIONS: Quantitative burden of consolidation or GGO on chest CT independently predict clinical deterioration or death in patients with COVID-19 pneumonia. CT-derived measures have incremental prognostic value over and above clinical parameters, and may be useful for risk stratifying patients with COVID-19. DA - 2020/10//undefined PY - 2020 DO - 10.1148/ryct.2020200389 VL - 2 IS - 5 SP - e200389 J2 - Radiol Cardiothorac Imaging LA - eng SN - 2638-6135 ER - TY - JOUR TI - High-dose ACEi might be harmful in COVID-19 patients with serious respiratory distress syndrome by leading to excessive bradykinin receptor activation. AU - Székács, B. AU - Várbíró, S. AU - Debreczeni, L. T2 - Physiology international AB - PURPOSE: We aimed to critically review the available information on the potential contribution of excessive kallikrein-kinin systems (KKSs) activation to severe respiratory inflammation in SARS-CoV-2 infection, and the likely consequence of ACE inhibition in seriously affected patients. METHODS: The literature related to the above topic was reviewed including papers that analysed the connections, actions, interactions, consequences and occasionally suggestions for rational interventions. RESULTS/CONCLUSION: Severe broncho-alveolar inflammation seems to be caused, at least in part, by upregulation of the KKS that increases plasma and/or local tissue concentrations of bradykinin (BK) in patients with COVID-19 infection. Besides KKS activation, suppression of ACE activity results in decreased bradykinin degradation, and these changes in concert can lead to excessive BK B1 and B2 receptor (BKB1R/BKB2R) activation. Aminopeptidase P (APP), and carboxypeptidase N also degrade bradykinin, but their protein expression and activity are unclear in COVID-19 infection. On the other hand, ACE2 expression is upregulated in patients with COVID-19 infection, so ACE2 activity is unlikely to be decreased despite blockade of part of ACE2 by the virus for entry into the cells. ACE2 cleaves lys-des-arginine9BK and arg-des-arginine9BK, the active metabolites of bradykinin, which stimulate the BKB1R receptor. Stimulation of BKB1R/BKB2R can exacerbate the pulmonary inflammatory response by causing vascular leakage and edema, vasodilation, smooth muscle spasm and stimulation of pain afferent nerves. Despite all uncertainties, it seems rational to treat comorbid COVID patients with serious respiratory distress syndrome with ARBs instead of high-dose ACE inhibitor (ACEi) that will further decrease bradykinin degradation and enhance BKB1R/BKB2R activation, but ACEi may not be contraindicated in patients with mild pulmonary symptoms. DA - 2021/04/23/ PY - 2021 DO - 10.1556/2060.2021.00007 VL - 108 IS - 1 SP - 1 EP - 9 J2 - Physiol Int LA - eng SN - 2498-602X KW - COVID-19 KW - ACE-inhibitor KW - ACE2 KW - angiotensin receptor blocker KW - bradykinin KW - cardiovascular KW - hypertension KW - kallikrein-kinin system KW - old patient KW - RAS KW - respiratory inflammation ER - TY - JOUR TI - Germline Genetic Variants of Viral Entry and Innate Immunity May Influence Susceptibility to SARS-CoV-2 Infection: Toward a Polygenic Risk Score for Risk Stratification. AU - Grolmusz, Vince Kornél AU - Bozsik, Anikó AU - Papp, János AU - Patócs, Attila T2 - Frontiers in immunology AB - The ongoing COVID-19 pandemic caused by the novel coronavirus, SARS-CoV-2 has affected all aspects of human society with a special focus on healthcare. Although older patients with preexisting chronic illnesses are more prone to develop severe complications, younger, healthy individuals might also exhibit serious manifestations. Previous studies directed to detect genetic susceptibility factors for earlier epidemics have provided evidence of certain protective variations. Following SARS-CoV-2 exposure, viral entry into cells followed by recognition and response by the innate immunity are key determinants of COVID-19 development. In the present review our aim was to conduct a thorough review of the literature on the role of single nucleotide polymorphisms (SNPs) as key agents affecting the viral entry of SARS-CoV-2 and innate immunity. Several SNPs within the scope of our approach were found to alter susceptibility to various bacterial and viral infections. Additionally, a multitude of studies confirmed genetic associations between the analyzed genes and autoimmune diseases, underlining the versatile immune consequences of these variants. Based on confirmed associations it is highly plausible that the SNPs affecting viral entry and innate immunity might confer altered susceptibility to SARS-CoV-2 infection and its complex clinical consequences. Anticipating several COVID-19 genomic susceptibility loci based on the ongoing genome wide association studies, our review also proposes that a well-established polygenic risk score would be able to clinically leverage the acquired knowledge. DA - 2021/// PY - 2021 DO - 10.3389/fimmu.2021.653489 VL - 12 SP - 653489 J2 - Front Immunol LA - eng SN - 1664-3224 KW - Humans KW - Genetic Predisposition to Disease KW - Immunity, Innate KW - *COVID-19 KW - *genetic susceptibility KW - *genotype-phenotype association studies KW - *innate immunity KW - *polygenic risk score KW - *risk stratification KW - *SARS-CoV-2 KW - *viral entry KW - COVID-19/*genetics/*immunology/virology KW - Germ Cells/*immunology KW - Multifactorial Inheritance KW - SARS-CoV-2/*physiology KW - Virus Internalization ER - TY - JOUR TI - Gender issues during the times of Covid-19 pandemic. AU - Grisold, Wolfgang AU - Moro, Elena AU - Ferretti, Maria Teresa AU - Aamodt, Anne Hege AU - Arabia, Gennarina AU - Lebedeva, Elena R. AU - Carvalho, Vanessa AU - Rakusa, Martin AU - Vonck, Kristl AU - Aybeck, Selma AU - Mansour, Alia Hassan AU - Goudier, Riadh AU - Giovannoni, Gavin AU - Jaarsma, Joke AU - Molnar, Maria Judit AU - Matczack, Magda AU - Bassetti, Claudio AU - de Visser, Marianne T2 - European journal of neurology AB - In this letter-to-the-editor the Task Force on Gender and Diversity issues in Neurology founded under the auspices of the European Academy of Neurology (EAN) addresses various gender issues that are arising during the COVID-19 pandemic. These issues concern different aspects, spanning from gender disparities in health care workforce to gender differences amongst patients suffering from COVID-19, risk factors, occurrence of neurological complications and (outcomes of) management. Due to the continuous flow of COVID-19 related papers this review cannot be comprehensive. We attempted to select the most relevant literature on this topic. DA - 2021/10// PY - 2021 DO - 10.1111/ene.14815 VL - 28 IS - 10 SP - e73 EP - e77 J2 - Eur J Neurol LA - eng SN - 1468-1331 1351-5101 KW - Covid-19 KW - diversity KW - gender KW - neurology KW - workforce ER - TY - JOUR TI - Mild Clinical Course of COVID-19 Infection in Chronic Myeloid Leukemia (CML) Patients Receiving Tyrosine Kinase Inhibitors (TKIs) without Interruption. AU - Demeter, Judit AU - Weisinger, Julia AU - Nagy, Zsolt T2 - Mediterranean journal of hematology and infectious diseases DA - 2021/// PY - 2021 DO - 10.4084/MJHID.2021.022 VL - 13 IS - 1 SP - e2021022 J2 - Mediterr J Hematol Infect Dis LA - eng SN - 2035-3006 KW - COVID-19 KW - SARS-CoV-2 KW - 25-OH vitamin D KW - ABL KW - CML KW - TKI ER - TY - JOUR TI - Impact of COVID-19 Pandemic on Emergency Inpatient Volume at a Tertiary Eye Care Center in Germany with Corneal Main Specialization. AU - Tóth, Gábor AU - Xanthopoulou, Kassandra AU - Stachon, Tanja AU - Németh, János AU - Hécz, Réka AU - Berkó-Göttel, Barbara AU - Pfuhl, Thorsten AU - Smola, Sigrun AU - Seitz, Berthold AU - Szentmáry, Nóra T2 - Klinische Monatsblatter fur Augenheilkunde AB - BACKGROUND: To estimate the impact of the COVID-19 pandemic on emergency inpatient volume in a tertiary eye care center in Germany with corneal main subspecialization. MATERIAL AND METHODS: A retrospective review of ocular emergency patients who attended the inpatient unit of the Department of Ophthalmology of Saarland University, Homburg/Saar, Germany during the COVID-19 pandemic, between 1 March and 30 April 2020, in comparison to the same time period in 2019. For each subject, clinical history and surgical reports were reviewed. After 24 March 2020, PCR examinations for SARS-CoV-2 were performed from throat swab specimens in all patients using real-time RT-PCR. RESULTS: Totally, 135 patients were admitted in 2019 and 115 patients in 2020 as emergency cases. The patient age at the time of admission did not differ significantly between the two time periods (63.6 ± 17.9 years vs. 62.5 ± 19.6 years) (p = 0.792), but the average length of hospital stays increased significantly for 2020 (4.0 ± 3.6 vs. 4.4 ± 2.7 days, p = 0.043). The percentage of admissions due to acute corneal hydrops (0% vs. 3.5%) increased significantly from 2019 to 2020 (χ(2) = 4.772, p = 0.028), however, there was not a significant difference between the two years for any other diagnosis (χ(2) ≤ 3.564, p ≥ 0.059). From 2019 to 2020, the percentage of acute intravitreal anti-VEGF injections decreased significantly (7.9% vs. 1.3%, χ(2) = 3.985, p = 0.045), but the proportion of other emergency surgeries did not differ between the two years (χ(2) ≤ 3.617, p ≥ 0.057). COVID-19 PCR examination was performed in 66 (57.4%) cases in 2020 and all samples (100%) were negative. CONCLUSIONS: The COVID pandemic did not change emergency inpatient volume in our department, but duration of hospital stay was extended on average by 8 hours, mainly due to additional COVID-19-PCR examinations. The proportion of the most frequently performed surgeries did not change remarkably between 2019 and 2020, but with the introduction of Muraine's sutures in 2019, the percentage of admissions with acute corneal hydrops (with or without subsequent surgery) increased for 2020. No urgent surgery had to be postponed due to the COVID-19 pandemic at our department; all operations were performed successfully. DA - 2021/06//undefined PY - 2021 DO - 10.1055/a-1327-3393 VL - 238 IS - 6 SP - 715 EP - 720 J2 - Klin Monbl Augenheilkd LA - eng SN - 1439-3999 0023-2165 L1 - https://www.thieme-connect.de/products/ejournals/pdf/10.1055/a-1327-3393.pdf ER - TY - JOUR TI - Countrywide population movement monitoring using mobile devices generated (big) data during the COVID-19 crisis. AU - Szocska, Miklos AU - Pollner, Peter AU - Schiszler, Istvan AU - Joo, Tamas AU - Palicz, Tamas AU - McKee, Martin AU - Asztalos, Aron AU - Bencze, Laszlo AU - Kapronczay, Mor AU - Petrecz, Peter AU - Toth, Benedek AU - Szabo, Adam AU - Weninger, Attila AU - Ader, Krisztian AU - Bacskai, Peter AU - Karaszi, Peter AU - Terplan, Gyozo AU - Tuboly, Gabor AU - Sohonyai, Adam AU - Szoke, Jozsef AU - Toth, Adam AU - Gaal, Peter T2 - Scientific reports AB - Mobile phones have been used to monitor mobility changes during the COVID-19 pandemic but surprisingly few studies addressed in detail the implementation of practical applications involving whole populations. We report a method of generating a "mobility-index" and a "stay-at-home/resting-index" based on aggregated anonymous Call Detail Records of almost all subscribers in Hungary, which tracks all phones, examining their strengths and weaknesses, comparing it with Community Mobility Reports from Google, limited to smartphone data. The impact of policy changes, such as school closures, could be identified with sufficient granularity to capture a rush to shops prior to imposition of restrictions. Anecdotal reports of large scale movement of Hungarians to holiday homes were confirmed. At the national level, our results correlated well with Google mobility data, but there were some differences at weekends and national holidays, which can be explained by methodological differences. Mobile phones offer a means to analyse population movement but there are several technical and privacy issues. Overcoming these, our method is a practical and inexpensive way forward, achieving high levels of accuracy and resolution, especially where uptake of smartphones is modest, although it is not an alternative to smartphone-based solutions used for contact tracing and quarantine monitoring. DA - 2021/03/15/ PY - 2021 DO - 10.1038/s41598-021-81873-6 VL - 11 IS - 1 SP - 5943 J2 - Sci Rep LA - eng SN - 2045-2322 KW - Humans KW - *SARS-CoV-2 KW - *Big Data KW - *Computers, Handheld KW - Contact Tracing KW - COVID-19/*epidemiology/prevention & control/virology KW - Geography, Medical KW - Hungary/epidemiology KW - Public Health Surveillance KW - Social Mobility/*statistics & numerical data ER - TY - JOUR TI - Physical Exercise as a Resilience Factor to Mitigate COVID-Related Allostatic Overload. AU - Eöry, Ajandek AU - Békési, Dora AU - Eöry, Ajandok AU - Rózsa, Sandor T2 - Psychotherapy and psychosomatics AB - INTRODUCTION: The long-lasting threat of COVID-19 makes it necessary to explore strategies to improve coping skills which enable us to master a balanced life in the face of adversity. OBJECTIVE: To unravel the most challenging aspects of COVID-19 in a nonclinical adult population and identify predictors of lost balance and consequent allostatic overload (AO). We examined the role of regular, moderate-intensity formula aerobic exercise (312 meridian exercise) in preventing allostatic overload through increasing well-being. METHODS: An online survey was conducted to measure CO-VID-related allostatic overload according to clinimetric criteria. The Psychosocial Index (PSI), Kellner's Symptom Questionnaire (KSQ), short Depression Anxiety Stress Scales (DASS-21), Public Health Surveillance Well-Being Scale -(PHS-WB), and Whiteley-7 were used to explore mental health characteristics. Univariate statistics logistic regression analysis and a general linear model were used. RESULTS: According to 442 valid answers, 217 adults practiced physical exercise (PE) frequently (fPE, 3-5 times/every day) while 120 did it less regularly (1-2 times/week), and 105 did not exercise/practiced irregularly (controls). Restriction-related stressors were most challenging, resulting in AO in 29% (n = 128) of the sample. The main predictors were additional stressors (p = 0.005) and anxiety symptoms (p < 0.001). The prevalence of AO was lower (p = 0.018) in the fPE group when compared to controls. KSQ distress symptoms were also lower in fPE (p < 0.0001), while total well-being was increased (p < 0.001) after adjusting for sex, age, and number of chronic diseases. According to the PHS-WB, both physical and mental well-being were higher (p = 0.003 and p = 0.004, respectively) in fPE. CONCLUSIONS: Frequent moderate exercise is associated with better mental and physical well-being and a lower prevalence of AO. DA - 2021/// PY - 2021 DO - 10.1159/000514331 VL - 90 IS - 3 SP - 200 EP - 206 J2 - Psychother Psychosom LA - eng SN - 1423-0348 0033-3190 KW - *312 meridian exercise KW - *Allostatic overload KW - *Physical exercise KW - *Resilience KW - *Well-being ER - TY - JOUR TI - The Journal of Cardiovascular Computed Tomography: 2020 Year in review. AU - Villines, Todd C. AU - Al'Aref, Subhi J. AU - Andreini, Daniele AU - Chen, Marcus Y. AU - Choi, Andrew D. AU - De Cecco, Carlo N. AU - Dey, Damini AU - Earls, James P. AU - Ferencik, Maros AU - Gransar, Heidi AU - Hecht, Harvey AU - Leipsic, Jonathon A. AU - Lu, Michael T. AU - Marwan, Mohamed AU - Maurovich-Horvat, Pál AU - Nicol, Edward AU - Pontone, Gianluca AU - Weir-McCall, Jonathan AU - Whelton, Seamus P. AU - Williams, Michelle C. AU - Arbab-Zadeh, Armin AU - Feuchtner, Gudrun M. T2 - Journal of cardiovascular computed tomography AB - The purpose of this review is to highlight the most impactful, educational, and frequently downloaded articles published in the Journal of Cardiovascular Computed Tomography (JCCT) for the year 2020. The JCCT reached new records in 2020 for the number of research submissions, published manuscripts, article downloads and social media impressions. The articles in this review were selected by the Editorial Board of the JCCT and are comprised predominately of original research publications in the following categories: Coronavirus disease 2019 (COVID-19), coronary artery disease, coronary physiology, structural heart disease, and technical advances. The Editorial Board would like to thank each of the authors, peer-reviewers and the readers of JCCT for making 2020 one of the most successful years in its history, despite the challenging circumstances of the global COVID-19 pandemic. DA - 2021/04//Mar- undefined PY - 2021 DO - 10.1016/j.jcct.2021.02.004 VL - 15 IS - 2 SP - 180 EP - 189 J2 - J Cardiovasc Comput Tomogr LA - eng SN - 1876-861X KW - Humans KW - Risk Factors KW - COVID-19 KW - *Biomedical Research KW - *Periodicals as Topic KW - Cardiac computed tomography KW - Cardiac CT KW - Computed Tomography Angiography KW - Coronary Angiography KW - Coronary artery calcium KW - Coronary Artery Disease/diagnostic imaging/physiopathology/virology KW - Coronary CT angiography KW - COVID-19/complications/diagnosis/*virology KW - Heart Diseases/diagnostic imaging/physiopathology/*virology KW - Host-Pathogen Interactions KW - Journal of cardiovascular computed tomography KW - Prognosis KW - SARS-CoV-2/*pathogenicity KW - Structural heart disease ER - TY - JOUR TI - [Severe hypoxaemia without dyspnoe in COVID-19 pneumonia]. AU - Losonczy, György AU - Lukácsovits, József AU - Süttő, Zoltán AU - Lorx, András AU - Müller, Veronika T2 - Orvosi hetilap AB - Összefoglaló. Számos közlemény született arról, hogy a COVID-19-pneumoniás betegek jelentős hányadában az artériás parciális oxigéntenzió kifejezetten alacsony, mégsem jellemző a dyspnoe, és a pulzusoximetria sem mutat - a csökkent oxigéntenzióval arányos - súlyos hypoxaemiát. A jelenséget "happy hypoxaemia" néven említik. Ugyanakkor a légszomjról nem panaszkodó, de súlyos alveolocapillaris O2-felvételi zavarban szenvedő COVID-19-pneumoniás betegek a legkisebb fizikai megterhelést sem tűrik, és állapotuk gyorsan kritikussá válhat, tehát a hypoxaemia mértékének időben való felismerése kulcskérdés. A jelen közleményben egy ilyen eset rövid ismertetése után összefoglaljuk a súlyos, de tünetmentes hypoxaemia hátterében meghúzódó élettani okokat. Ezek között szerepel a hypocapnia (respiratoricus alkalosis) is, mely alacsony oxigéntenzió mellett is a hemoglobin viszonylag megtartott oxigénszaturációját eredményezi. Ezért a mindennapi COVID-19-ellátásban a megismételt artériásvérgáz-meghatározások jelentősége nem hangsúlyozható eléggé. Orv Hetil. 2021; 162(10): 362-365. Summary. Many COVID-19 patients have very low arterial partial oxigen tension while severe dyspnoe does not develop. Pulse oxymetry indicates only moderate reduction of arterial O2 saturation in these patients. The phenomenon is named "happy hypoxaemia". Lack of (severe) dyspnoe and only moderately decreased O2 saturation in severely impaired alveolo-capillary O2 uptake may partially be explained by an increased oxygen affinity of hemoglobin in the presence of low arterial partial pressure of CO2. The latter results from increased alveolar ventilation, while low partial pressure of O2 in COVID-19 patients reflects right-to-left shunting of pulmonary blood flow and ventilation-perfusion mismatch of the diseased lungs. While such patients may have mild complaints as related to the real impairment of alveolo-capillary oxygen exchange, severe hypoxaemia is a negative prognostic factor of outcome in this state where severe clinical deterioration may rapidly appear. The latter circumstance together with the unusual relationship of O2 partial pressure and O2 saturation of hemoglobin in COVID-19 emphasize the importance of repeated complete arterial blood gas analyses in these patients. Orv Hetil. 2021; 162(10): 362-365. DA - 2021/03/07/ PY - 2021 DO - 10.1556/650.2021.32136 VL - 162 IS - 10 SP - 362 EP - 365 J2 - Orv Hetil LA - hun SN - 1788-6120 0030-6002 KW - Humans KW - Severity of Illness Index KW - *coronavirus KW - *koronavírus KW - *COVID-19/complications/therapy KW - *hypocapnia KW - *Hypoxia/etiology KW - *lung infection KW - *oxigénaffinitás KW - *oxygen affinity KW - *tüdőgyulladás ER - TY - JOUR TI - An Experience of Public Dental Care during the COVID-19 Pandemic: Reflection and Analysis. AU - Nemeth, Orsolya AU - Orsos, Mercedesz AU - Simon, Fanni AU - Gaal, Peter T2 - International journal of environmental research and public health AB - Since its emergence in China, the COVID-19 pandemic has become the number 1 health challenge in the world with all affected countries trying to learn from each other's experiences. When it comes to health services, dental care does not seem to be a priority area, despite the fact that it is among the highest risk medical specialisations in terms of spreading the infection. Using the Department of Community Dentistry of Semmelweis University as a case study, the objective of this paper is to introduce and analyze the system and organizational level measures, which have been implemented in dental care in Hungary during the first months of the COVID-19 outbreak. The system level measures to promote social distancing, to reduce the use of health services and to protect high risk health professionals, together with the deployment of protective equipment and the reorganization of patient pathways at the organizational level proved to be effective in keeping the outbreak in control. There are two, less frequently mentioned ingredients of successful coping with the COVID-19 challenge. First, mental health support is at least as important as physical protection. Second, most of the interventions do not require big financial investments, but behavioural change, which in turn requires leadership and change management skills. DA - 2021/02/16/ PY - 2021 DO - 10.3390/ijerph18041915 VL - 18 IS - 4 SP - 1915 J2 - Int J Environ Res Public Health LA - eng SN - 1660-4601 1661-7827 KW - Humans KW - Personal Protective Equipment KW - *COVID-19 KW - *community dentistry KW - *Dental Care KW - *dental management KW - *dental public health KW - *infection control KW - *pandemic KW - *Pandemics/prevention & control KW - COVID-19/*prevention & control KW - Hungary KW - Infection Control ER - TY - JOUR TI - Strategies to maintain high-quality education and communication among the paediatric and neonatal intensive care community during the COVID-19 pandemic. AU - Györgyi, Z. AU - Sperotto, F. AU - Medina Villanueva, A. AU - Kneyber, M. C. J. AU - Zanin, A. T2 - Medicina intensiva DA - 2021/02/10/ PY - 2021 DO - 10.1016/j.medin.2021.01.008 J2 - Med Intensiva LA - spa SN - 1578-6749 0210-5691 ER - TY - JOUR TI - Mental health-related stigma among psychiatrists in light of Covid-19. AU - Őri, Dorottya AU - Molnár, Tamás AU - Szocsics, Péter T2 - Asian journal of psychiatry DA - 2021/04//undefined PY - 2021 DO - 10.1016/j.ajp.2021.102620 VL - 58 SP - 102620 J2 - Asian J Psychiatr LA - eng SN - 1876-2026 1876-2018 KW - Humans KW - *COVID-19/epidemiology/psychology/virology KW - *Mental Disorders/epidemiology/psychology KW - *Mental Health/ethics/trends KW - *Social Stigma KW - Attitude of Health Personnel KW - Health Personnel/*psychology KW - Mental Health Services/ethics/standards KW - Occupational Stress/*prevention & control KW - Patient Acceptance of Health Care/psychology KW - Professional-Patient Relations/*ethics ER - TY - JOUR TI - National level adjustments to the challenges of the SARS-CoV2 pandemic on blood banking operations. AU - Matusovits, Andrea AU - Nagy, Sándor AU - Baróti-Tóth, Klára AU - Nacsa, János AU - Lázár, Mária AU - Marton, Imelda AU - Andrikovics, Hajnalka AU - Vokó, Zoltan AU - Tordai, Attila T2 - Transfusion AB - BACKGROUND: SARS-CoV2 causing coronavirus disease (COVID-19) is responsible for an unprecedented worldwide pandemic severely affecting all activities of societies including blood banking. We aimed to systematically collect key indicators in a nationally centralized blood banking system and to perform comparisons between 2020 and 2019. METHODS: Count data for January-December 2020 and 2019 were extracted from the integrated informatics system of Hungarian National Blood Transfusion Service and analyzed by simple graphics, tabulations, and statistics. RESULTS: Whole blood donation activity showed a highly significant decline due to a sharp decrease in field donations by an average fall of 24% (range:17%-28%) during March-May 2020 compared to identical period of 2019. A second, more moderate decline accompanied the second wave in late fall. The simultaneous increase in institutional donations did not counterbalance this decline. Donor exclusion rates fell significantly by an average of 1,1% (range:0.9%-1.6%) in the three spring lockdown-affected months. First-time and repeat donors showed decreased turn-out in larger proportions compared to highly repeat donors. Interestingly, among repeat and highly repeat donors, females showed less-pronounced declines compared to males while this was not observed among first-time donors. In June-September, a remarkable swing-back was observed among highly repeat female donors. Product utilization fell most notably for RBC (mean:26.2%) but also for PLT (mean:19.8%) and FFP (mean:24.3%) and showed a full recovery in June-September followed by a second decline. CONCLUSION: Trends and reaction patterns of blood banking reported by our study may be useful in future planning and adjustments of blood banking activities. DA - 2021/05//undefined PY - 2021 DO - 10.1111/trf.16346 VL - 61 IS - 5 SP - 1404 EP - 1411 J2 - Transfusion LA - eng SN - 1537-2995 0041-1132 KW - COVID-19 KW - blood banking KW - blood donors KW - SARS-CoV2 ER - TY - JOUR TI - Physical activity, screen time and the COVID-19 school closures in Europe - An observational study in 10 countries. AU - Kovacs, Viktoria A. AU - Starc, Gregor AU - Brandes, Mirko AU - Kaj, Monika AU - Blagus, Rok AU - Leskošek, Bojan AU - Suesse, Thomas AU - Dinya, Elek AU - Guinhouya, Benjamin C. AU - Zito, Viviana AU - Rocha, Paulo M. AU - Gonzalez, Benito Perez AU - Kontsevaya, Anna AU - Brzezinski, Michal AU - Bidiugan, Radu AU - Kiraly, Anita AU - Csányi, Tamás AU - Okely, Anthony D. T2 - European journal of sport science AB - To date, few data on how the COVID-19 pandemic and restrictions affected children's physical activity in Europe have been published. This study examined the prevalence and correlates of physical activity and screen time from a large sample of European children during the COVID-19 pandemic to inform strategies and provide adequate mitigation measures. An online survey was conducted using convenience sampling from 15 May to 22 June, 2020. Parents were eligible if they resided in one of the survey countries and their children aged 6-18 years. 8395 children were included (median age [IQR], 13 [10-15] years; 47% boys; 57.6% urban residents; 15.5% in self-isolation). Approximately two-thirds followed structured routines (66.4% [95%CI, 65.4-67.4]), and more than half were active during online P.E. (56.6% [95%CI, 55.5-57.6]). 19.0% (95%CI, 18.2-19.9) met the WHO Global physical activity recommendation. Total screen time in excess of 2 h/day was highly prevalent (weekdays: 69.5% [95%CI, 68.5-70.5]; weekend: 63.8% [95%CI, 62.7-64.8]). Playing outdoors more than 2 h/day, following a daily routine and being active in online P.E. increased the odds of healthy levels of physical activity and screen time, particularly in mildly affected countries. In severely affected countries, online P.E. contributed most to meet screen time recommendation, whereas outdoor play was most important for adequate physical activity. Promoting safe and responsible outdoor activities, safeguarding P.E. lessons during distance learning and setting pre-planned, consistent daily routines are important in helping children maintain healthy active lifestyle in pandemic situation. These factors should be prioritised by policymakers, schools and parents.Highlights To our knowledge, our data provide the first multi-national estimates on physical activity and total screen time in European children roughly two months after COVID-19 was declared a global pandemic.Only 1 in 5 children met the WHO Global physical activity recommendations.Under pandemic conditions, parents should set pre-planned, consistent daily routines and integrate at least 2-hours outdoor activities into the daily schedule, preferable on each day. Schools should make P.E. lessons a priority. Decision makers should mandate online P.E. be delivered by schools during distance learning. Closing outdoor facilities for PA should be considered only as the last resort during lockdowns. DA - 2021/03/29/ PY - 2021 DO - 10.1080/17461391.2021.1897166 SP - 1 EP - 10 J2 - Eur J Sport Sci LA - eng SN - 1536-7290 KW - Adolescents KW - children KW - coronavirus-19 KW - sedentary behaviour ER - TY - JOUR TI - Superficial temporal artery access for percutaneous coronary artery stenting during the COVID-19 pandemic: a case report. AU - Csavajda, Ádám AU - Bertrand, Olivier F. AU - Merkely, Béla AU - Ruzsa, Zoltán T2 - European heart journal. Case reports AB - BACKGROUND: The COVID-19 pandemic creates new challenges for healthcare, including invasive cardiology. CASE SUMMARY: We discuss the case of a 65-year-old man who presented with non-ST segment elevation myocardial infarction combined with bilateral pneumonia. The patient had known severe iliac artery lesions with prior interventions and bilateral subclavian artery occlusions. After unsuccessful femoral artery access, the diagnostic angiography and the right coronary artery percutaneous coronary intervention were successfully performed from ultrasound-guided lower superficial temporal artery access. DISCUSSION: We showed that superficial temporal access can be used as an alternate access site for diagnostic coronary angiography and intervention when standard wrist and femoral access sites are not readily accessible. DA - 2021/02//undefined PY - 2021 DO - 10.1093/ehjcr/ytaa520 VL - 5 IS - 2 SP - ytaa520 J2 - Eur Heart J Case Rep LA - eng SN - 2514-2119 KW - Case report KW - Coronary angioplasty KW - COVID-19 pandemic KW - Superficial temporal artery access ER - TY - JOUR TI - Potential Interplay between Nrf2, TRPA1, and TRPV1 in Nutrients for the Control of COVID-19. AU - Bousquet, Jean AU - Czarlewski, Wienczyslawa AU - Zuberbier, Torsten AU - Mullol, Joaquim AU - Blain, Hubert AU - Cristol, Jean-Paul AU - De La Torre, Rafael AU - Pizarro Lozano, Nieves AU - Le Moing, Vincent AU - Bedbrook, Anna AU - Agache, Ioana AU - Akdis, Cezmi A. AU - Canonica, G. Walter AU - Cruz, Alvaro A. AU - Fiocchi, Alessandro AU - Fonseca, Joao A. AU - Fonseca, Susana AU - Gemicioğlu, Bilun AU - Haahtela, Tari AU - Iaccarino, Guido AU - Ivancevich, Juan Carlos AU - Jutel, Marek AU - Klimek, Ludger AU - Kraxner, Helga AU - Kuna, Piotr AU - Larenas-Linnemann, Désirée E. AU - Martineau, Adrian AU - Melén, Erik AU - Okamoto, Yoshitaka AU - Papadopoulos, Nikolaos G. AU - Pfaar, Oliver AU - Regateiro, Frederico S. AU - Reynes, Jacques AU - Rolland, Yves AU - Rouadi, Philip W. AU - Samolinski, Boleslaw AU - Sheikh, Aziz AU - Toppila-Salmi, Sanna AU - Valiulis, Arunas AU - Choi, Hak-Jong AU - Kim, Hyun Ju AU - Anto, Josep M. T2 - International archives of allergy and immunology AB - In this article, we propose that differences in COVID-19 morbidity may be associated with transient receptor potential ankyrin 1 (TRPA1) and/or transient receptor potential vanilloid 1 (TRPV1) activation as well as desensitization. TRPA1 and TRPV1 induce inflammation and play a key role in the physiology of almost all organs. They may augment sensory or vagal nerve discharges to evoke pain and several symptoms of COVID-19, including cough, nasal obstruction, vomiting, diarrhea, and, at least partly, sudden and severe loss of smell and taste. TRPA1 can be activated by reactive oxygen species and may therefore be up-regulated in COVID-19. TRPA1 and TRPV1 channels can be activated by pungent compounds including many nuclear factor (erythroid-derived 2) (Nrf2)-interacting foods leading to channel desensitization. Interactions between Nrf2-associated nutrients and TRPA1/TRPV1 may be partly responsible for the severity of some of the COVID-19 symptoms. The regulation by Nrf2 of TRPA1/TRPV1 is still unclear, but suggested from very limited clinical evidence. In COVID-19, it is proposed that rapid desensitization of TRAP1/TRPV1 by some ingredients in foods could reduce symptom severity and provide new therapeutic strategies. DA - 2021/// PY - 2021 DO - 10.1159/000514204 VL - 182 IS - 4 SP - 324 EP - 338 J2 - Int Arch Allergy Immunol LA - eng SN - 1423-0097 1018-2438 KW - Humans KW - Severity of Illness Index KW - COVID-19 Testing KW - *COVID-19 KW - *Broccoli KW - *Cough challenge KW - *Nrf2 KW - *Pungent foods KW - *TRAP-1 KW - Antioxidants/metabolism KW - Biomarkers/metabolism KW - Brassica KW - COVID-19/complications/diagnosis/*diet therapy/*immunology KW - Desensitization, Immunologic/methods KW - Down-Regulation KW - NF-E2-Related Factor 2/*immunology KW - Nutrients/*immunology KW - Oxidative Stress/immunology KW - SARS-CoV-2/*immunology/pathogenicity KW - TRPA1 Cation Channel/*immunology KW - TRPV Cation Channels/*immunology KW - Up-Regulation ER - TY - JOUR TI - [Impact of the COVID‒19 pandemic on ophthalmic outpatient care at the Ophthalmology Department of the New St. John’s Hospital, Budapest]. AU - Széles, Rebeka AU - Szentmáry, Nóra AU - Burka, Gabriella AU - Nagy, Zoltán Zsolt AU - Gombos, Katalin AU - Hargitai, János T2 - Orvosi hetilap AB - Összefoglaló. Bevezetés: Az új típusú koronavírus-járvány (COVID-19) az egészségügyi ellátóhálózatot egy eddig ismeretlen helyzet elé állította. A nemzetközi adatok alapján a szemészeti járóbeteg-ellátásban jelentős változások alakultak ki. Célkitűzés: Felmérni a COVID-19-járvány okozta kvantitatív és kvalitatív változásokat az Észak-Közép-budai Centrum, Új Szent János Kórház és Szakrendelő Szemészeti Osztályának járóbeteg-szakellátásában. Módszer: A pandémia első hullámában (2020. április 1-30.) mért járóbeteg-forgalmi adatokat hasonlítottuk össze a megelőző év azonos periódusában rögzített adatokkal. A betegek demográfiai jellemzői mellett megvizsgáltuk a sürgősségi besorolásukat, valamint a panaszokhoz köthető fődiagnózis-csoportok eloszlását. Rögzítettük a telemedicina keretein belül történt ellátások számát. Eredmények: 2020 vizsgált időszakában 916, míg az előző év azonos hónapjában 2835 járóbeteg-eset került rögzítésre. A 2020-as időszakban a törvényi szabályozás szerint sürgős panaszokkal jelentkező betegek aránya nem változott (p = 0,38), azonban a szakorvosi megítélés szerint sürgős panaszokkal érkező betegek aránya nőtt (p<0,001) az előző évhez viszonyítva. A zöld hályog, kötőhártya-gyulladás, árpa, sérülés és nedves típusú maculadegeneratio miatt ellátásra jelentkező betegek aránya szignifikánsan nőtt (p<0,001 mind), míg a szürke hályog, a száraz típusú maculadegeneratio, egyéb, a szemhéj és a könnyutak betegségei, utóhályog miatt és a szemészeti betegség nélkül érkezők aránya csökkent (p<0,001 mind). A telemedicina keretei között ellátott betegek száma 2020-ban közel a tizenötszörösére emelkedett 2019-hez képest (p<0,001). Következtetés: A COVID-19-pandémia első hulláma során markáns betegszámcsökkenést regisztráltunk a szemészeti járóbeteg-szakellátásban. Több fődiagnózis-csoport esetén számolhatunk jelentős terápiavesztéssel és halasztott ellátási igény jelentkezésével. Az adatok kiértékelése segítséget nyújthat az elkövetkező években az ellátási folyamat proaktív átszervezésében, a humánerőforrás-szükségletek jobb tervezésében, valamint a teleoftalmológiai ellátás fejlesztésében. Orv Hetil. 2021; 162(6): 203-211. INTRODUCTION: The COVID-19 pandemic put the healthcare network in a hitherto unknown situation. The ophthalmic outpatient care changed internationally. OBJECTIVE: To assess the quantitative and qualitative changes of the outpatient specialty care at the Ophthalmology Department of the North-Central-Buda Center, New St. John's Hospital and Clinic, through the pandemic. METHOD: Outpatient service data during the first wave of the pandemic (April 2020) were compared with those in April 2019. Patient demographics, emergency classification, distribution of the main diagnostic groups (associated with complaints) and services provided via telemedicine were collected. RESULTS: There were 2835 patient visits in 2019 and 916 in 2020. For 2020, the proportion of patients with emergency classification according to legal regulations did not change (p = 0.38), however, using the ophthalmologist's classification increased (p<0.001) significantly. The proportion of patients with glaucoma, conjunctivitis, chalazeon, injury and wet macular degeneration increased (p<0.001 all), while the proportion of patients with cataract, dry macular degeneration, other diseases, other adnexal diseases, secondary cataract and without ophthalmic pathology decreased significantly (p<0.001 for all). Patient number using telemedicine treatment was about 15× of those treated in 2019 (p<0.001). CONCLUSION: During the first wave of the pandemic, a marked decrease in ophthalmic outpatient care volume was recorded. In the case of several main diagnosis groups, significant therapy loss and a delayed need for care could be expected. Evaluation of the data helps in the upcoming years in proactive reorganization of the care process, in better planning of human resource needs, and in improvement of teleophthalmology care. Orv Hetil. 2021; 162(6): 203-211. DA - 2021/02/07/ PY - 2021 DO - 10.1556/650.2021.32102 VL - 162 IS - 6 SP - 203 EP - 211 J2 - Orv Hetil LA - hun SN - 1788-6120 0030-6002 KW - Humans KW - *COVID-19 KW - Hungary KW - *COVID-19 pandemic KW - *COVID–19-pandémia KW - *emergency services KW - *fődiagnózis-csoport KW - *main diagnosis group KW - *Ophthalmology KW - *ophthalmology outpatient speciality care KW - *Pandemics KW - *sürgős ellátások KW - *szemészeti járóbeteg-szakellátás KW - *Telemedicine KW - *teleoftalmológia KW - *teleophthalmology KW - Ambulatory Care/*trends KW - Hospitals KW - Outpatients ER - TY - JOUR TI - A Potential Bioelectromagnetic Method to Slow Down the Progression and Prevent the Development of Ultimate Pulmonary Fibrosis by COVID-19. AU - Masaud, Syed Muzzammil AU - Szasz, Oliver AU - Szasz, A. Marcell AU - Ejaz, Huma AU - Anwar, Rana Attique AU - Szasz, Andras T2 - Frontiers in immunology AB - INTRODUCTION: Right now, we are facing a global pandemic caused by the coronavirus SARS-CoV-2 that causes the highly contagious human disease COVID-19. The number of COVID-19 cases is increasing at an alarming rate, more and more people suffer from it, and the death toll is on the rise since December 2019, when COVID-19 has presumably appeared. We need an urgent solution for the prevention, treatment, and recovery of the involved patients. METHODS: Modulated electro-hyperthermia (mEHT) is known as an immuno-supportive therapy in oncology. Our proposal is to apply this method to prevent the progression of the disease after its identification, to provide treatment when necessary, and deliver rehabilitation to diminish the fibrotic-often fatal-consequences of the infection. HYPOTHESIS: The effects of mEHT, which are proven for oncological applications, could be utilized for the inactivation of the virus or for treating the fibrotic consequences. The hypothesized mEHT effects, which could have a role in the antiviral treatment, it could be applied for viral-specific immune-activation and for anti-fibrotic treatments. DA - 2020/// PY - 2020 DO - 10.3389/fimmu.2020.556335 VL - 11 SP - 556335 J2 - Front Immunol LA - eng SN - 1664-3224 KW - Humans KW - *SARS-CoV-2 KW - *electric field KW - *Electric Stimulation Therapy KW - *heat-shock protein KW - *Hyperthermia, Induced KW - *immune-effect KW - *Immunotherapy KW - *modulated electro-hyperthermia KW - *rehabilitation KW - *SARS-CoV-21 KW - COVID-19/complications/epidemiology/*rehabilitation KW - Pulmonary Fibrosis/epidemiology/etiology/*rehabilitation ER - TY - JOUR TI - Circulating Levels of Tissue Plasminogen Activator and Plasminogen Activator Inhibitor-1 Are Independent Predictors of Coronavirus Disease 2019 Severity: A Prospective, Observational Study. AU - Henry, Brandon Michael AU - Cheruiyot, Isaac AU - Benoit, Justin L. AU - Lippi, Giuseppe AU - Prohászka, Zoltán AU - Favaloro, Emmanuel J. AU - Benoit, Stefanie W. T2 - Seminars in thrombosis and hemostasis DA - 2021/00//undefined PY - 2021 DO - 10.1055/s-0040-1722308 VL - 47 IS - 4 SP - 451 EP - 455 J2 - Semin Thromb Hemost LA - eng SN - 1098-9064 0094-6176 ER - TY - JOUR TI - Psycho-social factors associated with mental resilience in the Corona lockdown. AU - Veer, Ilya M. AU - Riepenhausen, Antje AU - Zerban, Matthias AU - Wackerhagen, Carolin AU - Puhlmann, Lara M. C. AU - Engen, Haakon AU - Köber, Göran AU - Bögemann, Sophie A. AU - Weermeijer, Jeroen AU - Uściłko, Aleksandra AU - Mor, Netali AU - Marciniak, Marta A. AU - Askelund, Adrian Dahl AU - Al-Kamel, Abbas AU - Ayash, Sarah AU - Barsuola, Giulia AU - Bartkute-Norkuniene, Vaida AU - Battaglia, Simone AU - Bobko, Yaryna AU - Bölte, Sven AU - Cardone, Paolo AU - Chvojková, Edita AU - Damnjanović, Kaja AU - De Calheiros Velozo, Joana AU - de Thurah, Lena AU - Deza-Araujo, Yacila I. AU - Dimitrov, Annika AU - Farkas, Kinga AU - Feller, Clémence AU - Gazea, Mary AU - Gilan, Donya AU - Gnjidić, Vedrana AU - Hajduk, Michal AU - Hiekkaranta, Anu P. AU - Hofgaard, Live S. AU - Ilen, Laura AU - Kasanova, Zuzana AU - Khanpour, Mohsen AU - Lau, Bobo Hi Po AU - Lenferink, Dionne B. AU - Lindhardt, Thomas B. AU - Magas, Dávid Á AU - Mituniewicz, Julian AU - Moreno-López, Laura AU - Muzychka, Sofiia AU - Ntafouli, Maria AU - O'Leary, Aet AU - Paparella, Ilenia AU - Põldver, Nele AU - Rintala, Aki AU - Robak, Natalia AU - Rosická, Anna M. AU - Røysamb, Espen AU - Sadeghi, Siavash AU - Schneider, Maude AU - Siugzdaite, Roma AU - Stantić, Mirta AU - Teixeira, Ana AU - Todorovic, Ana AU - Wan, Wendy W. N. AU - van Dick, Rolf AU - Lieb, Klaus AU - Kleim, Birgit AU - Hermans, Erno J. AU - Kobylińska, Dorota AU - Hendler, Talma AU - Binder, Harald AU - Myin-Germeys, Inez AU - van Leeuwen, Judith M. C. AU - Tüscher, Oliver AU - Yuen, Kenneth S. L. AU - Walter, Henrik AU - Kalisch, Raffael T2 - Translational psychiatry AB - The SARS-CoV-2 pandemic is not only a threat to physical health but is also having severe impacts on mental health. Although increases in stress-related symptomatology and other adverse psycho-social outcomes, as well as their most important risk factors have been described, hardly anything is known about potential protective factors. Resilience refers to the maintenance of mental health despite adversity. To gain mechanistic insights about the relationship between described psycho-social resilience factors and resilience specifically in the current crisis, we assessed resilience factors, exposure to Corona crisis-specific and general stressors, as well as internalizing symptoms in a cross-sectional online survey conducted in 24 languages during the most intense phase of the lockdown in Europe (22 March to 19 April) in a convenience sample of N = 15,970 adults. Resilience, as an outcome, was conceptualized as good mental health despite stressor exposure and measured as the inverse residual between actual and predicted symptom total score. Preregistered hypotheses (osf.io/r6btn) were tested with multiple regression models and mediation analyses. Results confirmed our primary hypothesis that positive appraisal style (PAS) is positively associated with resilience (p < 0.0001). The resilience factor PAS also partly mediated the positive association between perceived social support and resilience, and its association with resilience was in turn partly mediated by the ability to easily recover from stress (both p < 0.0001). In comparison with other resilience factors, good stress response recovery and positive appraisal specifically of the consequences of the Corona crisis were the strongest factors. Preregistered exploratory subgroup analyses (osf.io/thka9) showed that all tested resilience factors generalize across major socio-demographic categories. This research identifies modifiable protective factors that can be targeted by public mental health efforts in this and in future pandemics. DA - 2021/00//undefined PY - 2021 DO - 10.1038/s41398-020-01150-4 VL - 11 IS - 1 SP - 67 J2 - Transl Psychiatry LA - eng SN - 2158-3188 KW - Adult KW - Female KW - Humans KW - Male KW - Middle Aged KW - Young Adult KW - Cross-Sectional Studies KW - Regression Analysis KW - *Mental Health KW - *Resilience, Psychological KW - *Social Factors KW - COVID-19/prevention & control/*psychology KW - Disease Transmission, Infectious/prevention & control KW - Europe KW - Multivariate Analysis KW - Protective Factors KW - Social Support KW - Stress, Psychological/*prevention & control ER - TY - JOUR TI - Topography, Spike Dynamics, and Nanomechanics of Individual Native SARS-CoV-2 Virions. AU - Kiss, Bálint AU - Kis, Zoltán AU - Pályi, Bernadett AU - Kellermayer, Miklós S. Z. T2 - Nano letters AB - SARS-CoV-2, the virus responsible for the current COVID-19 pandemic, displays a corona-shaped layer of spikes which play a fundamental role in the infection process. Recent structural data suggest that the spikes possess orientational freedom and the ribonucleoproteins segregate into basketlike structures. How these structural features regulate the dynamic and mechanical behavior of the native virion are yet unknown. By imaging and mechanically manipulating individual, native SARS-CoV-2 virions with atomic force microscopy, here, we show that their surface displays a dynamic brush owing to the flexibility and rapid motion of the spikes. The virions are highly compliant and able to recover from drastic mechanical perturbations. Their global structure is remarkably temperature resistant, but the virion surface becomes progressively denuded of spikes upon thermal exposure. The dynamics and the mechanics of SARS-CoV-2 are likely to affect its stability and interactions. DA - 2021/03/24/ PY - 2021 DO - 10.1021/acs.nanolett.0c04465 VL - 21 IS - 6 SP - 2675 EP - 2680 J2 - Nano Lett LA - eng SN - 1530-6992 1530-6984 KW - Humans KW - Pandemics KW - *COVID-19 KW - *atomic force microscopy KW - *force spectroscopy KW - *mechanical resilience KW - *nanoindentation KW - *thermal stability KW - Biomechanical Phenomena KW - COVID-19/*virology KW - Hot Temperature KW - Microscopy, Atomic Force KW - Models, Molecular KW - Nanostructures/chemistry/ultrastructure KW - Nanotechnology KW - Protein Conformation KW - Protein Stability KW - SARS-CoV-2/*chemistry/*physiology/ultrastructure KW - Single Molecule Imaging KW - Spike Glycoprotein, Coronavirus/*chemistry/*physiology/ultrastructure KW - Thermodynamics KW - Virion/*chemistry/*physiology/ultrastructure ER - TY - JOUR TI - A plea for equitable global access to COVID-19 diagnostics, vaccination and therapy: The NeuroCOVID-19 Task Force of the European Academy of Neurology. AU - Sellner, Johann AU - Jenkins, Thomas M. AU - von Oertzen, Tim J. AU - Bassetti, Claudio L. AU - Beghi, Ettore AU - Bereczki, Daniel AU - Bodini, Benedetta AU - Cavallieri, Francesco AU - Di Liberto, Giovanni AU - Helbok, Raimund AU - Macerollo, Antonella AU - Maia, Luis F. AU - Oreja-Guevara, Celia AU - Özturk, Serefnur AU - Rakusa, Martin AU - Pisani, Antonio AU - Priori, Alberto AU - Sauerbier, Anna AU - Soffietti, Riccardo AU - Taba, Pille AU - Zedde, Marialuisa AU - Crean, Michael AU - Burlica, Anja AU - Twardzik, Alex AU - Moro, Elena T2 - European journal of neurology AB - Coronavirus disease 2019 (COVID-19), a multi-organ disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to challenge health and care systems around the globe. The pandemic has disrupted acute neurology services and routine patient care and has impacted the clinical course in patients with chronic neurological disease. COVID-19 appears to have exposed inequalities of societies and healthcare systems and had a disproportionate impact on already vulnerable communities. The next challenge will be to set up initiatives to stop disparities in all aspects related to COVID-19. From the medical perspective, there is a need to consider inequalities in prevention, treatment and long-term consequences. Some of the issues of direct relevance to neurologists are summarised. With this appraisal, the European Academy of Neurology NeuroCOVID-19 Task Force intends to raise awareness of the potential impact of COVID-19 on inequalities in healthcare and calls for action to prevent disparity at individual, national and supranational levels. DA - 2021/11//undefined PY - 2021 DO - 10.1111/ene.14741 VL - 28 IS - 11 SP - 3849 EP - 3855 J2 - Eur J Neurol LA - eng SN - 1468-1331 1351-5101 KW - COVID-19 KW - SARS-CoV-2 KW - neurology KW - advocacy KW - disparity KW - equitable global health KW - primary prevention ER - TY - JOUR TI - International Impact of COVID-19 on the Diagnosis of Heart Disease. AU - Einstein, Andrew J. AU - Shaw, Leslee J. AU - Hirschfeld, Cole AU - Williams, Michelle C. AU - Villines, Todd C. AU - Better, Nathan AU - Vitola, Joao V. AU - Cerci, Rodrigo AU - Dorbala, Sharmila AU - Raggi, Paolo AU - Choi, Andrew D. AU - Lu, Bin AU - Sinitsyn, Valentin AU - Sergienko, Vladimir AU - Kudo, Takashi AU - Nørgaard, Bjarne Linde AU - Maurovich-Horvat, Pál AU - Campisi, Roxana AU - Milan, Elisa AU - Louw, Lizette AU - Allam, Adel H. AU - Bhatia, Mona AU - Malkovskiy, Eli AU - Goebel, Benjamin AU - Cohen, Yosef AU - Randazzo, Michael AU - Narula, Jagat AU - Pascual, Thomas N. B. AU - Pynda, Yaroslav AU - Dondi, Maurizio AU - Paez, Diana T2 - Journal of the American College of Cardiology AB - BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has adversely affected diagnosis and treatment of noncommunicable diseases. Its effects on delivery of diagnostic care for cardiovascular disease, which remains the leading cause of death worldwide, have not been quantified. OBJECTIVES: The study sought to assess COVID-19's impact on global cardiovascular diagnostic procedural volumes and safety practices. METHODS: The International Atomic Energy Agency conducted a worldwide survey assessing alterations in cardiovascular procedure volumes and safety practices resulting from COVID-19. Noninvasive and invasive cardiac testing volumes were obtained from participating sites for March and April 2020 and compared with those from March 2019. Availability of personal protective equipment and pandemic-related testing practice changes were ascertained. RESULTS: Surveys were submitted from 909 inpatient and outpatient centers performing cardiac diagnostic procedures, in 108 countries. Procedure volumes decreased 42% from March 2019 to March 2020, and 64% from March 2019 to April 2020. Transthoracic echocardiography decreased by 59%, transesophageal echocardiography 76%, and stress tests 78%, which varied between stress modalities. Coronary angiography (invasive or computed tomography) decreased 55% (p < 0.001 for each procedure). In multivariable regression, significantly greater reduction in procedures occurred for centers in countries with lower gross domestic product. Location in a low-income and lower-middle-income country was associated with an additional 22% reduction in cardiac procedures and less availability of personal protective equipment and telehealth. CONCLUSIONS: COVID-19 was associated with a significant and abrupt reduction in cardiovascular diagnostic testing across the globe, especially affecting the world's economically challenged. Further study of cardiovascular outcomes and COVID-19-related changes in care delivery is warranted. DA - 2021/00//undefined PY - 2021 DO - 10.1016/j.jacc.2020.10.054 VL - 77 IS - 2 SP - 173 EP - 185 J2 - J Am Coll Cardiol LA - eng SN - 1558-3597 0735-1097 KW - Humans KW - Global Health KW - *coronavirus KW - *COVID-19 KW - *cardiac testing KW - *cardiovascular disease KW - *global health KW - Diagnostic Techniques, Cardiovascular/statistics & numerical data KW - Health Care Surveys KW - Heart Diseases/*diagnosis KW - International Agencies ER - TY - JOUR TI - On the role of bacterial metalloproteases in COVID-19 associated cytokine storm. AU - Földvári-Nagy, László AU - Schnabel, Tamás AU - Dörnyei, Gabriella AU - Korcsmáros, Tamás AU - Lenti, Katalin T2 - Cell communication and signaling : CCS AB - The cytokine release syndrome or cytokine storm, which is the hyper-induction of inflammatory responses has a central role in the mortality rate of COVID-19 and some other viral infections. Interleukin-6 (IL-6) is a key player in the development of cytokine storms. Shedding of interleukin-6 receptor (IL-6Rα) results in the accumulation of soluble interleukin-6 receptors (sIL-6R). Only relatively few cells express membrane-bound IL-6Rα. However, sIL-6R can act on potentially all cells and organs through the ubiquitously expressed gp130, the coreceptor of IL-6Rα. Through this, so-called trans-signaling, IL-6-sIL-6R is a powerful factor in the development of cytokine storms and multiorgan involvement. Some bacteria (e.g., Serratia marcescens, Staphylococcus aureus, Pseudomonas aeruginosa, Listeria monocytogenes), commonly considered to cause co-infections during viral pneumonia, can directly induce the shedding of membrane receptors, including IL-6Rα, or enhance endogenous shedding mechanisms causing the increase of sIL-6R level. Here we hypothesise that bacteria promoting shedding and increase the sIL-6R level can be an important contributing factor for the development of cytokine storms. Therefore, inhibition of IL-6Rα shedding by drastically reducing the number of relevant bacteria may be a critical element in reducing the chance of a cytokine storm. Validation of this hypothesis can support the consideration of the prophylactic use of antibiotics more widely and at an earlier stage of infection to decrease the mortality rate of COVID-19. Video abstract. DA - 2021/00//undefined PY - 2021 DO - 10.1186/s12964-020-00699-3 VL - 19 IS - 1 SP - 7 J2 - Cell Commun Signal LA - eng SN - 1478-811X KW - Humans KW - *COVID-19 KW - *Bacteria KW - *Cytokine storm KW - *IL-6 KW - *Metalloprotease KW - Bacteria/*enzymology KW - Bacterial Proteins/*metabolism KW - COVID-19/complications/*pathology/virology KW - Cytokine Release Syndrome/*etiology/microbiology KW - Interleukin-6/metabolism KW - Metalloproteases/*metabolism KW - Receptors, Interleukin-6/metabolism KW - SARS-CoV-2/isolation & purification KW - Signal Transduction ER - TY - JOUR TI - Interactions of Potential Anti-COVID-19 Compounds with Multispecific ABC and OATP Drug Transporters. AU - Telbisz, Ágnes AU - Ambrus, Csilla AU - Mózner, Orsolya AU - Szabó, Edit AU - Várady, György AU - Bakos, Éva AU - Sarkadi, Balázs AU - Özvegy-Laczka, Csilla T2 - Pharmaceutics AB - During the COVID-19 pandemic, several repurposed drugs have been proposed to alleviate the major health effects of the disease. These drugs are often applied with analgesics or non-steroid anti-inflammatory compounds, and co-morbid patients may also be treated with anticancer, cholesterol-lowering, or antidiabetic agents. Since drug ADME-tox properties may be significantly affected by multispecific transporters, in this study, we examined the interactions of the repurposed drugs with the key human multidrug transporters present in the major tissue barriers and strongly affecting the pharmacokinetics. Our in vitro studies, using a variety of model systems, explored the interactions of the antimalarial agents chloroquine and hydroxychloroquine; the antihelmintic ivermectin; and the proposed antiviral compounds ritonavir, lopinavir, favipiravir, and remdesivir with the ABCB1/Pgp, ABCG2/BCRP, and ABCC1/MRP1 exporters, as well as the organic anion-transporting polypeptide (OATP)2B1 and OATP1A2 uptake transporters. The results presented here show numerous pharmacologically relevant transporter interactions and may provide a warning on the potential toxicities of these repurposed drugs, especially in drug combinations at the clinic. DA - 2021/00//undefined PY - 2021 DO - 10.3390/pharmaceutics13010081 VL - 13 IS - 1 SP - 81 J2 - Pharmaceutics LA - eng SN - 1999-4923 KW - anti-COVID-19 agents KW - APP-Binding Cassette (ABC) transporters KW - in vitro functional studies KW - OATP transporters KW - repurposed drugs ER - TY - JOUR TI - Impact of the coronavirus disease 2019 (COVID-19) pandemic on the care of patients with acute and chronic aortic conditions. AU - Czerny, Martin AU - Gottardi, Roman AU - Puiu, Paul AU - Bernecker, Oliver Y. AU - Citro, Rodolfo AU - Della Corte, Alessandro AU - di Marco, Luca AU - Fink, Martina AU - Gosslau, Yvonne AU - Haldenwang, Peter Lukas AU - Heijmen, Robin H. AU - Hugas-Mallorqui, Maria AU - Iesu, Severino AU - Jacobsen, Oyvind AU - Jassar, Arminder S. AU - Juraszek, Andrzej AU - Kolowca, Maciej AU - Lepidi, Sandro AU - Marrocco-Trischitta, Massimiliano M. AU - Matsuda, Hitoshi AU - Meisenbacher, Katrin AU - Micari, Antonio AU - Minatoya, Kenji AU - Park, Kay-Hyun AU - Peterss, Sven AU - Petrich, Michael AU - Piffaretti, Gabriele AU - Probst, Chris AU - Reutersberg, Benedikt AU - Rosati, Fabrizio AU - Schachner, Bruno AU - Schachner, Thomas AU - Sorokin, Vitaly A. AU - Szeberin, Zoltan AU - Szopinski, Piotr AU - Di Tommaso, Luigi AU - Trimarchi, Santi AU - Verhoeven, Eric L. G. AU - Vogt, Ferdinand AU - Voetsch, Andreas AU - Walter, Tim AU - Weiss, Gabriel AU - Yuan, Xun AU - Benedetto, Filippo AU - De Bellis, Antonio AU - D Oria, Mario AU - Discher, Philipp AU - Zierer, Andreas AU - Rylski, Bartosz AU - van den Berg, Jos C. AU - Wyss, Thomas R. AU - Bossone, Eduardo AU - Schmidli, Jürg AU - Nienaber, Christoph AU - Accarino, Giulio AU - Baldascino, Francesco AU - Böckler, Dittmar AU - Corazzari, Claudio AU - D Alessio, Ilenia AU - de Beaufort, Hector AU - De Troia, Christopher AU - Dumfarth, Julia AU - Galbiati, Denise AU - Gorgatti, Filippo AU - Hagl, Christian AU - Hamiko, Marwan AU - Huber, Florian AU - Hyhlik-Duerr, Alexander AU - Ianelli, Gabriele AU - Iesu, Ivana AU - Jung, Joon-Chui AU - Kainz, Frieda-Maria AU - Katsargyris, Athanasios AU - Koter, Stephan AU - Kusmierczyk, Mariusz AU - Kolsut, Piotr AU - Lengyel, Balazs AU - Lomazzi, Chiara AU - Muneretto, Claudio AU - Nava, Giovanni AU - Nolte, Thomas AU - Pacini, Davide AU - Pleban, Eliza AU - Rychla, Miriam AU - Sakamoto, Kazuhisa AU - Shijo, Takayuki AU - Yokawa, Koki AU - Siepe, Matthias AU - Sirch, Joachim AU - Strauch, Justus AU - Sule, Jai Ajitchandra AU - Tobler, Eva-Luca AU - Walter, Corinna AU - Weigang, Ernst T2 - European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery AB - OBJECTIVES: To evaluate the impact of the coronavirus disease 2019 (COVID-19) pandemic on acute and elective thoracic and abdominal aortic procedures. METHODS: Forty departments shared their data on acute and elective thoracic and abdominal aortic procedures between January and May 2020 and January and May 2019 in Europe, Asia and the USA. Admission rates as well as delay from onset of symptoms to referral were compared. RESULTS: No differences in the number of acute thoracic and abdominal aortic procedures were observed between 2020 and the reference period in 2019 [incidence rates ratio (IRR): 0.96, confidence interval (CI) 0.89-1.04; P = 0.39]. Also, no difference in the time interval from acute onset of symptoms to referral was recorded (<12 h 32% vs > 12 h 68% in 2020, < 12 h 34% vs > 12 h 66% in 2019 P = 0.29). Conversely, a decline of 35% in elective procedures was seen (IRR: 0.81, CI 0.76-0.87; P < 0.001) with substantial differences between countries and the most pronounced decline in Italy (-40%, P < 0.001). Interestingly, in Switzerland, an increase in the number of elective cases was observed (+35%, P = 0.02). CONCLUSIONS: There was no change in the number of acute thoracic and abdominal aortic cases and procedures during the initial wave of the COVID-19 pandemic, whereas the case load of elective operations and procedures decreased significantly. Patients with acute aortic syndromes presented despite COVID-19 and were managed according to current guidelines. Further analysis is required to prove that deferral of elective cases had no impact on premature mortality. DA - 2021/05/08/ PY - 2021 DO - 10.1093/ejcts/ezaa452 VL - 59 IS - 5 SP - 1096 EP - 1102 J2 - Eur J Cardiothorac Surg LA - eng SN - 1873-734X 1010-7940 KW - Acute and elective thoracic and abdominal aortic procedures KW - Coronavirus disease 2019 pandemic ER - TY - JOUR TI - Primary prevention of COVID-19: Advocacy for vaccination from a neurological perspective. AU - Sellner, Johann AU - M Jenkins, Thomas AU - J von Oertzen, Tim AU - Bassetti, Claudio L. AU - Beghi, Ettore AU - Bereczki, Daniel AU - Bodini, Benedetta AU - Cavallieri, Francesco AU - Di Liberto, Giovanni AU - Helbok, Raimund AU - Macerollo, Antonella AU - Maia, Luis F. AU - Oreja-Guevara, Celia AU - Özturk, Serefnur AU - Rakusa, Martin AU - Sauerbier, Anna AU - Soffietti, Riccardo AU - Taba, Pille AU - Pisani, Antonio AU - Priori, Alberto AU - Zedde, Marialuisa AU - Crean, Michael AU - Burlica, Anja AU - Twardzik, Alex AU - Moro, Elena T2 - European journal of neurology DA - 2021/10// PY - 2021 DO - 10.1111/ene.14713 VL - 28 IS - 10 SP - 3226 EP - 3229 J2 - Eur J Neurol LA - eng SN - 1468-1331 1351-5101 ER - TY - JOUR TI - Deposition distribution of the new coronavirus (SARS-CoV-2) in the human airways upon exposure to cough-generated droplets and aerosol particles. AU - Madas, Balázs G. AU - Füri, Péter AU - Farkas, Árpád AU - Nagy, Attila AU - Czitrovszky, Aladár AU - Balásházy, Imre AU - Schay, Gusztáv G. AU - Horváth, Alpár T2 - Scientific reports AB - The new coronavirus disease 2019 (COVID-19) has been emerged as a rapidly spreading pandemic. The disease is thought to spread mainly from person-to-person through respiratory droplets produced when an infected person coughs, sneezes, or talks. The pathogen of COVID-19 is the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It infects the cells binding to the angiotensin-converting enzyme 2 receptor (ACE2) which is expressed by cells throughout the airways as targets for cellular entry. Although the majority of persons infected with SARS-CoV-2 experience symptoms of mild upper respiratory tract infection, in some people infections of the acinar airways result in severe, potentially fatal pneumonia. However, the induction of COVID-19 pneumonia requires that SARS-CoV-2 reaches the acinar airways. While huge efforts have been made to understand the spread of the disease as well as the pathogenesis following cellular entry, much less attention is paid to how SARS-CoV-2 from the environment reach the receptors of the target cells. The aim of the present study is to characterize the deposition distribution of SARS-CoV-2 in the airways upon exposure to cough-generated droplets and aerosol particles. For this purpose, the Stochastic Lung Deposition Model has been applied. Particle size distribution, breathing parameters supposing normal breathing through the nose, and viral loads were taken from the literature. We found that the probability of direct infection of the acinar airways due to inhalation of particles emitted by a bystander cough is very low. As the number of viruses deposited in the extrathoracic airways is about 7 times higher than in the acinar airways, we concluded that in most cases COVID-19 pneumonia must be preceded by SARS-CoV-2 infection of the upper airways. Our results suggest that without the enhancement of viral load in the upper airways, COVID-19 would be much less dangerous. The period between the onset of initial symptoms and the potential clinical deterioration could provide an opportunity for prevention of pneumonia by blocking or significantly reducing the transport of viruses towards the acinar airways. Therefore, even non-specific treatment forms like disinfection of the throat and nasal and oral mucosa may effectively keep the viral load of the upper airways low enough to avoid or prolong the progression of the disease. In addition, using a tissue or cloth in order to absorb droplets and aerosol particles emitted by own coughs of infected patients before re-inhalation is highly recommended even if they are alone in quarantine. DA - 2020/00//undefined PY - 2020 DO - 10.1038/s41598-020-79985-6 VL - 10 IS - 1 SP - 22430 J2 - Sci Rep LA - eng SN - 2045-2322 KW - Humans KW - Cough KW - *Respiratory Physiological Phenomena KW - Aerosols KW - Angiotensin-Converting Enzyme 2/metabolism KW - COVID-19/*pathology/*transmission KW - Receptors, Virus/metabolism KW - Respiratory System/virology KW - SARS-CoV-2/genetics/pathogenicity KW - Viral Load ER - TY - JOUR TI - Different mutations in SARS-CoV-2 associate with severe and mild outcome. AU - Nagy, Ádám AU - Pongor, Sándor AU - Győrffy, Balázs T2 - International journal of antimicrobial agents AB - INTRODUCTION: Genomic alterations in a viral genome can lead to either better or worse outcome and identifying these mutations is of utmost importance. Here, we correlated protein-level mutations in the SARS-CoV-2 virus to clinical outcome. METHODS: Mutations in viral sequences from the GISAID virus repository were evaluated by using "hCoV-19/Wuhan/WIV04/2019" as the reference. Patient outcomes were classified as mild disease, hospitalization and severe disease (death or documented treatment in an intensive-care unit). Chi-square test was applied to examine the association between each mutation and patient outcome. False discovery rate was computed to correct for multiple hypothesis testing and results passing FDR cutoff of 5% were accepted as significant. RESULTS: Mutations were mapped to amino acid changes for 3,733 non-silent mutations. Mutations correlated to mild outcome were located in the ORF8, NSP6, ORF3a, NSP4, and in the nucleocapsid phosphoprotein N. Mutations associated with inferior outcome were located in the surface (S) glycoprotein, in the RNA dependent RNA polymerase, in ORF3a, NSP3, ORF6 and N. Mutations leading to severe outcome with low prevalence were found in the ORF3A and in NSP7 proteins. Four out of 22 of the most significant mutations mapped onto a 10 amino acid long phosphorylated stretch of N indicating that in spite of obvious sampling restrictions the approach can find functionally relevant sites in the viral genome. CONCLUSIONS: We demonstrate that mutations in the viral genes may have a direct correlation to clinical outcome. Our results help to quickly identify SARS-CoV-2 infections harboring mutations related to severe outcome. DA - 2021/02//undefined PY - 2021 DO - 10.1016/j.ijantimicag.2020.106272 VL - 57 IS - 2 SP - 106272 J2 - Int J Antimicrob Agents LA - eng SN - 1872-7913 0924-8579 KW - Female KW - Humans KW - Male KW - SARS-CoV-2 KW - *Mutation KW - Coronavirus Nucleocapsid Proteins/genetics KW - COVID-19/*drug therapy/*etiology KW - death KW - genome KW - high-risk KW - Hospitalization KW - mutation KW - Mutation Rate KW - next generation sequencing KW - SARS-CoV-2/*genetics KW - Viral Nonstructural Proteins/genetics KW - Viral Proteins/genetics KW - Viroporin Proteins/genetics ER - TY - JOUR TI - COVID-19 associated with diabetes and other noncommunicable diseases led to a global health crisis. AU - Barone, Mark Thomaz Ugliara AU - Ngongo, Belinda AU - Harnik, Simone Bega AU - Oliveira, Lucas Xavier de AU - Végh, Dániel AU - de Luca, Patrícia Vieira AU - Pedrosa, Hermelinda Cordeiro AU - Giraudo, Franco AU - Cardona-Hernandez, Roque AU - Chaudhury, Nayanjeet AU - Menna-Barreto, Luiz T2 - Diabetes research and clinical practice AB - COVID-19 has gravely threatened high-risk populations, such as people with diabetes and other noncommunicable diseases, leading to disproportionate hospitalizations and deaths worldwide. It is well documented from previous outbreaks that diabetes increases the risk for poor outcomes due to SARS infection. In the present review, we bring evidence that the country and global level health crisis caused by COVID-19 could have been avoided or extremely minimized if measures to protect high-risk populations were implemented timely. In addition to general lockdowns, testing, tracing, isolation and hygiene measures, other specific interventions for diabetes and comorbidities management were shown crucial to allow the continuation of care services during the pandemic. These interventions included: teleconsultation, digital remote education andmonitoring, e-prescriptions, medicine delivery options, mobile clinics, and home point-of-care tests. In conclusion, we recommend prompt actions to protect the most vulnerable groups, valuing knowledge and experiences from previous outbreaks and lessons learned during the COVID-19 pandemic, in order to shield communities, health systems and the global economy. DA - 2021/01//undefined PY - 2021 DO - 10.1016/j.diabres.2020.108587 VL - 171 SP - 108587 J2 - Diabetes Res Clin Pract LA - eng SN - 1872-8227 0168-8227 KW - Humans KW - COVID-19 KW - Comorbidity KW - *Global Health KW - Coronavirus KW - COVID-19/*complications/transmission/virology KW - Diabetes KW - Global health KW - Health systems KW - Noncommunicable diseases KW - Noncommunicable Diseases/*epidemiology KW - SARS-CoV-2/*isolation & purification ER - TY - JOUR TI - [Effects of COVID-19 on psychological well-being, lifestyle and attitudes towards the origins of the pandemic in psychiatric patients and mentally healthy subjects: fi rst Hungarian descriptive results from a large international online study]. AU - Kulig, Barbara AU - Erdelyi-Hamza, Berta AU - Elek, Livia Priyanka AU - Kovacs, Illes AU - Smirnova, Daria AU - Fountoulakis, Konstantinos AU - Gonda, Xenia T2 - Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology AB - The COVID-2019 pandemic has presented a new situation affecting not only the somatic but the mental health of people worldwide and exposing the world including healthcare professionals to a challenge never experienced before. Therefore its effects on mental health, although can be estimated, but cannot be predicted, thus we are only halfways prepared for understanding as well as screening, preventing and treating the pandemic-related mental health problems. For this reason, the Mental Health Sector of the Scientific Researches Institute of the Pan-Hellenic Medical Association prepared a large, international online, general population study with participation from over 42 countries, assessing various aspects of general mental function, needs and behaviors that could occur during the COVID-19 outbreak, as a result of either the outbreak itself or the social measures adopted in order to control it. While the study is ongoing, here we present the first descriptive results from the Hungarian study sample including 738 adult participants collected during the first wave of COVID-19-associated lockdown, focusing on differences in the effect of COVID-19 on psychological and lifestyle measures, as well as attitudes towards the pandemic between mentally healthy participants and people with mental disorders. DA - 2020/12//undefined PY - 2020 VL - 22 IS - 4 SP - 154 EP - 165 J2 - Neuropsychopharmacol Hung LA - hun SN - 1419-8711 KW - Humans KW - SARS-CoV-2 KW - *COVID-19 KW - Hungary KW - *Pandemics KW - *Life Style KW - Attitude KW - Communicable Disease Control KW - Mental Health ER - TY - JOUR TI - Epicardial adipose tissue is associated with extent of pneumonia and adverse outcomes in patients with COVID-19. AU - Grodecki, Kajetan AU - Lin, Andrew AU - Razipour, Aryabod AU - Cadet, Sebastien AU - McElhinney, Priscilla A. AU - Chan, Cato AU - Pressman, Barry D. AU - Julien, Peter AU - Maurovich-Horvat, Pal AU - Gaibazzi, Nicola AU - Thakur, Udit AU - Mancini, Elisabetta AU - Agalbato, Cecilia AU - Menè, Robert AU - Parati, Gianfranco AU - Cernigliaro, Franco AU - Nerlekar, Nitesh AU - Torlasco, Camilla AU - Pontone, Gianluca AU - Slomka, Piotr J. AU - Dey, Damini T2 - Metabolism: clinical and experimental AB - AIM: We sought to examine the association of epicardial adipose tissue (EAT) quantified on chest computed tomography (CT) with the extent of pneumonia and adverse outcomes in patients with coronavirus disease 2019 (COVID-19). METHODS: We performed a post-hoc analysis of a prospective international registry comprising 109 consecutive patients (age 64 ± 16 years; 62% male) with laboratory-confirmed COVID-19 and noncontrast chest CT imaging. Using semi-automated software, we quantified the burden (%) of lung abnormalities associated with COVID-19 pneumonia. EAT volume (mL) and attenuation (Hounsfield units) were measured using deep learning software. The primary outcome was clinical deterioration (intensive care unit admission, invasive mechanical ventilation, or vasopressor therapy) or in-hospital death. RESULTS: In multivariable linear regression analysis adjusted for patient comorbidities, the total burden of COVID-19 pneumonia was associated with EAT volume (β = 10.6, p = 0.005) and EAT attenuation (β = 5.2, p = 0.004). EAT volume correlated with serum levels of lactate dehydrogenase (r = 0.361, p = 0.001) and C-reactive protein (r = 0.450, p < 0.001). Clinical deterioration or death occurred in 23 (21.1%) patients at a median of 3 days (IQR 1-13 days) following the chest CT. In multivariable logistic regression analysis, EAT volume (OR 5.1 [95% CI 1.8-14.1] per doubling p = 0.011) and EAT attenuation (OR 3.4 [95% CI 1.5-7.5] per 5 Hounsfield unit increase, p = 0.003) were independent predictors of clinical deterioration or death, as was total pneumonia burden (OR 2.5, 95% CI 1.4-4.6, p = 0.002), chronic lung disease (OR 1.3 [95% CI 1.1-1.7], p = 0.011), and history of heart failure (OR 3.5 [95% 1.1-8.2], p = 0.037). CONCLUSIONS: EAT measures quantified from chest CT are independently associated with extent of pneumonia and adverse outcomes in patients with COVID-19, lending support to their use in clinical risk stratification. DA - 2021/02//undefined PY - 2021 DO - 10.1016/j.metabol.2020.154436 VL - 115 SP - 154436 J2 - Metabolism LA - eng SN - 1532-8600 0026-0495 KW - Adult KW - Female KW - Humans KW - Male KW - Treatment Outcome KW - Middle Aged KW - Aged KW - Registries KW - Risk Assessment KW - Aged, 80 and over KW - *COVID-19 KW - *SARS-CoV-2 KW - Prognosis KW - *Computed tomography KW - *Epicardial adipose tissue KW - Adipose Tissue/*diagnostic imaging/metabolism KW - Cost of Illness KW - COVID-19/*complications/*diagnostic imaging/mortality KW - Critical Care/statistics & numerical data KW - Patient Admission/statistics & numerical data KW - Pericardium/*diagnostic imaging/metabolism KW - Pneumonia/*diagnostic imaging/*etiology/mortality KW - Prospective Studies KW - Tomography, X-Ray Computed ER - TY - JOUR TI - Comparison of clinical characteristics of patients with pandemic SARS-CoV-2-related and community-acquired pneumonias in Hungary - a pilot historical case-control study. AU - Horváth, Viktor J. AU - Hajdú, Noémi AU - Vági, Orsolya AU - Schnábel, Karolina AU - Szelke, Emese AU - Körei, Anna E. AU - Békeffy, Magdolna AU - Svébis, Márk M. AU - Domján, Beatrix A. AU - Berényi, Tamás AU - Takács, István AU - Ungvári, Zoltán AU - Kun, Attila AU - Tabák, Ádám G. T2 - GeroScience AB - The distinction between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related and community-acquired pneumonias poses significant difficulties, as both frequently involve the elderly. This study aimed to predict the risk of SARS-CoV-2-related pneumonia based on clinical characteristics at hospital presentation. Case-control study of all patients admitted for pneumonia at Semmelweis University Emergency Department. Cases (n = 30) were patients diagnosed with SARS-CoV-2-related pneumonia (based on polymerase chain reaction test) between 26 March 2020 and 30 April 2020; controls (n = 82) were historical pneumonia cases between 1 January 2019 and 30 April 2019. Logistic models were built with SARS-CoV-2 infection as outcome using clinical characteristics at presentation. Patients with SARS-CoV-2-related pneumonia were younger (mean difference, 95% CI: 9.3, 3.2-15.5 years) and had a higher lymphocyte count, lower C-reactive protein, presented more frequently with bilateral infiltrate, less frequently with abdominal pain, diarrhoea, and nausea in age- and sex-adjusted models. A logistic model using age, sex, abdominal pain, C-reactive protein, and the presence of bilateral infiltrate as predictors had an excellent discrimination (AUC 0.88, 95% CI: 0.81-0.96) and calibration (p = 0.27-Hosmer-Lemeshow test). The clinical use of our screening prediction model could improve the discrimination of SARS-CoV-2 related from other community-acquired pneumonias and thus help patient triage based on commonly used diagnostic approaches. However, external validation in independent datasets is required before its clinical use. DA - 2021/02//undefined PY - 2021 DO - 10.1007/s11357-020-00294-x VL - 43 IS - 1 SP - 53 EP - 64 J2 - Geroscience LA - eng SN - 2509-2723 2509-2715 KW - *SARS-CoV-2 KW - *Aging population KW - *Case-control study KW - *Pneumonia KW - *Prediction ER - TY - JOUR TI - [COVID-19 and the ethical issues of justice and rationing in health care, with particular regard to the Italian experience]. AU - Péter, Orsolya Márta T2 - Orvosi hetilap AB - Összefoglaló. A 2020. év elején kirobbant COVID-19-világjárvány többek között ráirányította a figyelmet az életmentő-életfenntartó kezelések igazságos elosztásának érzékeny kérdésére is. Európán belül elsőként Olaszországot sújtotta a katasztrófa, a válsághelyzetben pedig az érzéstelenítés, fájdalomcsillapítás, újraélesztés és intenzív ellátás területén tevékenykedő szakemberek olasz társasága, a SIAARTI 2020. március 6-án közzétett egy 15 pontos ajánlást. E szerint utilitarista megközelítéssel a rendelkezésre álló szűkös erőforrásokat azon betegek kezelésére kellene fordítani, akik túlélési esélye nagyobb, valamint több életévre számíthatnak a jövőben, mert ez biztosíthatja a lehető legtöbb ember számára a lehető legnagyobb hasznot. A javaslat komoly szakmai vitát robbantott ki, amely egyértelművé tette, hogy az orvosi eszközök igazságos elosztására vonatkozó diskurzust feltétlenül folytatni kell, nemcsak Olaszországon belül, hanem a pandémiától sújtott többi államban is. Orv Hetil. 2020; 161(45): 1899-1907. Summary. Among other queries, the explosion of the COVID-19 pandemic at the beginning of 2020 has firmly put in focus the sensitive issue of how to allocate scarcely available life-saving treatments in a fair and just manner. The first European country to face an emergency caused by the pandemic was Italy. In a rapidly escalating crisis, on 6th March 2020, the Italian Society of Anaesthesia, Analgesia, Resuscitation, and Intensive Care (SIAARTI) issued a series of 15 recommendations, suggesting that a utilitarian approach should be adopted in Italian health care and the extremely scarce resources should be reserved for patients with a greater probability of survival and life expectancy, in order to maximize the benefits for the largest possible number of people. The recommendations generated a heated debate among health care professionals, thereby evidencing that similar discussions must be initiated and pursued in all countries affected by the pandemic. Orv Hetil. 2020; 161(45): 1899-1907. DA - 2020/00//undefined PY - 2020 DO - 10.1556/650.2020.32043 VL - 161 IS - 45 SP - 1899 EP - 1907 J2 - Orv Hetil LA - hun SN - 1788-6120 0030-6002 KW - Humans KW - Betacoronavirus KW - COVID-19 KW - SARS-CoV-2 KW - Pandemics KW - *COVID-19 KW - *besorolás KW - *COVID–19 KW - *health care rationing KW - *Italy KW - *medical ethics KW - *Olaszország KW - *orvosi etika KW - *selection criteria KW - *Social Justice KW - *szelekciós kritériumok KW - Coronavirus Infections/epidemiology/*therapy KW - Health Care Rationing/*ethics KW - Italy KW - Pneumonia, Viral/epidemiology/*therapy ER - TY - JOUR TI - EAN consensus statement for management of patients with neurological diseases during the COVID-19 pandemic. AU - von Oertzen, T. J. AU - Macerollo, A. AU - Leone, M. A. AU - Beghi, E. AU - Crean, M. AU - Oztuk, S. AU - Bassetti, C. AU - Twardzik, A. AU - Bereczki, D. AU - Di Liberto, G. AU - Helbok, R. AU - Oreja-Guevara, C. AU - Pisani, A. AU - Sauerbier, A. AU - Sellner, J. AU - Soffietti, R. AU - Zedde, M. AU - Bianchi, E. AU - Bodini, B. AU - Cavallieri, F. AU - Campiglio, L. AU - Maia, L. F. AU - Priori, A. AU - Rakusa, M. AU - Taba, P. AU - Moro, E. AU - Jenkins, T. M. T2 - European journal of neurology AB - BACKGROUND AND PURPOSE: The recent SARS-CoV-2 pandemic has posed multiple challenges to the practice of clinical neurology including recognition of emerging neurological complications and management of coexistent neurological diseases. In a fast-evolving pandemic, evidence-based studies are lacking in many areas. This paper presents European Academy of Neurology (EAN) expert consensus statements to guide neurologists caring for patients with COVID-19. METHODS: A refined Delphi methodology was applied. In round 1, statements were provided by EAN scientific panels (SPs). In round 2, these statements were circulated to SP members not involved in writing them, asking for agreement/disagreement. Items with agreement >70% were retained for round 3, in which SP co-chairs rated importance on a five-point Likert scale. Results were graded by importance and reported as consensus statements. RESULTS: In round one, 70 statements were provided by 23 SPs. In round two, 259/1061 SP member responses were received. Fifty-nine statements obtained >70% agreement and were retained. In round three, responses were received from 55 co-chairs of 29 SPs. Whilst general recommendations related to prevention of COVID-19 transmission had high levels of agreement and importance, opinion was more varied concerning statements related to therapy. CONCLUSION: This is the first structured consensus statement on good clinical practice in patients with neurological disease during the COVID-19 pandemic that provides immediate guidance for neurologists. In this fast-evolving pandemic, a rapid response using refined Delphi methodology is possible, but guidance may be subject to change as further evidence emerges. DA - 2021/01//undefined PY - 2021 DO - 10.1111/ene.14521 VL - 28 IS - 1 SP - 7 EP - 14 J2 - Eur J Neurol LA - eng SN - 1468-1331 1351-5101 KW - Humans KW - *COVID-19 KW - *Pandemics KW - *chronic disease KW - *human KW - *neurology KW - *Patient Care Management KW - *practice guideline KW - Consensus KW - Delphi Technique KW - Guidelines as Topic KW - Nervous System Diseases/*therapy KW - Neurology ER - TY - JOUR TI - [Age-related D-dimer elevation and occasional lethality in SARS-CoV-2 infected patients]. AU - Nagy, Zsuzsanna AU - Vásárhelyi, Barna AU - Vajda, Zoltán T2 - Orvosi hetilap DA - 2020/10/11/ PY - 2020 DO - 10.1556/650.2020.31998 VL - 161 IS - 41 SP - 1739 EP - 1743 J2 - Orv Hetil LA - hun SN - 1788-6120 0030-6002 KW - Adult KW - Humans KW - Age Factors KW - Betacoronavirus KW - COVID-19 KW - SARS-CoV-2 KW - Severe Acute Respiratory Syndrome KW - Middle Aged KW - Retrospective Studies KW - Pandemics KW - *SARS-CoV-2 KW - Hungary/epidemiology KW - *D-dimer KW - *RT-PCR KW - Coronavirus Infections/blood/*mortality KW - Coronavirus/genetics/*isolation & purification KW - Fibrin Fibrinogen Degradation Products/*metabolism KW - Pneumonia, Viral/blood/*mortality KW - Reverse Transcriptase Polymerase Chain Reaction ER - TY - JOUR TI - Emergency dermatology: Three-month experience from an Italian academic outpatient clinic during lockdown for COVID-19 pandemic. AU - Kiss, Norbert AU - Cantoresi, Franca AU - Lampitelli, Salvatore AU - Marino, Raffaella AU - Bánvölgyi, András AU - Wikonkál, Norbert M. AU - Cantisani, Carmen T2 - Dermatologic therapy AB - Dermatology is a field of medicine where urgent cases occur commonly. However, access to specialized emergency dermatology services is very limited. Following the declaration of the COVID-19 pandemic, the cessation of all elective dermatology visits was widely urged. Accordingly, in Italy, a country severely affected by the pandemic, various measures were applied and the care at university clinics was limited to urgent cases. Here we retrospectively analyzed data of patients who presented at an Italian academic outpatient clinic reserved only for emergency cases. In total, 252 patients (109 males and 143 females) with a mean age of 55.25 ± 20.99 years were cared for at our clinic during a three-month period. We classified 10 patients (4%) as real emergency cases. Pityriasis rosea was diagnosed in three patients. Many patients sought care for skin cancer screening. In 131 patients (52%) dermoscopic skin examinations were performed. In 39 patients (15%), actinic keratosis or nonmelanoma skin cancer was detected, while melanoma was diagnosed in three patients, two of which were proven later as in situ melanoma. About 111 patients (44%) visited our clinic for other, nonurgent skin diseases. Our results imply that many patients felt that their skin problems required immediate attention, even if this could not be justified. Melanoma care may be considered an emergency care for its highly malignant potential and the possibility of rapid spreading. Adequately taken photos with a dermoscope may be readily read without the presence of specialist in the emergency room to prevent unnecessary delay in diagnosing oncologic skin diseases. DA - 2020/11//undefined PY - 2020 DO - 10.1111/dth.14390 VL - 33 IS - 6 SP - e14390 J2 - Dermatol Ther LA - eng SN - 1529-8019 1396-0296 KW - Adult KW - Female KW - Humans KW - Male KW - Middle Aged KW - Aged KW - Time Factors KW - Retrospective Studies KW - *COVID-19 KW - Italy KW - *Dermatology KW - *emergency dermatology KW - *Emergency Service, Hospital KW - *Outpatient Clinics, Hospital KW - *pityriasis rosea KW - *skin cancer-melanoma KW - Academic Medical Centers KW - Dermoscopy KW - Health Services Accessibility KW - Remote Consultation KW - Skin Diseases/*diagnosis/*therapy ER - TY - JOUR TI - Involvement of Medical Students During the Coronavirus Disease 2019 Pandemic: A Cross-Sectional Survey Study. AU - Drexler, Richard AU - Hambrecht, Jan M. AU - Oldhafer, Karl J. T2 - Cureus AB - BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic affects the education of medical students around the world and countries have had differing responses in dealing with this dynamic situation. The role of medical students in fighting this pandemic is controversial and it is yet to be elucidated how they can best be of service. The aim of this study is to evaluate the working fields of volunteering students and the impact of the pandemic on final year students from a student's perspective. METHODS: An anonymous online survey was conducted amongst 219 medical students from Hamburg (Germany), using an institutional online data collection program. RESULTS: A total of 137 questionnaires (63.5%) were completed. Of these, 97 participants were students from academic year three to five (70.8%) and 40 students were in the final year of medical school (29.2%). Of the 97 students from academic year three to five, 68 students (70.1%) signed up for voluntary duties during the pandemic. Interestingly, only 25.0% of the students were called for voluntary work in hospitals or health authorities. Final year students had already been working in hospitals since before the outbreak, with 35.0% of them assisting doctors in the treatment of COVID-19 positive patients during their placements. Using a 5-Point Likert Scale, the students who volunteered self-assessed their work as more useful and received more gratitude than final year students (p<0.01). CONCLUSIONS: The majority of medical students are willing to make a significant contribution in the response to COVID-19 and do not wish to be overlooked. Furthermore, the current pandemic offers novel educational opportunities for medical students. DA - 2020/00//undefined PY - 2020 DO - 10.7759/cureus.10147 VL - 12 IS - 8 SP - e10147 J2 - Cureus LA - eng SN - 2168-8184 KW - covid-19 KW - covid KW - education KW - medical education KW - medical school KW - medical student KW - pandemic KW - student KW - volunteer work ER - TY - JOUR TI - [Family medicine during COVID-19 pandemic]. AU - Vajer, Péter AU - Csenteri, Orsolya AU - Szabó, János AU - Tamás, Ferenc AU - Kalabay, László T2 - Orvosi hetilap DA - 2020/10/04/ PY - 2020 DO - 10.1556/650.2020.31954 VL - 161 IS - 40 SP - 1699 EP - 1705 J2 - Orv Hetil LA - hun SN - 1788-6120 0030-6002 KW - Humans KW - COVID-19 KW - *COVID-19 KW - *Pandemics KW - *COVID–19 KW - *family physician KW - *Family Practice KW - *háziorvos KW - *távkonzultáció KW - *teleconsultation KW - Coronavirus Infections/*epidemiology KW - Pneumonia, Viral/*epidemiology ER - TY - JOUR TI - Impact of Coronavirus Disease 2019 (COVID-19) Outbreak on Acute Admissions at the Emergency and Cardiology Departments Across Europe. AU - Sokolski, Mateusz AU - Gajewski, Piotr AU - Zymliński, Robert AU - Biegus, Jan AU - Berg, Jurrien M. Ten AU - Bor, Wilbert AU - Braunschweig, Frieder AU - Caldeira, Daniel AU - Cuculi, Florim AU - D'Elia, Emilia AU - Edes, Istvan Ferenc AU - Garus, Mateusz AU - Greenwood, John P. AU - Halfwerk, Frank R. AU - Hindricks, Gerhard AU - Knuuti, Juhani AU - Kristensen, Steen Dalby AU - Landmesser, Ulf AU - Lund, Lars H. AU - Lyon, Alexander AU - Mebazaa, Alexandre AU - Merkely, Béla AU - Nawrocka-Millward, Sylwia AU - Pinto, Fausto J. AU - Ruschitzka, Frank AU - Semedo, Edimir AU - Senni, Michele AU - Sepehri Shamloo, Alireza AU - Sorensen, Jacob AU - Stengaard, Carsten AU - Thiele, Holger AU - Toggweiler, Stefan AU - Tukiendorf, Andrzej AU - Verhorst, Patrick M. AU - Wright, David Jay AU - Zamorano, Pepe AU - Zuber, Michel AU - Narula, Jagat AU - Bax, Jeroen J. AU - Ponikowski, Piotr T2 - The American journal of medicine AB - PURPOSE: We evaluated whether the severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) pandemic was associated with changes in the pattern of acute cardiovascular admissions across European centers. METHODS: We set-up a multicenter, multinational, pan-European observational registry in 15 centers from 12 countries. All consecutive acute admissions to emergency departments and cardiology departments throughout a 1-month period during the COVID-19 outbreak were compared with an equivalent 1-month period in 2019. The acute admissions to cardiology departments were classified into 5 major categories: acute coronary syndrome, acute heart failure, arrhythmia, pulmonary embolism, and other. RESULTS: Data from 54,331 patients were collected and analyzed. Nine centers provided data on acute admissions to emergency departments comprising 50,384 patients: 20,226 in 2020 compared with 30,158 in 2019 (incidence rate ratio [IRR] with 95% confidence interval [95%CI]: 0.66 [0.58-0.76]). The risk of death at the emergency departments was higher in 2020 compared to 2019 (odds ratio [OR] with 95% CI: 4.1 [3.0-5.8], P < 0.0001). All 15 centers provided data on acute cardiology departments admissions: 3007 patients in 2020 and 4452 in 2019; IRR (95% CI): 0.68 (0.64-0.71). In 2020, there were fewer admissions with IRR (95% CI): acute coronary syndrome: 0.68 (0.63-0.73); acute heart failure: 0.65 (0.58-0.74); arrhythmia: 0.66 (0.60-0.72); and other: 0.68(0.62-0.76). We found a relatively higher percentage of pulmonary embolism admissions in 2020: odds ratio (95% CI): 1.5 (1.1-2.1), P = 0.02. Among patients with acute coronary syndrome, there were fewer admissions with unstable angina: 0.79 (0.66-0.94); non-ST segment elevation myocardial infarction: 0.56 (0.50-0.64); and ST-segment elevation myocardial infarction: 0.78 (0.68-0.89). CONCLUSION: In the European centers during the COVID-19 outbreak, there were fewer acute cardiovascular admissions. Also, fewer patients were admitted to the emergency departments with 4 times higher death risk at the emergency departments. DA - 2021/04//undefined PY - 2021 DO - 10.1016/j.amjmed.2020.08.043 VL - 134 IS - 4 SP - 482 EP - 489 J2 - Am J Med LA - eng SN - 1555-7162 0002-9343 KW - COVID-19 KW - SARS-CoV2 KW - Acute cardiovascular admissions KW - Acute coronary syndrome KW - Outbreak ER - TY - JOUR TI - Magnetic resonance imaging features of coronavirus disease 2019 (COVID-19) pneumonia: The first preliminary case series. AU - Torkian, Pooya AU - Rajebi, Hamid AU - Zamani, Taraneh AU - Ramezani, Naghi AU - Kiani, Pejman AU - Akhlaghpoor, Shahram T2 - Clinical imaging AB - RATIONALE AND OBJECTIVES: There is a rising onus on understanding the common features of COVID-19 pneumonia on different imaging modalities. In this study, we aimed to review and depict the common MRI features of COVID-19 pneumonia in our laboratory confirmed case series, the first comprehensive reported cohort in the literature. MATERIALS AND METHODS: Upon IRB approval, eight laboratory confirmed COVID-19 patients who presented to our outpatient imaging clinic underwent chest CT and, once various features of COVID-19 pneumonia were identified, a dedicated multisequence chest MRI was performed on the same day with an institutional protocol. Demographic data and the morphology, laterality and location of the lesions were recorded for each case. RESULTS: Five males and three females with the mean age of 40.63 ± 12.64 years old were present in this case series. Five cases had typical CT features with ground glass opacities and consolidations, readily visible on different MRI sequences. Three cases had indeterminate or atypical features which were also easily seen on MRI. The comprehensive review of MRI features for each case and representative images have been illustrated. CONCLUSION: Becoming familiar with typical findings of COVID-19 pneumonia in MRI is crucial for every radiologist. Although MRI is not the modality of choice for evaluation of pulmonary opacities, it has similar capabilities in detection of COVID-19 pneumonia when compared to chest CT. DA - 2021/01//undefined PY - 2021 DO - 10.1016/j.clinimag.2020.09.002 VL - 69 SP - 261 EP - 265 J2 - Clin Imaging LA - eng SN - 1873-4499 0899-7071 KW - Adult KW - Female KW - Humans KW - Male KW - SARS-CoV-2 KW - Middle Aged KW - Pandemics KW - *COVID-19 KW - Coronavirus KW - *Betacoronavirus KW - *Coronavirus Infections/epidemiology KW - *Pneumonia, Viral/diagnostic imaging/epidemiology KW - COVID-19 pneumonia KW - Lung/diagnostic imaging KW - Magnetic resonance imaging KW - Magnetic Resonance Imaging ER - TY - JOUR TI - Preoperative Chest Computed Tomography Screening for Coronavirus Disease 2019 in Asymptomatic Patients Undergoing Cardiac Surgery. AU - Knol, Wiebe G. AU - Thuijs, Daniel J. F. M. AU - Odink, Arlette E. AU - Maurovich-Horvat, Pál AU - de Jong, Pim A. AU - Krestin, Gabriel P. AU - Bogers, Ad J. J. C. AU - Budde, Ricardo P. J. T2 - Seminars in thoracic and cardiovascular surgery AB - Due to the outbreak of Severe Acute Respiratory Syndrome coronavirus (SARS-Cov-2), an efficient COVID-19 screening strategy is required for patients undergoing cardiac surgery. The objective of this prospective observational study was to evaluate the role of preoperative computed tomography (CT) screening for COVID-19 in a population of COVID-19 asymptomatic patients scheduled for cardiac surgery. Between the 29th of March and the 26th of May 2020, patients asymptomatic for COVID-19 underwent a CT-scan the day before surgery, with reverse-transcriptase polymerase-chain reaction (RT-PCR) reserved for abnormal scan results. The primary endpoint was the prevalence of abnormal scans, which was evaluated using the CO-RADS score, a COVID-19 specific grading system. In a secondary analysis, the rate of abnormal scans was compared between the screening cohort and matched historical controls who underwent routine preoperative CT-screening prior to the SARS-Cov-2 outbreak. Of the 109 patients that underwent CT-screening, an abnormal scan result was observed in 7.3% (95% confidence interval: 3.2-14.0%). One patient, with a normal screening CT, was tested positive for COVID-19, with the first positive RT-PCR on the ninth day after surgery. A rate of preoperative CT-scan abnormalities of 8% (n = 8) was found in the unexposed historical controls (P > 0.999). In asymptomatic patients undergoing cardiac surgery, preoperative screening for COVID-19 using computed tomography will identify pulmonary abnormalities in a small percentage of patients that do not seem to have COVID-19. Depending on the prevalence of COVID-19, this results in an unfavorable positive predictive value of CT screening. Care should be taken when considering CT as a screening tool prior to cardiac surgery. DA - 2021/// PY - 2021 DO - 10.1053/j.semtcvs.2020.09.027 VL - 33 IS - 2 SP - 417 EP - 424 J2 - Semin Thorac Cardiovasc Surg LA - eng SN - 1532-9488 1043-0679 KW - COVID-19 KW - Cardiac surgery KW - Computed tomography KW - Preoperative screening ER - TY - JOUR TI - COVID Isolation Eating Scale (CIES): Analysis of the impact of confinement in eating disorders and obesity-A collaborative international study. AU - Fernández-Aranda, Fernando AU - Munguía, Lucero AU - Mestre-Bach, Gemma AU - Steward, Trevor AU - Etxandi, Mikel AU - Baenas, Isabel AU - Granero, Roser AU - Sánchez, Isabel AU - Ortega, Emilio AU - Andreu, Alba AU - Moize, Violeta L. AU - Fernández-Real, Jose M. AU - Tinahones, Francisco J. AU - Diegüez, Carlos AU - Frühbeck, Gema AU - Le Grange, Daniel AU - Tchanturia, Kate AU - Karwautz, Andreas AU - Zeiler, Michael AU - Favaro, Angela AU - Claes, Laurence AU - Luyckx, Koen AU - Shekriladze, Ia AU - Serrano-Troncoso, Eduardo AU - Rangil, Teresa AU - Meler, Maria Eulalia Loran AU - Soriano-Pacheco, Jose AU - Carceller-Sindreu, Mar AU - Bujalance-Arguijo, Sara AU - Lozano, Meritxell AU - Linares, Raquel AU - Gudiol, Carlota AU - Carratala, Jordi AU - Sanchez-Gonzalez, Jessica AU - Machado, Paulo Pp AU - Håkansson, Anders AU - Túry, Ferenc AU - Pászthy, Bea AU - Stein, Daniel AU - Papezová, Hana AU - Bax, Brigita AU - Borisenkov, Mikhail F. AU - Popov, Sergey V. AU - Kim, Youl-Ri AU - Nakazato, Michiko AU - Godart, Nathalie AU - van Voren, Robert AU - Ilnytska, Tetiana AU - Chen, Jue AU - Rowlands, Katie AU - Treasure, Janet AU - Jiménez-Murcia, Susana T2 - European eating disorders review : the journal of the Eating Disorders Association AB - Confinement during the COVID-19 pandemic is expected to have a serious and complex impact on the mental health of patients with an eating disorder (ED) and of patients with obesity. The present manuscript has the following aims: (1) to analyse the psychometric properties of the COVID Isolation Eating Scale (CIES), (2) to explore changes that occurred due to confinement in eating symptomatology; and (3) to explore the general acceptation of the use of telemedicine during confinement. The sample comprised 121 participants (87 ED patients and 34 patients with obesity) recruited from six different centres. Confirmatory Factor Analyses (CFA) tested the rational-theoretical structure of the CIES. Adequate goodness-of-fit was obtained for the confirmatory factor analysis, and Cronbach alpha values ranged from good to excellent. Regarding the effects of confinement, positive and negative impacts of the confinement depends of the eating disorder subtype. Patients with anorexia nervosa (AN) and with obesity endorsed a positive response to treatment during confinement, no significant changes were found in bulimia nervosa (BN) patients, whereas Other Specified Feeding or Eating Disorder (OSFED) patients endorsed an increase in eating symptomatology and in psychopathology. Furthermore, AN patients expressed the greatest dissatisfaction and accommodation difficulty with remote therapy when compared with the previously provided face-to-face therapy. The present study provides empirical evidence on the psychometric robustness of the CIES tool and shows that a negative confinement impact was associated with ED subtype, whereas OSFED patients showed the highest impairment in eating symptomatology and in psychopathology. DA - 2020/11//undefined PY - 2020 DO - 10.1002/erv.2784 VL - 28 IS - 6 SP - 871 EP - 883 J2 - Eur Eat Disord Rev LA - eng SN - 1099-0968 1072-4133 KW - Adult KW - Female KW - Humans KW - Male KW - Adolescent KW - Middle Aged KW - Young Adult KW - Aged KW - *COVID-19 KW - COVID-19/*prevention & control KW - *COVID Isolation Eating Scale KW - *eating disorders KW - *obesity KW - Factor Analysis, Statistical KW - Feeding and Eating Disorders/*epidemiology KW - Obesity/*epidemiology KW - Psychiatric Status Rating Scales KW - Psychometrics KW - Social Isolation/*psychology KW - Spain/epidemiology ER - TY - JOUR TI - [Detection of the first appearance of SARS-CoV-2 virus in Hungary based on retrospective testing of respiratory samples]. AU - Szalai, Bálint AU - Hercegh, Éva AU - Magyar, Nóra AU - Déri, Dániel AU - Rózsa, Mónika AU - Molnár, Zsuzsanna AU - Kuti, Dávid AU - Kis, Zoltán AU - Szomor, Katalin AU - Takács, Mária AU - Barcsay, Erzsébet T2 - Orvosi hetilap AB - INTRODUCTION: In Hungary, SARS-CoV-2 was first detected in the swab samples of two Iranian patients on March 4, 2020. After finding the first positive cases, the question arose whether the virus had entered Hungary and caused infections before this date. Before March 4, 2020, except for the two above-mentioned samples, none of the 224 swab samples received specifically for SARS-CoV-2 tested positive. AIM: The National Reference Laboratory for Respiratory Viruses of the National Public Health Center aimed to carry out a retrospective study of the swab and other samples taken for testing respiratory virus infections between January 1, and April 19, 2020 sent by sentinel physicians within the influenza surveillance for diagnostic purposes. METHOD: For the study, we used swab samples taken weekly by sentinel physicians of the influenza surveillance service, and other samples received for diagnostic purposes. Tests were performed using real-time PCR. RESULTS: All the 465 swab samples sent by sentinel physicians were found to be SARS-CoV-2 negative. Also, of the 551 samples collected for diagnostic reasons of other respiratory viruses, no SARS-CoV-2 positive was found among those taken before March 4. CONCLUSION: Based on our data, it is very likely that prior to the first cases diagnosed on March 4, 2020, SARS-CoV-2 did not cause clinically symptomatic infections in Hungary. Orv Hetil. 2020; 161(38): 1619-1622. DA - 2020/09//undefined PY - 2020 DO - 10.1556/650.2020.32000 VL - 161 IS - 38 SP - 1619 EP - 1622 J2 - Orv Hetil LA - hun SN - 1788-6120 0030-6002 KW - Humans KW - COVID-19 KW - SARS-CoV-2 KW - Retrospective Studies KW - Clinical Laboratory Techniques KW - COVID-19 Testing KW - *COVID-19 KW - *SARS-CoV-2 KW - Hungary/epidemiology KW - *Pandemics KW - *COVID–19 KW - *légúti vírus surveillance KW - *respiratory virus surveillance KW - *retrospective study KW - *retrospektív vizsgálat KW - Betacoronavirus/genetics/*isolation & purification KW - Coronavirus Infections/*diagnosis/epidemiology/virology KW - Iran KW - Pneumonia, Viral/*diagnosis/epidemiology/virology KW - Population Surveillance/*methods KW - Real-Time Polymerase Chain Reaction ER - TY - JOUR TI - International Efforts to Save Healthcare Personnel during COVID-19. AU - Mohamed, Kawthar AU - Rezaei, Nima AU - Rodríguez-Román, Eduardo AU - Rahmani, Farzaneh AU - Zhang, Hongbo AU - Ivanovska, Mariya AU - A Makka, Sara AU - Joya, Musa AU - Makuku, Rangarirai AU - Islam, Md Shahidul AU - Radwan, Nesrine AU - Rahmah, Laila AU - Goda, Rayan AU - Abarikwu, Sunny O. AU - Shaw, Mujtaba AU - Zoghi, Samaneh AU - Irtsyan, Sevan AU - Ling, Irene AU - Cseprekal, Orsolya AU - Attig-Bahar, Faten AU - Hazar Sayar, Esra AU - Soloukey, Chagajeg AU - Grancini, Giulia T2 - Acta bio-medica : Atenei Parmensis AB - Coronavirus disease 2019 (COVID-19) pandemic is a global challenge. Several governments of the world have decided to take drastic actions in order to combat the spread of the disease, including the closing of air, maritime and land borders, as an extreme measure of isolation of each country/region. However, such measures had not prevented the disease from spreading globally; as COVID-19 has already spread in almost all countries. This virus's main victims are the healthcare personnel (HCP), who are physically and psychologically affected. The HCP serves as the first line of defense against this pandemic, what if we faced a significant loss in their number? And what if our HCP was going through a deep dark depression? The condition would be terrifying not only for now but also in the future. This raises the need for an intensified International collaboration, that mainly supports the HCP. We are throwing by challenging moments, and it is clear that social distancing, cooperation, hygiene awareness and abide by the recommendation and help of all governments, as well as obtaining the support of international organizations could be an excellent tool for preventing an increase in the number of cases, principally in countries and regions were COVID-19 is in the early stage of the epidemic. However, this is not the final solution for the current pandemic. An intensified global program, which mainly supports the HCP, then considers the other aspects of the COVID19 pandemic might bring this pandemic to a peaceful end. DA - 2020/09/07/ PY - 2020 DO - 10.23750/abm.v91i3.9891 VL - 91 IS - 3 SP - e2020044 J2 - Acta Biomed LA - eng SN - 2531-6745 0392-4203 KW - Humans KW - COVID-19 KW - SARS-CoV-2 KW - Coronavirus Infections/*epidemiology KW - Pneumonia, Viral/*epidemiology KW - *Betacoronavirus KW - Disease Transmission, Infectious/*prevention & control KW - Health Personnel/*organization & administration KW - Pandemics/*prevention & control ER - TY - JOUR TI - Saliva as a Candidate for COVID-19 Diagnostic Testing: A Meta-Analysis. AU - Czumbel, László Márk AU - Kiss, Szabolcs AU - Farkas, Nelli AU - Mandel, Iván AU - Hegyi, Anita AU - Nagy, Ákos AU - Lohinai, Zsolt AU - Szakács, Zsolt AU - Hegyi, Péter AU - Steward, Martin C. AU - Varga, Gábor T2 - Frontiers in medicine AB - Background: COVID-19 is a serious and potentially deadly disease. Early diagnosis of infected individuals will play an important role in stopping its further escalation. The present gold standard for sampling is the nasopharyngeal swab method. However, several recent papers suggested that saliva-based testing is a promising alternative that could simplify and accelerate COVID-19 diagnosis. Objectives: Our aim was to conduct a meta-analysis on the reliability and consistency of SARS-CoV-2 viral RNA detection in saliva specimens. Methods: We have reported our meta-analysis according to the Cochrane Handbook. We searched the Cochrane Library, Embase, Pubmed, Scopus, Web of Science and clinical trial registries for eligible studies published between 1 January and 25 April 2020. The number of positive tests and the total number of tests conducted were collected as raw data. The proportion of positive tests in the pooled data were calculated by score confidence-interval estimation with the Freeman-Tukey transformation. Heterogeneity was assessed using the I (2) measure and the χ(2)-test. Results: The systematic search revealed 96 records after removal of duplicates. Twenty-six records were included for qualitative analysis and 5 records for quantitative synthesis. We found 91% (CI 80-99%) sensitivity for saliva tests and 98% (CI 89-100%) sensitivity for nasopharyngeal swab (NPS) tests in previously confirmed COVID-19 patients, with moderate heterogeneity among the studies. Additionally, we identified 18 registered, ongoing clinical trials of saliva-based tests for detection of the virus. Conclusion: Saliva tests offer a promising alternative to NPS for COVID-19 diagnosis. However, further diagnostic accuracy studies are needed to improve their specificity and sensitivity. DA - 2020/// PY - 2020 DO - 10.3389/fmed.2020.00465 VL - 7 SP - 465 J2 - Front Med (Lausanne) LA - eng SN - 2296-858X KW - COVID-19 KW - SARS-CoV-2 KW - saliva KW - coronavirus KW - diagnostic tests KW - meta-analysis KW - systematic review ER - TY - JOUR TI - Correction to: COVID-19 research: promising tracks leading to uro-oncology. AU - Fazekas, Tamás AU - Szarvas, Tibor AU - Csizmarik, Anita AU - Hadaschik, Boris AU - Nyirády, Péter T2 - International urology and nephrology DA - 2021/01//undefined PY - 2021 DO - 10.1007/s11255-020-02613-9 VL - 53 IS - 1 SP - 95 J2 - Int Urol Nephrol LA - eng SN - 1573-2584 0301-1623 ER - TY - JOUR TI - [Effects of COVID-19 pandemic on acute ischemic stroke care. A single-centre retrospective analysis of medical collateral damage]. AU - Böjti, Péter Pál AU - Stang, Rita AU - Gunda, Bence AU - Sipos, Ildikó AU - Bereczki, Dániel T2 - Orvosi hetilap AB - INTRODUCTION: Early international observations report decreased number of acute ischemic stroke admissions and prolonged onset-to-treatment times during COVID-19 pandemic. AIM: Our goal was to assess the effect of COVID-19 pandemic on Hungarian acute ischemic stroke care. METHOD: We compared demographical and clinical characteristics, rate of intravenous and endovascular therapies and therapeutic time parameters of acute ischemic strokes admitted to a university stroke centre in a COVID-epidemic period (01/03/2020-30/04/2020) and an identical period of 2019. RESULTS: 86 patients were admitted during the COVID-period and 97 in the control period. Demographical and clinical characteristics of these periods were well-balanced. In the COVID-period, the proportion of patients arriving beyond 24 hours after onset increased by 13% (p = 0.046), the rate of endovascular interventions remained unchanged (8%), the rate of intravenous thrombolysis decreased from 26% to 16%, the mean onset-to-treatment time of thrombolysis increased by 20 minutes, while the mean door-to-treatment time increased by only 5 minutes. Behind the shift of arrival time categories, multivariable (year of examination, NIHSS, age) logistic regression shows that the year of examination might play a leading role (p = 0.096). CONCLUSION: In the COVID-period, admissions for acute ischemic strokes decreased by 11% and the proportion of cases certainly untreatable by reperfusion therapies (arriving beyond 24 hours after onset) increased significantly. While the rate of endovascular interventions remained unchanged, the absolute rate of intravenous thrombolysis decreased by 10% and the mean onset-to-treatment time showed a tendency to increase. In these changes, the COVID-epidemic itself and related out-of-hospital factors might play a leading role. Orv Hetil. 2020; 161(34): 1395-1399. DA - 2020/08//undefined PY - 2020 DO - 10.1556/650.2020.31936 VL - 161 IS - 34 SP - 1395 EP - 1399 J2 - Orv Hetil LA - hun SN - 1788-6120 0030-6002 KW - Humans KW - COVID-19 KW - Retrospective Studies KW - *coronavirus KW - *koronavírus KW - Hungary/epidemiology KW - *COVID-19 pandemic KW - *COVID–19-pandémia KW - *Pandemics KW - Patient Admission/statistics & numerical data KW - Coronavirus Infections/*epidemiology KW - Pneumonia, Viral/*epidemiology KW - *acute stroke KW - *akut stroke KW - *egészségügyi rendszer KW - *health care systems KW - *thrombolytic therapy KW - *thrombolyticus terápia KW - Brain Ischemia/*therapy KW - Stroke/*therapy KW - Time-to-Treatment/statistics & numerical data ER - TY - JOUR TI - Coronavirus disease 2019 in a psoriatic patient with concomitant chronic obstructive pulmonary disease under treatment with risankizumab. AU - Kiss, Norbert AU - Lőrincz, Kende AU - Medvecz, Márta AU - Fésűs, Luca AU - Csuha, Péter AU - Hermányi, Zsolt AU - Wikonkál, Norbert Miklós T2 - Dermatologic therapy DA - 2020/11//undefined PY - 2020 DO - 10.1111/dth.14186 VL - 33 IS - 6 SP - e14186 J2 - Dermatol Ther LA - eng SN - 1529-8019 1396-0296 KW - Humans KW - Male KW - Treatment Outcome KW - Aged KW - Host-Pathogen Interactions KW - *Pulmonary Disease, Chronic Obstructive/diagnosis/immunology KW - Antibodies, Monoclonal/adverse effects/*therapeutic use KW - Antiviral Agents/therapeutic use KW - Biological Products/adverse effects/*therapeutic use KW - COVID-19/diagnosis/drug therapy/immunology/*virology KW - Dermatologic Agents/adverse effects/*therapeutic use KW - Psoriasis/diagnosis/*drug therapy/immunology KW - SARS-CoV-2/drug effects/immunology/*pathogenicity ER - TY - JOUR TI - Gender differences in the battle against COVID-19: Impact of genetics, comorbidities, inflammation and lifestyle on differences in outcomes. AU - Anca, Pantea Stoian AU - Toth, Peter P. AU - Kempler, Peter AU - Rizzo, Manfredi T2 - International journal of clinical practice AB - It has been over six months now since the entire globe was struck by the new Coronavirus Disease 2019 (COVID‐19; aka severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]), which has affected 215 nations. The medical and scientific communities continue to search for and study potential treatments for COVID‐19 as well as an effective vaccine. As of 21 June 2020, 11.4 million cases have been confirmed worldwide, with approximately 530,000 deaths. A large number of scientific papers have been produced, hundreds of thousands of patients have been hospitalized and studied, several treatments and vaccines are being tested in randomized clinical trials, social distancing regulations have been implemented, with most of the planet in partial or full lockdown, and we have yet to control this pandemic. DA - 2021/02//undefined PY - 2021 DO - 10.1111/ijcp.13666 VL - 75 IS - 2 SP - e13666 J2 - Int J Clin Pract LA - eng SN - 1742-1241 1368-5031 ER - TY - JOUR TI - Companion animals likely do not spread COVID-19 but may get infected themselves. AU - Csiszar, Anna AU - Jakab, Ferenc AU - Valencak, Teresa G. AU - Lanszki, Zsófia AU - Tóth, Gábor Endre AU - Kemenesi, Gábor AU - Tarantini, Stefano AU - Fazekas-Pongor, Vince AU - Ungvari, Zoltan T2 - GeroScience AB - Coronavirus disease 2019 (COVID-19) is a highly contagious infectious disease caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). From the epidemiological data, the picture emerges that the more severe etiopathologies among COVID-19 patients are found in elderly people. The risk of death due to COVID-19 increases exponentially with age. Eight out of 10 COVID-19 related deaths occur in people older than 65 years of age. Older patients with comorbid conditions such as hypertension, heart failure, diabetes mellitus, asthma, chronic obstructive pulmonary disease, and cancer have a much higher case fatality rate. Governments and public health authorities all over the world have realized that protections of vulnerable older adults should be a priority during the COVID-19 pandemic. COVID-19 is a zoonotic disease. The SARS-CoV-2 virus was originally transmitted likely from a bat or a pangolin to humans. Recent evidence suggests that SARS-CoV-2, similar to other coronaviruses, can infect several species of animals, including companion animals such as dogs, cats, and ferrets although their viral loads remain low. While the main source of infection transmission therefore is human to human, there are a few rare cases of pets contracting the infection from a SARS-CoV-2-infected human. Although there is no evidence that pets actively transmit SARS-CoV-2 via animal-to-human transmission, senior pet ownership potentially may pose a small risk to older adults by (1) potentially enabling animal-to-human transmission of SARS-CoV-2 in the most vulnerable population and (2) by increasing the exposition risk for the elderly due to the necessity to care for the pet and, in the case of dogs, to take them outside the house several times per day. In this overview, the available evidence on SARS-CoV-2 infection in pets is considered and the potential for spread of COVID-19 from companion animals to older individuals and the importance of prevention are discussed. DA - 2020/10//undefined PY - 2020 DO - 10.1007/s11357-020-00248-3 VL - 42 IS - 5 SP - 1229 EP - 1236 J2 - Geroscience LA - eng SN - 2509-2723 2509-2715 KW - Humans KW - COVID-19 KW - SARS-CoV-2 KW - Animals KW - *SARS-CoV-2 KW - *Pandemics KW - *Betacoronavirus KW - *Aging KW - *Senescence KW - Coronavirus Infections/epidemiology/*transmission KW - Disease Transmission, Infectious/*statistics & numerical data KW - Pneumonia, Viral/epidemiology/*transmission KW - Zoonoses/epidemiology/*transmission ER - TY - JOUR TI - [Guidance on the special care of liver or kidney transplant recipients diagnosed with COVID-19]. AU - Remport, Ádám AU - Gerlei, Zsuzsanna AU - Cseprekál, Orsolya AU - Wagner, László AU - Földes, Katalin AU - Marton, Adrienn AU - Patonai, Attila AU - Török, Szilárd AU - Haboub-Sandil, Anita AU - Varga, Marina AU - Doros, Attila AU - Smudla, Anikó AU - Fazakas, János AU - Kóbori, László T2 - Orvosi hetilap AB - Due to the COVID-19 pandemic caused by infection with the novel, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), transplant medicine also had to face a new, hitherto unknown challenge. To be prepared for any possibility, we consider it important to summarize the current knowledge regarding COVID-19 of liver and kidney transplant patients. Very early reports from Spanish and French registry recorded fatality rates of 18.6% and 13%, respectively, in renal patients which suggests a moderately worse outcome compared to the general population. In patients with positive PCR test but not showing clinical signs, the reduction of immunosuppression is not advised. In the case of gastrointestinal or respiratory signs with fever, the discontinuation of mycophenolate or mTOR inhibitors is recommended with decrease of the trough levels of calcineurin inhibitors to the lowest effective limit. Stop (kidney transplanted patients) or decrease (liver transplanted patients) immunosuppression and maintain corticosteroids when pulmonal injury develops and consider anti-IL1 and anti-IL6 monoclonal antibody use when hyperinflammatory syndrome is evolving. No proven effective treatment for SARS-CoV-2 exists currently. The use of lopinavir/ritonavir should be avoided because of the severe drug interaction with calcineurin inhibitors. The efficacy and tolerability of hidroxychloroquin remains to be also questionable; enroll patients into clinical trial with remdesivir or favipiravir if available. COVID-19 is characterized by virus-induced endothelial dysfunction, procoagulant state and renin-angiotensin-aldosteron system imbalance. Early thromboprofilaxis combination with low-molecular-weight heparin and low-dose aspirin is strongly recommended with the maintenance of angiotensin-converting enzyme inhibitor (ACEI) or angiotensin-II-receptor blocker (ARB) therapy when they were prescribed earlier. Orv Hetil. 2020; 161(32): 1310-1321. DA - 2020/08//undefined PY - 2020 DO - 10.1556/650.2020.31923 VL - 161 IS - 32 SP - 1310 EP - 1321 J2 - Orv Hetil LA - hun SN - 1788-6120 0030-6002 KW - Humans KW - Betacoronavirus KW - COVID-19 KW - SARS-CoV-2 KW - Pandemics KW - *COVID-19 KW - *COVID–19 KW - *immunosuppression KW - *immunszuppresszió KW - *Kidney Transplantation KW - *liver transplantation KW - *Liver Transplantation KW - *májátültetés KW - *renal transplantation KW - *Transplant Recipients KW - *veseátültetés KW - Adrenal Cortex Hormones/therapeutic use KW - Calcineurin Inhibitors/adverse effects KW - Contraindications, Drug KW - Coronavirus Infections/*complications KW - Drug Combinations KW - Drug Interactions KW - Immunosuppression KW - Lopinavir/adverse effects KW - Pneumonia, Viral/*complications KW - Ritonavir/adverse effects ER - TY - JOUR TI - Care of the Patient With IBD Requiring Hospitalisation During the COVID-19 Pandemic. AU - Allez, Matthieu AU - Fleshner, Phillip AU - Gearry, Richard AU - Lakatos, Peter L. AU - Rubin, David T. T2 - Journal of Crohn's & colitis AB - The management of IBD has been highly affected in the context of the COVID-19 pandemic, with restriction of hospitalisations and unprecedented redeployment of health care resources. Hospital admissions of IBD patients should be limited to reduce the risks of coronavirus transmission. However, delaying hospitalisation of IBD patients with severe or complicated disease may increase the risk of poor outcomes. Delaying surgery in some cases may increase the risk of disease progression, postoperative morbidity, and disease complications. IBD patients who are infected with SARS-CoV-2 may have a higher risk of poor outcomes than the general population, potentially related to concomitant medications, especially corticosteroids. There is no evidence today that IBD patients with COVID-19 have worse outcomes if they receive immunosuppressant medications including thiopurines, biologics, and novel small molecules. This article summarises recommendations by the international membership of IOIBD regarding hospitalisations of IBD patients, either for active or complicated IBD or for severe COVID-19, and for management of IBD patients according to SARS-CoV-2 infectious status. DA - 2020/10/21/ PY - 2020 DO - 10.1093/ecco-jcc/jjaa150 VL - 14 IS - Supplement_3 SP - S774 EP - S779 J2 - J Crohns Colitis LA - eng SN - 1876-4479 1873-9946 KW - Humans KW - COVID-19 KW - SARS-CoV-2 KW - inflammatory bowel disease KW - Pandemics KW - Clinical Laboratory Techniques KW - COVID-19 Testing KW - *Betacoronavirus/isolation & purification KW - *Hospitalization KW - Coronavirus Infections/complications/diagnosis/*therapy KW - hospitalisation KW - Inflammatory Bowel Diseases/complications/*therapy KW - IOIBD KW - Pneumonia, Viral/complications/diagnosis/*therapy ER - TY - JOUR TI - Novel coronavirus epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit policy in Hungary. AU - Merkely, Béla AU - Szabó, Attila J. AU - Kosztin, Annamária AU - Berényi, Ervin AU - Sebestyén, Andor AU - Lengyel, Csaba AU - Merkely, Gergő AU - Karády, Júlia AU - Várkonyi, István AU - Papp, Csaba AU - Miseta, Attila AU - Betlehem, József AU - Burián, Katalin AU - Csóka, Ildikó AU - Vásárhelyi, Barna AU - Ludwig, Endre AU - Prinz, Gyula AU - Sinkó, János AU - Hankó, Balázs AU - Varga, Péter AU - Fülöp, Gábor Áron AU - Mag, Kornélia AU - Vokó, Zoltán T2 - GeroScience AB - After months of restrictive containment efforts to fight the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) epidemic, European countries are planning to reopen. To support the process, we conducted a cross-sectional survey among the Hungarian population to estimate the prevalence of infectious cases and prior SARS-CoV-2 exposure. A representative sample (n = 17,787) for the Hungarian population of 14 years or older living in private households (n = 8,283,810) was selected. The study was performed within 16 days after 50 days of restrictions, when the number of confirmed cases was stable low. Naso- and oropharyngeal smears and blood samples were collected for PCR and antibody testing. The testing was accompanied by a questionnaire about symptoms, comorbidities, and contacts. Design-based prevalence estimates were calculated. In total, 10,474 individuals (67.7% taken into account a sample frame error of 2315) of the selected sample participated in the survey. Of the tested individuals, 3 had positive PCR and 69 had positive serological test. Population estimate of the number of SARS-CoV-2 infection and seropositivity were 2421 and 56,439, respectively, thus active infection rate (2.9/10,000) and the prevalence of prior SARS-CoV-2 exposure (68/10,000) was low. Self-reported loss of smell or taste and body aches were significantly more frequent among those with SARS-CoV-2. In this representative, cross-sectional survey of the Hungarian population with a high participation rate, the overall active infection rate was low in sync with the prevalence of prior SARS-CoV-2 exposure. We demonstrated a potential success of containment efforts, supporting an exit strategy. NCT04370067, 30.04.2020. DA - 2020/08//undefined PY - 2020 DO - 10.1007/s11357-020-00226-9 VL - 42 IS - 4 SP - 1063 EP - 1074 J2 - Geroscience LA - eng SN - 2509-2723 2509-2715 KW - Adult KW - Female KW - Humans KW - Male KW - Adolescent KW - COVID-19 KW - SARS-CoV-2 KW - Middle Aged KW - Young Adult KW - Aged KW - Cross-Sectional Studies KW - Surveys and Questionnaires KW - Prevalence KW - *COVID-19 KW - *SARS-CoV-2 KW - Hungary KW - *Betacoronavirus KW - Pandemics/*prevention & control KW - *Communicable Disease Control KW - *Cross-sectional KW - *Health Policy KW - *Hungary KW - *Nationwide KW - *Social Isolation KW - Coronavirus Infections/diagnosis/*epidemiology/*prevention & control KW - Pneumonia, Viral/diagnosis/*epidemiology/*prevention & control ER - TY - JOUR TI - Synthesis of Antiviral Perfluoroalkyl Derivatives of Teicoplanin and Vancomycin. AU - Bereczki, Ilona AU - Csávás, Magdolna AU - Szűcs, Zsolt AU - Rőth, Erzsébet AU - Batta, Gyula AU - Ostorházi, Eszter AU - Naesens, Lieve AU - Borbás, Anikó AU - Herczegh, Pál T2 - ChemMedChem AB - The limited scope of antiviral drugs and increasing problem of antiviral drug resistance represent a global health threat. Glycopeptide antibiotics and their lipophilic derivatives have emerged as relevant inhibitors of diverse viruses. Herein, we describe a new strategy for the synthesis of dual hydrophobic and lipophobic derivatives of glycopeptides to produce selective antiviral agents without membrane-disrupting activity. Perfluorobutyl and perfluorooctyl moieties were attached through linkers of different length to azido derivatives of vancomycin aglycone and teicoplanin pseudoaglycone, and the new derivatives were evaluated against a diverse panel of viruses. The teicoplanin derivatives displayed strong anti-influenza virus activity at nontoxic concentrations. Some of the perfluoroalkylated glycopeptides were also active against a few other viruses such as herpes simplex virus or coronavirus. These data encourage further exploration of glycopeptide analogues for broad antiviral application. DA - 2020/09/03/ PY - 2020 DO - 10.1002/cmdc.202000260 VL - 15 IS - 17 SP - 1661 EP - 1671 J2 - ChemMedChem LA - eng SN - 1860-7187 1860-7179 KW - Humans KW - Animals KW - *coronavirus KW - *antiviral KW - *glycopeptide antibiotic KW - *influenza virus KW - *perfluoroalkyl KW - Anti-Bacterial Agents/chemical synthesis/chemistry/pharmacology KW - Antiviral Agents/*chemical synthesis/chemistry/pharmacology KW - Bacillus subtilis/drug effects KW - Catalysis KW - Cell Line KW - Cell Survival/drug effects KW - Coronavirus/drug effects KW - Dogs KW - Fluorocarbons/*chemistry KW - Microbial Sensitivity Tests KW - Palladium/chemistry KW - Staphylococcus aureus/drug effects KW - Structure-Activity Relationship KW - Teicoplanin/*chemistry KW - Vancomycin/*chemistry KW - Zika Virus/drug effects ER - TY - JOUR TI - COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. AU - Scarfò, Lydia AU - Chatzikonstantinou, Thomas AU - Rigolin, Gian Matteo AU - Quaresmini, Giulia AU - Motta, Marina AU - Vitale, Candida AU - Garcia-Marco, Jose Antonio AU - Hernández-Rivas, José Ángel AU - Mirás, Fatima AU - Baile, Mónica AU - Marquet, Juan AU - Niemann, Carsten U. AU - Reda, Gianluigi AU - Munir, Talha AU - Gimeno, Eva AU - Marchetti, Monia AU - Quaglia, Francesca Maria AU - Varettoni, Marzia AU - Delgado, Julio AU - Iyengar, Sunil AU - Janssens, Ann AU - Marasca, Roberto AU - Ferrari, Angela AU - Cuéllar-García, Carolina AU - Itchaki, Gilad AU - Špaček, Martin AU - De Paoli, Lorenzo AU - Laurenti, Luca AU - Levin, Mark-David AU - Lista, Enrico AU - Mauro, Francesca R. AU - Šimkovič, Martin AU - Van Der Spek, Ellen AU - Vandenberghe, Elisabeth AU - Trentin, Livio AU - Wasik-Szczepanek, Ewa AU - Ruchlemer, Rosa AU - Bron, Dominique AU - De Paolis, Maria Rosaria AU - Del Poeta, Giovanni AU - Farina, Lucia AU - Foglietta, Myriam AU - Gentile, Massimo AU - Herishanu, Yair AU - Herold, Tobias AU - Jaksic, Ozren AU - Kater, Arnon P. AU - Kersting, Sabina AU - Malerba, Lara AU - Orsucci, Lorella AU - Popov, Viola Maria AU - Sportoletti, Paolo AU - Yassin, Mohamed AU - Pocali, Barbara AU - Barna, Gabor AU - Chiarenza, Annalisa AU - Dos Santos, Gimena AU - Nikitin, Eugene AU - Andres, Martin AU - Dimou, Maria AU - Doubek, Michael AU - Enrico, Alicia AU - Hakobyan, Yervand AU - Kalashnikova, Olga AU - Ortiz Pareja, Macarena AU - Papaioannou, Maria AU - Rossi, Davide AU - Shah, Nimish AU - Shrestha, Amit AU - Stanca, Oana AU - Stavroyianni, Niki AU - Strugov, Vladimir AU - Tam, Constantine AU - Zdrenghea, Mihnea AU - Coscia, Marta AU - Stamatopoulos, Kostas AU - Rossi, Giuseppe AU - Rambaldi, Alessandro AU - Montserrat, Emili' AU - Foà, Robin AU - Cuneo, Antonio AU - Ghia, Paolo T2 - Leukemia AB - Chronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by immunodeficiency. Hence, patients with CLL might be considered more susceptible to severe complications from COVID-19. We undertook this retrospective international multicenter study to characterize the course of COVID-19 in patients with CLL and identify potential predictors of outcome. Of 190 patients with CLL and confirmed COVID-19 diagnosed between 28/03/2020 and 22/05/2020, 151 (79%) presented with severe COVID-19 (need of oxygen and/or intensive care admission). Severe COVID-19 was associated with more advanced age (≥65 years) (odds ratio 3.72 [95% CI 1.79-7.71]). Only 60 patients (39.7%) with severe COVID-19 were receiving or had recent (≤12 months) treatment for CLL at the time of COVID-19 versus 30/39 (76.9%) patients with mild disease. Hospitalization rate for severe COVID-19 was lower (p < 0.05) for patients on ibrutinib versus those on other regimens or off treatment. Of 151 patients with severe disease, 55 (36.4%) succumbed versus only 1/38 (2.6%) with mild disease; age and comorbidities did not impact on mortality. In CLL, (1) COVID-19 severity increases with age; (2) antileukemic treatment (particularly BTK inhibitors) appears to exert a protective effect; (3) age and comorbidities did not impact on mortality, alluding to a relevant role of CLL and immunodeficiency. DA - 2020/09//undefined PY - 2020 DO - 10.1038/s41375-020-0959-x VL - 34 IS - 9 SP - 2354 EP - 2363 J2 - Leukemia LA - eng SN - 1476-5551 0887-6924 KW - Female KW - Humans KW - Male KW - Age Factors KW - COVID-19 KW - SARS-CoV-2 KW - Middle Aged KW - Aged KW - Surveys and Questionnaires KW - Severity of Illness Index KW - Retrospective Studies KW - Pandemics KW - Comorbidity KW - Aged, 80 and over KW - Prognosis KW - *Betacoronavirus KW - Antineoplastic Agents/pharmacology/therapeutic use KW - Coronavirus Infections/diagnosis/mortality/*pathology KW - Leukemia, Lymphocytic, Chronic, B-Cell/*complications/drug therapy KW - Pneumonia, Viral/diagnosis/mortality/*pathology KW - Protein Kinase Inhibitors/pharmacology/therapeutic use KW - Pyrazoles/pharmacology/therapeutic use KW - Pyrimidines/pharmacology/therapeutic use ER - TY - JOUR TI - Reprogramming of the Antibacterial Drug Vancomycin Results in Potent Antiviral Agents Devoid of Antibacterial Activity. AU - Szűcs, Zsolt AU - Naesens, Lieve AU - Stevaert, Annelies AU - Ostorházi, Eszter AU - Batta, Gyula AU - Herczegh, Pál AU - Borbás, Anikó T2 - Pharmaceuticals (Basel, Switzerland) AB - Influenza A and B viruses are a global threat to human health and increasing resistance to the existing antiviral drugs necessitates new concepts to expand the therapeutic options. Glycopeptide derivatives have emerged as a promising new class of antiviral agents. To avoid potential antibiotic resistance, these antiviral glycopeptides are preferably devoid of antibiotic activity. We prepared six vancomycin aglycone hexapeptide derivatives with the aim of obtaining compounds having anti-influenza virus but no antibacterial activity. Two of them exerted strong and selective inhibition of influenza A and B virus replication, while antibacterial activity was successfully eliminated by removing the critical N-terminal moiety. In addition, these two molecules offered protection against several other viruses, such as herpes simplex virus, yellow fever virus, Zika virus, and human coronavirus, classifying these glycopeptides as broad antiviral molecules with a favorable therapeutic index. DA - 2020/06/29/ PY - 2020 DO - 10.3390/ph13070139 VL - 13 IS - 7 SP - 139 J2 - Pharmaceuticals (Basel) LA - eng SN - 1424-8247 KW - antiviral KW - glycopeptide antibiotic KW - human coronavirus KW - influenza virus KW - vancomycin aglycone hexapeptide ER - TY - JOUR TI - ARIA-EAACI statement on asthma and COVID-19 (June 2, 2020). AU - Bousquet, Jean AU - Jutel, Marek AU - Akdis, Cezmi A. AU - Klimek, Ludger AU - Pfaar, Oliver AU - Nadeau, Kari C. AU - Eiwegger, Thomas AU - Bedbrook, Anna AU - Ansotegui, Ignacio J. AU - Anto, Josep M. AU - Bachert, Claus AU - Bateman, Eric D. AU - Bennoor, Kazi S. AU - Berghea, Elena Camelia AU - Bergmann, Karl-Christian AU - Blain, Hubert AU - Bonini, Mateo AU - Bosnic-Anticevich, Sinthia AU - Boulet, Louis-Philippe AU - Brussino, Luisa AU - Buhl, Roland AU - Camargos, Paulo AU - Canonica, Giorgio Walter AU - Cardona, Victoria AU - Casale, Thomas AU - Chinthrajah, Sharon AU - Akdis, Mübeccel AU - Chivato, Tomas AU - Christoff, George AU - Cruz, Alvaro A. AU - Czarlewski, Wienczyslawa AU - Del Giacco, Stefano AU - Du, Hui AU - El-Gamal, Yehia AU - Fokkens, Wytske J. AU - Fonseca, Joao A. AU - Gao, Yadong AU - Gaga, Mina AU - Gemicioglu, Bilun AU - Gotua, Maia AU - Haahtela, Tari AU - Halpin, David AU - Hamelmann, Eckard AU - Hoffmann-Sommergruber, Karin AU - Humbert, Marc AU - Ilina, Nataliya AU - Ivancevich, Juan-Carlos AU - Joos, Guy AU - Khaitov, Musa AU - Kirenga, Bruce AU - Knol, Edward F. AU - Ko, Fanny W. AU - Koskinen, Seppo AU - Kowalski, Marek L. AU - Kraxner, Helga AU - Kudlay, Dmitry AU - Kuna, Piotr AU - Kupczyk, Maciej AU - Kvedariene, Violeta AU - Abdul Latiff, Amir H. AU - Le, Lan T. AU - Levin, Michael AU - Larenas-Linnemann, Desiree AU - Louis, Renaud AU - Masjedi, Mohammad R. AU - Melén, Erik AU - Mihaltan, Florin AU - Milenkovic, Branislava AU - Mohammad, Yousser AU - Morais-Almeida, Mario AU - Mullol, Joaquim AU - Namazova, Leyla AU - Neffen, Hugo AU - Nunes, Elisabete AU - O'Byrne, Paul AU - O'Hehir, Robyn AU - O'Mahony, Liam AU - Ohta, Ken AU - Okamoto, Yoshitaka AU - Onorato, Gabrielle L. AU - Panzner, Petr AU - Papadopoulos, Nikos G. AU - Passalacqua, Gianni AU - Patella, Vincenzo AU - Pawankar, Ruby AU - Pham-Thi, Nhân AU - Pigearias, Bernard AU - Popov, Todor A. AU - Puggioni, Francesca AU - Regateiro, Frederico S. AU - Rolla, Giovanni AU - Rottem, Menachem AU - Samolinski, Boleslaw AU - Sastre, Joaquin AU - Schwarze, Jurgen AU - Sheikh, Aziz AU - Scichilone, Nicola AU - Soto-Quiros, Manuel AU - Soto-Martinez, Manuel AU - Sova, Milan AU - Nicola, Stefania AU - Stelmach, Rafael AU - Suppli-Ulrik, Charlotte AU - Taborda-Barata, Luis AU - To, Teresa AU - Tomazic, Peter-Valentin AU - Toppila-Salmi, Sanna AU - Tsiligianni, Ioanna AU - Usmani, Omar AU - Valiulis, Arunas AU - Ventura, Maria Teresa AU - Viegi, Giovanni AU - Vontetsianos, Theodor AU - Wang, De Yun AU - Williams, Sian AU - Wong, Gary W. K. AU - Yorgancioglu, Arzu AU - Zernotti, Mario AU - Zidarn, Mihaela AU - Zuberbier, Torsten AU - Agache, Ioana T2 - Allergy DA - 2021/03//undefined PY - 2021 DO - 10.1111/all.14471 VL - 76 IS - 3 SP - 689 EP - 697 J2 - Allergy LA - eng SN - 1398-9995 0105-4538 KW - Humans KW - *SARS-CoV-2 KW - Angiotensin-Converting Enzyme 2/physiology KW - Asthma/*complications/drug therapy KW - COVID-19/*etiology ER - TY - JOUR TI - [Neurological aspects of the COVID-19 pandemic caused by the SARS-CoV-2 coronavirus]. AU - Bereczki, Dániel AU - Stang, Rita AU - Böjti, Péter AU - Kovács, Tibor T2 - Ideggyogyaszati szemle AB - By the spring of 2020 the COVID-19 outbreak caused by the new SARS-CoV-2 coronavirus has become a pandemic, requiring fast and efficient reaction from societies and health care systems all over the world. Fever, coughing and dyspnea are considered the major signs of COVID-19. In addition to the involvement of the respiratory system, the infection may result in other symptoms and signs as well. Based on reports to date, neurological signs or symptoms appear in 30-50% of hospitalized COVID-19 patients, with higher incidence in those with more severe disease. Classical acute neurological syndromes have also been reported to associate with COVID-19. A drop in the volume of services for other acute diseases has been described in countries with healthcare systems focusing on COVID-19. During the COVID-19 epidemic it is also important to provide appropriate continuous care for those with chronic neurological disorders. It will be the task of the future to estimate the collateral damage caused by the COVID-19 epidemic on the outcome of other neurological disorders, and to screen for the possible late neurological complications of the SARS-CoV-2 coronavirus infection. DA - 2020/05/30/ PY - 2020 DO - 10.18071/isz.73.0171 VL - 73 IS - 05-06 SP - 171 EP - 175 J2 - Ideggyogy Sz LA - hun SN - 0019-1442 KW - Humans KW - Betacoronavirus KW - COVID-19 KW - SARS-CoV-2 KW - *COVID-19 KW - *SARS-CoV-2 KW - *Pandemics KW - *Coronavirus Infections/epidemiology KW - *collateral damage KW - *Coronavirus KW - *neurological diseases KW - *neurological services KW - *neurological signs KW - *Pneumonia, Viral/epidemiology KW - Brain Diseases/physiopathology/*virology KW - Dysgeusia/physiopathology/virology KW - Nervous System Diseases/physiopathology/*virology KW - Nervous System/physiopathology/*virology KW - Olfaction Disorders/physiopathology/virology ER - TY - JOUR TI - The international European Academy of Neurology survey on neurological symptoms in patients with COVID-19 infection. AU - Moro, E. AU - Priori, A. AU - Beghi, E. AU - Helbok, R. AU - Campiglio, L. AU - Bassetti, C. L. AU - Bianchi, E. AU - Maia, L. F. AU - Ozturk, S. AU - Cavallieri, F. AU - Zedde, M. AU - Sellner, J. AU - Bereczki, D. AU - Rakusa, M. AU - Di Liberto, G. AU - Sauerbier, A. AU - Pisani, A. AU - Macerollo, A. AU - Soffietti, R. AU - Taba, P. AU - Crean, M. AU - Twardzik, A. AU - Oreja-Guevara, C. AU - Bodini, B. AU - Jenkins, T. M. AU - von Oertzen, T. J. T2 - European journal of neurology AB - BACKGROUND AND PURPOSE: Although the main clinical features of COVID-19 infection are pulmonary, several associated neurological signs, symptoms and diseases are emerging. The incidence and characteristics of neurological complications are unclear. For this reason, the European Academy of Neurology (EAN) core COVID-19 Task Force initiated a survey on neurological symptoms observed in patients with COVID-19 infection. METHODS: A 17-question online survey was made available on the EAN website and distributed to EAN members and other worldwide physicians starting on 9 April 2020. RESULTS: By 27 April 2020, proper data were collected from 2343 responders (out of 4199), of whom 82.0% were neurologists, mostly from Europe. Most responders (74.7%) consulted patients with COVID-19 mainly in emergency rooms and in COVID-19 units. The majority (67.0%) had evaluated fewer than 10 patients with neurological manifestations of COVID-19 (neuro COVID-19). The most frequently reported neurological findings were headache (61.9%), myalgia (50.4%), anosmia (49.2%), ageusia (39.8%), impaired consciousness (29.3%) and psychomotor agitation (26.7%). Encephalopathy and acute cerebrovascular disorders were reported at 21.0%. Neurological manifestations were generally interpreted as being possibly related to COVID-19; they were most commonly recognized in patients with multiple general symptoms and occurred at any time during infection. CONCLUSION: Neurologists are currently and actively involved in the management of neurological issues related to the COVID-19 pandemic. This survey justifies setting up a prospective registry to better capture the prevalence of patients with neuro COVID-19, neurological disease characteristics and the contribution of neurological manifestations to outcome. DA - 2020/09//undefined PY - 2020 DO - 10.1111/ene.14407 VL - 27 IS - 9 SP - 1727 EP - 1737 J2 - Eur J Neurol LA - eng SN - 1468-1331 1351-5101 KW - Humans KW - *coronavirus KW - *COVID-19 KW - Europe KW - Neurology KW - *neurological KW - *survey KW - Anosmia/*etiology KW - COVID-19/*complications KW - Headache/*etiology KW - Health Surveys KW - Myalgia/*etiology KW - Psychomotor Agitation/*etiology ER - TY - JOUR TI - The effect of social distance measures on COVID-19 epidemics in Europe: an interrupted time series analysis. AU - Vokó, Zoltán AU - Pitter, János György T2 - GeroScience AB - Following the introduction of unprecedented "stay-at-home" national policies, the COVID-19 pandemic recently started declining in Europe. Our research aims were to characterize the changepoint in the flow of the COVID-19 epidemic in each European country and to evaluate the association of the level of social distancing with the observed decline in the national epidemics. Interrupted time series analyses were conducted in 28 European countries. Social distance index was calculated based on Google Community Mobility Reports. Changepoints were estimated by threshold regression, national findings were analyzed by Poisson regression, and the effect of social distancing in mixed effects Poisson regression model. Our findings identified the most probable changepoints in 28 European countries. Before changepoint, incidence of new COVID-19 cases grew by 24% per day on average. From the changepoint, this growth rate was reduced to 0.9%, 0.3% increase, and to 0.7% and 1.7% decrease by increasing social distancing quartiles. The beneficial effect of higher social distance quartiles (i.e., turning the increase into decline) was statistically significant for the fourth quartile. Notably, many countries in lower quartiles also achieved a flat epidemic curve. In these countries, other plausible COVID-19 containment measures could contribute to controlling the first wave of the disease. The association of social distance quartiles with viral spread could also be hindered by local bottlenecks in infection control. Our results allow for moderate optimism related to the gradual lifting of social distance measures in the general population, and call for specific attention to the protection of focal micro-societies enriching high-risk elderly subjects, including nursing homes and chronic care facilities. DA - 2020/08//undefined PY - 2020 DO - 10.1007/s11357-020-00205-0 VL - 42 IS - 4 SP - 1075 EP - 1082 J2 - Geroscience LA - eng SN - 2509-2723 2509-2715 KW - Humans KW - COVID-19 KW - SARS-CoV-2 KW - Incidence KW - *COVID-19 KW - *Betacoronavirus KW - Pandemics/*prevention & control KW - *Communicable Disease Control KW - *Health Policy KW - *Social Isolation KW - *Europe KW - *Google community mobility reports KW - *Interrupted time series analysis KW - *Social distance KW - Coronavirus Infections/*epidemiology/*prevention & control KW - Europe/epidemiology KW - Interrupted Time Series Analysis KW - Pneumonia, Viral/*epidemiology/*prevention & control ER - TY - JOUR TI - Refugee camps and COVID-19: Can we prevent a humanitarian crisis? AU - Vonen, Hanne Dahl AU - Olsen, Merete Lan AU - Eriksen, Sara Soraya AU - Jervelund, Signe Smith AU - Eikemo, Terje Andreas T2 - Scandinavian journal of public health DA - 2021/02//undefined PY - 2021 DO - 10.1177/1403494820934952 VL - 49 IS - 1 SP - 27 EP - 28 J2 - Scand J Public Health LA - eng SN - 1651-1905 1403-4948 KW - Humans KW - SARS-CoV-2 KW - *COVID-19 KW - *Refugees KW - *Suicide KW - Greece KW - Refugee Camps ER - TY - JOUR TI - [Possibilities of telemedicine regarding the COVID-19 pandemic in light of the international and Hungarian experiences and recommendations]. AU - Győrffy, Zsuzsa AU - Békási, Sándor AU - Szathmári-Mészáros, Noémi AU - Németh, Orsolya T2 - Orvosi hetilap AB - The COVID-19 outbreak was formally announced as a pandemic by WHO on the 11th of March, 2020. This attracts attention to the possibilities of telemedicine again. In support of stopping the spread of the novel coronavirus infection, whilst keeping the healthcare system running and minimizing the risk of being infected, we also need to find new ways, methods, and platforms to deal with this pandemic. By providing a literature overview and sharing practical guidelines, including the special example of Hungarian teledentistry, we present both international and Hungarian initiatives to involve telemedicine on different levels of healthcare systems regarding COVID-19. Both international and national data show that telemedicine can play a major role in the triage process, early identification, diagnosis and treatment of infected individuals, and management of patient pathways in a way that ensures the medical team does not come into contact with potentially infected patients. It also plays an important role in remote monitoring of medical conditions and care of patients with chronic diseases and reconnects vulnerable groups of healthcare personnel to the care system. In addition to the potential benefits of telemedicine, we must not forget the limitations of this method. However, it is important to emphasize that due to its wide availability, telemedicine services can provide sufficient flexibility for both primary and specialist care (outpatient and inpatient clinical care). For that very reason, it is an urgent need to define the national professional guidelines, legal and financing possibilities in this field in a long-term sustainable way.* Orv Hetil. 2020; 161(24): 983-992. *Disclaimer: We closed the writing of this manuscript on the 30th of April, 2020. The COVID-19 pandemic and related research studies still have been changing dynamically since then. DA - 2020/06//undefined PY - 2020 DO - 10.1556/650.2020.31873 VL - 161 IS - 24 SP - 983 EP - 992 J2 - Orv Hetil LA - hun SN - 1788-6120 0030-6002 KW - Humans KW - COVID-19 KW - *COVID-19 KW - Hungary/epidemiology KW - *Pandemics KW - *Telemedicine KW - *COVID–19 KW - Coronavirus Infections/*epidemiology KW - Pneumonia, Viral/*epidemiology KW - *doctor-patient relationship KW - *orvos-beteg kapcsolat KW - *telemedicina KW - *telemedicine KW - *triage KW - *triázs ER - TY - JOUR TI - [Procoagulation, hypercoagulation and fibrinolytic “shut down” detected with ClotPro® viscoelastic tests in COVID-19 patients]. AU - Zátroch, István AU - Smudla, Anikó AU - Babik, Barna AU - Tánczos, Krisztián AU - Kóbori, László AU - Szabó, Zsuzsanna AU - Fazakas, János T2 - Orvosi hetilap AB - INTRODUCTION: International data indicate that arterial, venous and microvascular thrombosis or disseminated intravascular coagulation occur in more than 30% of hospitalized patients with COVID-19. This condition is characterized by high levels of D-dimer and fibrinogen, prolonged prothrombin time and activated partial thromboplastin time. METHOD: Blood samples from three COVID-19 patients treated in a Hungarian intensive care unit were collected and analyzed with ClotPro® tests. EX-tests, IN-test, FIB-tests, RVV-tests, and TPA-tests were performed. The results were interpreted with respect to the clinical condition of the patients. RESULTS: Procoagulation, hypercoagulation and either fibrinolysis or a "shut down" phenomenon of the fibrinolytic process were found with ClotPro®. The ClotPro® parameters were consistent with the conventional coagulation tests and corresponded with the criteria of non-overt disseminated intravascular coagulation. CONCLUSION: These findings encourage further investigations to elucidate the underlying pathophysiology of thromboembolic events in COVID-19 patients and may support the introduction of full dose anticoagulation with or without antiplatelet therapy. Interventional clinical trials may be helpful in defining the appropriate drug(s), for this purpose, the algorithms of administration, and the optimal duration of therapy. At present, the authorization of a clinical trial that attempts to answer these questions is in progress. Orv Hetil. 2020; 161(22): 899-907. DA - 2020/05//undefined PY - 2020 DO - 10.1556/650.2020.31870 VL - 161 IS - 22 SP - 899 EP - 907 J2 - Orv Hetil LA - hun SN - 1788-6120 0030-6002 KW - Humans KW - COVID-19 KW - Pandemics KW - *COVID-19 KW - *COVID–19 KW - *ClotPro® KW - *fibrinolysis “shut down” KW - *fibrinolysis „shut down” KW - *hypercoagulatio KW - *hypercoagulation KW - *thromboemboliás szövődmények KW - *thromboembolic complication KW - Blood Coagulation Tests KW - Coronavirus Infections/*physiopathology/*therapy KW - Disseminated Intravascular Coagulation/*diagnosis KW - Pneumonia, Viral/*physiopathology/*therapy ER - TY - JOUR TI - [Oncologic patient with COVID-19 discovered incidentally by PET/CT examination: (A COVID–19-pandémia orvosszakmai kérdései)]. AU - Czibor, Sándor AU - Kristóf, Emese AU - Kecskés, Kinga AU - Barra, Magdolna AU - Szántó, Péter AU - Maurovich-Horvat, Pál AU - Györke, Tamás T2 - Orvosi hetilap AB - The scientific literature of coronavirus-disease 2019 (COVID-19) is rapidly expanding. There is a growing evidence on the discrepancy between clinical symptoms and radiologic findings in many patients. This case report gives details about a patient with only mild symptoms but relatively severe radiological findings. The 75-year-old patient suffering from oncologic disease had a planned a F18-fluoro-deoxy-glucose positron-emission tomography/computer tomography scan with a routine oncological indication where incidental radiomorphologic findings of pneumonia suspect for COVID-19 were detected. After immediate isolation, the patient was transferred to the corresponding medical department, where further investigations verified the diagnosis of COVID-19. With this case, our aim is to raise the awareness for the importance of the instant evaluation of chest computer tomography series when performing planned imaging examination, especially in frail patients. With this practice, potential radiomorphologic findings of pneumonia suspect for COVID-19 could be identified in time, which fundamentally determines further patient management steps. Orv Hetil. 2020; 161(23): 971-976. DA - 2020/06//undefined PY - 2020 DO - 10.1556/650.2020.31848 VL - 161 IS - 23 SP - 971 EP - 976 J2 - Orv Hetil LA - hun SN - 1788-6120 0030-6002 KW - Humans KW - COVID-19 KW - Aged KW - Pandemics KW - *COVID-19 KW - *COVID–19 KW - *CT KW - *Incidental Findings KW - *PET/CT KW - *pneumonia KW - Coronavirus Infections/*diagnostic imaging/epidemiology KW - Neoplasms/*therapy KW - Pneumonia, Viral/*diagnostic imaging/epidemiology KW - Positron Emission Tomography Computed Tomography ER - TY - JOUR TI - Thoracic Anesthesia of Patients With Suspected or Confirmed 2019 Novel Coronavirus Infection: Preliminary Recommendations for Airway Management by the European Association of Cardiothoracic Anaesthesiology Thoracic Subspecialty Committee. AU - Şentürk, Mert AU - El Tahan, Mohamed R. AU - Szegedi, Laszlo L. AU - Marczin, Nandor AU - Karzai, Waheedullah AU - Shelley, Ben AU - Piccioni, Federico AU - Granell Gil, Manuel AU - Rex, Steffen AU - Sorbello, Massimiliano AU - Bence, Johan AU - Cohen, Edmond AU - Gregorio, Guido Di AU - Kawagoe, Izumi AU - Globokar, Mojca Drnovšek AU - Jimenez, Maria-José AU - Licker, Marc-Joseph AU - Mourisse, Jo AU - Mukherjee, Chirojit AU - Navarro, Ricard AU - Neskovic, Vojislava AU - Paloczi, Balazs AU - Paternoster, Gianluca AU - Pelosi, Paolo AU - Salaheldeen, Ahmed AU - Stoica, Radu AU - Unzueta, Carmen AU - Vanpeteghem, Caroline AU - Vegh, Tamas AU - Wouters, Patrick AU - Yapici, Davud AU - Guarracino, Fabio T2 - Journal of cardiothoracic and vascular anesthesia AB - The novel coronavirus has caused a pandemic around the world. Management of patients with suspected or confirmed coronavirus infection who have to undergo thoracic surgery will be a challenge for the anesthesiologists. The thoracic subspecialty committee of European Association of Cardiothoracic Anaesthesiology (EACTA) has conducted a survey of opinion in order to create recommendations for the anesthetic approach to these challenging patients. It should be emphasized that both the management of the infected patient with COVID-19 and the self-protection of the anesthesia team constitute a complicated challenge. The text focuses therefore on both important topics. DA - 2020/09//undefined PY - 2020 DO - 10.1053/j.jvca.2020.03.059 VL - 34 IS - 9 SP - 2315 EP - 2327 J2 - J Cardiothorac Vasc Anesth LA - eng SN - 1532-8422 1053-0770 KW - Humans KW - COVID-19 KW - SARS-CoV-2 KW - Pandemics KW - *coronavirus KW - *COVID-19 KW - *Betacoronavirus KW - Europe/epidemiology KW - *lung separation KW - *personal protective equipment KW - *thoracic anesthesia KW - Advisory Committees/*standards KW - Airway Management/methods/*standards KW - Anesthesia, Cardiac Procedures/methods/*standards KW - Anesthesiology/methods/standards KW - Coronavirus Infections/diagnosis/epidemiology/*surgery KW - Pneumonia, Viral/diagnosis/epidemiology/*surgery KW - Practice Guidelines as Topic/*standards ER - TY - JOUR TI - COVID-19: The immediate response of european academic dental institutions and future implications for dental education. AU - Quinn, Barry AU - Field, James AU - Gorter, Ronald AU - Akota, Ilze AU - Manzanares, Maria-Cristina AU - Paganelli, Corrado AU - Davies, Julia AU - Dixon, Jonathan AU - Gabor, Gerber AU - Amaral Mendes, Rui AU - Hahn, Petra AU - Vital, Sibylle AU - O'Brien, Judith AU - Murphy, Denis AU - Tubert-Jeannin, Stéphanie T2 - European journal of dental education : official journal of the Association for Dental Education in Europe AB - The COVID-19 pandemic has had an immediate and dramatic impact on dental education. The Association of Dental Education in Europe decided to carry out an investigation to assess the immediate response of European Academic Dental Institutions. An online survey was sent to both member and non-member dental schools to investigate the impact on non-clinical and clinical education, assessment and the well-being/pastoral care measures implemented. The preliminary findings and discussion are presented in this paper, for the responses collected between the 25 March and 5 April 2020. The survey at this time of publication is ongoing, and detailed results can be accessed https://adee.org/covid-19-european-dental-education%E2%80%99s-immediate-response. DA - 2020/11//undefined PY - 2020 DO - 10.1111/eje.12542 VL - 24 IS - 4 SP - 811 EP - 814 J2 - Eur J Dent Educ LA - eng SN - 1600-0579 1396-5883 KW - Humans KW - COVID-19 KW - SARS-CoV-2 KW - Pandemics KW - *COVID-19 KW - Europe KW - *Education, Dental KW - Curriculum KW - dental education KW - impact KW - public health KW - survey ER - TY - JOUR TI - COVID-19 research: promising tracks leading to uro-oncology. AU - Fazekas, Tamás AU - Szarvas, Tibor AU - Csizmarik, Anita AU - Hadaschik, Boris AU - Nyirády, Péter T2 - International urology and nephrology DA - 2020/06//undefined PY - 2020 DO - 10.1007/s11255-020-02490-2 VL - 52 IS - 6 SP - 995 EP - 997 J2 - Int Urol Nephrol LA - eng SN - 1573-2584 0301-1623 KW - Humans KW - COVID-19 KW - SARS-CoV-2 KW - Pandemics KW - *Biomedical Research KW - *Betacoronavirus KW - *Medical Oncology KW - *Urology KW - Coronavirus Infections/complications/epidemiology/*therapy KW - Pneumonia, Viral/complications/epidemiology/*therapy ER - TY - JOUR TI - Characteristics of doctors' fatality due to COVID-19 in Western Europe and Asia-Pacific countries. AU - Yoshida, I. AU - Tanimoto, T. AU - Schiever, N. AU - Patelli, F. AU - Kami, M. T2 - QJM : monthly journal of the Association of Physicians AB - Under the coronavirus disease 2019 (COVID-19) pandemic, the deaths of healthcare professionals have been increasingly reported worldwide. We performed a cross-sectional, observational study using news reports on the websites among selected countries as of April 2020. We found 120 dead medical doctors due to COVID-19 in Western Europe and Asia-Pacific countries; 67 in Italy (47 in the Northern part), 34 in China (22 in Hubei), 6 in France, 4 in the UK, the USA and Spain and 1 in South Korea, respectively. Among them, 90% were men, and specialties were reported as general practitioners for 30% and as physicians for 11.6%. The overall proportions of dead medical doctors amounted to 1.9 per 10 000 confirmed cases and 30.2 per 10 000 dead cases, respectively. Proactive measures are warranted to protect doctors especially who often encounters with COVID-19 patients. DA - 2020/10/01/ PY - 2020 DO - 10.1093/qjmed/hcaa159 VL - 113 IS - 10 SP - 713 EP - 714 J2 - QJM LA - eng SN - 1460-2393 1460-2725 KW - Female KW - Humans KW - Male KW - Betacoronavirus KW - COVID-19 KW - SARS-CoV-2 KW - Middle Aged KW - Aged KW - Cross-Sectional Studies KW - Mortality KW - Pandemics KW - Coronavirus Infections/*mortality KW - Global Health/*statistics & numerical data KW - Occupational Diseases/*mortality/virology KW - Occupational Exposure/prevention & control KW - Occupational Health/statistics & numerical data KW - Physicians/*statistics & numerical data KW - Pneumonia, Viral/*mortality ER - TY - JOUR TI - [The diagnostic value of rapid anti IgM and IgG detecting tests in the identification of patients with SARS CoV-2 virus infection]. AU - Vásárhelyi, Barna AU - Kristóf, Katalin AU - Ostorházi, Eszter AU - Szabó, Dóra AU - Prohászka, Zoltán AU - Merkely, Béla T2 - Orvosi hetilap AB - Introduction: At the end of March, 2020, rapid tests detecting the presence of antiviral IgM and IgG antibodies against SARS-CoV-2 virus were introduced in Hungary for the identification of SARS-CoV-2 infection (COVID-19 disease). Aim: We evaluated two rapid tests (Anhui and Clungene) in comparison with those of real-time PCR tests considered as the gold standard in the detection of infection. Method: Between 16, March and 14, April, 2020, we performed rapid IgM and IgG detecting tests without PCR; PCR without rapid tests; and PCR WITH rapid tests in 4140, 3210 and 1654 patients, respectively. (Out of these 1654 patients, Anhui and Clungene tests were used for testing in 625 and 1029 patients, respectively.) Patients were considered as positive in PCR and rapid tests when PCR positivity and IgM or IgG positivity occurred at any time, respectively. (Note: Clungene test is also marketed as 'Lungene'.) Results: The prevalence of PCR positivity in 4864 patients tested with PCR was 6.3%. The sensitivity and specificity of Anhui and Clungene tests were 33.3% and 72.85%, and 35.48% and 85.02%, respectively. At 6% PCR positivity, the positive and negative predictive values of Anhui and Clungene were 7.28%, 94.48%, 13.13%, and 95.38%, respectively. Conclusion: The low positive predictive values indicate that Anhui and Clungene rapid tests detecting the presence of anti-IgM and anti-IgG against SARS-CoV-2 virus infection are not suitable for screening SARS-CoV-2 vírus infection in the general population. These results strongly support that Anhui and Clungene rapid tests detecting IgM and IgG antibodies against SARS-CoV-2 virus should not be used in the differential diagnosis of infection. Orv Hetil. 2020; 161(20): 807-812. DA - 2020/05/01/ PY - 2020 DO - 10.1556/650.2020.31859 VL - 161 IS - 20 SP - 807 EP - 812 J2 - Orv Hetil LA - hun SN - 1788-6120 0030-6002 KW - Humans KW - Betacoronavirus KW - COVID-19 KW - SARS-CoV-2 KW - Pandemics KW - Clinical Laboratory Techniques KW - COVID-19 Testing KW - Sensitivity and Specificity KW - Predictive Value of Tests KW - Hungary KW - *COVID–19-pandémia KW - Real-Time Polymerase Chain Reaction KW - *’real-time’ PCR KW - *Antibodies, Viral/analysis KW - *COVID-19 pandemia KW - *gyorsteszt KW - *rapid tests KW - *real-time PCR KW - *SARS-CoV-2 novel coronavirus KW - *SARS-CoV-2 vírus KW - Coronavirus Infections/*diagnosis KW - Immunoassay/*methods KW - Immunoglobulin G/analysis KW - Immunoglobulin M/analysis KW - Pneumonia, Viral/*diagnosis ER - TY - JOUR TI - Postponement of Frontiers in Cardiovascular Biomedicine (FCVB) 2020 due to COVID-19: a look forward to 2021. AU - Ferdinandy, Péter AU - Koller, Ákos AU - Weber, Christian AU - Waltenberger, Johannes T2 - Cardiovascular research DA - 2020/06/01/ PY - 2020 DO - 10.1093/cvr/cvaa108 VL - 116 IS - 7 SP - e78 EP - e81 J2 - Cardiovasc Res LA - eng SN - 1755-3245 0008-6363 KW - Humans KW - Betacoronavirus KW - COVID-19 KW - SARS-CoV-2 KW - *Pandemics KW - *Pneumonia, Viral KW - *Appointments and Schedules KW - *Congresses as Topic KW - *Coronavirus Infections KW - Research ER - TY - JOUR TI - [Challenges of intensive care and anesthesiology related to COVID-19 pandemic. Practical considerations]. AU - Fülesdi, Béla AU - Sárkány, Péter AU - Szentkereszty, Zoltán AU - Gál, János T2 - Orvosi hetilap AB - Due to the coronavirus epidemic, healthcare systems face growing challenges all around the world nowadays. These challenges are the most critical in the field of intensive treatment and anesthesiology. One of the most important prerequisites of effective critical care treatment is preserving the involved healthcare workers from the infection, by providing them with detailed practical advices on the preventive measures and treatment strategies. The aim of the present review is to summarize the most important related knowledge available from previous experiences. Orv Hetil. 2020; 161(17): 652–659. DA - 2020/04/01/ PY - 2020 DO - 10.1556/650.2020.31808 VL - 161 IS - 17 SP - 652 EP - 659 J2 - Orv Hetil LA - hun SN - 1788-6120 0030-6002 KW - Humans KW - Betacoronavirus KW - COVID-19 KW - SARS-CoV-2 KW - Intensive Care Units KW - Hungary KW - *Pandemics KW - *COVID–19 KW - *Coronavirus Infections/epidemiology KW - *Pneumonia, Viral/epidemiology KW - *Anesthesiology/standards KW - *az egészségügyi dolgozók személyi védelme KW - *coronavirus epidemy KW - *Critical Care/standards KW - *intensive care KW - *intenzív terápia KW - *koronavírus-járvány KW - *personal protection of healthcare workers KW - Infection Control/methods ER - TY - JOUR TI - [The coronavirus-induced COVID-19 pandemic. Previous experiences and scientific evidences at the end of March, 2020]. AU - Váradi, András AU - Ferenci, Tamás AU - Falus, András T2 - Orvosi hetilap AB - The COVID-19 epidemic hit everyone, professionals and civilians alike. The possibility of a worldwide pandemic has long been theorized by epidemiologists, infectologists on the one hand, and sociologists and behavioral scientists dealing with communication and social habits on the other. Yet, faced with real-time events, daily infections and mortality statistics, almost everyone feels uninformed or disturbingly inexperienced. This summary aims to provide an overview of the latest scientific evidences. Of course, the incomplete material, compiled in late March 2020, will certainly contain a few elements that likely will be outdated in a few weeks. The authors hope that in the next publication we will all read much better and more hopeful prospects. Orv Hetil. 2020; 161(17): 644–651. DA - 2020/04/01/ PY - 2020 DO - 10.1556/650.2020.31830 VL - 161 IS - 17 SP - 644 EP - 651 J2 - Orv Hetil LA - hun SN - 1788-6120 0030-6002 KW - Humans KW - COVID-19 KW - SARS-CoV-2 KW - *coronavirus KW - *koronavírus KW - *Pandemics KW - *COVID–19 KW - *RT-PCR KW - *Betacoronavirus KW - *Coronavirus Infections/epidemiology KW - *Coronavirus KW - *Pneumonia, Viral/epidemiology KW - *reverse transcriptase polymerase chain reaction KW - *reverztranszkriptáz polimeráz-láncreakció KW - *testing KW - *tesztelés KW - *viral pandemics KW - *viral vaccines KW - *víruspandémiák KW - *vírusvakcinák ER - TY - JOUR TI - All together to Fight COVID-19. AU - Momtazmanesh, Sara AU - Ochs, Hans D. AU - Uddin, Lucina Q. AU - Perc, Matjaz AU - Routes, John M. AU - Vieira, Duarte Nuno AU - Al-Herz, Waleed AU - Baris, Safa AU - Prando, Carolina AU - Rosivall, Laszlo AU - Abdul Latiff, Amir Hamzah AU - Ulrichs, Timo AU - Roudenok, Vasili AU - Aldave Becerra, Juan Carlos AU - Salunke, Deepak B. AU - Goudouris, Ekaterini AU - Condino-Neto, Antonio AU - Stashchak, Anzhela AU - Kryvenko, Oleksandr AU - Stashchak, Mykola AU - Bondarenko, Anastasia AU - Rezaei, Nima T2 - The American journal of tropical medicine and hygiene AB - Novel coronavirus disease (COVID-19), named a pandemic by the WHO, is the current global health crisis. National and international collaboration are indispensable for combating COVID-19 and other similar potential outbreaks. International efforts to tackle this complex problem have led to remarkable scientific advances. Yet, as a global society, we can and must take additional measures to fight this pandemic. Undoubtedly, our approach toward COVID-19 was not perfect, and testing has not been deployed fast enough to arrest the epidemic early on. It is critical that we revise our approaches to be more prepared for pandemics as a united body by promoting global cooperation and commitment. DA - 2020/06//undefined PY - 2020 DO - 10.4269/ajtmh.20-0281 VL - 102 IS - 6 SP - 1181 EP - 1183 J2 - Am J Trop Med Hyg LA - eng SN - 1476-1645 0002-9637 KW - Humans KW - COVID-19 KW - SARS-CoV-2 KW - COVID-19 Testing KW - COVID-19 Vaccines KW - *Pandemics/prevention & control KW - Europe/epidemiology KW - Antiviral Agents/chemical synthesis/therapeutic use KW - Asia/epidemiology KW - Betacoronavirus/drug effects/*pathogenicity KW - Civil Defense/*organization & administration KW - Clinical Laboratory Techniques/standards/statistics & numerical data KW - Coronavirus Infections/diagnosis/drug therapy/*epidemiology/prevention & control KW - International Cooperation/*legislation & jurisprudence KW - Middle East/epidemiology KW - Pneumonia, Viral/diagnosis/drug therapy/*epidemiology/prevention & control KW - Viral Vaccines/biosynthesis/therapeutic use ER - TY - JOUR TI - Borderless collaboration is needed for COVID-19-A disease that knows no borders. AU - Mohamed, Kawthar AU - Rodríguez-Román, Eduardo AU - Rahmani, Farzaneh AU - Zhang, Hongbo AU - Ivanovska, Mariya AU - Makka, Sara A. AU - Joya, Musa AU - Makuku, Rangarirai AU - Islam, Md Shahidul AU - Radwan, Nesrine AU - Rahmah, Laila AU - Goda, Rayan AU - Abarikwu, Sunny O. AU - Shaw, Mujtaba AU - Zoghi, Samaneh AU - Irtsyan, Sevan AU - Ling, Irene AU - Cseprekal, Orsolya AU - Faten, Attig-Bahar AU - Hazar Sayar, Esra AU - Soloukey, Chagajeg AU - Grancini, Giulia AU - Rezaei, Nima T2 - Infection control and hospital epidemiology DA - 2020/10//undefined PY - 2020 DO - 10.1017/ice.2020.162 VL - 41 IS - 10 SP - 1245 EP - 1246 J2 - Infect Control Hosp Epidemiol LA - eng SN - 1559-6834 0899-823X N1 -

CODEN: ICEPE

N1 -

Correspondence Address: Rezaei, N.; Universal Scientific Education and Research Network (USERN), PhD Research Center for Immunodeficiencies, Children's Medical Center Hospital, Dr. Qarib St, Keshavarz Blvd, Iran; email: rezaei_nima@tums.ac.ir

N1 -

Export Date: 5 May 2020

N1 -

References: WHO Director-General's Opening Remarks at the Media Briefing on COVID-19-11 March 2020, , http://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-11-march-2020, WHO Date accessed: April 12, 2020;
Carlsson-Szlezak, P., Reeves, M., Swartz, P., Understanding the Economic Shock of Coronavirus, , http://hbr.org/2020/03/understanding-the-economic-shock-of-coronavirus, Date accessed: March 27, 2020;
Saghazadeh, A., Rezaei, N., Immune-epidemiological parameters of the novel coronavirus- A perspective (2020) Expert Rev Clin Immunol, , Apr 1;
Yousefzadegan, S., Rezaei, N., Death due to novel coronavirus disease (COVID-19) in three brothers (2020) Am J Tropical Med Hygiene, , Apr 10;
Moazzami, B., Razavi-Khorasani, N., Dooghaie Moghadam, A., Farokhi, E., Rezaei, N., COVID-19 and Telemedicine: Immediate action required for maintaining healthcare providers well-being (2020) J Clin Virol., , Apr 4;
A Global Approach Is the only Way to Fight COVID-19, the un Says As It Launches Humanitarian Response Plan, , http://www.unicef.org/press-releases/global-approach-only-way-fight-covid-19-un-says-it-launches-humanitarian-response, UNICEF Date accessed: April 12, 2020;
Small Pox Is Dead, , http://www.who.int/csr/disease/smallpox/WHO_RAS_SEP_ID0556_WorldHealth_May1980_ENG.pdf?ua=1, WHO. World Health Date accessed: April 11, 2020;
Rahmani, F., Keshavarz-Fathi, M., Hanaei, S., Universal scientific education and research network (USERN): Step strong in scientific networking (2019) Acta Med Iran, 57 (1), pp. 1-4

KW - Humans KW - Betacoronavirus KW - COVID-19 KW - SARS-CoV-2 KW - Pandemics/*prevention & control KW - *International Cooperation KW - Coronavirus Infections/epidemiology/*prevention & control/transmission KW - Infection Control/*methods KW - Pneumonia, Viral/epidemiology/*prevention & control/transmission ER - TY - JOUR TI - Flash survey on severe acute respiratory syndrome coronavirus-2 infections in paediatric patients on anticancer treatment. AU - Hrusak, Ondrej AU - Kalina, Tomas AU - Wolf, Joshua AU - Balduzzi, Adriana AU - Provenzi, Massimo AU - Rizzari, Carmelo AU - Rives, Susana AU - Del Pozo Carlavilla, María AU - Alonso, Maria E. V. AU - Domínguez-Pinilla, Nerea AU - Bourquin, Jean-Pierre AU - Schmiegelow, Kjeld AU - Attarbaschi, Andishe AU - Grillner, Pernilla AU - Mellgren, Karin AU - van der Werff Ten Bosch, Jutte AU - Pieters, Rob AU - Brozou, Triantafyllia AU - Borkhardt, Arndt AU - Escherich, Gabriele AU - Lauten, Melchior AU - Stanulla, Martin AU - Smith, Owen AU - Yeoh, Allen E. J. AU - Elitzur, Sarah AU - Vora, Ajay AU - Li, Chi-Kong AU - Ariffin, Hany AU - Kolenova, Alexandra AU - Dallapozza, Luciano AU - Farah, Roula AU - Lazic, Jelena AU - Manabe, Atsushi AU - Styczynski, Jan AU - Kovacs, Gabor AU - Ottoffy, Gabor AU - Felice, Maria S. AU - Buldini, Barbara AU - Conter, Valentino AU - Stary, Jan AU - Schrappe, Martin T2 - European journal of cancer (Oxford, England : 1990) AB - INTRODUCTION: Since the beginning of COVID-19 pandemic, it is known that the severe course of the disease occurs mostly among the elderly, whereas it is rare among children and young adults. Comorbidities, in particular, diabetes and hypertension, clearly associated with age, besides obesity and smoke, are strongly associated with the need for intensive treatment and a dismal outcome. A weaker immunity of the elderly has been proposed as a possible explanation of this uneven age distribution. Thus, there is concern that children treated for cancer may allso be at risk for an unfavourable course of infection. Along the same line, anecdotal information from Wuhan, China, mentioned a severe course of COVID-19 in a child treated for leukaemia. AIM AND METHODS: We made a flash survey on COVID-19 incidence and severity among children on anticancer treatment. Respondents were asked by email to fill in a short Web-based survey. RESULTS: We received reports from 25 countries, where approximately 10,000 patients at risk are followed up. At the time of the survey, more than 200 of these children were tested, nine of whom were positive for COVID-19. Eight of the nine cases had asymptomatic to mild disease, and one was just diagnosed with COVID-19. We also discuss preventive measures that are in place or should be taken and treatment options in immunocompromised children with COVID-19. CONCLUSION: Thus, even children receiving anticancer chemotherapy may have a mild or asymptomatic course of COVID-19. While we should not underestimate the risk of developing a more severe course of COVID-19 than that observed here, the intensity of preventive measures should not cause delays or obstructions in oncological treatment. DA - 2020/06//undefined PY - 2020 DO - 10.1016/j.ejca.2020.03.021 VL - 132 SP - 11 EP - 16 J2 - Eur J Cancer LA - eng SN - 1879-0852 0959-8049 N1 -

Chemicals/CAS: azithromycin, 83905-01-5, 117772-70-0, 121470-24-4; cisplatin, 15663-27-1, 26035-31-4, 96081-74-2; hydroxychloroquine, 118-42-3, 525-31-5

N1 -

CODEN: EJCAE

N1 -

Correspondence Address: Hrusak, O.; CLIP – Childhood Leukaemia InvestigationCzech Republic; email: Ondrej.Hrusak@lfmotol.cuni.cz

N1 -

Export Date: 5 May 2020

N1 -

References: Wu, Z., McGoogan, J.M., Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China (2019) J Am Med Assoc;
Ruan, Q., Yang, K., Wang, W., Jiang, L., Song, J., Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China (2020) Intensive Care Med, , [Epub ahead of print];
Lu, X., Zhang, L., Du, H., Zhang, J., Li, Y.Y., Qu, J., SARS-CoV-2 infection in children (2020) N Engl J Med, , NEJMc2005073;
Wei, M., Yuan, J., Liu, Y., Fu, T., Yu, X., Zhang, Z.-J., Novel coronavirus infection in hospitalized infants under 1 Year of age in China (2020) J Am Med Assoc, 129 (6), pp. 802-804;
Cai, J., Xu, J., Lin, D., Yang, Z., Xu, L., Qu, Z., A Case Series of children with 2019 novel coronavirus infection: clinical and epidemiological features (2020) Clin Infect Dis, , [Epub ahead of print];
Liu, W., Zhang, Q., Chen, J., Xiang, R., Song, H., Shu, S., Detection of Covid-19 in children in early January 2020 in Wuhan, China (2020) N Engl J Med, 382 (14), pp. 1370-1371. , NEJMc2003717;
Dong, Y., Mo, X., Hu, Y., Qi, X., Jiang, F., Jiang, Z., Epidemiological characteristics of 2143 pediatric patients with 2019 coronavirus disease in China (2020) Pediatrics, , [Epub ahead of print];
Chen, Z., Xiong, H., Li, J.X., Li, H., Tao, F., Yang, Y.T., COVID-19 with post-chemotherapy agranulocytosis in childhood acute leukemia: a case report (2020) Zhonghua Xue Ye Xue Za Zhi, 41, p. E004;
Sun, D., Li, H., Lu, X.-X., Xiao, H., Ren, J., Zhang, F.R., Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center's observational study (2020) World J Pediatr, , [Epub ahead of print];
Korean society of pediatric infectious diseases, Korean society of epidemiology, Korean society for antimicrobial therapy, Korean society for healthcare-associated infection control and prevention, korea centers for disease control and prevention. Report on the epidemiological features of coronavirus disease 2019 (COVID-19) outbreak in the Republic of Korea from january 19 to March 2, 2020 (2020) J Kor Med Sci, 35 (10), p. e112;
Ogimi, C., Englund, J.A., Bradford, M.C., Qin, X., Boeckh, M., Waghmare, A., Characteristics and outcomes of coronavirus infection in children: the role of viral factors and an immunocompromised state (2019) J Pediatric Infect Dis Soc, 8 (1), pp. 21-28;
Janka, G.E., Lehmberg, K., Hemophagocytic syndromes - an update (2014) Blood Rev, 28 (4), pp. 135-142;
Li, C.K., Zee, B., Lee, J., Chik, K.W., Ha, S.Y., Lee, V., Impact of SARS on development of childhood acute lymphoblastic leukaemia (2007) Leukemia, 21 (7), pp. 1353-1356;
Klein, K., Hasle, H., Abrahamsson, J., De Moerloose, B., Kaspers, G.J.L., Differences in infection prophylaxis measures between paediatric acute myeloid leukaemia study groups within the international Berlin–Frankfürt–Münster (I-BFM) study group (2018) Br J Haematol, 183 (1), pp. 87-95;
Shachor-Meyouhas, Y., Zaidman, I., Kra-Oz, Z., Arad-Cohen, N., Kassis, I., Detection, control, and management of a respiratory syncytial virus outbreak in a pediatric hematology-oncology department (2013) J Pediatr Hematol Oncol, 35 (2), pp. 124-128

KW - Child KW - Female KW - Humans KW - Male KW - Adolescent KW - COVID-19 KW - SARS-CoV-2 KW - Surveys and Questionnaires KW - Pandemics KW - *COVID-19 KW - *Betacoronavirus KW - *Anticancer chemotherapy KW - *Children KW - *Immunosuppression KW - Antineoplastic Agents/*therapeutic use KW - Coronavirus Infections/*complications/drug therapy KW - Neoplasms/complications/*drug therapy KW - Pneumonia, Viral/*complications/drug therapy ER - TY - JOUR TI - COVID-19 pandemic and cardiac imaging: EACVI recommendations on precautions, indications, prioritization, and protection for patients and healthcare personnel. AU - Skulstad, Helge AU - Cosyns, Bernard AU - Popescu, Bogdan A. AU - Galderisi, Maurizio AU - Salvo, Giovanni Di AU - Donal, Erwan AU - Petersen, Steffen AU - Gimelli, Alessia AU - Haugaa, Kristina H. AU - Muraru, Denisa AU - Almeida, Ana G. AU - Schulz-Menger, Jeanette AU - Dweck, Marc R. AU - Pontone, Gianluca AU - Sade, Leyla Elif AU - Gerber, Bernhard AU - Maurovich-Horvat, Pal AU - Bharucha, Tara AU - Cameli, Matteo AU - Magne, Julien AU - Westwood, Mark AU - Maurer, Gerald AU - Edvardsen, Thor T2 - European heart journal cardiovascular Imaging DA - 2020/06/01/ PY - 2020 DO - 10.1093/ehjci/jeaa072 VL - 21 IS - 6 SP - 592 EP - 598 J2 - Eur Heart J Cardiovasc Imaging LA - eng SN - 2047-2412 2047-2404 N1 -

Cited By :1

N1 -

Export Date: 5 May 2020

KW - Humans KW - COVID-19 KW - SARS-CoV-2 KW - Pandemics/*prevention & control KW - Betacoronavirus/isolation & purification KW - Coronavirus Infections/diagnostic imaging/epidemiology/*prevention & control/transmission KW - Echocardiography, Transesophageal/methods/standards KW - Echocardiography/*methods/*standards KW - Heart Diseases/*diagnostic imaging/*virology KW - Infectious Disease Transmission, Patient-to-Professional/*prevention & control KW - Pneumonia, Viral/diagnostic imaging/epidemiology/*prevention & control/transmission KW - Ultrasonography, Prenatal/methods/standards ER - TY - JOUR TI - Can chlorine dioxide prevent the spreading of coronavirus or other viral infections? Medical hypotheses. AU - Kály-Kullai, K. AU - Wittmann, M. AU - Noszticzius, Z. AU - Rosivall, László T2 - Physiology international AB - MOTIVATION: Viruses have caused many epidemics throughout human history. The novel coronavirus [10] is just the latest example. A new viral outbreak can be unpredictable, and development of specific defense tools and countermeasures against the new virus remains time-consuming even in today's era of modern medical science and technology. In the lack of effective and specific medication or vaccination, it would be desirable to have a nonspecific protocol or substance to render the virus inactive, a substance/protocol, which could be applied whenever a new viral outbreak occurs. This is especially important in cases when the emerging new virus is as infectious as SARS-CoV-2 [4]. AIMS AND STRUCTURE OF THE PRESENT COMMUNICATION: In this editorial, we propose to consider the possibility of developing and implementing antiviral protocols by applying high purity aqueous chlorine dioxide (ClO2) solutions. The aim of this proposal is to initiate research that could lead to the introduction of practical and effective antiviral protocols. To this end, we first discuss some important properties of the ClO2 molecule, which make it an advantageous antiviral agent, then some earlier results of ClO2 gas application against viruses will be reviewed. Finally, we hypothesize on methods to control the spread of viral infections using aqueous ClO2 solutions. DA - 2020/03/01/ PY - 2020 DO - 10.1556/2060.2020.00015 VL - 107 IS - 1 SP - 1 EP - 11 J2 - Physiol Int LA - eng SN - 2498-602X N1 -

Export Date: 5 May 2020

KW - Humans KW - COVID-19 KW - SARS-CoV-2 KW - Research Design KW - *Pandemics/prevention & control KW - Disease Transmission, Infectious/*prevention & control KW - *Betacoronavirus/drug effects/pathogenicity/physiology KW - *Communicable Diseases, Emerging/prevention & control/virology KW - *Coronavirus Infections/epidemiology/prevention & control/transmission/virology KW - *Pneumonia, Viral/epidemiology/prevention & control/transmission/virology KW - Antiviral Agents/pharmacology KW - Chlorine Compounds/*pharmacology KW - Clinical Protocols KW - Disinfectants/pharmacology KW - Oxides/*pharmacology KW - Pharmaceutical Solutions/pharmacology ER - TY - JOUR TI - Social markers of a pandemic: modeling the association between cultural norms and COVID-19 spread data AU - Kapitány-Fövény, M. AU - Sulyok, M. T2 - Humanities and Social Sciences Communications DA - 2020/// PY - 2020 DO - 10.1057/s41599-020-00590-z DP - Scopus VL - 7 IS - 1 SP - 97 J2 - Hum. Soc. Sci. Comm LA - English SN - 26629992 (ISSN) UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85091181237&doi=10.1057%2fs41599-020-00590-z&partnerID=40&md5=4a00d9c89ce04f806eab5fcc0d26ab20 N1 -

Cited By :1

N1 -

Correspondence Address: Kapitány-Fövény, M.; Faculty of Health Sciences, Semmelweis University, Vas utca 17, Hungary; email: m.gabrilovics@gmail.com

N1 -

Export Date: 8 December 2020

ER - TY - JOUR TI - Comparison of four PCR and two point of care assays used in the laboratory detection of SARS-CoV-2. AU - Kenyeres, Bence AU - Ánosi, Noel AU - Bányai, Krisztián AU - Mátyus, Mária AU - Orosz, László AU - Kiss, Andrea AU - Kele, Beatrix AU - Burián, Katalin AU - Lengyel, György T2 - Journal of virological methods AB - Seeing the global emergence and the lack of a definitive cure for COVID-19, it is essential to find the most sensitive and specific detection method to identify infected patients in a timely manner. Our paper aims to compare the clinical sensitivity of different commercial RT-qPCR (Genesig, 1copy, DNA-Techonolgy and Charité primer-probe sets), isothermal PCR (Ustar Isothermal Amplification-Real Time Fluorescent Assay) and immunochromatographic antigen detection (BOCREDIT COVID-19 Ag) assays developed to use in laboratory diagnosis of COVID-19. A total of 119 nasopharyngeal swab specimens were collected from symptomatic patients. A subset of samples, positive with two RT-qPCR assays were then tested with isothermal PCR and rapid antigen tests. Of the 119 specimens, 65 were positive by at least two PCR assays. All PCR assays showed substantial or perfect match, although some variations in the clinical performance was observed. Of the 37 and 32 remnant nasopharyngeal samples positive by RT-qPCR, respectively, three were positive by the BIOCREDIT COVID-19 Ag and 14 were detected by the isothermal amplification assay. In conclusion, in the clinical settings we recorded that each of the RT-qPCR assays was superior to other test formats, in particular, the routine use of the DNA-technology assay is recommended. Although alternative recommendations exist, we belive that the use of isothermal amplifiaction assays and antigen rapid tests for COVID-19 diagnosis can only serve as adjuncts while awaiting the PCR result because of their high false-negative rate. DA - 2021/04/16/ PY - 2021 DO - 10.1016/j.jviromet.2021.114165 VL - 293 SP - 114165 J2 - J Virol Methods LA - eng SN - 1879-0984 0166-0934 L1 - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8051013/pdf/main.pdf L2 - http://www.ncbi.nlm.nih.gov/pubmed/33872650 N1 -

CODEN: JVMED

N1 -

Correspondence Address: Lengyel, G.; Róbert Károly krt. 44Hungary; email: lgvirology@gmail.com

N1 -

Export Date: 12 May 2021

KW - Humans KW - COVID-19 KW - SARS-CoV-2 KW - Antigens, Viral KW - RT-qPCR KW - laboratory diagnostics KW - SARS CoV-2 KW - Laboratory diagnostics KW - COVID-19 Nucleic Acid Testing KW - Point-of-Care Testing KW - Reagent Kits, Diagnostic KW - Workflow ER - TY - JOUR TI - The corona-virus disease 2019 pandemic compromised routine care for hypertension: a survey conducted among excellence centers of the European Society of Hypertension AU - Weber, T. AU - Januszewicz, A. AU - Rosei, E. A. AU - Tsioufis, K. AU - Okorie, M. AU - Stergiou, G. S. AU - Volpe, M. AU - Kreutz, R. AU - Abraham, G. AU - Azizi, M. AU - Barna, I. AU - Barroso, W. K. S. AU - Brguljan, J. AU - Chapman, N. AU - De Backer, T. AU - Dorobantu, M. AU - Eckert, S. AU - Gaciong, Z. AU - Giannattasio, C. AU - Glover, M. AU - Gottsater, A. AU - Grassos, C. AU - Jarai, Z. AU - Aguila, F. J. AU - Kahan, T. AU - Lopez-Sublet, M. AU - Lovic, D. AU - Lurbe, E. AU - Makris, T. K. AU - Mallamaci, F. AU - Manolis, A. J. AU - Marketou, M. AU - Mazza, A. AU - Mediavilla, J. D. AU - Muiesan, M. L. AU - Muxfeldt, E. S. AU - Nasr, E. AU - Papadakis, I. AU - Parounak, Z. AU - Obregon, S. AU - Okorie, M. AU - Oliveras, A. AU - Pontremoli, R. AU - Raev, D. AU - Rajkumar, C. AU - Redon, J. AU - Robles, N. R. AU - Rump, L. C. AU - Sarzani, R. AU - Sierra, C. AU - Sirenko, Y. AU - Stojanov, V. AU - Tikkanen, I. AU - Vaclavik, J. AU - Veglio, F. AU - Viigimaa, M. AU - Webb, D. AU - Zebekakis, P. AU - Zweiker, R. AU - European Soc Hypertension Corona, V. T2 - Journal of Hypertension AB - Background: The Covid-19 pandemic caused a shutdown of healthcare systems in many countries. We explored the impact on hypertension care in the Excellence Center (EC) network of the European Society of Hypertension. Methods: We conducted a 17-question electronic survey among ECs. Results: Overall, 52 ECs from 20 European and three non-European countries participated, providing hypertension service for a median of 1500 hypertensive patients per center per year. Eighty-five percent of the ECs reported a shutdown lasting for 9 weeks (range 0-16). The number of patients treated per week decreased by 90%: from a median of 50 (range 10-400) before the pandemic to a median of 5.0 (range 0-150) during the pandemic (P < 0.0001). 60% of patients (range 0-100%) declared limited access to medical consultations. The majority of ECs (57%) could not provide 24-h ambulatory BP monitoring, whereas a median of 63% (range 0-100%) of the patients were regularly performing home BP monitoring. In the majority (75%) of the ECs, hypertension service returned to normal after the first wave of the pandemic. In 66% of the ECs, the physicians received many questions regarding the use of renin-angiotensin system (RAS) blockers. Stopping RAS-blocker therapy (in a few patients) either by patients or physicians was reported in 27 and 36.5% of the ECs. Conclusion: Patient care in hypertension ECs was compromised during the Covid-19-related shutdown. These data highlight the necessity to develop new strategies for hypertension care including virtual clinics to maintain services during challenging times. DA - 2021/01//undefined PY - 2021 DO - 10.1097/hjh.0000000000002703 VL - 39 IS - 1 SP - 190 EP - 195 J2 - J. Hypertens. LA - English SN - 0263-6352 UR - ://WOS:000612182400024 AN - WOS:000612182400024 KW - Covid-19 KW - blood pressure KW - Cardiovascular System & Cardiology KW - hypertension routine care KW - renin-angiotensin KW - system inhibitors ER - TY - JOUR TI - A COVID-19-járvány szülészeti vonatkozásai AU - Ács, Nándor AU - Supák, Dorina T2 - Orvosképzés AB - Ismert tény, hogy a várandósság során fellépő vírusfertőzések okozhatnak magzati rendellenességeket, és befolyásolhatják a terhesség kimenetelét is. A kínai Wuhanban 2019 decemberében megjelenő új koronavírus-fertőzés rendkívül gyorsan terjedő világjárványt eredményezett, az elmúlt évtized egyik legsúlyosabb közegészségügyi fenyegetését okozva. Az eddigi adatok alapján várandós nőknél nem kell súlyosabb lefolyású COVID-19-fertőzéssel számolni. A fertőzés megelőzésére ugyanazok a javaslatok érvényesek, mint az átlag populációban. Minden egészségügyi ellátónak saját protokoll kidolgozása javasolt az igazolt vagy COVID-19-gyanús esetek ellátására. A terhesség és a szülés menedzselése, valamint az újszülött ellátása nem tér el a megszokottól. Az édesanyákat, megfelelő higiénia és sebészi maszk alkalmazása mellett bátorítjuk a szoptatásra. DA - 2020/// PY - 2020 VL - 95 IS - 3 SP - 539 EP - 543 SN - 0030-6037 UR - https://www.semmelweiskiado.hu/termek/1624/orvoskepzes/2020-xcv-evfolyam-3432-58 ER - TY - JOUR TI - A magyarországi koronavírus-járvány alakulása és a meghozott intézkedések időbeliségének és hatékonyságának összehasonlítása más európai országokkal AU - Árva, Dorottya AU - Mészáros, Ágota AU - Szarvas, Zsófia AU - Madarász, Bálint AU - Fazekas-Pongor, Vince AU - Fehér, Ágnes AU - Ungvári, Zoltán T2 - Orvosképzés AB - Az új koronavírus-(SARS-CoV-2-) fertőzés Európa egyes országait különböző ütemben érte el, a megbetegedések aránya és a halálozás is eltérően alakult. Ehhez számos tényező hozzájárult, a lakosság korösszetételétől, egészségi állapotától kezdve, a járványügyi hatóságok és kormányzatok által meghozott védekező intézkedések gyorsaságáig és eredményességéig. A hazai helyzet összevetése más európai országokéval fontos tapasztalatokkal szolgálhat. Jelen rövid összefoglaló tanulmány ezen intézkedések időbeliségének és a járvány alakulásának vizsgálatát célozza Magyarországon, illetve további három, a járványterjedés eltérő dinamikája szempontjából reprezentatív európai országban: Ausztriában, Olaszországban és Svédországban. Megállapíthatjuk, hogy a magyarországi COVID-19-járvány első hulláma a kormányzat és a járványügyi hatóság határozott, gyors és hatékony intézkedéseinek köszönhetően a vizsgált többi országhoz képest jóval kedvezőbben alakult 2020 májusáig. A növekedés üteme hazánkban mutatkozott a legalacsonyabbnak mind az esetszámok,mind a halálozások terén. A járványügyi korlátozó intézkedések Magyarországon és Ausztriában kerültek leggyorsabban bevezetésre az első igazolt COVID-19-esetek regisztrálása után, míg Olaszországban ez 5–19 nappal, Svédországban pedig 30–35 nappal később következett be. Az eredményes intézkedéseknek köszönhetően Magyarországon 2020 májusáig valószínűleg több ezer életet sikerült megmenteni. DA - 2020/// PY - 2020 VL - 95 IS - 3 SP - 450 EP - 459 SN - 0030-6037 UR - https://www.semmelweiskiado.hu/termek/1624/orvoskepzes/2020-xcv-evfolyam-3432-58 ER - TY - JOUR TI - COVID-19-fertőzés kezelése az alapellátásban AU - Badak, Éva AU - Kalabay, Márton AU - Kalabay, László T2 - Orvosképzés AB - Magyarországon az orvos-beteg találkozások 70%-a az alapellátásban valósul meg, ezért a háziorvosnak kulcsszerepe van a COVID-19 fertőzésre gyanús betegek kiszűrésében, az otthoni karanténban lévő betegek kezelésének irányításában, az esetleges állapotromlás időben történő felismerésében. Emellett el kell látni a praxishoz tartozó többi, nem COVID-19 fertőzött beteget is. A COVID-19 világjárvány így jelentős terhet ró az alapellátásra is. A magyarországi háziorvosok életkori átlaga 58,2 év, 10%-uk 70 év feletti, ahol a koronavírus halálozása meghaladja a 8%-ot. Sokuk ezért telefonvégről dolgozik. A gyanús tüneteket észlelő betegek telefonon fordulhatnak háziorvosukhoz, aki egy előre összeállított csekklista alapján dönti el, hogy fenn áll-e COVID-19 fertőzés veszélye. Ezután szükséges az OMSZ-nál mintavételezést kérvényezni, a beteget házikaranténba helyezni. Fontos továbbá a betegség pontos BNO kódolása is. A nem COVID-19–ben szenvedő betegek ellátása gyökeresen átalakult. A páciensek csak halaszthatatlan, akut esetekben találkozhatnak háziorvosukkal, minden más orvos-beteg konzultáció telefonon történik. Számos országban gond a háziorvosok körében a nem elegendő védőfelszerelés készlet. Hazánkban ez különösen nagy probléma, mivel a háziorvosok jelentős hányada életkoránál fogva veszélyeztetett csoportba tartozik. Nemzetközi adatok alapján erre részlegesen ugyan, de megoldást nyújthat a videokonzultáció bevezetése a háziorvosi gyakorlatba. A járvány valószínűleg nem hagyja változás nélkül az egészségügyi ellátás, ezen belül a háziorvosi rendszer jövőbeli működését sem. Az internetes kapcsolattartást a járvány után még szélesebb körben, hatékonyabban ki lehetne használni. DA - 2020/// PY - 2020 VL - 95 IS - 3 SP - 555 EP - 561 SN - 0030-6037 UR - https://www.semmelweiskiado.hu/termek/1624/orvoskepzes/2020-xcv-evfolyam-3432-58 ER - TY - JOUR TI - A COVID-19-fertőzés ápolási és ápolásoktatási vonatkozásai AU - Balogh, Zoltán AU - Pápai, Tibor AU - Nagy, Zoltán Zsolt T2 - Orvosképzés AB - A COVID-19-világjárvány kapcsán az ápolás területén dolgozók és tanulók speciális képzése megkezdődött a Semmelweis Egyetem Egészségtudományi Karán. A hallgató felkészítése önkéntes alapon kezdődött meg a B-learning módszerrel. Kiemelt terület volt a kézhigiéné, a személyi védőeszközök használata, a fertőző betegek izolációja és ápolása. Képzést végeztünk az oxigénterápia, a légútbiztosítás, mesterséges lélegeztetés, invazív beavatkozások vonatkozásában. Az Egészségtudományi Karon 3 új oktatófilm készült a kézfertőtlenítésről, az artériás vér mintavételéről, az endotrachealis tubus használatáról és a betegek mobilizációjáról. Az ápolók és képzésük megfelelően és azonnal alkalmazkodott a COVID-19-járvány kihívásaihoz. DA - 2020/// PY - 2020 VL - 95 IS - 3 SP - 575 EP - 577 SN - 0030-6037 UR - https://www.semmelweiskiado.hu/termek/1624/orvoskepzes/2020-xcv-evfolyam-3432-58 ER - TY - JOUR TI - COVID-19 pulmonalis manifesztációi AU - Bárczi, Enikő AU - Müller, Veronika T2 - Orvosképzés AB - 2019 decemberében egy újfajta vírusos megbetegedés jelent meg a kínai Vuhan városában. A COVID-19-nek elnevezett SARS-CoV-2 vírus által okozott, sok esetben súlyos légúti kórkép a világ egészségügyi ellátásának a középpontjába került 2020 év első felében. A vírus által okozott pulmonalis megbetegedés jellegzetesen kétoldali atípusos pneumonia, amely súlyos légzési elégtelenséghez, sok esetben halálhoz vezethet. A közlemény megírásának idején több mint 233000 ember halálát és 3,2 millió megbetegedést okozott járvány néhány hónap alatt. Az új vírus terjedését elősegíti, hogy jelenleg nem rendelkezünk megfelelő immunitással, célzott terápiával, és a védőoltás kifejlesztése is még kutatási stádiumban van. DA - 2020/// PY - 2020 VL - 95 IS - 3 SP - 504 EP - 509 SN - 0030-6037 UR - https://www.semmelweiskiado.hu/termek/1624/orvoskepzes/2020-xcv-evfolyam-3432-58 ER - TY - JOUR TI - A kardiológia kihívásai a COVID-19-pandémia idején AU - Becker, Dávid AU - Fülöp, Gábor Áron AU - Sax, Balázs AU - Skoda, Réka AU - Merkely, Béla T2 - Orvosképzés AB - A COVID-19-pandémia jelenleg több, mint 3,5 millió embert betegített meg, és eddig közel 250 000 halálos áldozata van. A halálozás 3–5% közöttre tehető. Több ok vezet a betegek halálához, a vírus okozta súlyos pneumonia, következményes ARDS, citokinvihar mellett súlyos cardiovascularis szövődmények is kialakulhatnak. Ezen túlmenően a krónikus cardiovascularis betegségben szenvedők fokozott kockázatnak vannak ki téve. A közlemény tárgyalja az egyes patomechnanizmusokat, a különböző kardiológiai kórképeket, külön is tárgyalja a szívtranszplantált betegeket, és a járvány hatását az akut kardiológiai ellátásra. Ezen írás egy pillanatnyi helyzetet tükröz, hangsúlyozni kell, hogy naponta jelennek meg új adatok, elsősorban nagy esetszámú megfigyeléses vizsgálatok eredményei, melyek a COVID-19-cel kapcsolatos kardiológiai ellátást befolyásolhatják. DA - 2020/// PY - 2020 VL - 95 IS - 3 SP - 510 EP - 516 SN - 0030-6037 UR - https://www.semmelweiskiado.hu/termek/1624/orvoskepzes/2020-xcv-evfolyam-3432-58 ER - TY - JOUR TI - A COVID-19 gyermekgyógyászati vonatkozásai AU - Becsei, Dóra AU - Pajtók, Csenge AU - Körner, Anna AU - Szabó, J. Attila T2 - Orvosképzés AB - A COVID-19-pandémia 2019 decemberében indult a kínai Wuhanban. Azóta világszerte jelentős kihívás elé állítja a népességet, kifejezetten az egészségügyi dolgozókat. A fertőzés okozója SARS-COV-2RNS vírus. Április 26-án közel 3 millió bejelentett fertőzött volt ismert. Jelen ismereteink alapján a betegség gyermekekben kevésbé súlyos klinikai kórképpel és alacsony halálozással jár. Célunk az irodalmi adatok áttekintése a COVID-19 gyermekkori epidemiológiájáról, klinikai tüneteiről, laboratóriumi és képalkotó vizsgálatok eredményeiről, terápiás lehetőségekről. DA - 2020/// PY - 2020 VL - 95 IS - 3 SP - 532 EP - 538 SN - 0030-6037 UR - https://www.semmelweiskiado.hu/termek/1624/orvoskepzes/2020-xcv-evfolyam-3432-58 ER - TY - JOUR TI - A SARS-CoV-2 koronavírus által okozott COVID-19-járvány neurológiai vonatkozásai AU - Bereczki, Dániel AU - Stang, Rita AU - Böjti, Péter AU - Kovács, Tibor T2 - Orvosképzés AB - A SARS-CoV-2 koronavírus által okozott COVID-19 járvány 2020 tavaszára világszerte elterjedt, gyors és hatékony reakciót igényelve össztársadalmi szinten és az egészségügyi ellátás szervezésében is. A COVID-19 fő tünetének a lázat, a köhögést és a nehézlégzést tartják. A légzőszervi érintettségen túl a fertőzés egyéb panaszokat és tüneteket is okozhat. Az eddigi adatok alapján neurológiai jellegű panaszok és tünetek a kórházba kerülő COVID-19 betegek 30–50%-ánál előfordulnak, és gyakrabban jelentkeznek a súlyos állapotú eseteknél. Leírtak a COVID-19-hez társuló klasszikus akut neurológiai kórképeket is. A COVID-19 ellátásra fókuszáló egészségügyi ellátórendszerekben az egyéb akut ellátást igénylő kórképek szakellátásának visszaesését figyelték meg. A COVID-19-járvány során fontos feladat a krónikus neurológiai kórképekben szenvedők folyamatos ellátásának biztosítása is. A jövő feladata lesz a COVID-19-járvány által az egyéb neurológiai kórképekre kifejtett hatások felmérése, valamint annak megítélése, hogy a SARS-CoV-2 koronavírus által okozott fertőzés járhat-e késői neurológiai szövődményekkel. DA - 2020/// PY - 2020 VL - 95 IS - 3 SP - 517 EP - 521 SN - 0030-6037 UR - https://www.semmelweiskiado.hu/termek/1624/orvoskepzes/2020-xcv-evfolyam-3432-58 ER - TY - JOUR TI - Az orvosi képalkotás szerepe az új koronavírus-pandémiában AU - Futácsi, Balázs AU - Fejér, Bence AU - Maurovich-Horvat, Pál T2 - Orvosképzés AB - A 2019-es coronavírus betegség (COVID-19) diagnosztikájában a vírustörzs RNS izolációja mellett a radiológiai képalkotás alapvető szereppel rendelkezik. A radiológiai vizsgálatok helye a betegség felismerése és kezelése folyamán országonként, ajánlásonként eltérő. A képalkotói eszköztár áttekintése mellett, a nemzetközi tapasztalatokat és irányvonalakat vetjük össze saját tapasztalatainkkal, bemutatva a radiológia helyét a COVID-19 járványidőszakban. Elemezzük milyen hatásokkal volt a járványhelyzet a betegforgalmunkra, bemutatjuk milyen helyi sajátosságok, megfontolások mentén alakítottuk ki az Orvosi Képalkotó Klinika eljárásrendjét. A CT az alapvető diagnosztikán túl a betegség stádiumát és lefolyását is megbízhatóan tudja jelezni, mely mesterséges intelligencia alkalmazásával pontosítható és gyorsítható. A CT ugyanakkor nem kizárólagos modalitás, nem használható szűrőjellegű vizsgálatként, pozitív prediktív értéke csak jelentős tömeges megbetegedés esetén megbízható. A radiológia terén a COVID-19 pandémiában az aktuális fertőzöttségi szinteket figyelembe vevő olyan ajánlási és alkalmazási rendszerek alkalmazása szükséges, amelyek alapján igazodni lehet a járványügyi helyzet gyors változására. A képalkotás segítséget nyújt a diagnosztika, prognosztika és triage területén is. A járványhelyzet enyhülésével a valóban beteghasznot jelentő ellátási stratégiák azonosítása és követése javasolt. DA - 2020/// PY - 2020 VL - 95 IS - 3 SP - 470 EP - 478 SN - 0030-6037 UR - https://www.semmelweiskiado.hu/termek/1624/orvoskepzes/2020-xcv-evfolyam-3432-58 ER - TY - JOUR TI - Fül-orr-gégészeti ellátás COVID-járvány idején AU - Kraxner, Helga AU - Dános, Kornél AU - Szalóki, Tibor AU - Fent, Zoltán AU - Polony, Gábor AU - Gáborján, Anita AU - Szirmai, Ágnes AU - Tamás, László T2 - Orvosképzés AB - A 2019 végén Kínából kiinduló, azóta világjárvánnyá szélesedő COVID-19-nek elnevezett betegség új kihívások elé állította a fül-orr-gégészeti szakmát mind diagnosztikai, mind terápiás szempontból. A betegséget a SARS-CoV-2 elnevezésű vírus okozza, ami az orrgarat, valamint a szájgarat területéről mutatható ki a legnagyobb biztonsággal és a legkisebb megterhelést jelentő módon mind a beteg, mind a vizsgáló szempontjából. A járványhelyzetben a fül-orr-gégészeti szakma számára a szűrővizsgálatok végzése jelent új kihívást, hatalmas új feladatot. Ennek tükrében cikkünkben áttekintjük a diagnosztikus lehetőségeket, kiemelve az orrgarati és szájgarati mintavétel helyes módját, megbízhatóságát, egyéb diagnosztikus lehetőségek környezetébe illesztve. Emellett az általános fül-orr-gégészeti betegellátásban és a speciális szakambulanciák működésében a járványhelyzet hatására bekövetkező változásokat ismertetjük. Kiemelten foglalkozunk a műtéti ellátással, a sürgős műtétek indikációival, áttekintjük a járvány idejére vonatkozó technikai javaslatokat és a műtét közben alkalmazandó óvintézkedéseket, minden esetben elsődleges szempontként figyelembe véve a fertőzés terjedésének megakadályozását. DA - 2020/// PY - 2020 VL - 95 IS - 3 SP - 490 EP - 503 SN - 0030-6037 UR - https://www.semmelweiskiado.hu/termek/1624/orvoskepzes/2020-xcv-evfolyam-3432-58 ER - TY - JOUR TI - A COVID-19-pandémia aneszteziológiai és intenzív terápiás tapasztalatai és tudományos evidenciái 2020 május elején AU - Madách, Krisztina AU - Iványi, Zsolt AU - Orosz, Gábor AU - Gál, János T2 - Orvosképzés AB - A Világ Egészségügyi Szervezet (WHO) globális egészségügyi vészhelyzetet hirdetett amikor a SARS-CoV-2-járvány világszerte elterjedt. A COVID-19-betegeknél az intenzív terápiát igénylő légzési és többszervi elégtelenség rizikója magas. Ezen betegek intenzív terápiás ellátása kétféle szempontból is kihívást jelent. Először is, az intenzív kezelést igénylők száma, állapotának súlyossága és elhúzódó kezelési igénye könnyen túlterhelheti az egészségügyi rendszer kapacitását. Másodszor, a SARS-CoV-2-fertőzés oki terápiáját még nem fedezték fel, így ennek a magas intenzív osztályos mortalitású betegségnek a kezelése továbbra is tüneti. A referátum áttekintést nyújt azon intenzív terápiás tervezési és operációs lépésekről, munkaerő- menedzsmentről, melyek segítségével az intenzív terápiás kapacitás adaptálható egy hirtelen megnövekedő ellátási igényhez, valamint az aktuálisan rendelkezésre álló bizonyítékok alapján összefoglalja a COVID-19-betegek intenzív terápiás kezelési lehetőségeit (ide értve a gépi lélegeztetést és a farmakológiai kutatásokat). DA - 2020/// PY - 2020 VL - 95 IS - 3 SP - 479 EP - 489 SN - 0030-6037 UR - https://www.semmelweiskiado.hu/termek/1624/orvoskepzes/2020-xcv-evfolyam-3432-58 ER - TY - JOUR TI - A COVID-19-járvány hazai története AU - Merkely, Béla AU - Varga, Péter AU - Kosztin, Annamária AU - Fülöp, Gábor AU - Schwertner, Walter Richárd AU - Szabó, Attila T2 - Orvosképzés AB - Az első új típusú koronavírus-fertőzés 2020.03. 05-én igazolódott Magyarországon. A korai korlátozóintézkedéseknek és a Semmelweis Egyetem által vezetett szűrőprorgam adatai alapján, a négy orvosi egyetem és egy országos lefedettségű hazai magánlabor által végzett PCR vizsgálatok eredményei a magyarországi COVID-19-fertőzöttség és átfertőzöttség prevalenciáját alacsonynak mutatják. DA - 2020/// PY - 2020 VL - 95 IS - 3 SP - 438 EP - 445 SN - 0030-6037 UR - https://www.semmelweiskiado.hu/termek/1624/orvoskepzes/2020-xcv-evfolyam-3432-58 ER - TY - JOUR TI - A koronavírus- (COVID-19-) fertőzés szemészeti tüneteiről és a szemészeti teendőkről AU - Nagy, Zoltán Zsolt T2 - Orvosképzés AB - A COVID-19 vírusfertőzés 2020 elején világjárvánnyá vált, terjedése elsősorban cseppfertőzéssel és aeroszolizációval történik. A jellegzetes légúti tünetek (száraz köhögés, láz, tüdőgyulladás) mellett szemészeti tünetek (conjunctivitis, follicularis conjunctivitis, chemosis, könnyezés) is megjelentek. A szemészeti tünetek gyakorisága eltérő az eddigi adatok szerint. A célzott vizsgálatok során a könnyben és a kötőhártyában is sikerült a vírust izolálni, ezért a szemészeti úton történő fertőzés módja nem zárható ki. A szemészeti és sürgősségi osztályon dolgozóknak fokozott figyelemmel kell védekezniük a szemészeti úton terjedő fertőzések ellen, ezért maszk,védőszemüveg és fertőzés esetén plexiből készült sisakviselése is javasolt. A közleményben áttekintésre kerülnek a szemészeti eltérésekkel kapcsolatos irodalmi adatok, a védekezés módja, a terápiás lehetőségek és azok lehetséges mellékhatásai, valamint a sürgősségi ellátást igénylő szemészeti kórképek, továbbá a szemészeti osztályok tevékenységének átszervezési szempontjai a járvány idején. DA - 2020/// PY - 2020 VL - 95 IS - 3 SP - 527 EP - 531 SN - 0030-6037 UR - https://www.semmelweiskiado.hu/termek/1624/orvoskepzes/2020-xcv-evfolyam-3432-58 ER - TY - JOUR TI - Fogorvosi és szájsebészeti ellátás átszervezése a COVID-19-pandémia alatt a Semmelweis Egyetem Fogorvostudományi Karán AU - Németh, Orsolya AU - Németh, Zsolt AU - Hermann, Péter T2 - Orvosképzés AB - Március 11-én Magyarország kormánya epidemiológiai veszélyhelyzetet hirdetett ki, ezzel egyidőben a WHO pandémiává nyilvánította a COVID-19-járványt. Az események hatására kizárólag sürgősségi betegellátásra korlátozták a fogászati alap- és szakellátást. A magyarországi korlátozó intézkedések világviszonylatban is kifejezetten szigorúnak tekinthetők, szükségességüket azonban indokolja a fogorvosi beavatkozások többsége által generált aeroszol által jelentett nagyfokú rizikó a fertőzés továbbterjedésében. Mind az államilag finanszírozott, mind a magánszféra fogorvosi szolgáltatóit váratlanul érte a rendkívüli helyzet, melynek eredményeképpen többségük felfüggesztette működését. A Semmelweis Egyetem Fogorvostudományi Kara, mint az ország legnagyobb fogorvosképző helye és a régió legnagyobb betegellátója komoly kihívásokkal szembesült, hiszen a sürgősségi betegellátás fenntartása, a dolgozói és páciensbiztonság új protokolljainak kialakítása és adaptálása sürgető és komoly megmérettetést jelentett az intézmények életében. A Kar mindhárom betegellátó tömbjében (Oktatási Centrum, Arc-Állcsont-Szájsebészeti és Fogászati Klinika, Fogászati és Szájsebészeti Oktató Intézet) közös ellátási rend került bevezetésre. A potenciálisan fertőzött személyek azonosítására és kiszűrésére szolgáló állomásként bevezetésre került a „triage”. A Karon betegellátást végző orvosi és szakdolgozói személyzet biztonságának érdekében elengedhetetlen a megfelelő minőségű és mennyiségű speciális védőfelszerelés, ennek elosztása a Semmelweis Egyetem klinikái között központi forrásból, a betegforgalomnak megfelelően történt. Május 4-től a kezdeti szigorítások enyhítését rendelte el az Egészségügyi Minisztérium, melynek keretein belül a fogorvosi alap- és szakellátás újraindításának megfelelő, biztonságos kivitelezése új kihívások elé állítja a Kart. DA - 2020/// PY - 2020 VL - 95 IS - 3 SP - 548 EP - 554 SN - 0030-6037 UR - https://www.semmelweiskiado.hu/termek/1624/orvoskepzes/2020-xcv-evfolyam-3432-58 ER - TY - JOUR TI - A COVID-19 patológiai vonatkozásai AU - Pápay, Judit T2 - Orvosképzés AB - A COVID-19-betegséget okozó SARS-CoV-2 a 2002–2003-ban járványhoz vezető SARS-CoV vírushoz hasonlóan, az ACE2-receptor felhasználásával jut be a célsejtekbe, és elsősorban a légzőrendszer károsításával vezet gyakran fatális szövődményhez. Klinikailag ARDS alakul ki, amelynek hátterében leggyakrabban akut alveolaris károsodás (diffuse alveolar damage, DAD) áll. A szívben megfigyelt nem ischaemiás elváltozások nagy valószínűséggel a citokinvihar, a hyperinflammatoricus szindróma és a fokozott koagulabilitás következtében jönnek létre. Renalis szövődményként részben az ARDS-asszociált akut veseelégtelenség, részben a vírus közvetlen jelenlétével magyarázható, a proximalis tubulusokat érintő károsodás figyelhető meg. Tüdő-, agy- és vesekárosodást egyaránt elszenvedő betegeknél az elváltozások hátterében multifokális thromboembolisatiót tapasztaltak. Az idegrendszeri szövődmények centrális és perifériás érintettség alapján sorolhatók külön csoportba. Utóbbiak közül járványügyi szempontból is fontos az egyébként tünetmentes betegekben kialakuló szaglási és ízérzési zavarok kialakulása, mely vírushordozásra hívja fel a figyelmet. Különösen jelentős annak felismerése, hogy míg a SARS-CoV elsősorban immunkárosodott betegeket érintett, addig a SARS-CoV-2 az egyéb, olyan alapbetegségben szenvedőket is, akiknél az endothelsejtek a vírusfertőzést megelőző károsodása prediszponáló tényező lehet. Ilyen károsodáshoz vezethet többek között a dohányzás, a magas vérnyomás, a cukorbetegség, és a már fennálló cardiovascularis betegség. DA - 2020/// PY - 2020 VL - 95 IS - 3 SP - 464 EP - 469 SN - 0030-6037 UR - https://www.semmelweiskiado.hu/termek/1624/orvoskepzes/2020-xcv-evfolyam-3432-58 ER - TY - JOUR TI - A jót keresd, ne a rosszat – megküzdés járvány idején. A COVID-19 pszichés hatásai AU - Perczel-Forintos, Dóra T2 - Orvosképzés AB - A koronavírus-járvány kezdete óta számos országban karantént rendeltek el. Mind a karantén, mind a járvány fokozott érzelmi reakciókat válthat ki: szorongást, a hangulati élet nyomottságát, haragot, reménytelenséget, ingerültséget. Poszttraumás állapot is kialakulhat, különösen a karanténba zárt gyermekeknél, illetve egészségügyi dolgozóknál. A karantén közben a legfőbb stresszforrás a járvány ismeretlensége, kontrollálhatatlansága és a tájékoztatás hiányából adódó bizonytalanság. Ezzel szemben karantén után a tisztaságmánia és az egészségszorongás fokozódhat, az anyagi veszteségek és nehézségek egzisztenciális szorongáshoz, alkohol abúzushoz vezethetnek. A karantén következményeinek enyhítésében társadalmi szinten a legfontosabb teendő a pontos és gyakori tájékoztatás, a karantén védőhatásának hangsúlyozása és lehető legrövidebb ideje, védőfelszerelés és források biztosítása. Mivel a járvány idején az egészségügyi dolgozók extrém terhelésnek vannak kitéve, fokozott figyelemmel és megbecsüléssel kell feléjük fordulni. Mind számukra, mind a lakosság mentális egészsége védelmében elengedhetetlen telefonos lelkisegély-szolgálatok felállítása. A lelki egészség megőrzése járvány idején különösen fontos. A pozitív pszichológiai kutatások eredményei szerint a következő tényezők segíthetnek a rendkívüli helyzettel való megküzdésben: a szorongás normalizálása, a katasztrofizáló gondolkodás csökkentése, strukturált napirend kialakítása, felelős hírfogyasztás,hála és önegyüttérzés kialakítása. A relaxáció, a mindfulness technikák,valamint a testmozgás szintén nélkülözhetetlenek a világjárvánnyal való megküzdésben. A rendkívüli helyzetben a hatóságoknak körültekintően kell mérlegelni, hogy a kötelező tömeges karanténnak (kijárási tilalomnak) nagyobb legyen a hozama, mint az ára, vagyis amennyire lehetséges, a pozitív hatásai érvényesüljenek azzal a pszichés teherrel szemben,amit az elzártság, magány vagy egyedüllét jelent. DA - 2020/// PY - 2020 VL - 95 IS - 3 SP - 562 EP - 569 SN - 0030-6037 UR - https://www.semmelweiskiado.hu/termek/1624/orvoskepzes/2020-xcv-evfolyam-3432-58 ER - TY - JOUR TI - A pszichiátriai intézményrendszer és szakmai közösség feladatai a COVID-19-járvánnyal kapcsolatban AU - Réthelyi, János T2 - Orvosképzés AB - A COVID-19-járvány előzmények nélküli helyzetet teremtett, és teljesen új kihívások és feladatok elé állította az egészségügyi ellátórendszert világszerte és Magyarországon is. A pszichiátriai intézményrendszer és szakmai közösség nem a COVID-19-járvány okozta „háború frontvonalában harcol”, ugyanakkor nagyon fontos feladatai lettek az egészségügy „hátországban”. Ezek közül a legfontosabb megoldandó feladatok az alábbiak: A pszichiátriai betegséggel élők biztonságos ellátása a járványügyi korlátozások idején is, digitális, telemedicinális, járóbeteg-, nappali kórházi és szükség esetén fekvőbeteg-keretek között. Ehhez a pszichiátriai ellátó intézményeken belül intermedier osztályok felállítása vált szükségessé, valamint a sürgősségi betegellátó és egyéb szomatikus osztályokkal való szoros együttműködés. Külön fel kellett készülni a szuicid kísérletek, az addiktológiai problémák és általában a relapszusok számának növekedésére, valamint a járványügyi szempontból magas kockázatú hajléktalan és idős betegcsoportok ellátására. A klasszikus konzultációs pszichiátria keretében biztosítani szükséges a COVID-19-betegséggel kezelt páciensek pszichiátriai konzíliumi vizsgálatait. Sok egyéb országos kezdeményezés mellett a Semmelweis Egyetem Pszichiátriai és Pszichoterápiás Klinika az egyetemi egészségügyi dolgozók részére konzultációs, szupportív pszichoterápiás, krízisintervenciós lehetőséget szervezett meg és biztosít a Klinikai Pszichológiai Tanszékkel és a Magatartástudományi Intézettel közösen. A tudományos fronton ezen túlmenően számos vizsgálat indul jelenleg világszerte a koronavírus-betegség hosszú távú neuropszichiátriai, neuropszichológiai hatásainak, valamint a nem fertőzött populáción belül a karanténszituáció mentálhygiénés és érzelmi hatásainak kutatására. Összefoglalva, a koronavírus-járvány váratlan helyzetében a pszichiáter és pszichológus munkatársaknak részéről olyan innovatív megoldások váltak szükségessé, melyeket a későbbi járvány nélküli időszakban is kamatoztatni fogunk tudni. DA - 2020/// PY - 2020 VL - 95 IS - 3 SP - 570 EP - 574 SN - 0030-6037 UR - https://www.semmelweiskiado.hu/termek/1624/orvoskepzes/2020-xcv-evfolyam-3432-58 ER - TY - JOUR TI - A SARS-CoV-2 vírus gyógyszercélpontjai és a COVID-19-betegség gyógyszeres kezelési lehetőségei AU - Riba, Pál AU - Varga, Zoltán AU - Király, Kornél AU - Kató, Erzsébet AU - Ferdinandy, Péter T2 - Orvosképzés AB - A SARS-CoV-2 által okozott COVID-19-járvány 2019 novemberében kezdődött Kínában. Azóta a világ minden országában megjelent, a WHO 2020. március 11-én világjárvánnyá nyilvánította. A pandémia hatalmas kihívások elé állította az emberiséget, óriási erőfeszítések folynak hatásos gyógyszerek és védettséget biztosító vakcinák kifejlesztésére. A SARS-CoV-2 koronavírus az RNS-vírusok közé tartozik, rokona a SARS-1 és MERS vírusnak. A vírus a nyálkahártya sejteket támadja, de feltételeznek egyéb közvetlen szervi hatásokat, köztük szívizom-károsító hatást is. Bár az esetek többségében a betegség lefolyása enyhe, a súlyos állapotba kerülő betegekben kétoldali vírusos tüdőgyulladás és ARDS-szerű állapot alakulhat ki, amely halálos lehet. A lehetséges gyógyszer-támadáspontok meghatározásához ismerni kell a vírus életciklusát. Jelenleg nem érhető még el bizonyítottan hatásos gyógyszer a fertőzés leküzdésére, azonban számos, más indikációval már elfogadott, vagy elfogadás előtt álló hatóanyaggal folynak klinikai vizsgálatok. Cikkünkben a lehetséges támadáspontokat és az újrapozicionálható gyógyszerekkel szerzett eddigi tapasztalatokat foglaljuk össze. DA - 2020/// PY - 2020 VL - 95 IS - 3 SP - 578 EP - 583 SN - 0030-6037 UR - https://www.semmelweiskiado.hu/termek/1624/orvoskepzes/2020-xcv-evfolyam-3432-58 ER - TY - JOUR TI - A SARS-CoV-2 strukturális jellemzése AU - Szabó, Dóra AU - Ostorházi, Eszter AU - Kristóf, Katalin AU - Prohászka, Zoltán AU - Vásárhelyi, Barna T2 - Orvosképzés AB - A közlemény rövid összefoglalás a SARS-CoV-2 vírus felépítésében részt vevő fehérjék – az S-glikoprotein, az E-glikoprotein, az Mglikoprotein és az N-nukleoprotein – szerkezetéről, összetételéről és a vírusreplikációban betöltött szerepéről. DA - 2020/// PY - 2020 VL - 95 IS - 3 SP - 446 EP - 449 SN - 0030-6037 UR - https://www.semmelweiskiado.hu/termek/1624/orvoskepzes/2020-xcv-evfolyam-3432-58 ER - TY - JOUR TI - Koronavírus-járvány az idősotthonokban. Kihívások és a megelőzés lehetőségei AU - Tóth, Miklós T2 - Orvosképzés AB - Az idős emberek ellátására specializálódott bentlakásos ápolási intézményekben fokozott a koronavírus járvány ill. betegség (COVID-19) kitörésének a kockázata. Ezen intézmények lakóinál gyakoriak a krónikus háttérbetegségek, úgymint a magas vérnyomás, cukorbetegség, krónikus cardio-és cerebrovascularis betegségek, krónikus obstruktív légúti betegség, rosszindulatú daganat és Alzheimer-kór. A kísérő betegséggel bíró, 65 évnél idősebb betegeknek kifejezetten magas a kockázata, hogy a koronavírussal történő megfertőződés esetén súlyos, akár halálra vezető állapot alakuljon ki. A 80 évnél idősebbeknél a halálozás jóval 25% felett is lehet. A legújabb klinikai tanulmányok szerint az idősotthonok tünetmentes lakói és személyzete fontos szerepet játszanak a járványnak az idősotthonon belüli gyors terjedésében. Mindez azt jelenti, hogy önmagában a tünet-orientált szűrés nem kellően jó stratégia. A tünetes betegek szűrése és az infekciókontrollt célzó intézkedések mellett az idősotthonok lakóin és személyzetén végzett rutinszerű, tömeges PCR-vizsgálatra és periodikus újratesztelésre van szükség. Közleményünkben összefoglaljuk az idősotthonokat sújtó COVID-19-járvány megelőzését, fékezését célzó ajánlásokat. Amennyiben rendelkezésünkre áll a SARS-CoV-2 elleni hatékony és biztonságos vakcina, az idősotthonok lakói és személyzete – az egészségügy egyéb dolgozóihoz hasonlóan – elsőbbséget kell, hogy élvezzenek a védőoltás felvétele során. DA - 2020/// PY - 2020 VL - 95 IS - 3 SP - 522 EP - 526 SN - 0030-6037 UR - https://www.semmelweiskiado.hu/termek/1624/orvoskepzes/2020-xcv-evfolyam-3432-58 ER - TY - JOUR TI - Hematológiai ellátás a COVID-19-pandémia árnyékában. Tapasztalatok és javaslatok a járvány kapcsán a Semmelweis Egyetem III. Sz. Belgyógyászati Klinika nappali kórházából AU - Varga, Gergely AU - Masszi, Tamás T2 - Orvosképzés AB - A COVID-19 járvány megfékezésének legfőbb eszköze a szociális távolságtartás, ami a fertőzés szempontjából nagy rizikójúnak tekintett személyek minél teljesebb izolációját jelenti. De mi van, ha ezek az emberek daganatos betegek, és időszakosan legalábbis kórházi kezelést igényelnek? Hogyan lehet racionálisan egyensúlyba hozni a kezelés szükségességét és a fertőzés átvitelének minimalizálását? Beszámolónk a Semmelweis Egyetem III. Sz. Belgyógyászati Klinika nappali kórházának a COVID-19 járvány kapcsán kialakított stratégiáját foglalja össze, és fogalmaz meg javaslatokat az egyes itt gyógyított hematológiai betegségcsoportokra vonatkozóan. DA - 2020/// PY - 2020 VL - 95 IS - 3 SP - 544 EP - 547 SN - 0030-6037 UR - https://www.semmelweiskiado.hu/termek/1624/orvoskepzes/2020-xcv-evfolyam-3432-58 ER - TY - JOUR TI - Laboratóriumi vizsgálati lehetőségek a COVID-19-járványt okozó SARS-CoV-2 vírus kimutatására AU - Vásárhelyi, Barna AU - Ostorházi, Eszter AU - Kristóf, Katalin AU - Prohászka, Zoltán AU - Szabó, Dóra T2 - Orvosképzés AB - A klinikai laboratóriumi diagnosztikai gyakorlatban a COVID-19-járványt okozó SARS-CoV2 vírus jelenlétét, illetve a vírusexpozíció során termelt antitesteket mutatják ki. A vírus jelenléte a légúti mintában jelenlevő vírus-PNS kimutatásán alapszik; erre az aktuálisan aranystandardnak tekintett real-time PCR-reakciót alkalmazzák. A PCR reakció hátránya, hogy speciális vegyszereket, laboratóriumi hátteret igényel, az eredményre pedig a standard módszerek mellett minimum 4 órát kell várni. Ezért széles körben próbálnak meg a PCR helyettesítésére szerológiai gyorsteszteket használni. A szerológiai gyorstesztek a vírus elleni antitestek jelenlétét mutatják ki, de a fertőző képesség kimutatására nem alkalmasak. Előnyük, hogy 15 percen belül eredményt adnak, nem igényelnek speciális laboratóriumi hátteret. Hátrányuk, hogy nem tisztázott az eredmény klinikai jelentősége. A hamarosan bevezetésre kerülő, vérből végzett szerológiai tesztek (IgG-,IgM-kimutatás) reprodukálhatósága várhatóan nagyobb. Ezek várhatóan fertőzésen átesett személyek felismerését segíthetik. Laboratóriumi teszttől függetlenül a kivizsgálás pontosságát egyértelműen fokozza, ha a beteget a vizsgálat előtt kikérdik és a tünetek alapján indikálják vizsgálatát. DA - 2020/// PY - 2020 VL - 95 IS - 3 SP - 460 EP - 463 SN - 0030-6037 UR - https://www.semmelweiskiado.hu/termek/1624/orvoskepzes/2020-xcv-evfolyam-3432-58 ER - TY - JOUR TI - Sulfobutylether-beta-cyclodextrin-enabled antiviral remdesivir: Characterization of electrospun- and lyophilized formulations AU - Szente, Lajos AU - Puskás, István AU - Sohajda, Tamás AU - Varga, Erzsébet AU - Vass, Panna AU - Nagy, Zsombor Kristóf AU - Farkas, Attila AU - Várnai, Bianka AU - Béni, Szabolcs AU - Hazai, Eszter T2 - Carbohydrate Polymers AB - Veklury™ by Gilead Sciences, Inc., containing antiviral drug, remdesivir (REM) has received emergency authorization in the USA and in Europe for COVID-19 therapy. Here, for the first time, we describe details of the non-covalent, host-guest type interaction between REM and the solubilizing excipient, sulfobutylether-beta-cyclodextrin (SBECD) that results in significant solubility enhancement. Complete amorphousness of the cyclodextrin-enabled REM formulation was demonstrated by X-ray diffraction, thermal analysis, Raman chemical mapping and electron microscopy/energy dispersive spectroscopy. The use of solubilizing carbohydrate resulted in a 300-fold improvement of the aqueous solubility of REM, and enhanced dissolution rate of the drug enabling the preparation of stable infusion solutions for therapy. 2D ROESY NMR spectroscopy provided information on the nature of REM–excipient interaction and indicated the presence of inclusion phenomenon and the electrostatic attraction between anionic SBECD and nitrogen-containing REM in aqueous solution. DA - 2021/00/15/ PY - 2021 DO - 10.1016/j.carbpol.2021.118011 VL - 264 SP - 118011 J2 - Carbohydrate Polymers SN - 0144-8617 UR - https://www.sciencedirect.com/science/article/pii/S0144861721003982 KW - Remdesivir KW - 2D ROESY NMR KW - Differential scanning calorimetry KW - Electrostatic interaction KW - Inclusion KW - RAMAN-mapping KW - Solubilization KW - Sulfobutylether-beta-cyclodextrin KW - X-ray diffraction ER - TY - JOUR TI - Antimicrobial Resistance in the Context of the Sustainable Development Goals: A Brief Review AU - Gajdacs, M. AU - Urban, E. AU - Stajer, A. AU - Barath, Z. T2 - European Journal of Investigation in Health Psychology and Education AB - The reduction in infectious disease morbidity and mortality may be attributed to a variety of factors; however, improved sanitation and public health, and the introduction of vaccines and antibiotics are among the most significant. The development of antimicrobial resistance (AMR) in bacterial pathogens is an expected consequence of evolutionary adaptation to these noxious agents and the widespread use of these drugs has significantly sped up this process. Infections caused by multidrug resistant pathogens are directly associated with worse clinical outcomes, longer hospital stays, excess mortality in the affected patients and an increasing burden and costs on the healthcare infrastructure. The Sustainable Development Goals (SDGs) were published in 2015 by the United Nations to serve as a global blueprint for a better, more equitable, more sustainable life on our planet. The SDGs contextualize AMR as a global public health and societal issue; in addition, the continuing emergence of AMR may limit the attainment on many SDGs. The aim of this mini-review is to provide insight on the interface between attainment of SDGs and the clinical problem of drug resistance in bacteria. DA - 2021/01/09/ PY - 2021 DO - 10.3390/ejihpe11010006 DP - Web of Science VL - 11 IS - 1 SP - 71 EP - 82 J2 - Eur. J. Invest. Health Psychol. Educ. LA - English N1 -

ISI Document Delivery No.: RC9BQ
Times Cited: 0
Cited Reference Count: 92
Gajdacs, Mario Urban, Edit Stajer, Anette Barath, Zoltan
Gajdacs, Mario/J-1118-2019
Gajdacs, Mario/0000-0003-1270-0365
Janos Bolyai Research Scholarship of the Hungarian Academy of SciencesHungarian Academy of Sciences [BO/00144/20/5]; New National Excellence Program of the Ministry for Innovation and Technology from the source of the National Research, Development and Innovation Fund [UNKP-20-5-SZTE-330]; Ministry of Human Capacities, Hungary [20391-3/2018/FEKUSTRAT]; ESCMID's "30 under 30" Award; Multidisciplinary Digital Publishing Institute (MDPI)
M.G. was supported by the Janos Bolyai Research Scholarship (BO/00144/20/5) of the Hungarian Academy of Sciences. The research was supported by the UNKP-20-5-SZTE-330 New National Excellence Program of the Ministry for Innovation and Technology from the source of the National Research, Development and Innovation Fund. Support from Ministry of Human Capacities, Hungary, grant number 20391-3/2018/FEKUSTRAT is acknowledged. M.G. would also like to acknowledge the support of ESCMID's "30 under 30" Award. Part of the article processing charge (APC) was kindly funded by Multidisciplinary Digital Publishing Institute (MDPI).
0
2
Mdpi
Basel
2254-9625

KW - COVID-19 KW - (SDGs) KW - antibiotic resistance KW - antibiotics KW - global health KW - health policy KW - MDR KW - poverty KW - Psychology KW - Sustainable Development Goals ER - TY - JOUR TI - Comparison of virus neutralization activity and results of 10 different anti-SARS-CoV-2 serological tests in COVID-19 recovered plasma donors AU - Szabó, Zsófia AU - Szabó, Tamás AU - Bodó, Kornélia AU - Kemenesi, Gábor AU - Földes, Fanni AU - Kristóf, Katalin AU - Barabás, Eszter AU - Vásárhelyi, Barna AU - Prohászka, Zoltán AU - Fodor, Eszter AU - Jakab, Ferenc AU - Berki, Timea AU - Lacza, Zsombor T2 - Practical Laboratory Medicine AB - Serological testing is a tool to predict protection against later infection. This potential heavily relies on antibody levels showing acceptable agreement with gold standard virus neutralization tests. The aim of our study was to investigate diagnostic value of the available serological tests in terms of predicting virus neutralizing activity of serum samples drawn 5-7 weeks after onset of symptoms from 101 donors with a history of COVID-19. Immune responses against Receptor Binding Domain (RBD), Spike1 and 2 proteins and Nucleocapsid antigens were measured by various ELISA tests. Neutralizing antibody activity in serum samples was assessed by a cell-based virus neutralization test. Spearman correlation coefficients between serological and neutralization results ranged from 0.41 to 0.91 indicating moderate to strong correlation between ELISA test results and virus neutralization. The sensitivity and specificity of ELISA tests in the prediction of neutralization were 35-100% and 35-90% respectively. No clear cut off levels can be established that would reliably indicate neutralization activity. For some tests, however, a value below which the sample is not expected to neutralize can be established. Our data suggests that several of the ELISA kits tested may be suitable for epidemiological surveys 1-2 months after the infection, estimating whether a person may have recently exposed to the virus. Sensitivities considerably superseding specificity at the cut-off values proposed by the manufacturers suggest greater potential in the identification of insufficient antibody responses than in confirming protection. Nevertheless, the former might be important in assessing response to vaccination and characterizing therapeutic plasma preparations. DA - 2021/05// PY - 2021 DO - 10.1016/j.plabm.2021.e00222 DP - PubMed VL - 25 SP - e00222 J2 - Pract Lab Med LA - eng SN - 2352-5517 L2 - http://www.ncbi.nlm.nih.gov/pubmed/33898689 KW - COVID-19 KW - SARS-CoV-2 KW - Antibody response KW - AUC, area under the curve KW - Correlate of protection KW - COVID-19, coronavirus disease 2019 KW - ECDC, European Centre for Disease Prevention and Control KW - NAbs, neutralizing antibodies KW - NC, Nucleocapsid KW - Neutralization KW - OD, optical density KW - ROC, receiver operating characteristic KW - S1, Spike protein 1 KW - S2, Spike protein 2 KW - SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2 KW - Serological test KW - VNT, virus neutralization test ER - TY - JOUR TI - Perceived stress in the time of COVID-19: the association with brooding and COVID-related rumination in adults with and without migraine AU - Kovács, Lilla Nóra AU - Baksa, Dániel AU - Dobos, Dóra AU - Eszlári, Nóra AU - Gecse, Kinga AU - Kocsel, Natália AU - Juhász, Gabriella AU - Kökönyei, Gyöngyi T2 - BMC psychology AB - BACKGROUND: The main goal of this research was to explore whether migraineurs had a higher level of perceived stress than healthy controls during the times of the coronavirus and related restrictive measures, and to examine the relationship between different subtypes of rumination and perceived stress in these groups. We measured two facets of depressive rumination, brooding and reflection, along with rumination about the current COVID-19 situation to see whether these different subtypes of rumination explained perceived stress among migraineurs and healthy controls. METHODS: Healthy adults (n = 64) and migraine patients (n = 73) filled out self-report questionnaires online. A multiple linear regression model was used to test whether depressive rumination (i.e. brooding and reflection) and COVID-related rumination explained perceived stress among adults with and without migraine during the times of COVID-19, after controlling for gender, age, migraine/control group status and migraine disability. RESULTS: Although we did not find any difference in the level of perceived stress among migraineurs and the control group, perceived stress was more strongly associated with brooding as well as COVID-related rumination among migraineurs than healthy controls. COVID-related rumination and brooding (but not reflection) explained the level of perceived stress after controlling for gender, age, migraine/control group status and migraine disability. CONCLUSIONS: The similar degree of perceived stress among migraineurs and the control group may imply that there is great variation in the personal experience of people regarding the pandemic, that may be determined by numerous other factors. Our results demonstrate that ruminating about the pandemic and related difficulties, as well as brooding (but not reflection) appear to be associated with higher level of perceived stress during the times of the coronavirus. This association was slightly stronger among migraineurs, hinting at the increased vulnerability of this patient group in stressful situations like the COVID-19 pandemic. Our results also suggest that ruminating about the pandemic and its consequences is weakly associated with trait-level depressive rumination, thus may be more contingent on specific factors. DA - 2021/04/30/ PY - 2021 DO - 10.1186/s40359-021-00549-y DP - PubMed VL - 9 IS - 1 SP - 68 J2 - BMC Psychol LA - eng SN - 2050-7283 ST - Perceived stress in the time of COVID-19 L2 - http://www.ncbi.nlm.nih.gov/pubmed/33931113 KW - COVID-19 KW - Brooding KW - COVID-related rumination KW - Depressive rumination KW - Migraine KW - Perceived stress KW - Rumination ER - TY - JOUR TI - Population Movement Monitoring Based on Mobile Phone usage Data to Support Pandemic Decision Making AU - Gaal, Peter AU - Szocska, Miklos AU - Joo, Tamas AU - Palicz, Tamas T2 - Ercim News AB - The analysis of routinely generated Big Data is increasingly seen as an inexpensive method to support evidence-based policymaking and implementation. Analysing routine data generated as a result of the use of mobile phones has long been recognised as a potential method to monitor population movement. This would provide invaluable information on the impact of social distancing measures that were implemented at an unprecedented scale during the COVID-19 pandemic [1]. While population movement monitoring on the basis of mobile phone use seems an obvious choice to support the management of the outbreak, several technical questions need addressing: in particular, the challenge of collating data from different mobile network providers. There are also data protection concerns, such as the need to comply fully with General Data Protection Regulation of the European Union (GDPR), which limits the feasibility of using the data in this way. DA - 2021/00//undefined PY - 2021 DP - Web of Science IS - 124 SP - 16 EP - 17 J2 - ERCIM News LA - English SN - 0926-4981 ER - TY - JOUR TI - COVIDOUTCOME-estimating COVID severity based on mutation signatures in the SARS-CoV-2 genome AU - Nagy, Ádám AU - Ligeti, Balázs AU - Szebeni, János AU - Pongor, Sándor AU - Györffy, Balázs T2 - Database: The Journal of Biological Databases and Curation AB - Numerous studies demonstrate frequent mutations in the genome of SARS-CoV-2. Our goal was to statistically link mutations to severe disease outcome. We used an automated machine learning approach where 1594 viral genomes with available clinical follow-up data were used as the training set (797 'severe' and 797 'mild'). The best algorithm, based on random forest classification combined with the LASSO feature selection algorithm, was employed to the training set to link mutation signatures and outcome. The performance of the final model was estimated by repeated, stratified, 10-fold cross validation (CV) and then adjusted for multiple testing with Bootstrap Bias Corrected CV. We identified 26 protein and Untranslated Region (UTR) mutations significantly linked to severe outcome. The best classification algorithm uses a mutation signature of 22 mutations as well as the patient's age as the input and shows high classification efficiency with an area under the curve (AUC) of 0.94 [confidence interval (CI): [0.912, 0.962]] and a prediction accuracy of 87% (CI: [0.830, 0.903]). Finally, we established an online platform (https://covidoutcome.com/) that is capable to use a viral sequence and the patient's age as the input and provides a percentage estimation of disease severity. We demonstrate a statistical association between mutation signatures of SARS-CoV-2 and severe outcome of COVID-19. The established analysis platform enables a real-time analysis of new viral genomes. DA - 2021/05/08/ PY - 2021 DO - 10.1093/database/baab020 DP - PubMed VL - 2021 SP - baab020 J2 - Database (Oxford) LA - eng SN - 1758-0463 L1 - https://academic.oup.com/database/article-pdf/doi/10.1093/database/baab020/37898830/baab020.pdf L2 - http://www.ncbi.nlm.nih.gov/pubmed/33963845 ER - TY - JOUR TI - Hairy cell leukemia and COVID-19 adaptation of treatment guidelines AU - Grever, Michael AU - Andritsos, Leslie AU - Banerji, Versha AU - Barrientos, Jacqueline C. AU - Bhat, Seema AU - Blachly, James S. AU - Call, Timothy AU - Cross, Matthew AU - Dearden, Claire AU - Demeter, Judit AU - Dietrich, Sasha AU - Falini, Brunangelo AU - Forconi, Francesco AU - Gladstone, Douglas E. AU - Gozzetti, Alessandro AU - Iyengar, Sunil AU - Johnston, James B. AU - Juliusson, Gunnar AU - Kraut, Eric AU - Kreitman, Robert J. AU - Lauria, Francesco AU - Lozanski, Gerard AU - Parikh, Sameer A. AU - Park, Jae AU - Polliack, Aaron AU - Ravandi, Farhad AU - Robak, Tadeusz AU - Rogers, Kerry A. AU - Saven, Alan AU - Seymour, John F. AU - Tadmor, Tamar AU - Tallman, Martin S. AU - Tam, Constantine S. AU - Tiacci, Enrico AU - Troussard, Xavier AU - Zent, Clive AU - Zenz, Thorsten AU - Zinzani, Pier Luigi AU - Wörmann, Bernhard T2 - Leukemia AB - Standard treatment options in classic HCL (cHCL) result in high response rates and near normal life expectancy. However, the disease itself and the recommended standard treatment are associated with profound and prolonged immunosuppression, increasing susceptibility to infections and the risk for a severe course of COVID-19. The Hairy Cell Leukemia Foundation (HCLF) has recently convened experts and discussed different clinical strategies for the management of these patients. The new recommendations adapt the 2017 consensus for the diagnosis and management with cHCL to the current COVID-19 pandemic. They underline the option of active surveillance in patients with low but stable blood counts, consider the use of targeted and non-immunosuppressive agents as first-line treatment for cHCL, and give recommendations on preventive measures against COVID-19. DA - 2021/07// PY - 2021 DO - 10.1038/s41375-021-01257-7 DP - PubMed VL - 35 IS - 7 SP - 1864 EP - 1872 J2 - Leukemia LA - eng SN - 1476-5551 L1 - https://www.nature.com/articles/s41375-021-01257-7.pdf L2 - http://www.ncbi.nlm.nih.gov/pubmed/33947938 KW - Humans KW - COVID-19 KW - SARS-CoV-2 KW - Severity of Illness Index KW - Pandemics KW - Consensus KW - Leukemia, Hairy Cell KW - Practice Guidelines as Topic ER - TY - JOUR TI - Longitudinal proteomic analysis of plasma from patients with severe COVID-19 reveal patient survival-associated signatures, tissue-specific cell death, and cell-cell interactions AU - Filbin, Michael R. AU - Mehta, Arnav AU - Schneider, Alexis M. AU - Kays, Kyle R. AU - Guess, Jamey R. AU - Gentili, Matteo AU - Fenyves, Bánk G. AU - Charland, Nicole C. AU - Gonye, Anna L. K. AU - Gushterova, Irena AU - Khanna, Hargun K. AU - LaSalle, Thomas J. AU - Lavin-Parsons, Kendall M. AU - Lilley, Brendan M. AU - Lodenstein, Carl L. AU - Manakongtreecheep, Kasidet AU - Margolin, Justin D. AU - McKaig, Brenna N. AU - Rojas-Lopez, Maricarmen AU - Russo, Brian C. AU - Sharma, Nihaarika AU - Tantivit, Jessica AU - Thomas, Molly F. AU - Gerszten, Robert E. AU - Heimberg, Graham S. AU - Hoover, Paul J. AU - Lieb, David J. AU - Lin, Brian AU - Ngo, Debby AU - Pelka, Karin AU - Reyes, Miguel AU - Smillie, Christopher S. AU - Waghray, Avinash AU - Wood, Thomas E. AU - Zajac, Amanda S. AU - Jennings, Lori L. AU - Grundberg, Ida AU - Bhattacharyya, Roby P. AU - Parry, Blair Alden AU - Villani, Alexandra-Chloé AU - Sade-Feldman, Moshe AU - Hacohen, Nir AU - Goldberg, Marcia B. T2 - Cell Reports. Medicine AB - Mechanisms underlying severe COVID-19 disease remain poorly understood. We analyze several thousand plasma proteins longitudinally in 306 COVID-19 patients and 78 symptomatic controls, uncovering immune and non-immune proteins linked to COVID-19. Deconvolution of our plasma proteome data using published scRNAseq datasets reveals contributions from circulating immune and tissue cells. Sixteen percent of patients display reduced inflammation yet comparably poor outcomes. Comparison of patients who died to severely ill survivors identifies dynamic immune cell-derived and tissue-associated proteins associated with survival, including exocrine pancreatic proteases. Using derived tissue-specific and cell type-specific intracellular death signatures, cellular ACE2 expression, and our data, we infer whether organ damage resulted from direct or indirect effects of infection. We propose a model in which interactions among myeloid, epithelial, and T cells drive tissue damage. These datasets provide important insights and a rich resource for analysis of mechanisms of severe COVID-19 disease. DA - 2021/05/18/ PY - 2021 DO - 10.1016/j.xcrm.2021.100287 DP - PubMed VL - 2 IS - 5 SP - 100287 J2 - Cell Rep Med LA - eng SN - 2666-3791 L2 - http://www.ncbi.nlm.nih.gov/pubmed/33969320 ER - TY - JOUR TI - Szülészeti megfontolások a COVID-19-járvány kapcsán AU - Ács, Nándor AU - Supák, Dorina T2 - Magyar Nőorvosok Lapja AB - Ismert tény, hogy a várandósság során fellépő vírusfertőzések okozhatnak magzati rendellenességeket, és befolyásolhatják a terhesség kimenetelét is. A kínai Wuhanban 2019 decemberében megjelenő új koronavírus-fertőzés rendkívül gyorsan terjedő világjárványt eredményezett, az elmúlt évtized egyik legsúlyosabb közegészségügyi fenyegetését okozva. Az eddigi adatok alapján várandós nőknél nem kell súlyosabb lefolyású COVID-19-fertőzéssel számolnunk. A fertőzés megelőzésére ugyanazok a javaslatok érvényesek, mint az átlagpopulációban. Minden egészségügyi ellátónak saját protokoll kidolgozása javasolt az igazolt, vagy COVID-19 gyanús esetek ellátására. A terhesség és a szülés menedzselése, valamint az újszülött ellátása nem tér el a megszokottól. Az édesanyákat, megfelelő higiénia és sebészi maszk alkalmazása mellett bátorítjuk a szoptatásra. DA - 2020/// PY - 2020 VL - 83 IS - 4 SP - 207 EP - 212 J2 - Magy Noorv Lapja LA - magyar SN - 0025-021X KW - covid-19 KW - járvány KW - koronavírus KW - MOB ER - TY - JOUR TI - A transthoracalis és transoesophagealis echokardiográfiás vizsgálat indikációi, protokollja, valamint a betegek és az ellátószemélyzet védelme : A Magyar Kardiológusok Társasága – Kardiovaszkuláris Képalkotó Munkacsoport állásfoglalása a COVID-19-pandémiára fókuszálva AU - Ágoston, Gergely AU - Kovács, Attila AU - Apor, Astrid AU - Pozsonyi, Zoltán AU - Dénes, Mónika AU - Tóth, Attila AU - Maurovich-Horvat, Pál AU - Faludi, Réka T2 - Cardiologia Hungarica AB - A Kínában 2019 decemberében megjelent koronavírus- (SARS-CoV-2-) járvány, amely a COVID-19 megbetegedést okozza, 2020 márciusára pandémiává nőtte ki magát, jelentősen megterhelve az egészségügyi ellátó rendszert. A jelenleg elérhető adatok alapján a vírus viszonylag ellenálló, könnyen és gyorsan terjed, így az egészségügyi ellátórendszerben a védekezés különös figyelmet igényel. A rendelkezésre álló adatokból arra következtethetünk, hogy a SARS-CoV-2-fertőzésre a kardiovaszkuláris betegségben szenvedők fogékonyabbak, és a fertőzés e betegekben magasabb morbiditással és mortalitással jár, így kiemelt rizikócsoportot jelentenek. Echokardiográfiás vizsgálatra a kardiológiai klinikai gyakorlatban gyakran van szükség. A vizsgálat szoros kontaktust jelent a páciens és az orvos között, ebből következik, hogy a páciensnek is könnyen átadható a betegség, és az egészségügyi ellátószemélyzet is könnyen fertőződhet. A jelenlegi szituációban az egészségügyi ellátószemélyzet feladata egyrészt, hogy saját magát és családtagjait védje a fertőzéstől, másrészt kötelessége megtenni mindent annak érdekében, hogy a betegellátás során a páciensek ne fertőződjenek meg. Természetesen feladatunk, hogy a valóban szükséges echokardiográfiás vizsgálatok ebben a helyzetben is megtörténjenek a nem COVID-19-pácienseknél és az igazoltan fertőzött betegeknél is. Jelenlegi állásfoglalásunk kitér a vizsgálat indikációjára, minőségére, az egészségügyi személyzet és a beteg védelmére (izolációs technikák, védőfelszerelések), az echokardiográfiás készülékek és helyiségek megválasztására és megfelelő prevenciójára. DA - 2020/// PY - 2020 DO - 10.26430/CHUNGARICA.2020.50.2.88 VL - 50 IS - 2 SP - 88 EP - 92 LA - magyar SN - 0133-5596 KW - covid-19 KW - járvány KW - koronavírus ER - TY - JOUR TI - A COVID-19 és a szív- és érrendszeri betegségek összefüggései AU - Apor, Astrid T2 - Cardiologia Hungarica DA - 2020/// PY - 2020 DO - 10.26430/CHUNGARICA.2020.50.2.83 DP - DOI.org (Crossref) VL - 50 IS - 2 SP - 83 EP - 87 J2 - Cardiologia Hungarica SN - 01335596, 15880230 UR - http://cardiologia.hungarica.eu/index.php/2020/04/23/a-covid-19-es-a-sziv-es-errendszeri-betegsegek-osszefuggesei-2/ Y2 - 2021/05/12/09:13:03 KW - covid-19 ER - TY - JOUR TI - A COVID-19 táplálkozási vonatkozásai : narratív áttekintés AU - Biró, György AU - Barna, Mária T2 - Metabolizmus DA - 2020/// PY - 2020 VL - 18 IS - 5 SP - 364 EP - 368 LA - magyar SN - 1589-7311 UR - https://repo.lib.semmelweis.hu/handle/123456789/8589 KW - covid-19 KW - járvány KW - koronavírus ER - TY - JOUR TI - A COVID-19-vírusjárvány tapasztalatai a Semmelweis Egyetem, Szemészeti Klinikájának betegellátásában AU - Nagy, Zoltán Zsolt AU - Tóth, Gábor T2 - Szemészet DA - 2020/// PY - 2020 VL - 157 IS - 3 SP - 191 EP - 195 LA - magyar SN - 0039-8101 UR - https://www.researchgate.net/publication/344897416_A_COVID-19-virusjarvany_tapasztalatai_a_Semmelweis_Egyetem_Szemeszeti_Klinikajanak_betegellatasaban KW - covid-19 KW - járvány KW - koronavírus ER - TY - JOUR TI - Koronavírus-járvány az idősotthonokban : kihívások és a megelőzés lehetőségei AU - Tóth, Miklós T2 - Idősgyógyászat DA - 2020/// PY - 2020 VL - 5 IS - 1 SP - 7 EP - 11 LA - magyar SN - 2498-8057 KW - covid-19 KW - járvány KW - koronavírus ER - TY - JOUR TI - Addendum a Koronavírus járvány az idősotthonokban c. közleményhez AU - Tóth, Miklós T2 - Idősgyógyászat DA - 2020/// PY - 2020 VL - 5 IS - 1 SP - 17 LA - magyar SN - 2498-8057 KW - covid-19 KW - járvány KW - koronavírus ER - TY - JOUR TI - A SARS-CoV2-járvány hatása a hazai vérellátásra AU - Tordai, Attila AU - Nagy, Sándor AU - Baróti-Tóth, Klára AU - Marton, Imelda AU - Lázár, Mária AU - Demeter, Judit AU - Masszi, Tamás AU - Matusovits, Andrea T2 - Hematológia–Transzfuziológia AB - Absztrakt: A súlyos akut légúti szindrómát kiváltó, új típusú koronavírus, a SARS-CoV2 olyan példátlan világjárványt okozott, amely szélsőséges terhelést jelent a még a legfejlettebb országok egészségügyi rendszereire is és azok társadalmaira. Az újonnan emberi kórokozóvá váló vírus ellen sem védőoltás, sem hatékony célzott terápia nem áll rendelkezésre. A járványhelyzetre reagálva a világszerte, köztük Magyarországon is, meghozott szigorú korlátozások a vérellátás tevékenységét egyfelől a donációs hajlandóság és aktivitás kifejezett csökkenése, másfelől a felhasználók igényeinek nehezebben jósolható csökkenése révén érintették. Az OVSz országos adatai szerint a vörösvérsejt-, illetve plazmakészítmények felhasználása mintegy 30%-os, míg a thrombocytakészítményeké mintegy 20%-os csökkenést mutatott 2020. április hónapban az előző év azonos időszakához képest. Ugyanebben az időszakban a mobil véradási események száma országosan 61%-kal, a véradásra megjelent donorok száma pedig 28%-kal csökkent. A korábban járványt okozó légúti vírusokkal és a SARS-CoV2-vel is meglevő klinikai tapasztalatok alapján nem valószínűsíthető az új koronavírus hematogén úton történő átvitele, így a véradás előtti szűrés sem indokolt a potenciálisan fertőzöttek kiszűrését segítő általános óvintézkedések betartása mellett. A hematológiai betegellátásban a vérkészítmények felhasználásának csökkenése kisebb mértékű volt, és kifejezett szóródást mutatott a vizsgált szegedi és budapesti egyetemi központok összehasonlításában. Az új kórokozó elleni vakcina és célzott kezelés hiányában a SARS-CoV2 elleni konvaleszcens plazmaterápia ígéretes és racionális, azonnal hozzáférhető terápiás lehetőség. Az FDA kivételesen gyorsan meghozott bátorító állásfoglalása és irányelve hatására több párhuzamos, nagyobb esetszámú és a korszerű klinikai kutatási szempontokat is figyelembe vevő, a SARS-CoV2 elleni konvaleszcens plazmaterápiára irányuló klinikai vizsgálat indult az USA-ban és más nyugati országokban, köztük Magyarországon is a vérellátó szolgálatok aktív részvételével. DA - 2020/06// PY - 2020 DO - 10.1556/2068.2020.53.2.6 DP - DOI.org (Crossref) VL - 53 IS - 2 SP - 96 EP - 105 SN - 0324-7309 UR - https://akjournals.com/view/journals/2068/53/2/article-p96.xml Y2 - 2021/05/12/09:50:41 L1 - https://akjournals.com/downloadpdf/journals/2068/53/2/article-p96.pdf KW - covid-19 ER - TY - JOUR TI - A COVID-19 és az akut stroke kapcsolata : epidemiológia és patofiziológia AU - Böjti, Péter Pál AU - Bereczki, Dániel T2 - Metabolizmus DA - 2020/// PY - 2020 VL - 18 IS - 5 SP - 311 EP - 314 LA - magyar SN - 1589-7311 KW - covid-19 KW - járvány KW - koronavírus ER - TY - JOUR TI - Az új koronavírus (SARS-CoV-2) és a COVID-19 AU - Csóka, Mária T2 - Magyar Belorvosi Archívum DA - 2020/// PY - 2020 VL - 73 IS - 3 SP - 117 EP - 142 J2 - Magy Belorv Arch LA - magyar SN - 0133-5464 UR - http://www.belgyogyasztarsasag.hu/upload/belgyogyasz/magazine/mba_2020_3_hirdetes_nelkul.pdf#page=14 KW - covid-19 KW - járvány KW - koronavírus ER - TY - JOUR TI - COVID-19 a gyermekeknél: enyhébb lefolyás és kedvezőbb prognózis, mint a felnőtteknél AU - Budai, Lívia T2 - Gyermekgyógyászati Továbbképző Szemle AB - Kína Hupej tartományában, Wuhanban 2019 decemberében egy újfajta fertőzés kezdett el terjedni, a súlyos akut respiratorikus szindróma koronavírus 2 (SARS-CoV-2) okozta koronavírus-betegség 2019, vagyis a COVID-19. A kórokozó a hetedik a koronavírusok sorában. 2020. március 11-én az Egészségügyi Világszervezet (WHO) pandémiának minősítette a járványt, és egy valós idejű, interaktív számlálórendszert indított el a Johns Hopkins Egyetem (Baltimore, Maryland, USA), amely a kórkép okozta morbiditást és mortalitást hivatott számszerűsíteni. 2020. március 18-ára már több mint 200 000 beteget jelzett a rendszer, és a pandémia következtében elhunytak száma meghaladta a 8000-et, ami 4,0%-os halálozási rátának felel meg. Annak ellenére, hogy nagyszámú tudományos közlemény foglalkozott a felnőtteknél tapasztalható COVID-19 sajátosságaival, és némelyikben kisszámú beteg gyermek is szerepelt, viszonylag kevés közlemény jelent meg a gyermekeknél tapasztalt COVID-19-cel kapcsolatban. DA - 2020/// PY - 2020 VL - 25 IS - szept SP - 18 EP - 23 LA - magyar SN - 1585-4396 KW - covid-19 KW - járvány KW - koronavírus ER - TY - JOUR TI - Tapasztalatok a járvány kezdetén észlelt első COVID-19 betegek ellátásával kapcsolatban a Semmelweis Egyetem Pulmonológiai Klinikán AU - Csoma, Balázs AU - Bárczi, Enikő AU - Mészáros, Martina AU - Büdi, Lilla AU - Horváth, Péter AU - Erdélyi, Tamás AU - Vincze, Krisztina AU - Süttő, Zoltán AU - Bíró, Andrea AU - Dombai, Brigitta AU - Vámos, Melinda AU - Fekete, Dorottya AU - Müller, Veronika T2 - Medicina Thoracalis (Budapest) DA - 2020/// PY - 2020 VL - 73 IS - 3 SP - 192 EP - 195 J2 - Med Thorac (Bp) LA - magyar SN - 0238-2571 KW - covid-19 KW - járvány KW - koronavírus KW - MOB ER - TY - JOUR TI - A COVID-19 világjárvány pszichés vonatkozásai : egy nemzetközi vizsgálat előzetes magyarországi adatai AU - Erdélyi-Hamza, Berta AU - Gonda, Xénia T2 - Orvosok Lapja DA - 2020/// PY - 2020 VL - 17 IS - 6 SP - 32 EP - 33 LA - magyar SN - 1785-7198 KW - covid-19 KW - járvány KW - koronavírus ER - TY - JOUR TI - A COVID-19 és a RAS-gátló-kezelés : fókuszban az angiotenzinreceptor-antagonisták AU - Farsang, Csaba T2 - Metabolizmus DA - 2020/// PY - 2020 VL - 18 IS - 3 SP - 217 EP - 219 LA - magyar SN - 1589-7311 KW - covid-19 KW - járvány KW - koronavírus ER - TY - JOUR TI - A COVID-19-kutatás uroonkológiai vonatkozásai AU - Fazekas, Tamás AU - Csizmarik, Anita AU - Szarvas, Tibor AU - Szűcs, Miklós AU - Nyirády, Péter T2 - Magyar Urológia AB - A SARS-2-koronavírus és a COVID-19 betegség az utóbbi néhány hónapban eddig talán soha nem látott mértékben, egyik pillanatról a másikra változtatta meg orvosi gyakorlatunkat, életünket. A vírus megismerésében és a járvány elleni harcban váratlan helyről, az uroonkológia területéről érkeztek kiemelkedő kutatási eredmények. Mind a vírus bejutását biztosító TMPRSS2-fehérjével, mind a BCG-oltással és annak lehetséges protektív szerepével kapcsolatos vizsgálatoknak jelentős urológiai vonatkozásai vannak. Az alábbiakban ismertetett tanulmányok és vizsgálati eredmények egyedi és kiemelkedő lehetőséget biztosítanak a további kutatások számára a témában. DA - 2020/// PY - 2020 VL - 32 IS - 2 SP - 61 EP - 63 LA - magyar SN - 0864-8921 KW - covid-19 KW - járvány KW - koronavírus ER - TY - JOUR TI - A nemszteroid típusú gyulladáscsökkentő szerek kockázatáról : fókuszban az aceclofenac AU - Farsang, Csaba T2 - Lege Artis Medicinae AB - A nemszteroid típusú gyulladáscsökkentők (NSAID) az orvoslásban a leggyakrabban alkalmazott szerek közé tartoznak. Ennek ellenére számos tanulmányban hangsúlyozták, hogy az NSAID-ok károsíthatják nemcsak a gastrointestinalis (GI), hanem a cardiovascularis (CV) rendszert is, növelhetik a vérnyomást, a coronariaesemények (angina, myocardiuminfarktus) és a stroke gyakoriságát, emellett vesekárosodást is okozhatnak. A National Institute for Health and Care Excellence (NICE) nem talált bizonyítékot arra, hogy az NSAID-ok alkalmazása fokozná a Covid-19 kockázatát, vagy rontana a Covid-19-ben szenvedő betegek állapotán. Az egyes hatóanyagok nemkívánatos hatásainak gyakorisága és súlyossága azonban jelentős eltéréseket mutat. Sokáig úgy tűnt, hogy az NSAID-ok fokozódó GI kockázata arányban van a COX-1/COX-2 szelektivitással, a cardiovascularis kockázat pedig a COX-2/COX-1 szelektivitással, az újabb adatok azonban ezt nem támasztják alá egyértelműen. A rendelkezésre álló irodalom alapján, a gast­ro­intestinalis és a cardiovascularis nem­kí­vá­natos eseményeket tekintve, az ace­clofenac mellékhatásprofilja az NSAID-ok között a legkedvezőbbnek tűnik. DA - 2020/// PY - 2020 DO - 10.33616/ lam.30.047 VL - 30 IS - 12 SP - 575 EP - 580 J2 - Lege Artis Med LA - magyar SN - 0866-4811 KW - covid-19 KW - járvány KW - koronavírus ER - TY - JOUR TI - Az immunválasz néhány újonnan felismert hatásmechanizmusa és az immunológia szemléleti átalakulása AU - Falus, András T2 - Lege Artis Medicinae AB - Az immunológia az egészséges és kóros immunválaszt tanulmányozó komplex tu­domány. Ez az élettani, patofiziológiai tu­dományág az egyes mechanizmusok megértését elsősorban sejt- és molekuláris biológiai, genetikai, epigenetikai és (neu­ro)­en­do­kri­nológiai megközelítéssel, illetve a patológiás folyamatok részleteinek feltárásával vég­zi. Az immunológia egyike a na­gyon gyorsan fejlődő tudományoknak, eredményei visszahatnak más diszciplínákra is el­mé­leti (például hálózattudományok, rend­szer-biológia) és módszertani (monoklonális ellenanyagok, biomarkerek, immunoassay-ek) szinten egyaránt. Az immunológusok az elmúlt évtizedekben számos szemléleti változást értek meg, és sok, a hatásmechanizmusokban megnyilvánuló lényegi részletkérdés érvényesülését ismerték fel. DA - 2020/// PY - 2020 DO - 10.33616/lam.30.040 VL - 30 IS - 11 SP - 505 EP - 512 J2 - Lege Artis Med LA - magyar SN - 0866-4811 KW - covid-19 KW - járvány KW - koronavírus ER - TY - JOUR TI - A COVID-19 és a RAS-gátló-kezelés : fókuszban az angiotenzinreceptor-antagonisták AU - Farsang, Csaba T2 - Háziorvos Továbbképző Szemle DA - 2020/// PY - 2020 VL - 25 IS - 7 SP - 527 EP - 530 LA - magyar SN - 1219-8641 KW - covid-19 KW - járvány KW - koronavírus ER - TY - JOUR TI - A renin–angiotenzin–aldoszteron rendszer gátlása súlyos akut légúti tünetegyüttest okozó koronavírus 2 (SARS-CoV-2) járvány idején AU - Nagy, Viktor T2 - Cardiologia Hungarica DA - 2020/// PY - 2020 DO - 10.26430/CHUNGARICA.2020.50.2.93 DP - DOI.org (Crossref) VL - 50 IS - 2 SP - 93 EP - 99 J2 - Cardiologia Hungarica SN - 01335596, 15880230 UR - http://cardiologia.hungarica.eu/index.php/2020/04/23/a-renin-angiotenzin-aldoszteron-rendszer-gatlasa-sulyos-akut-leguti-tunetegyuttest-okozo-koronavirus-2-sars-cov-2-jarvany-idejen-2/ Y2 - 2021/05/12/10:38:41 KW - covid-19 ER - TY - JOUR TI - A szív mágneses rezonanciás vizsgálatának szerepe lezajlott COVID-19-fertőzést követően AU - Szabó, Liliána AU - Juhász, Vencel AU - Dohy, Zsófia AU - Hirschberg, Kristóf AU - Czimbalmos, Csilla AU - Tóth, Attila AU - Suhai, Ferenc Imre AU - Merkely, Béla AU - Vágó, Hajnalka T2 - Cardiologia Hungarica AB - Habár elsősorban a "súlyos akut légúti tünetegyüttest okozó koronavírus-2" (SARS-CoV-2) okozta fertőzés tüdőmanifesztációi ismertek, mindinkább kiemelt figyelmet kapnak a betegség kardiovaszkuláris szövődményei is. A szív mágneses rezonanciás (MR) vizsgálata a kamrai volumenek, morfológia és funkció megítélésére alkalmas módszer, amely speciális szekvenciák révén alkalmas a szöveti ödéma, illetve nekrózis/fibrózis kimutatására. Az újabb T2- és T1-mapping technikáknak köszönhetően pedig a szívizmot diffúzan érintő eltérések is vizsgálhatóak. A COVID-19 betegség szív érintettségének megítélésében a szív-MR mind nagyobb tudományos figyelmet kap. Ennek oka, hogy mint szöveti karakterizálásra alkalmas noninvazív képalkotó modalitás, potenciális szerepe van a betegség esetleges szövődményeinek kimutatásában, továbbá troponin-pozitivitás esetén a miokardiális sérülés differenciáldiagnosztikájában. Összefoglaló közleményünkben a szív-MR-vizsgálat szerepét tárgyaljuk a SARS-CoV-2-fertőzést követően. DA - 2021/// PY - 2021 DO - 10.26430/CHUNGARICA.2021.51.1.18 DP - DOI.org (Crossref) VL - 51 IS - 1 SP - 18 EP - 22 J2 - Cardiologia Hungarica SN - 01335596, 15880230 UR - http://cardiologia.hungarica.eu/index.php/2021/03/11/a-sziv-magneses-rezonancias-vizsgalatanak-szerepe-lezajlott-covid-19-fertozest-kovetoen-3/?preview=true Y2 - 2021/05/12/10:39:01 KW - covid-19 ER - TY - JOUR TI - Táplálásterápia COVID-19 kórállapotban és a rehabilitáció fázisában : összefoglaló referátum AU - Molnár, Andrea AU - Vonyik, Gabriella AU - Székács, Béla T2 - Idősgyógyászat DA - 2020/// PY - 2020 VL - 5 IS - 1 SP - 12 EP - 17 LA - magyar SN - 2498-8057 UR - http://online.pubhtml5.com/syrl/auvd/#p=14 KW - covid-19 KW - járvány KW - koronavírus ER - TY - JOUR TI - Egészséges, biztonságos tojástermékek az időskori fehérjepótláshoz : III. rész, élőflórás ToTu termékek - megfelelő aminosav- és fehérjepótlás a Covid-19 járvány idején AU - Németh, Csaba AU - Lelbach, Ádám AU - Tóth, Adrienn AU - Sárközy, Szilvia AU - Surányi, József AU - Friedrich, László T2 - Idősgyógyászat DA - 2020/// PY - 2020 VL - 5 IS - 1 SP - 18 EP - 25 LA - magyar SN - 2498-8057 KW - covid-19 KW - járvány KW - koronavírus ER - TY - JOUR TI - ACE1-ACE2-kinin-kallikrein rendszer viszonyrendszere SARS-CoV-2 fertőzött idős hipertóniás betegekben: következmények a tüdő és szisztémás gyulladásra (mini-review és ajánlás) AU - Székács, Béla AU - Debreczeni, Lóránd AU - Várbíró, Szabolcs T2 - Idősgyógyászat DA - 2020/// PY - 2020 VL - 5 IS - 1 SP - 4 EP - 6 LA - magyar SN - 2498-8057 KW - covid-19 KW - járvány KW - koronavírus ER - TY - JOUR TI - COVID-19: a citokinviharon innen és túl... AU - Szekanecz, Zoltán AU - Bálint, Péter AU - Balog, Attila AU - Barta, Zsolt AU - Czirják, László AU - Géher, Pál AU - Kovács, László AU - Kumánovics, Gábor AU - Nagy, György AU - Rákóczi, Éva AU - Szamosi, Szilvia AU - Szűcs, Gabriella AU - Vályi-Nagy, István AU - Várkonyi, István AU - Constantin, Tamás T2 - Immunológiai Szemle DA - 2020/// PY - 2020 VL - 12 IS - 4 SP - 5 EP - 15 LA - magyar SN - 2061-0203 UR - http://publicatio.bibl.u-szeged.hu/21179/1/Szekanecz2ImmunolSzemle2020.pdf KW - covid-19 KW - járvány KW - koronavírus KW - MOB ER - TY - JOUR TI - A COVID-19-járvánnyal kapcsolatos legfontosabb szemészeti teendők az ambuláns és műtéti ellátás területén AU - Nagy, Zoltán Zsolt AU - Gadó, Klára T2 - Szemészet DA - 2020/// PY - 2020 VL - 157 IS - 3 SP - 182 EP - 190 LA - magyar SN - 0039-8101 UR - http://repo.lib.semmelweis.hu/handle/123456789/8608 KW - covid-19 KW - járvány KW - koronavírus ER - TY - JOUR TI - A COVID-19 és a véralvadás AU - Gadó, Klára AU - Domján, Gyula T2 - Orvostovábbképző Szemle AB - Súlyos COVID-19 betegségben igen sokszor fordul elő thromboemboliás esemény. A kórházi felvételkor detektált coagulopathia - emelkedett D-dimer-és fibrinogénszint, megnyúlt protrombinidő, csökkent plazminogénszint, alacsony trombocitaszám - a halálozás egyértelmű prediktora. Nagyon fontos, hogy a kórházi felvételkor thrombosis-kockázat-becslés történjen, melynek alapján megfelelő, sokszor a szokásos dózist meghaladó tromboprofilaxis szükséges kis molekulatömegű heparin formájában. A tromboprofilaxist a hazabocsátást követően is ajánlatos folytatni. DA - 2020/// PY - 2020 VL - 27 IS - 9 SP - 50 EP - 54 LA - magyar SN - 1218-2583 UR - http://repo.lib.semmelweis.hu/handle/123456789/8586 KW - covid-19 KW - járvány KW - koronavírus KW - MOB ER - TY - JOUR TI - Covid-19 és perifériás verőérbetegség AU - Farkas, Katalin T2 - Hypertonia és Nephrologia AB - A perifériás verőérbetegségben (PAD) szenvedő betegeket több szempontból is negatívan érinti a koronavírus-járvány. A szokásosnál kevesebb orvos- beteg találkozás miatt nehezebb a betegség vagy a betegség progressziójának felismerése. A járvány miatti bezártság erősíti a mozgásszegény életmódot, ami a fizikai terhelés hiánya révén elfedheti a PAD tüneteit. A másik veszély, hogy a cardiovascularis betegségben szenvedő betegek különösen veszélyeztetettek a súlyos Covid-19-betegség szempontjából, körükben jelentősen megnő a mortalitás kockázata. Érszűkületes beteg Covid-19-fertőzésének otthoni kezelése esetén szoros obszerváció szükséges, hogy megfelelő időben lehessen dönteni a kórházi kezelés szükségességéről. A fokozatosan minden PAD-beteg számára elérhető védőoltás jelentheti a megoldást a betegség megelőzésére. DA - 2021/// PY - 2021 DO - 10.33668/hn.25.009 VL - 25 IS - 2 SP - 87 EP - 89 LA - magyar SN - 1418-477X KW - covid-19 KW - járvány KW - koronavírus ER - TY - JOUR TI - Védőoltások a Covid-19-pandémia ellen AU - Falus, András AU - Szekanecz, Zoltán T2 - Lege Artis Medicinae DA - 2021/// PY - 2021 DO - 10.33616/lam.31.002 DP - DOI.org (Crossref) VL - 31 IS - 1-2 SP - 29 EP - 33 J2 - Lege Artis Med SN - 08664811, 20634161 UR - https://elitmed.hu/en/publications/lege-artis-medicinae/vaccines-against-covid-19-pandemic Y2 - 2021/05/12/11:48:08 L1 - https://elitmed.hu/en/publications/lege-artis-medicinae/vaccines-against-covid-19-pandemic/pdf-download KW - covid-19 ER - TY - JOUR TI - Hypertonia és Covid-19 - I. rész : az életkor, az alapbetegségek és az ACEI/ARB kezelés jelentősége hypertoniában és társbetegségeiben a SARS-CoV-2-fertőzés során AU - Kékes, Ede AU - Székács, Béla AU - Nagy, Judit AU - Kovács, Tibor T2 - Hypertonia és Nephrologia DA - 2020/// PY - 2020 DO - 10.33668/hn.24.011 VL - 24 IS - 3 SP - 115 EP - 120 LA - magyar SN - 1418-477X KW - covid-19 KW - járvány KW - koronavírus ER - TY - JOUR TI - Hypertonia és Covid-19 - II. rész : a renin-angiotenzin és kinin-kallikrein rendszer megváltozó kapcsolatának, a kétfajta támadáspontú RAS-gátló kezelésnek lehetséges eltérő következményei idős hypertoniás betegek SARS-CoV-2 fertőzést követő tüdő- és szisztémás gyulladás válaszában AU - Székács, Béla AU - Kékes, Ede AU - Nagy, Judit AU - Kovács, Tibor T2 - Hypertonia és Nephrologia AB - A szerzők áttekintik azokat a komponenseket és mechanizmusokat a keringésszabályozásban alapvető jelentőségű két nagy regulációs rendszerben, amelyek belső egyensúlya és kapcsolatai a SARS-CoV-2 fertőzés során kórosan változnak, és ezáltal fokozzák a súlyos klinikai állapotba torkollással fenyegető tüdő- és szisztémás gyulladás állapotot. Megvizsgálják azt a kérdést, hogy a fertőző ágens szervezeti celluláris behatolásának potenciális elősegítésén túl, az áldozatok között kiugróan magas arányszámú idős hypertoniás betegek RAS-gátló gyógyszerelése hogyan befolyásolja ezeket a változásokat, feltételezhető-e különbség az ACEi és ARB támadáspontú kezelési rendszer anti-, proinflammatorikus befolyása között a Covid-19-járványban. Az áttekintés a koronavírus-fertőzésre adott közvetlen immunológiai választ jelentősen meghaladó gyulladás patomechanikai hátterére fókuszál: az idős hypertoniás betegeknek alapállapotban is fennálló immunmódosulásainak jelentőségére és a kulcskomponensekre, mint angiotenzin-II, ACE-2, angiotenzin- 1–7, bradikinin, ARB, ACEI. A következtetésben a SARS-CoV-2 fertőzött (idős) hypertoniás betegek RAS-gátló kezelésében a támadáspont optimalizálásának mérlegelése ajánlott. DA - 2020/// PY - 2020 DO - 10.33668/hn.24.023 VL - 24 IS - 5 SP - 205 EP - 213 LA - magyar SN - 1418-477X KW - covid-19 KW - járvány KW - koronavírus ER - TY - JOUR TI - Az új típusú koronavírus okozta megbetegedés (COVID–19): összefoglaló hematológusoknak I. – virológia, molekuláris patogenezis és klinikum AU - Szabó, Bálint Gergely AU - Bobek, Ilona AU - Réti, Marienn AU - Gopcsa, László AU - Mathiász, Dóra AU - Lakatos, Botond AU - Bekő, Gabriella AU - Pető, Mónika AU - Sinkó, János AU - Mikala, Gábor AU - Kis, Zoltán AU - Szlávik, János AU - Reményi, Péter AU - Vályi-Nagy, István T2 - Hematológia–Transzfuziológia AB - Absztrakt: A COVID–19 a SARS-CoV-2 vírus által okozott, járványosan terjedő, légúti kiindulású betegség. A kórokozó magas patogenitású, zoonotikus eredetű humán coronavírus, mely hatékonyan terjed emberről emberre cseppfertőzéssel és közeli kontaktussal. A medián lappangási idő 5 nap, a maximum 14 nap. A COVID–19 kardinális tünetei a láz, dyspnoe és száraz köhögés. Az esetek 80%-a enyhe lefolyású, 5%-ban azonban intenzív terápiás ellátás és gépi lélegeztetés válik szükségessé. A COVID–19 akár súlyos, az egész szervezetre kiterjedő citokinvihart is kiválthat, mely gyors beavatkozás nélkül végzetes kimenetelű lehet. Jelen összefoglaló – melyet a diagnosztikai és terápiás szempontokat tárgyaló társközlemény követ – a betegséggel kapcsolatban 2020. május 25-ig elérhető legfőbb nemzetközi és hazai irodalmi eredményeket ismerteti; elsősorban, de nem kizárólag hematológus kollégák számára. DA - 2020/06// PY - 2020 DO - 10.1556/2068.2020.53.2.4 DP - DOI.org (Crossref) VL - 53 IS - 2 SP - 68 EP - 80 SN - 0324-7309 ST - Az új típusú koronavírus okozta megbetegedés (COVID–19) UR - https://akjournals.com/view/journals/2068/53/2/article-p68.xml Y2 - 2021/05/12/12:07:44 L1 - https://akjournals.com/downloadpdf/journals/2068/53/2/article-p68.pdf KW - covid-19 ER - TY - JOUR TI - Az új típusú koronavírus okozta megbetegedés (COVID–19): összefoglaló hematológusoknak II. – a diagnosztika, terápia és prevenció lehetőségei AU - Szabó, Bálint Gergely AU - Bobek, Ilona AU - Réti, Marienn AU - Gopcsa, László AU - Mathiász, Dóra AU - Lakatos, Botond AU - Bekő, Gabriella AU - Pető, Mónika AU - Sinkó, János AU - Mikala, Gábor AU - Kis, Zoltán AU - Szlávik, János AU - Reményi, Péter AU - Vályi-Nagy, István T2 - Hematológia–Transzfuziológia AB - Absztrakt: A COVID–19 a SARS-CoV-2 vírus által okozott, járványosan terjedő, légúti kiindulású betegség. A kórokozó magas patogenitású, zoonotikus eredetű humán coronavírus, mely hatékonyan terjed emberről emberre cseppfertőzéssel és közeli kontaktussal. A vírusdiagnosztika a légutakból vett minta PCR-vizsgálatán alapul, melynek ismétlésére szükség lehet a fertőzés kizárására. A PCR-eredményt a klinikummal egybe kell vetni, mivel a preszimptomatikus beteg már vírust üríthet, a gyógyultak PCR-pozitivitása pedig hetekig elhúzódik. A terápiás stratégiák két ágát az antivirális gyógyszerek, valamint a hiperinflammációt gátló immunmodulánsok adják. Jelen összefoglalásunk a második azon két társközlemény közül, melyek célja a 2020. május 25-ig elérhető legfőbb nemzetközi és hazai betegséggel kapcsolatos eredmények ismertetése, elsősorban, de nem kizárólag hematológus kollégák számára. DA - 2020/06// PY - 2020 DO - 10.1556/2068.2020.53.2.5 DP - DOI.org (Crossref) VL - 53 IS - 2 SP - 81 EP - 95 SN - 0324-7309 ST - Az új típusú koronavírus okozta megbetegedés (COVID–19) UR - https://akjournals.com/view/journals/2068/53/2/article-p81.xml Y2 - 2021/05/12/12:07:56 L1 - https://akjournals.com/downloadpdf/journals/2068/53/2/article-p81.pdf KW - covid-19 ER - TY - JOUR TI - Tápanyagok szerepe az immunrendszer támogatásában, a COVID-19 elleni védekezésben AU - Fekete, Mónika AU - Fazekas-Pongor, Vince AU - Kerti, Mária AU - Varga, János Tamás T2 - Orvostovábbképző Szemle DA - 2021/// PY - 2021 VL - 28 IS - 2 SP - 45 EP - 50 LA - magyar SN - 1218-2583 UR - http://otszonline.hu/borgyogyaszat/cikk/tapanyagok_szerepe_az_immunrendszer__tamogatasaban__a_covid_19_elleni_vedekezesben KW - covid-19 KW - járvány KW - koronavírus KW - MOB ER - TY - JOUR TI - COVID-19-világjárvány: a fertőzés lefolyása és a gyógyszerkutatások reménykeltő eredményei AU - Varga, János Tamás AU - Kerpel-Fronius, Anna AU - Madurka, Ildikó AU - Elek, Jenő AU - Tóth, Krisztina AU - Temesi, Gabriella AU - Simon, Beatrix AU - Szilágyi, Ruth AU - Fazekas-Pongor, Vince AU - Fekete, Mónika AU - Bogos, Krisztina AU - Horváth, Ildikó T2 - Orvostovábbképző Szemle DA - 2021/// PY - 2021 VL - 28 IS - 2 SP - 87 EP - 94 LA - magyar SN - 1218-2583 UR - http://otszonline.hu/borgyogyaszat/cikk/covid_19_vilagjarvany__a_fertozes_lefolyasa_es_a_gyogyszerkutatasok_remenykelto_eredmenyei KW - covid-19 KW - járvány KW - koronavírus KW - MOB ER - TY - JOUR TI - A COVID-19 hatása 1-es típusú diabétesszel élő gyermekekre AU - Körner, Anna T2 - Gyermekorvos Továbbképzés DA - 2021/// PY - 2021 VL - 20 IS - 1 SP - 30 EP - 33 LA - magyar SN - 1589-0309 KW - covid-19 KW - járvány KW - koronavírus ER - TY - JOUR TI - Az Egyesült Államokban jelenleg engedélyezett mRNS COVID-19 vakcinák alkalmazásának ideiglenes klinikai megfontolásai AU - Tamási, Lilla AU - Süttő, Bence T2 - Medicina Thoracalis (Budapest) DA - 2021/// PY - 2021 DP - MTMT VL - 74 IS - 1 SP - 27 EP - 32 J2 - Med Thorac (Bp) LA - Hungarian SN - 0238-2571 UR - https://m2.mtmt.hu/api/publication/31897569 ER - TY - JOUR TI - A COVID-19 megbetegedést okozó SARS-CoV-2 diagnosztikája AU - Takács, Mária AU - Pályi, Bernadett AU - Szomor, Katalin AU - Barcsay, Erzsébet AU - Kis, Zoltán T2 - Orvosok Lapja DA - 2020/// PY - 2020 VL - 17 IS - 6 SP - 12 EP - 14 LA - magyar SN - 1785-7198 KW - covid-19 KW - járvány KW - koronavírus ER - TY - JOUR TI - A szociális ágazat szabályozása a COVID-19 első hullámában AU - László-Kovács, Edina T2 - Szociálpolitikai Szemle DA - 2020/// PY - 2020 DP - MTMT VL - 2020 IS - 3-4 SP - 5 EP - 25 LA - Hungarian SN - 2416-1357 UR - https://m2.mtmt.hu/api/publication/31719964 ER - TY - JOUR TI - Different Trends in Excess Mortality in a Central European Country Compared to Main European Regions in the Year of the COVID-19 Pandemic (2020): a Hungarian Analysis AU - Bogos, K. AU - Kiss, Z. AU - Kerpel Fronius, A. AU - Temesi, G. AU - Elek, J. AU - Madurka, I. AU - Cselkó, Z. AU - Csányi, P. AU - Abonyi-Tóth, Z. AU - Rokszin, G. AU - Barcza, Z. AU - Moldvay, J. T2 - Pathology and Oncology Research AB - Objective: This study examined cumulative excess mortality in European countries in the year of the Covid-19 pandemic and characterized the dynamics of the pandemic in different countries, focusing on Hungary and the Central and Eastern European region. Methods: Age-standardized cumulative excess mortality was calculated based on weekly mortality data from the EUROSTAT database, and was compared between 2020 and the 2016–2019 reference period in European countries. Results: Cumulate weekly excess mortality in Hungary was in the negative range until week 44. By week 52, it reached 9,998 excess deaths, corresponding to 7.73% cumulative excess mortality vs. 2016–2019 (p-value = 0.030 vs. 2016–2019). In Q1, only Spain and Italy reported excess mortality compared to the reference period. Significant increases in excess mortality were detected between weeks 13 and 26 in Spain, United Kingdom, Belgium, Netherland and Sweden. Romania and Portugal showed the largest increases in age-standardized cumulative excess mortality in the Q3. The majority of Central and Eastern European countries experienced an outstandingly high impact of the pandemic in Q4 in terms of excess deaths. Hungary ranked 11th in cumulative excess mortality based on the latest available data of from the EUROSTAT database. Conclusion: Hungary experienced a mortality deficit in the first half of 2020 compared to previous years, which was followed by an increase in mortality during the second wave of the COVID-19 pandemic, reaching 7.7% cumulative excess mortality by the end of 2020. The excess was lower than in neighboring countries with similar dynamics of the pandemic. © Copyright © 2021 Bogos, Kiss, Kerpel Fronius, Temesi, Elek, Madurka, Cselkó, Csányi, Abonyi-Tóth, Rokszin, Barcza and Moldvay. DA - 2021/// PY - 2021 DO - 10.3389/pore.2021.1609774 DP - Scopus VL - 27 SP - 1609774 J2 - Pathol. Oncol. Res. LA - English SN - 12194956 (ISSN) UR - https://www.scopus.com/inward/record.uri?eid=2-s2.0-85104934422&doi=10.3389%2fpore.2021.1609774&partnerID=40&md5=e941189024d6c61a1158877133fe9dde N1 -

CODEN: POREF

N1 -

Correspondence Address: Kiss, Z.; 2nd Department of Medicine and Nephrological Center, Hungary; email: dr.zoltan.kiss.privat@gmail.com

N1 -

Export Date: 12 May 2021

KW - Hungary KW - age-standardized mortality rate KW - covid-19 pandemic KW - cumulative death KW - excess mortality ER - TY - JOUR TI - Brave new world an update on COVID-19 pandemic – A review AU - Gadó, K. AU - Domján, Gy. AU - Nagy, Z.Z. T2 - Developments in Health Sciences AB - Epidemics and pandemics have happened throughout the history of mankind. Before the end of the 20th century, scientific progress successfully eradicated several of the pathogens. While no one has to be afraid of smallpox anymore, there are some new pathogens that have never caused human disease before. Coronaviruses are a family of enveloped RNA viruses. In the 21st century, three of them have caused serious pandemics, including severe acute respiratory syndrome in 2002 and Middle East Respiratory Syndrome in 2012. In 2019 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the coronavirus disease-19 (COVID-19) pandemic, which has destroyed hundreds of thousands of lives and continues to rage. DA - 2020/12/03/ PY - 2020 DO - 10.1556/2066.2020.00009 DP - DOI.org (Crossref) VL - 3 IS - 2 SP - 44 EP - 51 J2 - Dev Health Sci SN - 2630-9378, 2630-936X UR - https://akjournals.com/view/journals/2066/3/2/article-p44.xml Y2 - 2021/05/14/07:52:45 L1 - https://akjournals.com/downloadpdf/journals/2066/3/2/article-p44.pdf ER - TY - JOUR TI - Javaslat a hypertonia telemedicinális gondozására a Covid-19-pandémia során AU - Nemcsik, János AU - Páll, Dénes AU - Járai, Zoltán T2 - Hypertonia és Nephrologia DA - 2020/// PY - 2020 VL - 24 IS - Suppl. 1 SP - S1 EP - S9 LA - magyar SN - 1418-477X UR - https://elitmed.hu/kiadvanyaink/hypertonia-es-nephrologia/javaslat-a-hypertonia-telemedicinalis-gondozasara-a-covid-19-pandemia-soran KW - járvány KW - koronavírus ER - TY - JOUR TI - Fiatal kutatók nehézségei a COVID–19 járvány alatt AU - Dékány, Éva Katalin AU - Alpár, Donát AU - Bálint, Erika AU - Béni, Szabolcs AU - Csupor, Dezső AU - Gselmann, Eszter AU - Kóspál, Ágnes AU - Máté, Ágnes AU - Toldi, Gergely AU - Török, Péter AU - Solymosi, Katalin T2 - Magyar Tudomány DA - 2020/// PY - 2020 DO - 10.1556/2065.181.2020.12.13 DP - MTMT VL - 181 IS - 12 SP - 1688 EP - 1697 LA - Hungarian SN - 0025-0325 UR - https://m2.mtmt.hu/api/publication/31682457 ER - TY - JOUR TI - A COVID-19 járvány hatása a téveszmék tematikájára AU - Girasek, Hunor AU - Gazdag, Gábor T2 - Psychiatria Hungarica AB - A COVID-19 járványt az Egészségügyi Világszervezet 2020. március 11-én világjárvánnyá nyilvánította. A betegség kitörése és terjedése világszerte félelmet, bizonytalanságot és szorongást váltott ki az emberekből. A járvány közvetlen és közvetett módon is hatással van a mentális problémákra, ugyanis a vírustól való félelem kiválthat vagy súlyosbíthat mentális betegségeket, továbbá befolyással lehet a tünetek megjelenésére. Esettanulmányok támasztják alá, hogy ez a rendkívüli helyzet hatással lehet a téveszmék és hallucinációk tartalmára, emellett pedig hozzájárulhat a pszichotikus relapszus előidézéséhez. Közleményünkben a szakirodalom rövid áttekintésén túl a Jahn Ferenc Dél-pesti Kórház és Rendelőintézet Addiktológiai és Pszichiátriai Centrum három pszichotikus betegének esetét ismertetjük, akiknek téveszméire, hallucinációira hatással volt a COVID-19 pandémia. Két esetben feltehetőleg pszichoszociális stresszorok mentén kialakult reaktív, átmeneti pszichotikus epizód tüneteit, egy esetben pedig egy pszichotikus betegségben szenvedő páciens pozitív tüneteit határozta meg a COVID-19. DA - 2020/// PY - 2020 VL - 35 IS - 4 SP - 471 EP - 475 LA - magyar SN - 0237-7896 KW - járvány KW - koronavírus ER - TY - JOUR TI - A magyarországi szociális ágazat és a COVID-19 – a Semmelweis Egyetem Szociális Vezetőképző Tudásközpontja kutatásának tükrében AU - Nyitrai, Imre T2 - Szociálpolitikai Szemle AB - A Semmelweis Egyetem Szociális Vezetőképző Tudásközpontja 2020. júniusában, célzott körben lefolytatott COVID-19 kutatásában 509 intézmény vezetője, véleményformáló (stakeholder) szakembere vett részt. Az egyetemen végzett hallgatók, az alumni kör válaszait eseténként – kumulált adatokat generálva – kiegészítettük az adott időszakban, mesterszintű képzésben résztvevő hallgatók válaszaival. A szociális vezetői körre teljes mértékben reprezentatív kutatás igazolta azt a hipotézist, amely szerint a kevés áldozattal járó, veszélyhelyzeti védekezés mögött a szociális intézmények vezetési-szervezési rugalmassága, az intézményvezetők személyes rátermettsége, gyorsasága, előrelátása és a józan, támogató fenntartói kör attitűdje áll. A szociális intézmények korlátosan képesek külső erőforrások megteremtésére, generálására, ezért a járványhelyzet kezdeti szakaszában (is) a belső erőforrások átcsoportosítása és rendkívüli magas megterhelése árán tudtak sikeresen védekezni. A kezdeti, magas érzelmi elköteleződést mutató helyzet után (a tágabb társadalom felől) korlátozott szolidaritást élnek meg az érintettek, és meglehetősen borús jövőképet festenek fel. A válaszok elemzését – ahogyan a kérdéseket is – csoportosítva végeztük, ahol a szervezeti, a vezetői és kiemelten az emberi erőforrást érintő kérdések válaszainak összefoglalása mellett kísérletet teszünk további, levonható tanulságok megjelenítésére is. DA - 2020/// PY - 2020 DP - MTMT VL - 6 IS - 3-4 SP - 26 EP - 50 LA - Hungarian SN - 2416-1357 UR - https://m2.mtmt.hu/api/publication/31683480 ER - TY - JOUR TI - A COVID-19 immunológiai és reumatológiai vonatkozásai AU - Szekanecz, Zoltán AU - Bálint, Péter Vince AU - Balog, Attila AU - Czirják, László AU - Géher, Pál AU - Kovács, László AU - Kumánovics, Gábor AU - Nagy, György AU - Rákóczi, Éva AU - Szamosi, Szilvia AU - Szűcs, Gabriella AU - Constantin, Tamás T2 - Immunológiai Szemle AB - Kínában egy új típusú koronavírus, a SARS-CoV-2 jelent meg a COVID-19-nek nevezett betegséget okozva. Ezen összefoglalóban, a fertőzés reumatológiai és immunológiai vonatkozásait kiemelve, áttekintjük a SARS-CoV-2-fertôzés lényegesebb sejtes és molekuláris mechanizmusait, különös tekintettel az immunológiai és gyulladásos folyamatokra. Ezt követően bemutatjuk a COVID-19-hez társuló citokinvihar, klinikailag a macrophagaktivációs szindróma (MAS), illetve szekunder haemophagocytás lymphohistiocytosis (HLH) főbb jellemzőit. Külön szólunk azon reumatológiai gyógyszerekről, amelyeknek szerepe lehet a COVID-19 kezelésében. Végül a reumatológiai betegek járvány alatti kezelésének, gondozásának gyakorlati vonatkozásait mutatjuk be. DA - 2020/// PY - 2020 DP - MTMT VL - 12 IS - 2 SP - 5 EP - 17 LA - Hungarian SN - 2061-0203 UR - https://m2.mtmt.hu/api/publication/31368048 N1 -

Másodközlés: Szekanecz Zoltán; Bálint Péter;  Balog Attila; Czirják László; Géher Pál; Kovács László; Kumánovics Gábor; Nagy György; Rákóczi Éva; Szamosi Szilvia; Szűcs Gabriella; Constantin Tamás: A COVID-19 immunológiai és reumatológiai vonatkozásai. MOZGÁSSZERVI TOVÁBBKÉPZŐ SZEMLE : INTERDISZCIPLINÁRIS SZAKMAI LAP (2630-8924 ): 3 2 pp 1-13 (2020) [MTMT azonosító: 31651058]

ER - TY - JOUR TI - Tapasztalatok a COVID-19 dolgozói szűrésről a Semmelweis Egyetem Pulmonológiai Klinikáján AU - Bárczi, Enikő AU - Mészáros, Martina AU - Büdi, Lilla AU - Csoma, Balázs AU - Kristóf, Katalin AU - Hegedűsné Ballai, Judit AU - Müller, Veronika T2 - Medicina Thoracalis (Budapest) DA - 2020/// PY - 2020 VL - 73 IS - 3 SP - 196 EP - 199 J2 - Med Thorac (Bp) LA - magyar SN - 0238-2571 KW - járvány KW - koronavírus KW - MOB ER - TY - JOUR TI - Mini-Factor H Modulates Complement-Dependent IL-6 and IL-10 Release in an Immune Cell Culture (PBMC) Model: Potential Benefits Against Cytokine Storm. AU - Kozma, Gergely Tibor AU - Mészáros, Tamás AU - Bakos, Tamás AU - Hennies, Mark AU - Bencze, Dániel AU - Uzonyi, Barbara AU - Győrffy, Balázs AU - Cedrone, Edward AU - Dobrovolskaia, Marina A. AU - Józsi, Mihály AU - Szebeni, János T2 - Frontiers in immunology AB - Cytokine storm (CS), an excessive release of proinflammatory cytokines upon overactivation of the innate immune system, came recently to the focus of interest because of its role in the life-threatening consequences of certain immune therapies and viral diseases, including CAR-T cell therapy and Covid-19. Because complement activation with subsequent anaphylatoxin release is in the core of innate immune stimulation, studying the relationship between complement activation and cytokine release in an in vitro CS model holds promise to better understand CS and identify new therapies against it. We used peripheral blood mononuclear cells (PBMCs) cultured in the presence of autologous serum to test the impact of complement activation and inhibition on cytokine release, testing the effects of liposomal amphotericin B (AmBisome), zymosan and bacterial lipopolysaccharide (LPS) as immune activators and heat inactivation of serum, EDTA and mini-factor H (mfH) as complement inhibitors. These activators induced significant rises of complement activation markers C3a, C4a, C5a, Ba, Bb, and sC5b-9 at 45 min of incubation, with or without ~5- to ~2,000-fold rises of IL-1α, IL-1β, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13 and TNFα at 6 and 18 h later. Inhibition of complement activation by the mentioned three methods had differential inhibition, or even stimulation of certain cytokines, among which effects a limited suppressive effect of mfH on IL-6 secretion and significant stimulation of IL-10 implies anti-CS and anti-inflammatory impacts. These findings suggest the utility of the model for in vitro studies on CS, and the potential clinical use of mfH against CS. DA - 2021/// PY - 2021 DO - 10.3389/fimmu.2021.642860 VL - 12 SP - 642860 J2 - Front Immunol LA - eng SN - 1664-3224 KW - COVID-19 KW - cytokine release syndrome KW - anaphylatoxins KW - complement activation/inhibition KW - factor H KW - immune stimulation KW - whole blood assay KW - zymosan ER - TY - JOUR TI - Nem várt fordulat 2020 tavaszán - a Covid-19 járvány hatása a geriátriai ellátást is érintő felgyorsult digitalizációra : a telemedicina elterjedése AU - Lelbach, Ádám AU - Szedlacsek, Zsolt T2 - Idősgyógyászat DA - 2020/// PY - 2020 VL - 5 IS - 1 SP - 26 EP - 28 LA - magyar SN - 2498-8057 KW - járvány KW - koronavírus ER - TY - JOUR TI - A visszamaradó légzési problémákkal küszködő COVID-19 betegségen átesettek tüdőgyógyászati ambuláns rehabilitációs programjának bevezetése Magyarországon : szakmai összefoglaló AU - Szilasi, Mária AU - Varga, János Tamás T2 - Orvostovábbképző Szemle DA - 2021/// PY - 2021 VL - 28 IS - 2 SP - 95 EP - 96 LA - magyar SN - 1218-2583 KW - járvány KW - koronavírus KW - MOB ER - TY - JOUR TI - A betegségkockázat kapcsolata a fizikai aktivitással és a fittséggel AU - Fekete, Mónika AU - Szilasi, Mária AU - Fazekas-Pongor, Vince AU - Németh, Anna Noémi AU - Varga, János Tamás T2 - Medicina Thoracalis (Budapest) DA - 2021/// PY - 2021 DP - MTMT VL - 74 IS - 2 SP - 82 EP - 90 J2 - Med Thorac (Bp) LA - Hungarian SN - 0238-2571 UR - https://m2.mtmt.hu/api/publication/31605078 ER - TY - JOUR TI - Az ICS szerepe koronavírus fertőzött obstruktív betegek terápiájában AU - Varga, János Tamás AU - Böcskei, Renáta AU - Putz, Zsuzsanna T2 - Medicina Thoracalis (Budapest) DA - 2021/// PY - 2021 DP - MTMT VL - 74 IS - 2 SP - 126 EP - 134 J2 - Med Thorac (Bp) LA - Hungarian SN - 0238-2571 UR - https://m2.mtmt.hu/api/publication/31957792 ER - TY - JOUR TI - [Creating conditions for male partner involvement in birth in the Hungarian obstetric wards during the COVID-19 pandemic] AU - Lengyel, Ingrid Krisztina AU - Ács, Nándor T2 - Orvosi Hetilap AB - Összefoglaló. Bevezetés: Az Egészségügyi Világszervezet adatai alapján 2020 őszére a világ minden régióját elérte az új koronavírus (SARS-CoV-2) okozta fertőzés. Magyarországon 2020 márciusában az első esetek - több más betegjogi kérdés mellett - ráirányították a figyelmet a betegtájékoztatás kiemelt fontosságára, annak jogszabály szerinti betartására, valamint az alkalmazás során fellépő nehézségekre. Tekintve, hogy az együttszülés lehetősége az utóbbi évtizedekben egyre népszerűbb a családtervezés és a közös életkezdés folyamatában, az apák felkészítése a szülésre - a járványhelyzet miatt megváltozott tájékoztatási szigorítások összehangolásával - a szülészeti osztályok jelentős feladata lett. A betegtájékoztatás teljes körű alkalmazása során számos szempontot kellett figyelembe venni ahhoz, hogy a szülés az anya és az apa számára pozitív emlék maradjon, még olyan helyzetben is, mint a COVID-19-járvány. Célkitűzés: Elemezni kívántuk, hogy a magyarországi szülészeti osztályokon hogyan lehetett a világjárvány idején is betartani a hatályos jogszabályokat és eljárásrendeket, milyen intézkedések váltak szükségessé az együttszülés gyakorlatának fenntartásához, és egyidejűleg biztosítani, hogy a szülőnőnek és férfi partnerének a tájékoztatáshoz való jogai ne sérüljenek. Módszer: Online 14 feleletválogatós kérdőívet küldtünk valamennyi magyarországi, állami fenntartású kórház és klinika szülészeti osztálya vezetőjének. A beérkezett kérdőívek adatait összevetettük az intézmények honlapján az együttszüléssel kapcsolatos információkkal is. Eredmények: A 2020. március 20. és szeptember 20. közötti fél évben a várandós párok tájékoztatása során a szolgáltatók minden esetben a hatályos eljárásrendeket követték, ez azonban több esetben többlet anyagi ráfordítást és szervezést jelentett számukra. Következtetés: Adataink rámutatnak arra, hogy az együttszüléssel kapcsolatosan a szülésre érkezők igyekeznek a lehető legjobban tájékozódni, és ugyanolyan elvárásaik vannak a szülés körülményeit illetően, mint a járványmentes időszakban. Amennyiben a tájékoztatás kielégítő és részletes számukra, az esetleges hátrányos változtatásokat is jobban tolerálják. A járványra tekintettel valamennyi osztályon megmaradt az együttszülés lehetősége, a megfelelő járványügyi intézkedések megtartása mellett. Orv Hetil. 2021; 162(21): 824-829. SUMMARY: INTRODUCTION: According to data collected by the World Health Organization, by the autumn of 2020, all regions of the world were affected by SARS-CoV-2 viral infection. In Hungary, the first cases were detected in March 2020, and the epidemic, among several other patient rights issues, drew attention to the paramount importance of patient information, its compliance with the law, and the difficulties encountered in its application. During the last decades, the possibility of male partner involvement in birth has become increasingly popular in the process of family planning and starting a life together. Preparing fathers for childbirth and coordinating information restrictions that have changed due to the epidemic is a priority for obstetric departments. The full application of patient information requires a number of considerations to ensure that childbirth remains a positive memory for mother and father, even in a situation such as the COVID-19 pandemic. OBJECTIVE: We wanted to analyze how the obstetric wards in Hungary were able to comply with the laws and procedures in force at the time of the pandemic, what measures became necessary for creating male partner involvement in births, and at the same time to ensure that the rights of the mother and the father are not violated. METHOD: We sent an online questionnaire to the head of the obstetrics department of all Hungarian state hospitals and clinics, using 14 multiple-choice questions. The data of the received questionnaires were also compared with the information related to male partner involvement in births published on the websites of the institutions. RESULTS: In the period from 20 March to 20 September 2020, in terms of informing pregnant couples, the service providers always followed the procedures in force, but in several cases this meant more financial expenditure and organization for them. CONCLUSION: Our data showed that those who give birth insist on the best possible information about conditions of male partner involvement in births, have the same expectations about the conditions of childbirth as during the epidemic-free period. If the information is satisfactory and detailed for them, they are more tolerant of adverse changes. In view of the epidemic, the possibility of father involvement in birth remained in all departments available, while maintaining appropriate epidemiological measures. Orv Hetil. 2021; 162(21): 824-829. DA - 2021/05/23/ PY - 2021 DO - 10.1556/650.2021.32226 DP - PubMed VL - 162 IS - 21 SP - 824 EP - 829 J2 - Orv Hetil LA - hun SN - 1788-6120 L2 - http://www.ncbi.nlm.nih.gov/pubmed/34023816 KW - COVID-19 KW - betegtájékoztatás KW - COVID–19 KW - együttszülés KW - eljárásrend KW - epidemiological measures KW - father involvement in birth KW - járványügyi intézkedések KW - patient information KW - procedure ER - TY - JOUR TI - [The impact of the COVID‒19 pandemic on organ donation and transplantation in Hungary in 2020] AU - Mihály, Sándor AU - Egyed-Varga, Anita AU - Trnka-Szántay, Kinga AU - Deme, Orsolya AU - Holtzinger, Emese AU - Nacsa, János AU - Piros, László T2 - Orvosi Hetilap AB - Összefoglaló. Bevezetés: A SARS-CoV-2-világjárvány terjedése drasztikus változásokat okozott a mindennapi betegellátásban, amelyek érintették a szervadományozás és -átültetés területét is, így csökkent az élő és az elhunyt donorokból történő donációk és transzplantációk száma világszerte. Az esetszám csökkenése mellett a transzplantált és egyben immunszupprimált betegek védelme érdekében további biztonsági intézkedéseket kellett bevezetni. Módszer: A vizsgálat célja a COVID-19-járvány hazai donációs és transzplantációs aktivitásra gyakorolt hatásának kimutatása volt 2020-ban, a megelőző évvel történő összehasonlításban. A magyar eredményeket összehasonlítottuk elsősorban az Eurotransplant, illetve az Európai Unió tagállamainak adataival is. Eredmények: A lakosságszámra súlyozott, regisztrált COVID-19-fertőzöttség és -halálozás tekintetében nem igazoltunk 2020-ban kiemelkedő eltérést itthon az Eurotransplant-tagállamokhoz képest. A hazai szervdonációs potenciál nem csökkent a vizsgált időszakban, ugyanakkor 38,33%-kal csökkent az agyhalott szervdonorok száma Magyarországon, míg az Eurotransplantban átlagosan 8,64%-kal és 23 adatközlő európai országban 17,55%-kal. Az elhunytból történt szervátültetések száma 29,27%-kal csökkent, különösen a szív- és a májátültetések esetén. A külföldről kapott szervek száma 21,13%-kal és aránya 12,34%-kal emelkedett. Az élő donoros veseátültetések száma nem változott. 2020-ban 25%-kal kevesebb új beteget regisztráltak, mint 2019-ben, és a várólista-mortalitás 28%-kal növekedett az előző évhez képest, kifejezetten a veseátültetésre várók között. Következtetés: A hazai szervátültetési program biztonságos: donoreredetű SARS-CoV-2-átvitel nem történt hazánkban. A szervdonációs potenciál és a COVID-19-járvány mellett a szervdonációs és -transzplantációs aktivitás jelentősen csökkent Magyarországon 2020. márciustól az év végéig. A legtöbb európai országban átmeneti és kisebb mértékű szervdonációs csökkenést regisztráltak. A szervátültetések száma nem csökkent olyan mértékben, mint a donorszám, mert az Eurotransplantból több donorszerv érkezett hazánkba, mint amennyit külföldre küldtünk. Orv Hetil. 2021; 162(23): 890-896. SUMMARY: INTRODUCTION: The spread of the SARS-CoV-2 pandemic has resulted in drastic changes in day-to-day patient care, which has also affected the field of organ donation and transplantation, thus reducing the number of donations and transplants from living and deceased donors worldwide. In addition to the reduction in the number of cases, additional safety measures had to be introduced to protect transplanted and implicatively immunosuppressed patients. METHOD: The aim of the study was to demonstrate the impact of the COVID-19 epidemic on domestic donation and transplantation activity in 2020, compared to the previous year. We also compared the Hungarian results with the data of the Eurotransplant and the European Union member states. RESULTS: In terms of population-weighted, registered COVID-19 infection and mortality, we did not find a significant difference in Hungary in 2020 compared to the Eurotransplant member states. The national organ donation potential did not diminish in the period under review, however, the number of brain-dead organ donors decreased by 38.33% in Hungary, while in the Eurotransplant it did by 8.64% on average and in 23 reporting European countries by 17.55%. The number of organ transplants from the deceased decreased by 29.27%, especially regarding heart and liver transplants. Both the number and the proportion of organs received from abroad increased by 21.13% and 12.34%, respectively. The number of living donor kidney transplants did not change. In 2020, 25% fewer new patients were registered than in 2019 and the mortality on waiting list increased by 28% compared to the previous year, especially among those waiting for a kidney transplant. CONCLUSION: The national organ transplantation program is safe: donor-derived SARS-CoV-2 transmission did not occur in Hungary. In addition to the organ donation potential and the COVID-19 pandemic, organ donation and transplantation activity decreased significantly in Hungary from March 2020 until the end of the year. Transient and smaller reductions in organ donation rates have been reported in most European countries. The number of organ transplants did not decrease as much as the number of donors, because more donor organs arrived in Hungary from the Eurotransplant than we sent abroad. Orv Hetil. 2021; 162(23): 890-896. DA - 2021/06/06/ PY - 2021 DO - 10.1556/650.2021.32268 DP - PubMed VL - 162 IS - 23 SP - 890 EP - 896 J2 - Orv Hetil LA - hun SN - 1788-6120 L2 - http://www.ncbi.nlm.nih.gov/pubmed/34091437 KW - Humans KW - COVID-19 KW - SARS-CoV-2 KW - Pandemics KW - Hungary KW - Europe KW - COVID–19 KW - organ donation KW - Organ Transplantation KW - SARS-CoV-2 pandemic KW - SARS-CoV-2-járvány KW - szervadományozás KW - Tissue and Organ Procurement KW - transplantation KW - transzplantáció ER - TY - JOUR TI - Safety Precautions for Self-Performed Severe Acute Respiratory Syndrome Coronavirus 2 Tests: A Case of a Swallowed Swab AU - Molnár, Dávid AU - Zsigmond, Ferenc AU - Helfferich, Frigyes T2 - Cureus AB - Oropharyngeal and nasopharyngeal specimens collected by swabbing are the pillars of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) diagnostics. Commercially available rapid antigen tests and self-sampling polymerase chain reaction services have made specimen collection available anytime and anywhere in nonmedical settings. In this study, we report the case of a 45-year-old man who accidentally ingested a swab during self-performed SARS-CoV-2 rapid antigen testing. Imaging studies revealed an elongated foreign body in the stomach. Urgent gastroscopy confirmed the presence of the swabbing applicator in the gastric lumen, which was retrieved using a loop without any complications. Millions of SARS-CoV-2 tests are performed daily, of which an increasing proportion are performed by laypeople. Foreign bodies account for a particular set of complications, which can be avoided by cautious sampling and using the correct technique. Radiopaque labeling of instruments would be useful. Otherwise, rare serious events can occur that may require immediate medical interventions. DA - 2021/05/28/ PY - 2021 DO - 10.7759/cureus.15297 DP - DOI.org (Crossref) VL - 13 IS - 5 SP - e15297 LA - en SN - 2168-8184 ST - Safety Precautions for Self-Performed Severe Acute Respiratory Syndrome Coronavirus 2 Tests UR - https://www.cureus.com/articles/60013-safety-precautions-for-self-performed-severe-acute-respiratory-syndrome-coronavirus-2-tests-a-case-of-a-swallowed-swab Y2 - 2021/06/10/06:21:36 L1 - https://www.cureus.com/articles/60013-safety-precautions-for-self-performed-severe-acute-respiratory-syndrome-coronavirus-2-tests-a-case-of-a-swallowed-swab.pdf ER - TY - JOUR TI - COVID-19 related cardiac complications - from clinical evidences to basic mechanisms. Opinion paper of the ESC Working Group on Cellular Biology of the Heart AU - Pesce, Maurizio AU - Agostoni, Piergiuseppe AU - Bøtker, Hans-Erik AU - Brundel, Bianca AU - Davidson, Sean M. AU - De Caterina, Raffaele AU - Ferdinandy, Peter AU - Girao, Henrique AU - Gyöngyösi, Mariann AU - Hulot, Jean-Sebastien AU - Lecour, Sandrine AU - Perrino, Cinzia AU - Schulz, Rainer AU - Sluijter, Joost P. G. AU - Steffens, Sabine AU - Tancevski, Ivan AU - Gollmann-Tepeköylü, Can AU - Tschöpe, Carsten AU - van Linthout, Sophie AU - Madonna, Rosalinda T2 - Cardiovascular Research AB - The pandemic of Coronavirus disease (COVID)-19 is a global threat, causing high mortality, especially in the elderly. The main symptoms and the primary cause of death are related to interstitial pneumonia. Viral entry also into myocardial cells mainly via the angiotensin converting enzyme type 2 (ACE2) receptor and excessive production of pro-inflammatory cytokines, however, also make the heart susceptible to injury. In addition to the immediate damage caused by the acute inflammatory response, the heart may also suffer from long-term consequences of COVID-19, potentially causing a post-pandemic increase in cardiac complications. Although the main cause of cardiac damage in COVID-19 remains coagulopathy with micro- (and to a lesser extent macro-) vascular occlusion, open questions remain about other possible modalities of cardiac dysfunction, such as direct infection of myocardial cells, effects of cytokines storm, and mechanisms related to enhanced coagulopathy. In this opinion paper, we focus on these lesser appreciated possibilities and propose experimental approaches that could provide a more comprehensive understanding of the cellular and molecular bases of cardiac injury in COVID-19 patients. We first discuss approaches to characterize cardiac damage caused by possible direct viral infection of cardiac cells, followed by formulating hypotheses on how to reproduce and investigate the hyperinflammatory and pro-thrombotic conditions observed in the heart of COVID-19 patients using experimental in vitro systems. Finally, we elaborate on strategies to discover novel pathology biomarkers using omics platforms. DA - 2021/08/29/ PY - 2021 DO - 10.1093/cvr/cvab201 DP - PubMed VL - 117 IS - 10 SP - 2148 EP - 2160 J2 - Cardiovasc Res LA - eng SN - 1755-3245 L2 - http://www.ncbi.nlm.nih.gov/pubmed/34117887 KW - COVID-19 KW - SARS-CoV-2 KW - inflammation KW - disease modelling KW - infection KW - myocardial injury ER - TY - JOUR TI - [SARS-CoV-2 infection and COVID‒19 in Gaucher disease: indications for vaccination] AU - Maródi, László T2 - Orvosi Hetilap AB - Összefoglaló. Az új típusú koronavírus (SARS-CoV-2) okozta pandémia kezdetén a szakmai közvélemény általános vélekedése a Gaucher-kóros betegek fokozott érzékenységét vetítette elő, magas morbiditási és mortalitási mutatókkal. Meglepő módon azonban az eddigi, nagyszámú betegen, az Egyesült Államokban, Európában és Izraelben végzett klinikai tanulmányok azt mutatják, hogy ezen súlyos anyagcsere-betegségben sem a fertőzésnek kitett betegek morbiditási adatait, sem a ritkán kialakult fertőzések súlyosságát tekintve nem áll fenn csökkent immunvédekezés a SARS-CoV-2-vel szemben. Ezen immunológiai és infektológiai paradoxon lehetséges magyarázata, hogy a betegek makrofágjaiban és más sejtjeiben felhalmozódó glükocerebrozid gyulladásos állapotot tart fenn, amely hátrányos a kórokozó vírus intracelluláris túlélése szempontjából. A közleményben összefoglaljuk a témakörben eddig megjelent tanulmányok adatait, az általános prevencióval és a vakcinációval kapcsolatos ajánlásokat, és kitérünk az 1-es típusú interferonok (IFNα és IFNω) közelmúltban megismert szerepére a SARS-CoV-2-vel szembeni immunitásban. Orv Hetil. 2021; 162(24): 938-942. Summary. At the start of the pandemic caused by the novel coronavirus (SARS-CoV-2), the Gaucher disease community anticipated that infection with this emerging viral pathogen would be associated with high morbidity and mortality in individuals with this chronic metabolic disorder. Surprisingly, however, preliminary studies suggest that Gaucher disease does not confer a higher risk of severe, life-threatening effects of SARS-CoV-2 infection, and no severe cases have been reported in large cohorts of patients from the United States, Europe and Israel. It is thought that the accumulation of glucocerebroside in the cells of Gaucher patients may promote immune tolerance rather than inflammation on exposure to SARS-CoV-2. We review here the current concepts of Gaucher disease and SARS-CoV-2 infection, focusing particularly on general prevention and vaccination. We also discuss the susceptibility to COVID-19 of patients with inborn errors of type 1 interferon (IFNα and IFNω) immunity. Orv Hetil. 2021; 162(24): 938-942. DA - 2021/06/13/ PY - 2021 DO - 10.1556/650.2021.32272 DP - PubMed VL - 162 IS - 24 SP - 938 EP - 942 J2 - Orv Hetil LA - hun SN - 1788-6120 ST - SARS-CoV-2 infection and COVID‒19 in Gaucher disease L2 - http://www.ncbi.nlm.nih.gov/pubmed/34120104 KW - Humans KW - Male KW - COVID-19 KW - SARS-CoV-2 KW - Vaccination KW - Europe KW - COVID–19 KW - ACE KW - APECED KW - Gaucher Disease ER - TY - JOUR TI - Biologia Futura: is ADAM 17 the reason for COVID-19 susceptibility in hyperglycemic and diabetic patients? AU - Stepanova, Ganna T2 - Biologia Futura AB - COVID-19 is a disease-causing current pandemic. It prevails in patients with pre-existing conditions such as diabetes and hypertension. Renin–angiotensin system was identified as a center of COVID-19 pathophysiology. There is a current controversy concerning the usage of ACE inhibitors and AR blockers in patients with COVID-19. Multiple clinical trials are on the way to determine the effect of RAS blockers in patients with COVID-19. ACE2 receptor is thought to be the point of entry utilized by a coronavirus. However, other factors have been identified which potentially facilitate SARS-CoV-2 entry into the cell. ADAM17 could facilitate viral entry in hyperglycemic and diabetic patients. Insulin is an ADAM17 inhibitor. Heme oxygenase (HO)-1 level is reduced in diabetic patients, contributing to the worst outcome for patients with poor glycemic control. The combined therapy of glycemic control and antioxidant response to oxidative stress could be explored in patients with COVID-19. DA - 2021/09// PY - 2021 DO - 10.1007/s42977-021-00092-2 DP - DOI.org (Crossref) VL - 72 IS - 3 SP - 291 EP - 297 J2 - BIOLOGIA FUTURA LA - en SN - 2676-8615, 2676-8607 ST - Biologia Futura UR - https://link.springer.com/10.1007/s42977-021-00092-2 Y2 - 2021/06/18/07:13:40 L1 - https://link.springer.com/content/pdf/10.1007/s42977-021-00092-2.pdf ER - TY - JOUR TI - Impact of COVID-19 on Cardiovascular Testing in the United States Versus the Rest of the World AU - Hirschfeld, Cole B. AU - Shaw, Leslee J. AU - Williams, Michelle C. AU - Lahey, Ryan AU - Villines, Todd C. AU - Dorbala, Sharmila AU - Choi, Andrew D. AU - Shah, Nishant R. AU - Bluemke, David A. AU - Berman, Daniel S. AU - Blankstein, Ron AU - Ferencik, Maros AU - Narula, Jagat AU - Winchester, David AU - Malkovskiy, Eli AU - Goebel, Benjamin AU - Randazzo, Michael J. AU - Lopez-Mattei, Juan AU - Parwani, Purvi AU - Vitola, Joao V. AU - Cerci, Rodrigo J. AU - Better, Nathan AU - Raggi, Paolo AU - Lu, Bin AU - Sergienko, Vladimir AU - Sinitsyn, Valentin AU - Kudo, Takashi AU - Nørgaard, Bjarne Linde AU - Maurovich-Horvat, Pál AU - Cohen, Yosef A. AU - Pascual, Thomas N. B. AU - Pynda, Yaroslav AU - Dondi, Maurizio AU - Paez, Diana AU - Einstein, Andrew J. AU - INCAPS-COVID Investigators Group T2 - JACC. Cardiovascular imaging AB - OBJECTIVES: This study sought to quantify and compare the decline in volumes of cardiovascular procedures between the United States and non-US institutions during the early phase of the coronavirus disease-2019 (COVID-19) pandemic. BACKGROUND: The COVID-19 pandemic has disrupted the care of many non-COVID-19 illnesses. Reductions in diagnostic cardiovascular testing around the world have led to concerns over the implications of reduced testing for cardiovascular disease (CVD) morbidity and mortality. METHODS: Data were submitted to the INCAPS-COVID (International Atomic Energy Agency Non-Invasive Cardiology Protocols Study of COVID-19), a multinational registry comprising 909 institutions in 108 countries (including 155 facilities in 40 U.S. states), assessing the impact of the COVID-19 pandemic on volumes of diagnostic cardiovascular procedures. Data were obtained for April 2020 and compared with volumes of baseline procedures from March 2019. We compared laboratory characteristics, practices, and procedure volumes between U.S. and non-U.S. facilities and between U.S. geographic regions and identified factors associated with volume reduction in the United States. RESULTS: Reductions in the volumes of procedures in the United States were similar to those in non-U.S. facilities (68% vs. 63%, respectively; p = 0.237), although U.S. facilities reported greater reductions in invasive coronary angiography (69% vs. 53%, respectively; p < 0.001). Significantly more U.S. facilities reported increased use of telehealth and patient screening measures than non-U.S. facilities, such as temperature checks, symptom screenings, and COVID-19 testing. Reductions in volumes of procedures differed between U.S. regions, with larger declines observed in the Northeast (76%) and Midwest (74%) than in the South (62%) and West (44%). Prevalence of COVID-19, staff redeployments, outpatient centers, and urban centers were associated with greater reductions in volume in U.S. facilities in a multivariable analysis. CONCLUSIONS: We observed marked reductions in U.S. cardiovascular testing in the early phase of the pandemic and significant variability between U.S. regions. The association between reductions of volumes and COVID-19 prevalence in the United States highlighted the need for proactive efforts to maintain access to cardiovascular testing in areas most affected by outbreaks of COVID-19 infection. DA - 2021/09// PY - 2021 DO - 10.1016/j.jcmg.2021.03.007 DP - PubMed VL - 14 IS - 9 SP - 1787 EP - 1799 J2 - JACC Cardiovasc Imaging LA - eng SN - 1876-7591 L2 - http://www.ncbi.nlm.nih.gov/pubmed/34147434 KW - COVID-19 KW - coronavirus KW - cardiovascular disease KW - cardiovascular imaging KW - diagnostic cardiovascular procedure ER - TY - JOUR TI - Clinical outcome, risk assessment, and seasonal variation in hospitalized COVID-19 patients-Results from the CORONA Germany study AU - Gessler, Nele AU - Gunawardene, Melanie A. AU - Wohlmuth, Peter AU - Arnold, Dirk AU - Behr, Juergen AU - Gloeckner, Christian AU - Herrlinger, Klaus AU - Hoelting, Thomas AU - Pape, Ulrich-Frank AU - Schreiber, Ruediger AU - Stang, Axel AU - Wesseler, Claas AU - Willems, Stephan AU - Arms, Charlotte AU - Herborn, Christoph U. T2 - PloS One AB - BACKGROUND: After one year of the pandemic and hints of seasonal patterns, temporal variations of in-hospital mortality in COVID-19 are widely unknown. Additionally, heterogeneous data regarding clinical indicators predicting disease severity has been published. However, there is a need for a risk stratification model integrating the effects on disease severity and mortality to support clinical decision-making. METHODS: We conducted a multicenter, observational, prospective, epidemiological cohort study at 45 hospitals in Germany. Until 1 January 2021, all hospitalized SARS CoV-2 positive patients were included. A comprehensive data set was collected in a cohort of seven hospitals. The primary objective was disease severity and prediction of mild, severe, and fatal cases. Ancillary analyses included a temporal analysis of all hospitalized COVID-19 patients for the entire year 2020. FINDINGS: A total of 4704 COVID-19 patients were hospitalized with a mortality rate of 19% (890/4704). Rates of mortality, need for ventilation, pneumonia, and respiratory insufficiency showed temporal variations, whereas age had a strong influence on the course of mortality. In cohort conducting analyses, prognostic factors for fatal/severe disease were: age (odds ratio (OR) 1.704, CI:[1.221-2.377]), respiratory rate (OR 1.688, CI:[1.222-2.333]), lactate dehydrogenase (LDH) (OR 1.312, CI:[1.015-1.695]), C-reactive protein (CRP) (OR 2.132, CI:[1.533-2.965]), and creatinine values (OR 2.573, CI:[1.593-4.154]. CONCLUSIONS: Age, respiratory rate, LDH, CRP, and creatinine at baseline are associated with all cause death, and need for ventilation/ICU treatment in a nationwide series of COVID 19 hospitalized patients. Especially age plays an important prognostic role. In-hospital mortality showed temporal variation during the year 2020, influenced by age. TRIAL REGISTRATION NUMBER: NCT04659187. DA - 2021/// PY - 2021 DO - 10.1371/journal.pone.0252867 DP - PubMed VL - 16 IS - 6 SP - e0252867 J2 - PLoS One LA - eng SN - 1932-6203 L2 - http://www.ncbi.nlm.nih.gov/pubmed/34138888 ER - TY - JOUR TI - The Role of Type III Interferons in Human Disease AU - Malik, Aniko E. AU - Issekutz, Thomas B. AU - Derfalvi, Beata T2 - Clinical and Investigative Medicine. Medecine Clinique Et Experimentale AB - PURPOSE: This literature review summarizes the main immunological characteristics of type III interferons (IFN) and highlights the clinically relevant aspects and future therapeutic perspectives for these inflammatory molecules. SOURCE: Relevant articles in PubMed MEDLINE from the first publication (2003) until 2020. N=101 articles were included in this review. PRINCIPAL FINDINGS: Type III IFNs represent a relatively newly described inflammatory cytokine family. Although they induce substantially similar signalling to the well-known type I IFNs, significant functional differences make these molecules remarkable. Type III IFNs have extensive biological effects, contributing to the pathogenesis of several diseases and also offering new diagnostic and therapeutic approaches: 1) their potent anti-viral properties make them promising therapeutics against viral hepatitis and even against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is causing the current coronavirus disease 2019 (COVID-19) pandemic; 2) imbalances in the IFN-λs contribute to several forms of chronic inflammation (e.g., systemic and organ-specific autoimmune diseases) and potentially predict disease progression and therapeutic response to biologic therapies; and 3) the antitumor properties of the type III IFNs open up new therapeutic perspectives against malignant diseases. CONCLUSION: Over the last 18 years, researchers have gathered extensive information about the presence and role of these versatile inflammatory cytokines in human diseases, but further research is needed to clarify the mechanistic background of those observations. Better understanding of their biological activities will permit us to use type III IFNs more efficiently in new diagnostic approaches and individualized therapies, consequently improving patient care. DA - 2021/06/14/ PY - 2021 DO - 10.25011/cim.v44i2.36622 DP - PubMed VL - 44 IS - 2 SP - E5 EP - 18 J2 - Clin Invest Med LA - eng SN - 1488-2353 L2 - http://www.ncbi.nlm.nih.gov/pubmed/34152702 KW - literature review KW - type II interferon ER - TY - JOUR TI - Cardiac Magnetic Resonance Findings in Patients Recovered From COVID-19: Initial Experiences in Elite Athletes AU - Vago, Hajnalka AU - Szabo, Liliana AU - Dohy, Zsofia AU - Merkely, Bela T2 - JACC. Cardiovascular imaging DA - 2021/06// PY - 2021 DO - 10.1016/j.jcmg.2020.11.014 DP - PubMed VL - 14 IS - 6 SP - 1279 EP - 1281 J2 - JACC Cardiovasc Imaging LA - eng SN - 1876-7591 ST - Cardiac Magnetic Resonance Findings in Patients Recovered From COVID-19 L1 - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7837171/pdf/main.pdf L2 - http://www.ncbi.nlm.nih.gov/pubmed/33341416 KW - Humans KW - COVID-19 KW - SARS-CoV-2 KW - Predictive Value of Tests KW - Consensus KW - Angiography KW - Athletes KW - Magnetic Resonance Spectroscopy KW - Radial Artery ER - TY - JOUR TI - A Covid19 járvány során hozott egészségügyi intézkedések és hatásaik Magyarországon és Ausztriában AU - Szerencsés, Viktória AU - Palicz, Tamás AU - Joó, Tamás AU - Lám, Judit AU - Demeter-Fülöp, Virág AU - Ugrin, Irina T2 - Belügyi Szemle AB - A 2020-as Covid19 járvány első hullámát követően érdemes áttekinteni a járvány visszaszorítása és kezelése érdekében meghozott intézkedéseket, mert azok tapasztalatai fogják meghatározni az előttünk álló időszak védekezési stratégiáját. Elemzésünkben Magyarország és Ausztria járványügyi intézkedéseit vettük végig, kizárólag az egészségügy területére koncentrálva. Mivel osztrák szomszédunknál kb. két héttel korábban jelent meg az első új típusú koronavírusos megbetegedés, így az ő rendelkezéseik fontos támpontot jelentettek számunkra a korlátozó intézkedések bevezetése során. Az egészségügyi ellátórendszer zavartalan működésének biztosítása hasonló kihívás elé állította mind Magyarországot, mind Ausztriát. A meghozott intézkedésekben is sok hasonlóság mutatkozik, a főbb irányok azonosok voltak, ugyanakkor az intézkedések bevezetésének időbeliségében felfedezhetők különbségek a két ország között. Az eltéréseket az intézkedések bevezetésének pontos dátuma és az első koronavírusos esetek megjelenésétől eltelt napok száma alapján mutatjuk be. A rendvédelem szempontjából is tanulságos lehet egy strukturált áttekintés az egészségügyi intézkedésekről, mert ebben a járványidőszakban került bevezetésre a Belügyminisztérium által irányított kórházparancsnoki rendszer, amely mind a rendvédelemben, mind az egészségügyben dolgozók számára új helyzetet teremtett. DA - 2021/01/15/ PY - 2021 DO - 10.38146/BSZ.2021.1.6 DP - DOI.org (Crossref) VL - 69 IS - 1 SP - 123 EP - 141 J2 - BSZ SN - 2677-1632, 2062-9494 UR - https://ojs.mtak.hu/index.php/belugyiszemle/article/view/5176 Y2 - 2021/06/30/08:05:15 L1 - https://ojs.mtak.hu/index.php/belugyiszemle/article/download/5176/4101 ER - TY - JOUR TI - Covid-19 és a Parkinson-kór AU - Tóth, Adrián AU - Takáts, Annamária T2 - Lege Artis Medicinae AB - Parkinson’s disease is the elderly people’s condition which increases the risk of infections in the upper airways in its ad­vanced stages. Specific diseases (as hypertension, diabetes mellitus), older age and the male sex are significantly worsening the course of COVID-19. It would be challenging to examine parallel these diseases, since they are raising two important ques­tions. First, if Parkinson’s disease be a risk factor of COVID-19 morbidity and mortality. Se­condly, how the COVID-19 pandemic can influence the Parkinson’s disease patients. The authors are seeking answers to these questions based on the published results in the topic concerned. DA - 2021/// PY - 2021 DO - 10.33616/lam.31.014 DP - DOI.org (Crossref) VL - 31 IS - 5-6 SP - 201 EP - 205 J2 - LAM SN - 08664811, 20634161 UR - https://elitmed.hu/en/publications/lege-artis-medicinae/covid-19-and-parkinsons-disease Y2 - 2021/07/07/12:30:36 ER - TY - JOUR TI - Hypertonia, COPD és Covid-19. Fókuszban az antihipertenzív terápia AU - Farsang, Csaba T2 - Lege Artis Medicinae AB - Chronic obstructive pulmonary disease is a very common comorbidity of hypertension and it is often unrecognised by physicians. The factors involved in the pathomechanism of both diseases should be realised when choosing treatment. Among factors, hypoxia, increased tone of sympathetic nervous system and activation of renin-angiotensin-aldosterone system should primarily be considered. Vascular wall damage and endothelial dysfunction has an important role in both conditions. The goals of treatment are elimination of risk factors, optimizing the blood pressure, the consequential prevention of cardio-cerebrovascular, renal and pulmonary damage; finally prolonging the patients’ life and improving their quality of life as well. Both hypertension and COPD significantly worsen the condition of COVID-19 patients since they increase the severity of the disease and the rate of in-patients’ and their mortality. In the treatment of hypertension among COPD and COVID-19 patients there must be emphasized the medication inhibiting of renin-angiotensin-aldosterone system, such as angiotensin-converting en­zyme inhibitors or angiotensin-II AT1 re­cep­tor antagonists. Special attention concerned the beneficial effect of mineralocorticoid receptor antagonist spironolactone. Other antihypertensive drugs (calcium channel blockers, thiazide-like diu­retics, high selectivity β1 receptor antagonists) may supplement the treatment if necessary. Long-acting β2 receptor agonists, muscarinic receptor antagonists and inhalation corticosteroids may be administered in double or triple combination also in hypertension and COPD as well. It is important to note, that statin therapy and also vitamin D3 improve the condition of COVID-19 patients. DA - 2021/// PY - 2021 DO - 10.33616/lam.31.013 DP - DOI.org (Crossref) VL - 31 IS - 5-6 SP - 193 EP - 199 J2 - LAM SN - 08664811, 20634161 UR - https://elitmed.hu/en/publications/lege-artis-medicinae/hypertension-copd-and-covid-19-focus-on-antihypertensive-therapy Y2 - 2021/07/07/12:31:45 ER - TY - JOUR TI - Epilepszia koronavírus-járvány idején AU - Szűcs, Anna AU - Halász, Péter AU - Narula, Lalit T2 - Lege Artis Medicinae AB - We aim to review the impact of COVID-19 pandemic on epilepsy and epilepsy-care. While the virus has no specific link with epilepsy, it may affect the nervous system both directly and indirectly, leading to seizures in several ways. The hyper-coagulable state occurring with the infection may cause strokes leading to seizures. The infection may first manifest in the form of disturbances of consciousness and behaviour, seizures, and even status epilepticus. The interactions of antiviral/antiepileptic drugs need to be taken into account during treatment. The hypercoagulable state induced by COVID-2 infection may cause stroke, which leads to seizures. The infection can occur also as an impaired consciousness of non-epileptic origin. Interactions of antiviral/antiepileptic drugs have also to be taken into account. The pandemic itself as well as quarantines and social distancing may cause anxiety and insomnia, challenge continuous antiepileptic supply; each one carrying the risk of seizing. Young epilepsy patients with learning disabilities and mental health issues are most vulnerable, justifying their hyper-protection. The danger of infection has highlighted the role of telemedicine. Internet-based video communication may ensure full care for chro­nic patients. Those methods favour bes­­ted patients with higher education. Epilepsy does not increase directly the risk of infection, but its comorbidities may worsen the course of the disease. Brain lesions and hypoxia, stress, insomnia and fever joining the infection increase seizure susceptibility. Because the danger of infection ma­de telemedicine an essential tool of pa­tient care, education and better computer supply for those in need is crucial. DA - 2021/// PY - 2021 DO - 10.33616/lam.31.015 DP - DOI.org (Crossref) VL - 31 IS - 5-6 SP - 207 EP - 213 J2 - LAM SN - 08664811, 20634161 UR - https://elitmed.hu/en/publications/lege-artis-medicinae/epilepsy-in-coronavirus-pandemic Y2 - 2021/07/07/12:34:38 ER - TY - JOUR TI - Neurodegenerative proteinopathies associated with neuroinfections AU - Danics, Krisztina AU - Forrest, Shelley L. AU - Kapas, Istvan AU - Erber, Irene AU - Schmid, Susanne AU - Törő, Klára AU - Majtenyi, Katalin AU - Kovacs, Gabor G. T2 - Journal of Neural Transmission (Vienna, Austria: 1996) AB - Infectious agents, including viruses and bacteria, are proposed to be involved in the pathogenesis of Alzheimer's disease (AD). According to this hypothesis, these agents have capacity to evade the host immune system leading to chronic infection, inflammation, and subsequent deposition of Aβ and phosphorylated-tau in the brain. Co-existing proteinopathies and age-related pathologies are common in AD and the brains of elderly individuals, but whether these are also related to neuroinfections remain to be established. This study determined the prevalence and distribution of neurodegenerative proteinopathies in patients with infection-induced acute or chronic inflammation associated with herpes simplex virus (HSV) encephalitis (n = 13) and neurosyphilis (n = 23). The mean age at death in HSV patients was 53 ± 12 years (range 24-65 years) and survival was 9 days-6 years following initial infection. The mean age at death and survival in neurosyphilis patients was 60 ± 15 years (range 36-86 years) and 1-5 years, respectively. Neuronal tau-immunoreactivity and neurites were observed in 8 HSV patients and 19 neurosyphilis patients, and in approximately half of these, this was found in regions associated with inflammation and expanding beyond regions expected from the Braak stage of neurofibrillary degeneration. Five neurosyphilis patients had cortical ageing-related tau astrogliopathy. Aβ-plaques were found in 4 HSV patients and 11 neurosyphilis patients. Lewy bodies were observed in one HSV patient and two neurosyphilis patients. TDP-43 pathology was absent. These observations provide insights into deposition of neurodegenerative proteins in neuroinfections, which might have implications for COVID-19 patients with chronic and/or post-infectious neurological symptoms and encephalitis. DA - 2021/07/05/ PY - 2021 DO - 10.1007/s00702-021-02371-7 DP - PubMed J2 - J Neural Transm (Vienna) LA - eng SN - 1435-1463 L2 - http://www.ncbi.nlm.nih.gov/pubmed/34223998 KW - Alzheimer’s disease KW - Herpes simplex virus KW - Neuro-infection KW - Neurosyphilis KW - Proteinopathy KW - Tau ER - TY - JOUR TI - Covid-19-fertőzést követő időszak táplálkozási ajánlásai élsportolók számára AU - Fekete, Mónika AU - Varga, János Tamás T2 - Új Diéta: A magyar dietetikusok lapja (2001-) DA - 2021/// PY - 2021 DP - MTMT VL - 30 IS - 2 SP - 2 EP - 4 J2 - Új Diéta (Győr) (2001) LA - Hungarian SN - 1587-169X UR - https://m2.mtmt.hu/api/publication/32021298 ER - TY - JOUR TI - A véralvadás változásai COVID-19 megbetegedésben AU - Gadó, Klára AU - Markovics, Dorina AU - Virág, Andrea AU - Vajda, Zoltán AU - Domján, Gyula T2 - Érbetegségek / Hungarian Journal of Vascular Diseases DA - 2021/// PY - 2021 DP - MTMT VL - 28 IS - 2 SP - 27 EP - 31 J2 - Érbetegségek / Hung J Vasc Dis LA - Hungarian SN - 1218-3636 UR - https://m2.mtmt.hu/api/publication/32077817 ER - TY - JOUR TI - Impact of the COVID-19 Pandemic on Family Carers of Older People Living with Dementia in Italy and Hungary AU - Kostyál, László Árpád AU - Széman, Zsuzsa AU - Almási, Virág Erzsébet AU - Fabbietti, Paolo AU - Quattrini, Sabrina AU - Socci, Marco AU - Lamura, Giovanni AU - Gagliardi, Cristina T2 - Sustainability AB - The COVID-19 pandemic has had a major effect on both older people with dementia and families caring for them. This paper presents the results of an online survey carried out among Italian and Hungarian family carers of people with dementia during the first pandemic wave (May–July 2020, n = 370). The research questions were the following: (1) How has the pandemic changed the lives of family carers? (2) How did government restriction measures change the availability of care-related help? (3) What other changes did families experience? Results show that about one-quarter of both subsamples experienced a deterioration in their financial status. A decline in both general and mental health was also reported. Due to “lockdown”, family carers’ burden increased substantially. Utilization of care-related help decreased, and the share of those left with no help increased in both countries. Cross-country differences emerged in terms of dementia care system, severity of the first pandemic wave, and measures put in place by governments. Findings outline the weaknesses of support structures and their country-specific vulnerabilities to a worldwide pandemic. To better protect people with dementia in the future, it is essential to strengthen their family carers, and support structures need to be re-evaluated and re-designed. DA - 2021/06/24/ PY - 2021 DO - 10.3390/su13137107 DP - DOI.org (Crossref) VL - 13 IS - 13 SP - 7107 J2 - Sustainability LA - en SN - 2071-1050 UR - https://www.mdpi.com/2071-1050/13/13/7107 Y2 - 2021/07/20/10:40:02 L1 - https://www.mdpi.com/2071-1050/13/13/7107/pdf ER - TY - JOUR TI - COVID-19-vakcináció gasztroenterológiai kórképekben AU - Miheller, Pál AU - Patai, Árpád V. AU - Szijártó, Attila T2 - Háziorvos Továbbképző Szemle DA - 2021/// PY - 2021 VL - 26 IS - 6 SP - 396 EP - 399 LA - magyar SN - 1219-8641 KW - járvány KW - koronavírus ER - TY - JOUR TI - A COVID-19 betegség szemészeti vonatkozásai AU - Nagy, Zoltán Zsolt T2 - Orvostovábbképző Szemle AB - A kötőhártya felőli fertőződés lehetőségével számolnunk kell, ezért a szemészeti vizsgálatokban részt vevőknek különleges figyelmet kell fordítaniuk a személyes védelmükre, illetve a páciensek védelmére. A szájmaszkon kívül a plasztik védőpajzs használata a réslámpás vizsgálatok során, valamint a védőszemüvegek alkalmazása továbbra is indokolt és kötelező. Ezt a tényt a más szakmákban dolgozóknak is figyelmébe ajánljuk. Fontos, hogy a sürgősségi és az intenzív ellátást nyújtó orvosok, ápoló személyzet tisztában legyenek a COVID-19 intenzív terápiája alatt potenciálisan fellépő szemészeti tünetekkel, azok ellátásával, elkerülésük lehetőségével. DA - 2021/// PY - 2021 VL - 28 IS - 2 SP - 17 EP - 19 LA - magyar SN - 1218-2583 KW - járvány KW - koronavírus ER - TY - JOUR TI - The efficacy of virtual distance training of intensive therapy and anaesthesiology among fifth-year medical students during the COVID-19 pandemic: a cross-sectional study AU - Kovács, Enikő AU - Kállai, András AU - Fritúz, Gábor AU - Iványi, Zsolt AU - Mikó, Vivien AU - Valkó, Luca AU - Hauser, Balázs AU - Gál, János T2 - BMC medical education AB - BACKGROUND: The coronavirus disease (COVID-19) brought several challenges in medical education. The aim of our study was to investigate whether virtual distance trainings (VDT) organized during the COVID-19 pandemic at our university were effective in replacing in-person bed-side education in intensive therapy and anaesthesiology among fifth-year medical students, both from students' and instructors' perspectives. METHODS: This was a cross-sectional study consisting of three parts: a 20-item students' questionnaire filled out by students participating in VDT, a 22-item instructors' questionnaire filled out by instructors taking part in virtual distance education and a 20-item knowledge test completed by students participating in VDT, as well as by students visiting bed-side trainings (BT) during the same semester, before COVID-19 pandemic. The questionnaires focused on effectiveness, content, self-preparedness, technical background and interactivity of VDT. Instructors' and students' responses given to the common questions, as well as the knowledge test results were compared. Mann-Whitney U test was used for group comparisons and binary logistic regression was performed to analyze the influence of previous health-care experience on students' feeling of self-preparedness. RESULTS: One hundred thirthen students (response rate {RR}: 68%) and 29 instructors (RR: 97%) filled out the questionnaires. The majority of students found our VDT useful and effective; however, a considerable number of participants felt disadvantaged by taking VDT instead of BT sessions and would recommend keeping virtual distance education methods combined with BT. Instructors found VDT overall effective and deemed the transfer of their knowledge satisfactory; however, they described worse interactivity and contact with students during virtual sessions compared to in-person teaching. Instructors showed a clearer consensus that VDT should not replace BT in the future, while students' answers were more divided in this regard. Previous health-care experience did not influence students' feeling of self-preparedness. One hundred and twenty-seven students (56 after VDT {RR: 34%}; 71 after BT {RR: 67%}) completed the end-of-semester knowledge test. Students attending VDT performed better than students visiting BT (median score VDT:83.5 vs BT:77.3; p = 0.015). CONCLUSIONS: Virtual distance learning incorporating virtual practice sessions was effective in maintaining continuous education of intensive therapy and anaesthesiology among fifth-year medical students during the COVID-19 outbreak. DA - 2021/07/22/ PY - 2021 DO - 10.1186/s12909-021-02826-1 DP - PubMed VL - 21 IS - 1 SP - 393 J2 - BMC Med Educ LA - eng SN - 1472-6920 ST - The efficacy of virtual distance training of intensive therapy and anaesthesiology among fifth-year medical students during the COVID-19 pandemic L1 - https://bmcmededuc.biomedcentral.com/track/pdf/10.1186/s12909-021-02826-1 L2 - http://www.ncbi.nlm.nih.gov/pubmed/34294079 KW - Humans KW - COVID-19 KW - SARS-CoV-2 KW - Cross-Sectional Studies KW - Pandemics KW - Anaesthesiology KW - Anesthesiology KW - Education, Distance KW - Intensive therapy KW - Medical education KW - Students, Medical KW - Virtual learning ER - TY - JOUR TI - The effect of a single dose of BNT162b2 vaccine on the incidence of severe COVID-19 infection in patients on chronic hemodialysis: a single-centre study AU - Cserep, Gabor AU - Morrow, David AU - Latchford, Karen AU - Jesset, Rachael AU - Dosa, Agnes AU - Kirmizis, Dimitrios T2 - Clinical and Experimental Nephrology AB - INTRODUCTION: In this single-centre retrospective observational study, the 8-week safety and the efficiency of a single dose of BNT162b2 vaccine was studied in 83 HD patients. METHODS: All clinically stable adult ESRD patients on chronic HD for at least 4 weeks were screened for participation in the study. Exclusion criteria for enrollment in the study included a medical history of COVID-19 infection within the last 12 weeks or delivery of both vaccine doses less than 8 weeks apart from each other. The same patients during the 8-week period that preceded the vaccination served as controls of themselves. The vaccine was administered intramuscularly in the deltoid muscle, on a dialysis day, at least 30 min either pre- or post-dialysis. The primary end-point of the study was severe COVID-19 infection, and/or death due to COVID-19 pneumonitis. Furthermore, all vaccinated patients were scrutinized for any local or systemic reactions within the first 7 days post-vaccination. RESULTS: Amongst 113 adult HD patients in our Unit, in total 83 patients had the first 30 μg dose of the BNT162b2 vaccine and were considered eligible to be included in the study. The 8-week survival rate was 91% for the controls and 100% for the vaccine group. No life-threatening allergic reaction or other side-effect was observed post-vaccination. CONCLUSION: The BNT162b2 vaccine can be safely used in HD patients and seems to offer significant protection against the infection even after the first vaccine dose. DA - 2022/01// PY - 2022 DO - 10.1007/s10157-021-02118-4 DP - PubMed VL - 26 IS - 1 SP - 54 EP - 58 J2 - Clin Exp Nephrol LA - eng SN - 1437-7799 ST - The effect of a single dose of BNT162b2 vaccine on the incidence of severe COVID-19 infection in patients on chronic hemodialysis L1 - https://link.springer.com/content/pdf/10.1007/s10157-021-02118-4.pdf L2 - http://www.ncbi.nlm.nih.gov/pubmed/34324086 KW - COVID-19 KW - BNT162b2 vaccine KW - Hemodialysis ER - TY - JOUR TI - Impact of the COVID-19 pandemic on nuclear medicine departments in Europe AU - Moreira, Ana Paula AU - Jamar, François AU - Ozcan, Zehra AU - Piciu, Doina AU - Als, Claudine AU - Franceschi, Maja AU - Trägårdh, Elin AU - Zagar, Ivana AU - Sowa-Staszczak, Anna AU - Cachin, Florent AU - Bennink, Roel AU - Forrer, Flavio AU - Adamsen, Tom Christian AU - Fotopolous, Andreas AU - Kalnina, Marika AU - Jensen, Lars Thorbjørn AU - Mussalo, Hanna AU - Simanek, Milan AU - Garcia-Cañamaque, Lina AU - Nazarenko, Sergei AU - Mihailovic, Jasna AU - Bar-Sever, Zvi AU - O'Connell, Martin AU - Miladinova, Daniela AU - Graham, Richard AU - Giubbini, Raffaele AU - Kaliská, Lucia AU - Rozić, Damir AU - Krause, Bernd J. AU - Gallowitsch, Hans-Jürgen AU - Györke, Tamás AU - Sediene, Severina AU - Rumyantsev, Pavel AU - Wadsak, Wolfgang AU - Kunikowska, Jolanta T2 - European Journal of Nuclear Medicine and Molecular Imaging DA - 2021/10// PY - 2021 DO - 10.1007/s00259-021-05484-z DP - PubMed VL - 48 IS - 11 SP - 3361 EP - 3364 J2 - Eur J Nucl Med Mol Imaging LA - eng SN - 1619-7089 L1 - https://link.springer.com/content/pdf/10.1007/s00259-021-05484-z.pdf L2 - http://www.ncbi.nlm.nih.gov/pubmed/34328532 ER - TY - JOUR TI - The Use of CytoSorb Therapy in Critically Ill COVID-19 Patients: Review of the Rationale and Current Clinical Experiences AU - Ruiz-Rodríguez, Juan Carlos AU - Molnar, Zsolt AU - Deliargyris, Efthymios N. AU - Ferrer, Ricard T2 - Critical Care Research and Practice AB - The COVID-19 pandemic has led to the biggest global health crisis of our lifetime. There is accumulating evidence that a substantial number of critically ill COVID-19 patients exhibit a dysregulated host response manifesting as cytokine storm or cytokine release syndrome, which in turn contributes to the high observed rates of mortality. Just as in other hyperinflammatory conditions, extracorporeal cytokine removal may have potential beneficial effects in this subgroup of COVID-19 patients. The CytoSorb blood purification device is the most extensively investigated cytokine removal platform with considerable evidence suggesting that early intervention can provide rapid hemodynamic stabilization and improvement in vital organ functions. The purpose of this review is to provide an overview of the pathophysiological background of hyperinflammation in COVID-19 and to summarize the currently available evidence on the effects of hemoadsorption in these patients. DA - 2021/// PY - 2021 DO - 10.1155/2021/7769516 DP - PubMed VL - 2021 SP - 7769516 J2 - Crit Care Res Pract LA - eng SN - 2090-1305 ST - The Use of CytoSorb Therapy in Critically Ill COVID-19 Patients L1 - https://downloads.hindawi.com/journals/ccrp/2021/7769516.pdf L2 - http://www.ncbi.nlm.nih.gov/pubmed/34336280 ER - TY - JOUR TI - Impact of COVID-19 on the imaging diagnosis of cardiac disease in Europe AU - Williams, Michelle Claire AU - Shaw, Leslee AU - Hirschfeld, Cole B. AU - Maurovich-Horvat, Pal AU - Nørgaard, Bjarne L. AU - Pontone, Gianluca AU - Jimenez-Heffernan, Amelia AU - Sinitsyn, Valentin AU - Sergienko, Vladimir AU - Ansheles, Alexey AU - Bax, Jeroen J. AU - Buechel, Ronny AU - Milan, Elisa AU - Slart, Riemer H. J. A. AU - Nicol, Edward AU - Bucciarelli-Ducci, Chiara AU - Pynda, Yaroslav AU - Better, Nathan AU - Cerci, Rodrigo AU - Dorbala, Sharmila AU - Raggi, Paolo AU - Villines, Todd C. AU - Vitola, Joao AU - Malkovskiy, Eli AU - Goebel, Benjamin AU - Cohen, Yosef AU - Randazzo, Michael AU - Pascual, Thomas N. B. AU - Dondi, Maurizio AU - Paez, Diana AU - Einstein, Andrew J. AU - INCAPS COVID Investigators Group T2 - Open Heart AB - OBJECTIVES: We aimed to explore the impact of the COVID-19 pandemic on cardiac diagnostic testing and practice and to assess its impact in different regions in Europe. METHODS: The online survey organised by the International Atomic Energy Agency Division of Human Health collected information on changes in cardiac imaging procedural volumes between March 2019 and March/April 2020. Data were collected from 909 centres in 108 countries. RESULTS: Centres in Northern and Southern Europe were more likely to cancel all outpatient activities compared with Western and Eastern Europe. There was a greater reduction in total procedure volumes in Europe compared with the rest of the world in March 2020 (45% vs 41%, p=0.003), with a more marked reduction in Southern Europe (58%), but by April 2020 this was similar in Europe and the rest of the world (69% vs 63%, p=0.261). Regional variations were apparent between imaging modalities, but the largest reductions were in Southern Europe for nearly all modalities. In March 2020, location in Southern Europe was the only independent predictor of the reduction in procedure volume. However, in April 2020, lower gross domestic product and higher COVID-19 deaths were the only independent predictors. CONCLUSION: The first wave of the COVID-19 pandemic had a significant impact on care of patients with cardiac disease, with substantial regional variations in Europe. This has potential long-term implications for patients and plans are required to enable the diagnosis of non-COVID-19 conditions during the ongoing pandemic. DA - 2021/08// PY - 2021 DO - 10.1136/openhrt-2021-001681 DP - PubMed VL - 8 IS - 2 SP - e001681 J2 - Open Heart LA - eng SN - 2053-3624 L1 - https://openheart.bmj.com/content/openhrt/8/2/e001681.full.pdf L2 - http://www.ncbi.nlm.nih.gov/pubmed/34353958 KW - Humans KW - COVID-19 KW - Predictive Value of Tests KW - Europe KW - Health Care Surveys KW - coronary artery disease KW - Heart Diseases KW - cardiac imaging techniques KW - Cardiac Imaging Techniques KW - Cardiologists KW - Healthcare Disparities KW - Practice Patterns, Physicians' ER - TY - JOUR TI - Laboratory parameters predicting mortality of adult in-patients with COVID-19 associated cytokine release syndrome treated with high-dose tocilizumab AU - Lakatos, Botond AU - Szabo, Balint Gergely AU - Bobek, Ilona AU - Gopcsa, Laszlo AU - Beko, Gabriella AU - Kiss-Dala, Noemi AU - Petrik, Borisz AU - Gaspar, Zsofia AU - Farkas, Balazs Ferenc AU - Sinko, Janos AU - Remenyi, Peter AU - Szlavik, Janos AU - Valyi-Nagy, Istvan T2 - Acta Microbiologica Et Immunologica Hungarica AB - Large randomized clinical trials in severe Coronavirus Disease 2019 (COVID-19) patients have proven efficacy of intravenous tocilizumab. Our aim was to describe the laboratory parameters predicting in-hospital mortality of patients with tocilizumab administration in COVID-19 associated cytokine release syndrome (CRS).We evaluated high-dose (8 mg/kg) intravenous tocilizumab administration in severe and critically ill COVID-19 adult patients fulfilling predefined strict CRS criteria. A single-centre, prospective, observational cohort study was carried out among consecutive adult (≥18 years of age) in-patients with COVID-19 between April 1 and December 31, 2020. The primary endpoint was 28-day all-cause mortality. The changes in laboratory parameters from baseline on day 7 and 14 after administration of tocilizumab were analysed.In total, 1801 patients were admitted to our centre during the study period. One hundred and six patients received tocilizumab, and among them 62 (58.5%) required intensive care unit admittance while 25 (23.6%) deceased. At day 7 after tocilizumab administration, inflammatory markers (CRP, IL-6, ferritin) and lactate dehydrogenase (LDH) values were significantly lower among survivors. Subsequently, at day 14, differences of IL-6 and LDH levels has become more pronounced between subgroups. Restoration of absolute lymphocyte count (ALC) by day 7 and 14 was insufficient among patients who died.In our cohort, administration of high-dose tocilizumab for COVID-19 patients with CRS demonstrated clinical and sustained biochemical parameter improvement in 76.4%. In this patient population high and increasing LDH, IL-6, and low ALC levels had a predictive role for mortality. DA - 2021/09/08/ PY - 2021 DO - 10.1556/030.2021.01526 DP - PubMed VL - 68 IS - 3 SP - 145 EP - 152 J2 - Acta Microbiol Immunol Hung LA - eng SN - 1588-2640 L1 - https://akjournals.com/downloadpdf/journals/030/aop/article-10.1556-030.2021.01526/article-10.1556-030.2021.01526.pdf L2 - http://www.ncbi.nlm.nih.gov/pubmed/34370690 KW - COVID-19 KW - SARS-CoV-2 KW - cytokine release syndrome KW - interleukin-6 KW - tocilizumab ER - TY - JOUR TI - A Covid-19 neurológiai szövődményei AU - Lambertus, Iván AU - Dobronyi, Levente AU - Bereczki, Dániel AU - Kovács, Tibor T2 - Lege Artis Medicinae AB - A Covid-19 megbetegedést okozó SARS-CoV-2 2021-re a világ valamennyi országában elterjedt, elsősorban légúti tünetekkel járó megbetegedést okozva, amely súlyos esetben légzési elégtelenséggel járó tüdőgyulladás formájában zajlik. A világjárvány kezdete óta jelennek meg esetismertetések, összefoglaló vizsgálatok a fertőzés neurológiai tüneteiről, szövődményekről (például myalgia, anosmia, ageusia, encephalitis, encephalopathia, cerebrovascularis megbetegedések, Guillain–Barré-szindróma, különféle neuropathiák). Ugyanakkor ismeretes, hogy a terápiás próbálkozások kapcsán alkalmazott gyógyszereknek is lehetnek idegrendszeri mellékhatásai. Összefoglalónk a rendelkezésre álló hazai és nemzetközi irodalmat összegezve igyekszik a gyakorlatban is hasznos áttekintést adni a SARS-CoV-2-fertőzés jelenleg ismert neurológiai szövődményeiről. DA - 2021/// PY - 2021 DO - 10.33616/lam.31.018 DP - DOI.org (Crossref) VL - 31 IS - 7 SP - 259 EP - 264 J2 - LAM SN - 08664811, 20634161 UR - https://elitmed.hu/en/publications/lege-artis-medicinae/neurological-complications-of-covid-19 Y2 - 2021/08/19/09:00:54 ER - TY - JOUR TI - mRNS alapú vakcinák a COVID-19 járvány elleni küzdelemben AU - Dalmadiné Kiss Borbála AU - Király Márton AU - Virág Dávid AU - Antal István AU - Ludányi Krisztina T2 - Gyógyszerészet AB - A SARS-CoV-2 vírus okozta világjárvány megfékezésében nagy reményeket fűznek a szakemberek az mRNS alapú vakcinákhoz, így a szerzők áttekintik a COVID-19 megbetegedés hátterében álló, a vakcinafejlesztés során megcélozható legfontosabb immunológiai folyamatokat, az mRNS vakcinák működésének alapjait, a hatékonyságuk növelésének módjait és az ipari léptékű gyártást lehetővé tevő új technológiákat. Törekednek továbbá a hivatkozott irodalmak alapján az oltóanyagfejlesztés és -engedélyezés során felmerülő problémák, kérdések elemző összefoglalására. DA - 2021/// PY - 2021 DP - Matarka VL - 65 IS - 3 SP - 138 EP - 144 SN - 0017-6036 UR - https://mgyt.hu/wp-content/uploads/2021/03/Gygyszet-2103-ELOZETES.pdf#page=5 N1 -

Source: Matarka

ER - TY - JOUR TI - Impact of COVID-19 on ischemic stroke care in Hungary AU - Böjti, Péter Pál AU - Szilágyi, Géza AU - Dobi, Balázs AU - Stang, Rita AU - Szikora, István AU - Kis, Balázs AU - Kornfeld, Ákos AU - Óváry, Csaba AU - Erőss, Lóránd AU - Banczerowski, Péter AU - Kuczyński, Wojciech AU - Bereczki, Dániel T2 - GeroScience AB - Data about the coronavirus disease 2019 (COVID-19) pandemic's collateral damage on ischemic stroke (IS) care during the second epidemic wave in Central Europe are limited. We sought to evaluate the impact of the COVID-19 outbreak on Hungarian IS care during the two epidemic waves. This retrospective observational study was based on a nationwide reimbursement database that encompasses all IS admissions and all reperfusion interventions, i.e., intravenous thrombolysis (IVT) and endovascular therapy (EVT) from 2 January 2017 to 31 December 2020 in Hungary. COVID-19 pandemic's effect on the number of IS admissions and reperfusion interventions were analyzed using different statistics: means, medians, trends, relative rates, and linear relationships. The mean and median values of IS admissions and reperfusion interventions decreased only in some measure during the COVID-periods. However, trend analysis demonstrated a significant decline from the trends. The decline's dynamic and amplitude have differed for each variable. In contrast to IVT, the number of IS admissions and EVTs negatively correlated with the epidemic waves' amplitude. Besides, the decrease in the number of IS admissions was more pronounced than the decrease in the number of reperfusion interventions. Our study demonstrated a significant disruption in IS care during the COVID-19 epidemic in Hungary, in which multiple different factors might play a role. The disproportionate reduction of IS admission numbers could partially be explained by the effect of health emergency operative measures and changes in patients' social behavior. Further studies are needed to evaluate the causes of our observations. DA - 2021/10//undefined PY - 2021 DO - 10.1007/s11357-021-00424-z DP - PubMed VL - 43 IS - 5 SP - 2231 EP - 2248 J2 - Geroscience LA - eng SN - 2509-2723 L2 - http://www.ncbi.nlm.nih.gov/pubmed/34406562 KW - COVID-19 KW - Hungary KW - Epidemiology KW - Stroke KW - Thrombectomy KW - Thrombolysis ER - TY - JOUR TI - Háziorvosok és a COVID-vakcináció AU - Rurik, Imre AU - Torzsa, Péter T2 - Medicus Universalis DA - 2021/// PY - 2021 VL - 54 IS - 1 SP - 10 EP - 12 LA - magyar SN - 0133-1973 KW - járvány KW - koronavírus ER - TY - JOUR TI - SARS-CoV-2 fertőzés okozta tüdőkárosodás : tüdőrák és a COVID-19 a TERAVOLT vizsgálat tükrében AU - Szondy, Klára AU - Futácsi, Balázs AU - Kis, Sándor T2 - Klinikai Onkológia AB - A Covid-19-járvány remélhetőleg vége felé, cikkünkben rövid áttekintést kívánunk adni a fertőzésről, a kórokozóról, a második hullám végére kialakult hatékonynak tűnő kezelési lehetőségekről, a tüdőkárosodásról és a TERAVOLT klinikai vizsgálatról, amely összefoglalja tüdőrákban szenvedő, kezelést kapó és/vagy nem kapó SARS-CoV-2 vírussal fertőződött betegek életkilátásait, a diagnosztika területén létrejött szabályokat (bronchoszkópia, mellkasröntgen, mellkasi CT), és néhány szóban a védőoltásokról is szó esik. A szerzők rövid áttekintést adnak a légzőszervi és daganatos betegek fertőzés alatti kezeléséről, az inhalációs készítmények, immunterápia, kemoterápia folytathatóságáról. DA - 2021/// PY - 2021 VL - 8 IS - 1 SP - 25 EP - 30 LA - magyar SN - 2064-5058 UR - https://klinikaionkologia.hu/sars-cov-2-fertozes-okozta-tudokarosodas-tudorak-es-a-covid-19-a-teravolt-vizsgalat-tukreben/ KW - járvány KW - koronavírus ER - TY - JOUR TI - A COVID-19 és a reumatológia összefüggései AU - Szekanecz, Z AU - Bálint, Péter Vince AU - Balog, A AU - Constantin, Tamás AU - Czirják, László AU - Géher, P AU - Kovács, L AU - Kumánovics, Gábor AU - Nagy, György AU - Rákóczi, É AU - Szamosi, S AU - Szűcs, G T2 - Immunológiai Szemle DA - 2021/// PY - 2021 DP - MTMT VL - 13 IS - 2 SP - 4 EP - 16 LA - Hungarian UR - https://m2.mtmt.hu/api/publication/31969553 ER - TY - JOUR TI - A poszt-COVID-19 betegség tüdőgyógyászati rehabilitációja AU - Fekete, Mónika AU - Szarvas, Zsófia AU - Fazekas-Pongor, Vince AU - Fehér, Ágnes AU - Jáky-Kováts, Zsuzsanna Ágnes AU - Lukácsovits, József AU - Horváth, Gábor AU - Müller, Veronika AU - Varga, János Tamás T2 - Orvostovábbképző Szemle DA - 2021/// PY - 2021 DP - MTMT VL - 28 IS - 8 SP - 21 EP - 24 UR - https://m2.mtmt.hu/api/publication/32005376 ER - TY - JOUR TI - Gyógyszeres terápiás javaslat COVID-19-ben AU - Szekanecz, Zoltán AU - Bogos, Krisztina AU - Constantin, Tamás AU - Fülesdi, Béla AU - Müller, Veronika AU - Rákóczi, Éva AU - Várkonyi, István AU - Vályi-Nagy, István T2 - Gyermekgyógyászati Továbbképző Szemle AB - Az új típusú koronavírus-fertőzés (COVID-19) nagy terhet ró az egészségügyi ellátórendszerre és a társadalomra. A betegségnek három nagy szakasza van, melyek alapvetően meghatározzák a kezelést. Az I-IIA fázisban az antivirális, míg a IIB-III. fázisban a gyulladásgátló kezelés áll előtérben, melyhez intenzív terápiás, szupportív kezelés csatlakozik. A jelen ajánlás kizárólag a gyógyszeres kezelésre vonatkozik, és a rendelkezésre álló bizonyítékok alapján foglalja össze a terápiás lehetőségeket. Emellett egy javasolt kezelési algoritmust is tartalmaz. DA - 2021/// PY - 2021 VL - 26 IS - 3 SP - 67 EP - 74 LA - magyar SN - 1585-4396 N1 -

Utánközlés, első közlés: Medical Tribune - http://medicalonline.hu/gyogyitas/cikk/gyogyszeres_terapias_javaslat_covid_19_ben

KW - járvány KW - koronavírus ER - TY - JOUR TI - EDTA-Induced Pseudothrombocytopenia Up to 9 Months After Initial COVID-19 Infection Associated with Persistent Anti-SARS-CoV-2 IgM/IgG Seropositivity AU - Bereczki, Dániel AU - Nagy, Béla AU - Kerényi, Adrienne AU - Nagy, Gábor AU - Szarka, Krisztina AU - Kristóf, Katalin AU - Szalay, Balázs AU - Vásárhelyi, Barna AU - Bhattoa, Harjit P. AU - Kappelmayer, János T2 - Laboratory Medicine AB - Platelets have a role in vascular complications of COVID-19-related viral coagulopathy. Although immune-induced thrombocytopenia has been described mostly in moderate-to-severe COVID-19, the prognostic role of platelet count in COVID-19 is still controversial. Pseudothrombocytopenia has been reported to represent COVID-19-associated coagulopathy in critical illness, and transient EDTA-dependent pseudothrombocytopenia lasting less than 3 weeks was described in a patient with severe acute COVID-19 pneumonia. In our case study, EDTA-induced pseudothrombocytopenia was still present at 9 months after an initial SARS-CoV-2 virus infection in an apparently recovered 60 year old man. The persistence of antinucleocapside and antispike antibodies 9 months after the initial infection suggests that EDTA-induced pseudothrombocytopenia may be related to anti-SARS-CoV-2 IgG or IgM antibodies. We should acknowledge the possibility that pseudothrombocytopenia may also appear in some patients after seroconversion after the launch of large-scale vaccination programs. DA - 2022/03/07/ PY - 2022 DO - 10.1093/labmed/lmab050 DP - PubMed VL - 53 IS - 2 SP - 206 EP - 209 J2 - Lab Med LA - eng SN - 1943-7730 L2 - http://www.ncbi.nlm.nih.gov/pubmed/34415328 KW - COVID-19 KW - anti-Spike 1 and Spike 2 (anti-S1/S2) IgG test KW - anti-Spike 1 receptor binding domain (anti-S1-RBD) KW - antinucleocapsid antibody KW - EDTA-induced pseudothrombocytopenia KW - persisting anti-SARS-CoV-2 IgM/IgG seropositivity KW - SARS-CoV-2 virus infection ER - TY - JOUR TI - COVID-19-betegek komplex rehabilitációja AU - Varga János Tamás AU - Madurka Ildikó AU - Boros Erzsébet AU - Czibók Csilla AU - Kováts Zsuzsanna AU - Bogos Krisztina AU - Müller Veronika AU - Szilasi Mária T2 - Rehabilitáció DA - 2021/// PY - 2021 DP - Matarka VL - 31 IS - 2 SP - 36 EP - 49 SN - 0866-479X UR - https://m2.mtmt.hu/api/publication/32030236 N1 -

Source: Matarka

ER - TY - JOUR TI - Invasive fungal infections among critically ill adult COVID-19 patients: First experiences from the national centre in Hungary AU - Szabo, Balint Gergely AU - Lakatos, Botond AU - Bobek, Ilona AU - Szabo, Edina AU - Szlavik, Janos AU - Vályi-Nagy, István T2 - Journal De Mycologie Medicale AB - INTRODUCTION: Data suggests that invasive fungal infections (IFI) might complicate COVID-19. Our goal was to describe characteristics of IFI among critically ill COVID-19 adults. METHODS: A retrospective observational case-series analysis was done between March-July 2020. Consecutive patients with critical COVID-19 were eligible, and have been included when proven or putative/probable IFI could be confirmed during their course. For COVID-19 diagnosis, ECDC definitions and WHO severity criteria were followed. Candidaemia was diagnosed according to the ESCMID 2012 guideline. Invasive pulmonary aspergillosis (IPA) was defined following EORTC/MSG, ECMM/ISHAM and modified AspICU criteria. Outcome variables were rates of IFIs, in-hospital all-cause mortality, rate and time to negative respiratory SARS-CoV-2 PCR. RESULTS: From 90 eligible patients, 20 (22.2%) fulfilled criteria for IFI. Incidence rate for IFI was 2.02 per 100 patient-days at ICU. Patients were mostly elderly males with significant comorbidities, requiring mechanical ventilation because of ARDS. IFI could be classified as candidaemia in 7/20 (40%), putative/probable IPA in 16/20 (80.0%). Isolated species of candidaemia episodes were Candida albicans (4/9, 44.4%), Candida glabrata (3/9, 33.3%), Candida parapsilosis (1/9, 11.1%), Candida metapsilosis (1/9, 11.1%). Mold isolates from lower respiratory tract were Aspergillus fumigatus, BAL galactomannan positivity was prevalent (16/20, 80.0%). Mortality was 12/20 (60.0%) with a median time to death of 31.0±37.0 (5-89) days. Only 9/20 (45.0%) patients reached SARS-CoV-2 PCR negativity after a median time of 20.0±12.0 (3-38) days. CONCLUSION: In this small cohort of critically ill COVID-19 adults, morbidity and mortality related to invasive fungal infections proved to be significant. DA - 2021/08/14/ PY - 2021 DO - 10.1016/j.mycmed.2021.101198 DP - PubMed VL - 31 IS - 4 SP - 101198 J2 - J Mycol Med LA - eng SN - 1773-0449 ST - Invasive fungal infections among critically ill adult COVID-19 patients L2 - http://www.ncbi.nlm.nih.gov/pubmed/34428666 KW - COVID-19 KW - Cytokine storm KW - Aspergillosis KW - Candidaemia KW - Invasive fungal infection ER - TY - JOUR TI - Animal reservoirs of SARS-CoV-2: calculable COVID-19 risk for older adults from animal to human transmission AU - Valencak, Teresa G. AU - Csiszar, Anna AU - Szalai, Gabor AU - Podlutsky, Andrej AU - Tarantini, Stefano AU - Fazekas-Pongor, Vince AU - Papp, Magor AU - Ungvari, Zoltan T2 - GeroScience AB - The current COVID-19 pandemic, caused by the highly contagious respiratory pathogen SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), has already claimed close to three million lives. SARS-CoV-2 is a zoonotic disease: it emerged from a bat reservoir and it can infect a number of agricultural and companion animal species. SARS-CoV-2 can cause respiratory and intestinal infections, and potentially systemic multi-organ disease, in both humans and animals. The risk for severe illness and death with COVID-19 significantly increases with age, with older adults at highest risk. To combat the pandemic and protect the most susceptible group of older adults, understanding the human-animal interface and its relevance to disease transmission is vitally important. Currently high infection numbers are being sustained via human-to-human transmission of SARS-CoV-2. Yet, identifying potential animal reservoirs and potential vectors of the disease will contribute to stronger risk assessment strategies. In this review, the current information about SARS-CoV-2 infection in animals and the potential spread of SARS-CoV-2 to humans through contact with domestic animals (including dogs, cats, ferrets, hamsters), agricultural animals (e.g., farmed minks), laboratory animals, wild animals (e.g., deer mice), and zoo animals (felines, non-human primates) are discussed with a special focus on reducing mortality in older adults. DA - 2021/10//undefined PY - 2021 DO - 10.1007/s11357-021-00444-9 DP - PubMed VL - 43 IS - 5 SP - 2305 EP - 2320 J2 - Geroscience LA - eng SN - 2509-2723 ST - Animal reservoirs of SARS-CoV-2 L2 - http://www.ncbi.nlm.nih.gov/pubmed/34460063 KW - Coronavirus KW - Aging KW - Agricultural animals KW - Immunosenescence KW - Zoo animals KW - Zoonosis ER - TY - JOUR TI - A COVID-19 gyermekgyógyászati vonatkozásai AU - Tory, Kálmán T2 - Gyermekorvos Továbbképzés DA - 2021/// PY - 2021 VL - 20 IS - 3 SP - 150 EP - 154 LA - magyar SN - 1589-0309 KW - járvány KW - koronavírus ER - TY - JOUR TI - Coronavirus Pandemic - #STAYHOME: How Are You Holding Up? Questions And Tips For 11-18-Year-Olds To Make It Better AU - Szentiványi, Dóra AU - Horváth, Lili Olga AU - Kjeldsen, Anne AU - Buist, Kirsten L. AU - Farkas, Bernadett Frida AU - Ferenczi-Dallos, Gyöngyvér AU - Garas, Péter AU - Győri, Dóra AU - Győrfi, Ágnes AU - Győrfi, Dóra AU - Ravens-Sieberer, Ulrike AU - Balázs, Judit T2 - Neuropsychopharmacologia Hungarica AB - Háttér: A COVID-19 pandémia kitörése óta a bevezetett korlátozások a serdülő korosztályt is erőteljesen érintik, ugyanis a fiataloktól a vírushelyzet alatt elvárt viselkedés ellentétes azzal, ami az átlagos fejlődés során jellemzi őket. A serdülők normatív krízissel érintett korosztálya amúgy is különösen sérülékeny, emellett a korlátozások miatt időlegesen elérhetetlenné válhatnak számukra szociális és egészségügyi szolgáltatások, továbbá akár elhanyagolásnak, vagy bántalmazásnak is ki lehetnek téve, mely a pandémia alatt láthatatlanná válhat az ellátó- és jelzőrendszer tagjai számára. Célkitűzés: 1. A lelki egészség és életminőség felmérése a pandémia különböző szakaszaiban és a járvány lezárultával. 2. A résztvevők érdeklődési köréhez igazított, igényeire szabott lelki egészségfejlesztő intervenció. 3. Átfogó online prevenciós program tervezése. 4. Nemzetközi team bevonásával a program kulturális adaptálása. 5. A jövőbeli hasonló helyzetek esetére evidenciákon alapuló beavatkozási tervek készítése. Módszerek: Online vizsgálatunkba 11-18 éves serdülők és szüleik/gondviselőik kerülnek bevonásra európai és europán kívüli országokból. Az utánkövetéses adatgyűjtés során megkeressük a résztvevőket, hogy önkitöltős kérdőívcsomag segítségével felmérjük az életminőségüket, lelki egészségüket, szükségleteiket és attitűdjeiket a járványhelyzettel kapcsolatban. A hazai adatgyűjtést kutatócsoportunk elsőként kezdte meg, a járvány első hulláma, az Európa szerte bevezetett korlátozások idején, 2020 márciusában. Ezt követően a rendszeres utánkövetés (kezdetben heti, majd havi, két havi, három havi) segítségével vizsgáljuk, hogyan változnak a serdülők és szüleik szükségletei, mentális egészségük és életminőségük. Vizsgálatunkat egy éves keretben tervezzük, mely 2021. márciusában zárul. A legutóbbi utánkövetés 2020 decemberében zajlott. A prevenciós program tervezése jelenleg is zajlik. Várható eredményeink: A vizsgálatunk eredményei alapján kidolgozásra kerülő prevenciós program segíti a mentális egészség megőrzését, javítja az életminőséget, növeli a fiatalok bevonódását, hogy betartsák a vírushelyzet miatti korlátozásokat, megkönnyíti a visszailleszkedést a járványt követő nyitás során. Továbbá információt kaphatunk a fiatalok általános jóllétéről egy extrém, fenyegető szituációban. Következtetések: Eredményeink segíthetik az esetleges jövőben fenyegető szituációra vonatkozó irányelvek és az átfogó prevenció kidolgozását. DA - 2021/// PY - 2021 VL - 23 IS - 1 SP - 208 EP - 214 LA - angol SN - 1419-8711 UR - https://epa.oszk.hu/02400/02454/00081/pdf/EPA02454_neuropsychopharmacologia_hungarica_2021_01_208-214.pdf KW - járvány KW - koronavírus ER - TY - JOUR TI - Ophthalmic signs and complications of the COVID-19 infection AU - Nagy, Z. Z. T2 - Developments in Health Sciences AB - Abstract Coronavirus-19 infection caused a mysterious pandemic worldwide. Some people experienced flu-like symptoms, while others have died due to pulmonary complications. Besides droplet spread, other routes of infection started to be suspected, such as through eye contact. During the first phase of the pandemic, pulmonary symptoms were in focus, later other signs and symptoms were also published. Eyelid, anterior and posterior segment symptoms, neuro-ophthalmic complications, and orbital problems related to COVID-19 infections are discussed in this article. It is important to detect the serious signs and symptoms to prevent late, sight threatening complications of COVID-19 infection. DA - 2021/07/30/ PY - 2021 DO - 10.1556/2066.2021.40001 DP - DOI.org (Crossref) VL - 3 IS - 4 SP - 79 EP - 82 J2 - DHS SN - 2630-9378, 2630-936X UR - https://akjournals.com/view/journals/2066/3/4/article-p79.xml Y2 - 2021/09/02/12:40:45 L1 - https://akjournals.com/downloadpdf/journals/2066/3/4/article-p79.pdf ER - TY - JOUR TI - A H-UNCOVER vizsgálat eredményei és hatása a magyarországi járványkezelésre AU - Merkely, Béla Péter AU - Fülöp, Gábor Áron AU - Kosztin, Annamária AU - Vokó, Zoltán T2 - Scientia et Securitas AB - A HUNgarian COronaVirus disease-19 Epidemiological Research (H-UNCOVER) vizsgálat egy országos szintű reprezentatív felmérés volt, melyet az Innovációs és Technológiai Minisztérium (ITM) támogatásával végzett el a négy orvostudományi képzést folytató magyar egyetem a Központi Statisztikai Hivatallal (KSH) együttműködve. A vizsgálat célja az volt, hogy egy reprezentatív mintán keresztül felmérje a magyar lakosság SARS-CoV-2 átfertőzöttségét, és támaszul szolgáljon a koronavírus első hulláma kapcsán meghozott restriktív intézkedések utáni lazításra. A világszinten is jelentős méretű vizsgálat alacsony átfertőzöttségi arányt mutatott, így nemcsak a restriktív intézkedések hatékonyságát mutatta meg, de egy biztos járványügyi támaszt jelentett a gazdaság újranyitásának tervezéséhez. DA - 2021/// PY - 2021 DO - 10.1556/112.2021.00016 DP - MTMT VL - 2 IS - 1 SP - 54 EP - 61 J2 - Sci et Sec SN - 2732-2688 UR - https://m2.mtmt.hu/api/publication/32124405 ER - TY - JOUR TI - Az epidemiológiai surveillance és járványmatematikai előrejelzések szerepe a pandémiás hullámok megelőzésében, mérséklésében – hol tartunk most, és hová kellene eljutni AU - Oroszi, Beatrix AU - Horváth, Judit Krisztina AU - Túri, Gergő AU - Krisztalovics, Katalin AU - Röst, Gergely T2 - Scientia et Securitas AB - A Járványmatematikai és Epidemiológiai Projekt egy egyedülálló kezdeményezés Magyarországon, mely jelentős tudást és tapasztalatot halmozott fel a COVID–19 világjárvány során. Jelen tanulmány a pandémia 2. hullámának példáján keresztül áttekinti, hogy miként működött a járványügyi észlelés és monitorozás rendszere, hogyan, milyen eredményekkel végezték a projekt munkatársai a helyzet- és kockázatértékelést, az előrejelzések készítését, végül javaslatokat fogalmaz meg a surveillance- és előrejelző rendszer fejlesztésére a járványügyi biztonság növelése érdekében.A 2. járványhullám 2020. június 22. és 2021. január 24. között zajlott Magyarországon, melynek során a megerősített COVID–19 esetek száma 356 197 fő volt, ami az első hullámban regisztrált esetszám 87-szerese. Összesen 12 226 megerősített COVID–19 halálesetet regisztráltak, az első hullámban jelentett szám 21-szeresét. Az országos R érték először 2020 augusztusában emelkedett 1,0 fölé. Mintegy 3 héttel azután, hogy az R érték augusztus utolsó hetében tartósan 1,0 fölé emelkedett, a halálos kimenetelű COVID–19 esetszámok növekedése is elindult, mivel a fiatalokról a járvány az idősebb korosztályokra is átterjedt. Mindezt a matematikai modellezési eredmények hetekkel korábban jelezték. November elején az előrejelzés 12 000 fő feletti kórházi ápoltat vetített előre a karácsonyi időszakra, melynek el-kerülésére kormányzati intézkedéscsomag készült. A 2020. november 11-i szigorítás a járványt az eredeti pályáról eltérítette, így a kórházban kezeltek száma a 2. hullámban az előrejelzésnek megfelelően 8018 főnél elérte a csúcsot, majd csökkenni kezdett. Január elején a modellezés azt mutatta, hogy a lecsengő szakaszban, az akkori intézkedések mellett is képes az időközben hazánkban is megjelent új variáns, a gyorsabban terjedő SARS-CoV-2 B.1.1.7, járvány-ügyi fordulatot hozni, ami szintén megvalósult. Összességében az epidemiológiai helyzetértékelés és matematikai modellezés képes volt a második hullám minden fő aspektusát időben és jól megragadni, a veszélyes folyamatokat előre jelezni és ezzel lehetőséget adni a gyors reagálásra. A 2. hullám tapasztalatai megmutatták, hogy a járványmatematikai és epidemiológiai képességek milyen hozzá-adott értékkel bírnak a döntéstámogatásban. Az észlelési és előrejelzési rendszereink megerősítése és a matematikai modellezéssel egységes keretrendszerben történő továbbfejlesztése további lehetőségeket nyithat meg az észlelés, megelőzés, egészségügyi és gazdasági károk elhárítása érdekében szükséges döntési folyamatok bizonyítékalapú támogatásában, és az ország járványügyi biztonságának növelésében. DA - 2021/// PY - 2021 DO - 10.1556/112.2021.00007 DP - MTMT VL - 2 IS - 1 SP - 38 EP - 53 J2 - Sci et Sec SN - 2732-2688 UR - https://m2.mtmt.hu/api/publication/32124363 ER - TY - JOUR TI - A COVID–19 patológiája. Halálok SARS-CoV-2-fertőzésben: vírusfertőzésben vagy vírusfertőzéssel? AU - Schaff, Zsuzsa AU - Danics, Krisztina AU - Pesti, Adrián AU - Lotz, Gábor AU - Várkonyi, Tibor AU - Dobi, Deján AU - Vályi-Nagy, István AU - Törő, Klára Andrea AU - Glasz, Tibor AU - Kiss, András T2 - Scientia et Securitas AB - A SARS-CoV-2-pandémia óta a Semmelweis Egyetemen és egyéb intézményekben rendszeresen végeznek boncolá-sokat, melyek feltárták a COVID–19 jellegzetességeit. A legsúlyosabb kép a tüdőben mutatkozik, melynek légtelen-sége változó kiterjedésű, oka összetett, így tüdővizenyő, fehérjében gazdag izzadmány, az erek vérrög okozta elzáró-dása és gyulladás. A szív, a vese, az agy és a máj változó mértékben érintett, érrögösödés, elhalás, degeneratív elváltozások mutatkoznak. A SARS-CoV-2-vírus fehérjéi (tüske, nukleokapszid) és a vírus genetikai anyaga (RNS) kimutatható az egyes szervekben, leginkább a tüdőben. Klinikopatológiai elemzéssel megállapítható, hogy a halál a SARS-CoV-2-fertőzés mint közvetlen kórok következménye, vagy egyéb krónikus megbetegedés, melyet súlyosbí-tott a SARS-CoV-2-fertőzés, vagy a halál a vírusfertőzéstől függetlenül következett be. DA - 2021/// PY - 2021 DO - 10.1556/112.2021.00002 VL - 2 IS - 1 SP - 94 EP - 99 J2 - Sci et Sec SN - 2732-2688 UR - https://m2.mtmt.hu/api/publication/32124642 ER - TY - JOUR TI - Favipiravir treatment does not influence disease progression among adult patients hospitalized with moderate-to-severe COVID-19: a prospective, sequential cohort study from Hungary AU - Szabo, Balint Gergely AU - Lenart, Katalin Szidonia AU - Petrik, Borisz AU - Gaspar, Zsofia AU - Kiss-Dala, Noemi AU - Szlavik, Janos AU - Valyi-Nagy, Istvan AU - Lakatos, Botond AU - Saint Ladislaus COVID-19 Collaborative T2 - GeroScience AB - Data suggests that favipiravir (FVP) could be used against SARS-CoV-2. Our aim was to investigate the role of FVP in COVID-19 treatment. A prospective sequential cohort study was performed among adults hospitalized at our center between March and August 2020 with moderate-to-severe, PCR-confirmed COVID-19. For diagnosis and severity, ECDC and WHO definitions were utilized. Patients were screened for inclusion by a priori criteria and included in the FVP cohort if standard-of-care (SOC) + FVP or the non-FVP cohort if SOC ± other antivirals without FVP were administered for > 48 h from diagnosis. Treatment allocation was done per national guidelines, based on severity and drug availability. Primary endpoint was disease progression, a composite of 14-day all-cause death, need for mechanical ventilation, or immunomodulatory therapy. The impact of FVP exposure on disease progression was analyzed by binomial logistic regression. In all, 150 patients were included, 75 in each cohort. Disease progression (17/75, 22.7% vs. 10/75, 13.3%, p = 0.13), 14-day all-cause death (9/75, 12.0% vs. 10/75, 13.3%, p = 0.8), and need for mechanical ventilation (8/75, 10.7% vs. 4/75, 5.3%, p = 0.22) were similar, while immunomodulatory therapies were required more frequently among patients receiving FVP (10/75, 13.3% vs. 1/75, 1.3%, p < 0.01). The use of favipiravir was not retained as a protective factor against disease progression in multivatiate analysis. Time to antiviral therapy from PCR positivity, disease severity, need for oxygen supportation, and ICU admittance rates did not differ statistically between cohorts. In this study, favipiravir did not seem to positively affect disease progression. DA - 2021/10//undefined PY - 2021 DO - 10.1007/s11357-021-00452-9 DP - PubMed VL - 43 IS - 5 SP - 2205 EP - 2213 J2 - Geroscience LA - eng SN - 2509-2723 ST - Favipiravir treatment does not influence disease progression among adult patients hospitalized with moderate-to-severe COVID-19 L2 - http://www.ncbi.nlm.nih.gov/pubmed/34476717 KW - COVID-19 KW - SARS-CoV-2 KW - Antiviral KW - Favipiravir ER - TY - JOUR TI - Prognostic Impact of Acute Cardiovascular Events in COVID-19 Hospitalized Patients—Results from the CORONA Germany Study AU - Gunawardene, Melanie A. AU - Gessler, Nele AU - Wohlmuth, Peter AU - Heitmann, Kathrin AU - Anders, Philipp AU - Jaquet, Kai AU - Herborn, Christoph U. AU - Arnold, Dirk AU - Bein, Berthold AU - Bergmann, Martin W. AU - Herrlinger, Klaus R. AU - Stang, Axel AU - Schreiber, Ruediger AU - Wesseler, Claas AU - Willems, Stephan T2 - Journal of Clinical Medicine AB - Background: Acute myocardial injury (AMJ), assessed by elevated levels of cardiac troponin, is associated with fatal outcome in coronavirus disease 2019 (COVID-19). However, the role of acute cardiovascular (CV) events defined by clinical manifestation rather than sole elevations of biomarkers is unclear in hospitalized COVID-19 patients. Objective: The aim of this study was to investigate acute clinically manifest CV events in hospitalized COVID-19 patients. Methods: From 1 March 2020 to 5 January 2021, we conducted a multicenter, prospective, epidemiological cohort study at six hospitals from Hamburg, Germany (a portion of the state-wide 45-center CORONA Germany cohort study) enrolling all hospitalized COVID-19 patients. Primary endpoint was occurrence of a clinically manifest CV-event. Results: In total, 132 CV-events occurred in 92 of 414 (22.2%) patients in the Hamburg-cohort: cardiogenic shock in 10 (2.4%), cardiopulmonary resuscitation in 12 (2.9%), acute coronary syndrome in 11 (2.7%), de-novo arrhythmia in 31 (7.5%), acute heart-failure in 43 (10.3%), myocarditis in 2 (0.5%), pulmonary-embolism in 11 (2.7%), thrombosis in 9 (2.2%) and stroke in 3 (0.7%). In the Hamburg-cohort, mortality was 46% (42/92) for patients with a CV-event and 33% (27/83) for patients with only AMJ without CV-event (OR 1.7, CI: (0.94–3.2), p = 0.077). Mortality was higher in patients with CV-events (Odds ratio(OR): 4.8, 95%-confidence-interval(CI): [2.9–8]). Age (OR 1.1, CI: (0.66–1.86)), atrial fibrillation (AF) on baseline-ECG (OR 3.4, CI: (1.74–6.8)), systolic blood-pressure (OR 0.7, CI: (0.53–0.96)), potassium (OR 1.3, CI: (0.99–1.73)) and C-reactive-protein (1.4, CI (1.04–1.76)) were associated with CV-events. Conclusion: Hospitalized COVID-19 patients with clinical manifestation of acute cardiovascular events show an almost five-fold increased mortality. In this regard, the emergence of arrhythmias is a major determinant. DA - 2021/09/02/ PY - 2021 DO - 10.3390/jcm10173982 DP - DOI.org (Crossref) VL - 10 IS - 17 SP - 3982 J2 - JCM LA - en SN - 2077-0383 UR - https://www.mdpi.com/2077-0383/10/17/3982 Y2 - 2021/09/09/07:29:37 ER - TY - JOUR TI - Interactions of anti-COVID-19 drug candidates with hepatic transporters may cause liver toxicity and affect pharmacokinetics AU - Ambrus, Csilla AU - Bakos, Éva AU - Sarkadi, Balázs AU - Özvegy-Laczka, Csilla AU - Telbisz, Ágnes T2 - Scientific Reports AB - Transporters in the human liver play a major role in the clearance of endo- and xenobiotics. Apical (canalicular) transporters extrude compounds to the bile, while basolateral hepatocyte transporters promote the uptake of, or expel, various compounds from/into the venous blood stream. In the present work we have examined the in vitro interactions of some key repurposed drugs advocated to treat COVID-19 (lopinavir, ritonavir, ivermectin, remdesivir and favipiravir), with the key drug transporters of hepatocytes. These transporters included ABCB11/BSEP, ABCC2/MRP2, and SLC47A1/MATE1 in the canalicular membrane, as well as ABCC3/MRP3, ABCC4/MRP4, SLC22A1/OCT1, SLCO1B1/OATP1B1, SLCO1B3/OATP1B3, and SLC10A1/NTCP, residing in the basolateral membrane. Lopinavir and ritonavir in low micromolar concentrations inhibited BSEP and MATE1 exporters, as well as OATP1B1/1B3 uptake transporters. Ritonavir had a similar inhibitory pattern, also inhibiting OCT1. Remdesivir strongly inhibited MRP4, OATP1B1/1B3, MATE1 and OCT1. Favipiravir had no significant effect on any of these transporters. Since both general drug metabolism and drug-induced liver toxicity are strongly dependent on the functioning of these transporters, the various interactions reported here may have important clinical relevance in the drug treatment of this viral disease and the existing co-morbidities. DA - 2021/09/08/ PY - 2021 DO - 10.1038/s41598-021-97160-3 DP - PubMed VL - 11 IS - 1 SP - 17810 J2 - Sci Rep LA - eng SN - 2045-2322 L1 - https://www.nature.com/articles/s41598-021-97160-3.pdf L2 - http://www.ncbi.nlm.nih.gov/pubmed/34497279 ER - TY - JOUR TI - A COVID-19-association-dependent categorization of death causes in 100 autopsy cases AU - Danics, Krisztina AU - Pesti, Adrián AU - Törő, Klára AU - Kiss-Dala, Noémi AU - Szlávik, János AU - Lakatos, Botond AU - Radnai, Andrea AU - Balázs, Tamás AU - Bacskai, Miklós AU - Dobi, Deján AU - Várkonyi, Tibor AU - Glasz, Tibor AU - Lotz, Gábor AU - Kiss, András AU - Schaff, Zsuzsa AU - Vályi-Nagy, István T2 - GeroScience AB - From March through December 2020, 100 autopsies were performed (Semmelweis University, Budapest, Hungary), with chart review, of patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection demonstrated by real-time reverse-transcription polymerase chain reaction testing (mean age, 74.73 years, range 40-102 years; 50 males, mean age 71.96 years, and 50 females, mean age 77.5 years). Classified by the date of death, 21 cases were from the pandemic's "first wave" (March through July) and 79 from the "second wave" (August through December). Three mortality categories were defined by relevance of SARS-CoV-2 infection: (1) "strong" association (n=57), in which COVID-19 was primary responsible for death; (2) "contributive" association (n=27), in which a pre-existing condition independent of COVID-19 was primary responsible for death, albeit with substantial COVID-19 co-morbidity; (3) "weak" association (n=16), in which COVID-19 was minimally or not at all responsible for death. Distributions among categories differed between the first wave, in which the "contributive" association cases dominated (strong: 24%, contributive: 48%, weak: 28%), and the second wave, in which the "strong" association cases dominated (strong: 66%, contributive: 21%, weak: 13%). Charted co-morbidities included hypertension (85 %), cardiovascular diseases (71 %), diabetes (40 %), cerebrovascular diseases (31 %), chronic respiratory diseases (30 %), malignant tumors (20 %), renal diseases (19 %), diseases of the central nervous system (15 %), and liver diseases (6 %). Autopsy evaluation analyzed alterations on macroscopy as well as findings on microscopy of scanned and scored sections of formalin-fixed, paraffin-embedded tissue samples (50-80 blocks/case). Severity of histological abnormalities in the lung differed significantly between "strong" and "contributive" (p<0.0001) and between "strong" and "weak" categories (p<0.0001). Abnormalities included diffuse alveolar damage, macrophage infiltration, and vascular and alveolar fibrin aggregates (lung), with macro- and microvascular thrombi and thromboemboli (lung, kidney, liver). In conclusion, autopsies clarified in what extent COVID-19 was responsible for death, demonstrated the pathological background of clinical signs and symptoms, and identified organ alterations that led to the death. Clinicopathologic correlation, with conference discussions of severity of co-morbidities and of direct pathological signs of disease, permitted accurate categorization of cause of death and COVID-19 association as "strong," "contributive," or "weak." Lung involvement, with reduced ventilatory capacity, was the primary cause of death in the "strong" and "contributive" categories. Shifts in distribution among categories, with "strong" association between COVID-19 and death dominating in the second wave, may reflect improved clinical management of COVID-19 as expertise grew. DA - 2021/10//undefined PY - 2021 DO - 10.1007/s11357-021-00451-w DP - PubMed VL - 43 IS - 5 SP - 2265 EP - 2287 J2 - Geroscience LA - eng SN - 2509-2723 L2 - http://www.ncbi.nlm.nih.gov/pubmed/34510338 KW - COVID-19 KW - SARS-CoV-2 KW - Autopsy KW - Cause of death KW - Histopathology ER - TY - JOUR TI - Unequal burden of COVID-19 in Hungary: a geographical and socioeconomic analysis of the second wave of the pandemic AU - Oroszi, Beatrix AU - Juhász, Attila AU - Nagy, Csilla AU - Horváth, Judit Krisztina AU - McKee, Martin AU - Ádány, Róza T2 - BMJ global health AB - INTRODUCTION: We describe COVID-19 morbidity, mortality, case fatality and excess death in a country-wide study of municipalities in Hungary, exploring the association with socioeconomic status. METHODS: The spatial distribution of morbidity, mortality and case fatality was mapped using hierarchical Bayesian smoothed indirectly standardised ratios. Indirectly standardised ratios were used to evaluate the association between deprivation and the outcome measures. We looked separately at morbidity and mortality in the 10 districts with the highest and 10 districts with the lowest share of Roma population. RESULTS: Compared with the national average, the relative incidence of cases was 30%-36% lower in the most deprived quintile but the relative mortality and case fatality were 27%-32% higher. Expressed as incidence ratios relative to the national average, the most deprived municipalities had a relative incidence ratio of 0.64 (CI: 0.62 to 0.65) and 0.70 (CI: 0.69 to 0.72) for males and females, respectively. The corresponding figures for mortality were 1.32 (CI: 1.20 to 1.44) for males and 1.27 (CI: 1.16 to 1.39) for females and for case fatality 1.27 (CI: 1.16 to 1.39) and 1.32 (CI: 1.20 to 1.44) for males and females, respectively. The excess death rate (per 100 000) increased with deprivation levels (least deprived: 114.12 (CI: 108.60 to 119.84) and most deprived: 158.07 (CI: 149.30 to 167.23)). The 10 districts where Roma formed the greatest share of the population had an excess mortality rate 17.46% higher than the average for the most deprived quintile. CONCLUSIONS: Those living in more deprived municipalities had a lower risk of being identified as a confirmed COVID-19 case but had a higher risk of death. An inverse association between trends in morbidity and mortality by socioeconomic conditions should be a cause for concern and points to the need for responses, including those involving vaccination, to pay particular attention to inequalities and their causes. DA - 2021/09// PY - 2021 DO - 10.1136/bmjgh-2021-006427 DP - PubMed VL - 6 IS - 9 SP - e006427 J2 - BMJ Glob Health LA - eng SN - 2059-7908 ST - Unequal burden of COVID-19 in Hungary L2 - http://www.ncbi.nlm.nih.gov/pubmed/34518205 KW - COVID-19 KW - epidemiology KW - public health KW - geographic information systems ER - TY - JOUR TI - A Covid-19-fertőzés terhességi manifesztációi AU - Török, Marianna AU - Vezér, Márton AU - Zubek, László AU - Keszthelyi, Márton AU - Várbíró, Szabolcs T2 - Lege Artis Medicinae AB - Magyarországon 2020 márciusa óta tu­dunk igazolt Covid-19-fertőzöttekről. A SARS-CoV-2 okozta betegségről kez­detben úgy tudtuk, hogy nem jelent különösebb veszélyt a várandósokra, de va­lószínűleg az egyre növekvő esetszámok és az új mutációk létrejötte miatt ma már ezt nem állíthatjuk. A legújabb eredmények szerint várandósság esetén nő a kórházi kezelés, az invazív lélegeztetés, a ha­lál kockázata, fokozódik a koraszülés és csá­szár­metszés esélye. Úgy tűnik, hogy vertikális fertőzés csak az esetek kis százalékában jelentkezik. Magyarországon tudomásunk szerint eddig hét várandós nő vesztette életét a Covid-19 miatt. További szigorú vizsgálatokra van szükség a terhességi szövődmények pontosabb ismere­téhez. DA - 2021/// PY - 2021 DO - 10.33616/LAM.31.026 VL - 31 IS - 8-9 SP - 351 EP - 356 LA - hu SN - 0866-4811 UR - https://elitmed.hu/kiadvanyaink/lege-artis-medicinae/a-covid-19-fertozes-terhessegi-manifesztacioi Y2 - 2021/09/21/12:19:09 L2 - https://elitmed.hu/kiadvanyaink/lege-artis-medicinae/a-covid-19-fertozes-terhessegi-manifesztacioi ER - TY - JOUR TI - A Covid-19 klinikai kimenetelének súlyosságát nemcsak a pszichiátriai kórállapot, hanem a pszichiátriai gyógyszerelés is befolyásolja AU - Nadubinszky, Gábor AU - Vonyik, Gabriella AU - Székács, Béla T2 - Lege Artis Medicinae DA - 2021/// PY - 2021 DO - 10.33616/LAM.31.027 DP - MTMT VL - 31 IS - 8-9 SP - 357 EP - 362 J2 - Lege Art Med LA - Hungarian SN - 0866-4811 UR - https://m2.mtmt.hu/api/publication/32218498 ER - TY - JOUR TI - Bradikinin-citokin vihar és patomechanizmusa igen súlyos Covid-19-fertőzésben AU - Székács, Béla AU - Várbíró, Szabolcs AU - Kékes, Ede AU - Debreczeni, Lóránd T2 - Lege Artis Medicinae DA - 2021/// PY - 2021 DO - 10.33616/LAM.31.028 DP - MTMT VL - 31 IS - 8-9 SP - 363 EP - 372 J2 - Lege Art Med LA - Hungarian SN - 0866-4811 UR - https://m2.mtmt.hu/api/publication/32218610 ER - TY - JOUR TI - A Covid-19-fertőzés lehetséges szemészeti tünetei és szövődményei AU - Nagy, Zoltán Zsolt T2 - Lege Artis Medicinae AB - A 2019 decemberében Kínában kitört Covid-19 világjárvánnyá vált. A kezdeti, szinte kizárólag légzőszervi tünetek után egyéb nem specifikus, de a Covid-pandémiával összefüggő tünetegyüttesekről jelentek meg beszámolók az irodalomban, így egyre több szemészeti tünet, szövődmény vált ismertté. Az alapvető szemészeti ismeretek azért is fontosak, mert a járvány cseppfertőzéssel terjed, és a nyálkahártyák szerepe ebben kiemelten jelentős. A szem legfontosabb nyálkahártyája a kötőhártya. A kötőhártyát elérő vírusrészecskék a könnyel könnyen bejutnak az orrba, majd az orrgaratba, végül elérhetik a légzőrendszert, vagyis szemészeti úton is terjedhet a fertőzés. Ugyanakkor több közleményben is vitatják a szemészeti úton történő fertőzés valószínűségét. A jelen közlemény a legfontosabb szemészeti, valamint neurooftalmológiai tüneteket foglalja össze. Az intenzív osztályokon a figyelem az életfunkciók fenntartására összpontosul, azonban az életben maradó betegeknél fontos a szemészeti szövődmények megelőzése, illetve azok időben történő kezelése. DA - 2021/// PY - 2021 VL - 31 IS - 8-9 SP - 385 EP - 389 LA - hu SN - 0866-4811 UR - https://elitmed.hu/kiadvanyaink/lege-artis-medicinae/a-covid-19-fertozes-lehetseges-szemeszeti-tunetei-es-szovodmenyei Y2 - 2021/09/21/12:45:45 L2 - https://elitmed.hu/kiadvanyaink/lege-artis-medicinae/a-covid-19-fertozes-lehetseges-szemeszeti-tunetei-es-szovodmenyei ER - TY - JOUR TI - Covid19: citokinek viharában AU - Szekanecz, Zoltán AU - Constantin, Tamás T2 - Magyar Tudomány DA - 2021/02/01/ PY - 2021 DO - 10.1556/2065.182.2021.2.10 DP - DOI.org (Crossref) VL - 182 IS - 2 SP - 226 EP - 239 J2 - Ma.Tud. SN - 00250325 ST - Covid19 UR - https://www.mersz.hu/dokumentum/matud202102__15 Y2 - 2021/09/21/12:50:10 L1 - https://mersz.hu/mod/object.php?objazonosito=matud202102_f54402_i1 ER - TY - JOUR TI - Well-being, resilience and post-traumatic growth in the era of Covid-19 pandemic AU - Gonda, Xenia AU - Tarazi, Frank I. T2 - European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology DA - 2022/01// PY - 2022 DO - 10.1016/j.euroneuro.2021.08.266 DP - PubMed VL - 54 SP - 65 EP - 66 J2 - Eur Neuropsychopharmacol LA - eng SN - 1873-7862 L1 - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413303/pdf/main.pdf L2 - http://www.ncbi.nlm.nih.gov/pubmed/34538545 ER - TY - JOUR TI - The Impact of COVID-19 on the Preparation for the Tokyo Olympics: A Comprehensive Performance Assessment of Top Swimmers AU - Csulak, Emese AU - Petrov, Árpád AU - Kováts, Tímea AU - Tokodi, Márton AU - Lakatos, Bálint AU - Kovács, Attila AU - Staub, Levente AU - Suhai, Ferenc Imre AU - Szabó, Erzsébet Liliána AU - Dohy, Zsófia AU - Vágó, Hajnalka AU - Becker, Dávid AU - Müller, Veronika AU - Sydó, Nóra AU - Merkely, Béla T2 - International Journal of Environmental Research and Public Health AB - BACKGROUND: The Olympic preparation of athletes has been highly influenced by COVID and post-COVID syndrome. As the complex screening of athletes is essential for safe and successful sports, we aimed to repeat the 2019-year sports cardiology screening of the Olympic Swim Team before the Olympics and to compare the results of COVID and non-COVID athletes. METHODS: Patient history, electrocardiogram, laboratory tests, body composition analysis, echocardiography, cardiopulmonary exercise test (CPET) were performed. We used time-ranking points to compare swimming performance. RESULTS: From April 2019, we examined 46 elite swimmers (24 ± 4 years). Fourteen swimmers had COVID infection; all cases were mild. During CPET there was no difference in the performance of COVID (male: VO2 max 55 ± 4 vs. 56.5 ± 5 mL/kg/min, p = 0.53; female: VO2 max 54.6 ± 4 vs. 56 ± 5.5 mL/kg/min, p = 0.86) vs. non-COVID athletes (male VO2 max 56.7 ± 5 vs. 55.5 ± 4.5 mL/kg/min, p = 0.50; female 49.6 ± 3 vs. 50.7 ± 2.6 mL/kg/min, p = 0.47) between 2019 and 2021. When comparing the time results of the National Championships, 54.8% of the athletes showed an improvement (p = 0.75). CONCLUSIONS: COVID infection with short-term detraining did not affect the performance of well-trained swimmers. According to our results, the COVID pandemic did not impair the effectiveness of the preparation for the Tokyo Olympics. DA - 2021/09/16/ PY - 2021 DO - 10.3390/ijerph18189770 DP - PubMed VL - 18 IS - 18 SP - 9770 J2 - Int J Environ Res Public Health LA - eng SN - 1660-4601 ST - The Impact of COVID-19 on the Preparation for the Tokyo Olympics L2 - http://www.ncbi.nlm.nih.gov/pubmed/34574691 KW - COVID-19 KW - athlete KW - cardiopulmonary exercise test KW - performance assessment KW - swimming ER - TY - JOUR TI - Immunerősítés a Covid-19-érában : a gyógyszerész ajánlása AU - Budai, Lívia T2 - Új Diéta DA - 2021/// PY - 2021 VL - 30 IS - 3 SP - 9 EP - 11 LA - magyar SN - 1587-169X KW - járvány KW - koronavírus ER - TY - JOUR TI - A COVID-19-betegség okozta szervi károsodások patológiája AU - Lotz, Gábor AU - Danics, Krisztina AU - Pesti, Adrián AU - Várkonyi, Tibor AU - Dobi, Deján AU - Vályi-Nagy, István AU - Törő, Klára AU - Glasz, Tibor AU - Kiss, András AU - Schaff, Zsuzsa T2 - Klinikai Onkológia DA - 2021/// PY - 2021 VL - 8 IS - 3 SP - 211 EP - 218 LA - magyar SN - 2064-5058 KW - járvány KW - koronavírus ER - TY - JOUR TI - Plasma P-selectin is an early marker of thromboembolism in COVID-19 AU - Fenyves, Bánk G. AU - Mehta, Arnav AU - MGH COVID-19 Collection & Processing Team AU - Kays, Kyle R. AU - Beakes, Caroline AU - Margolin, Justin AU - Goldberg, Marcia B. AU - Hacohen, Nir AU - Filbin, Michael R. T2 - American Journal of Hematology DA - 2021/12/01/ PY - 2021 DO - 10.1002/ajh.26372 DP - PubMed VL - 96 IS - 12 SP - E468 EP - E471 J2 - Am J Hematol LA - eng SN - 1096-8652 L2 - http://www.ncbi.nlm.nih.gov/pubmed/34622480 ER - TY - JOUR TI - [Changes in suicide mortality of Hungary during the first year of the COVID-19 pandemic] AU - Osváth, Péter AU - Bálint, Lajos AU - Németh, Attila AU - Kapitány, Balázs AU - Rihmer, Zoltán AU - Döme, Péter T2 - Orvosi Hetilap AB - Összefoglaló. Bevezetés: Az öngyilkosság fő rizikófaktorának a pszichiátriai zavarokat tekintjük. A COVID-19 többek között neuropszichiátriai kórképek kialakulásához is vezethet. Ezen túl a pandémia egyéb velejárói, mint például az izoláció vagy a munkahelyvesztés, a társadalom egészséges tagjaiban is stresszhez, végül pszichiátriai zavarokhoz vezethetnek. Célkitűzés: Vizsgálatunk célja annak a teóriának a tesztelése volt, hogy a fenti tényezők miatt együtt járt-e a járvány a hazai suicid halálozás csökkenő trendjének irányváltásával. Módszer: Vizsgálatunkban a megszakított idősorok elemzésének módszerét használtuk, a becslésekhez kvázi-Poisson-regressziót alkalmazva, hogy összehasonlítsuk a 2010 és 2020 közötti időszak havi bontású adataiból kirajzolódó trendek alapján a járvány időszakában (2020. március-december) "elvárt" öngyilkossági esetszámokat a ténylegesen bekövetkezett esetek számával. Eredmények: A COVID-19-hónapok alatt a férfiak által elkövetett öngyilkosságok száma szignifikánsan, 18%-kal nőtt, ahhoz a trendhez képest, amely a COVID-19 hiányában állt volna elő. A teljes populációban szintén szignifikáns, 16%-os emelkedést lehetett megfigyelni, míg a nők által elkövetett öngyilkosságok száma nem tért el szignifikánsan a pre-COVID-19-időszak trendje alapján elvárt értéktől. Megbeszélés és következtetés: A járvány kitörése utáni időszakban a magyar férfiak szignifikánsan gyakrabban követtek el öngyilkosságot, míg a nőknél az adatok nem tükröztek lényegi változást. A más országokban kivitelezett vizsgálatok eredményei érdekes módon inkább csökkenést vagy nem szignifikáns változást jeleztek, amikor a COVID-19-éra suicid számait az azt megelőző időszakok számaival hasonlították össze. A hazai és a nemzetközi eredmények közti eltérések magyarázata egyelőre még nem ismert, így a téma mindenképpen további vizsgálatokat igényel. Orv Hetil. 2021; 162(41): 1631-1636. SUMMARY: INTRODUCTION: Psychiatric disorders are the main risk factors for suicide. COVID-19 may result in the appearance of neuropsychiatric syndromes. Moreover, other corollaries of the pandemic (e.g., isolation, job loss) may lead to increasing stress and, ultimately, psychiatric disorders even among the non-infected population. OBJECTIVE: We aimed to test the theory of whether the pandemic, due to the aforementioned factors, was associated with the reversal of the declining suicide rate trend in Hungary. METHOD: To compare the observed number of suicides during the COVID-19 months (March-December 2020) with the expected numbers, we used an interrupted time series model and, for the estimations, quasi-Poisson regression. Expected numbers were calculated based on trends derived from monthly data between 2010 and 2020. RESULTS: During the months of the pandemic, the number of suicides among males rose significantly by 18% compared to the hypothetical trend that would have occurred in the absence of COVID-19. A significant increase (16%) was also observed in the total population. By contrast, the number of female suicides did not differ significantly from the number expected based on the pre-COVID-19 trend. DISCUSSION AND CONCLUSION: After the outbreak of the epidemic, Hungarian males committed significantly more suicides, while no relevant changes were observed among females. Interestingly, studies from other countries found either no change or decrease when comparing suicide numbers from the COVID-19 period with the corresponding numbers from the pre-COVID-19 period. The explanation for this discrepancy is still lacking, so further investigations are needed. Orv Hetil. 2021; 162(41): 1631-1636. DA - 2021/10/10/ PY - 2021 DO - 10.1556/650.2021.32346 DP - PubMed VL - 162 IS - 41 SP - 1631 EP - 1636 J2 - Orv Hetil LA - hun SN - 1788-6120 L2 - http://www.ncbi.nlm.nih.gov/pubmed/34633983 KW - COVID-19 KW - Hungary KW - suicide KW - COVID–19 KW - Magyarország KW - öngyilkosság KW - suicidium ER - TY - JOUR TI - To prevent being stressed-out: Allostatic overload and resilience of general practitioners in the era of COVID-19. A cross-sectional observational study AU - Békési, Dóra AU - Teker, Illés AU - Torzsa, Péter AU - Kalabay, László AU - Rózsa, Sándor AU - Eőry, Ajándék T2 - The European Journal of General Practice AB - BACKGROUND: Responsibility of general practitioners (GPs) in delivering safe and effective care is always high but during the COVID-19 pandemic they face even growing pressure that might result in unbearable stress load (allostatic overload, AO) leading to disease. OBJECTIVES: We aimed to measure AO of Hungarian GPs during the COVID-19 pandemic and explore their recreational resources to identify potential protective factors against stress load. METHODS: In a mixed-method design, Fava's clinimetric approach to AO was applied alongside the Psychosocial Index (PSI); Kellner's symptom questionnaire (SQ) to measure depression, anxiety, hostility and somatisation and the Public Health Surveillance Well-being Scale (PHS-WB) to determine mental, social, and physical well-being. Recreational resources were mapped. Besides Chi-square and Kruskal-Wallis tests, regression analysis was applied to identify explanatory variables of AO. RESULTS: Data of 228 GPs (68% females) were analysed. Work-related changes caused the biggest challenges leading to AO in 60% of the sample. While female sex (OR: 1.99; CI: 1.06; 3.74, p = 0.032) and other life stresses (OR: 1.4; CI: 1.2; 1.6, p < 0.001) associated with increased odds of AO, each additional day with 30 min for recreation purposes associated with 20% decreased odds (OR: 0.838; CI: 0.72; 0.97, p = 0.020). 3-4 days a week when time was ensured for recreation associated with elevated mental and physical well-being, while 5-7 days associated with lower depressive and anxiety symptoms, somatisation, and hostility. CONCLUSION: Under changing circumstances, resilience improvement through increasing time spent on recreation should be emphasised to prevent GPs from the adverse health consequences of stress load. DA - 2021/12// PY - 2021 DO - 10.1080/13814788.2021.1982889 DP - PubMed VL - 27 IS - 1 SP - 277 EP - 285 J2 - Eur J Gen Pract LA - eng SN - 1751-1402 ST - To prevent being stressed-out L2 - http://www.ncbi.nlm.nih.gov/pubmed/34633272 KW - COVID-19 KW - Allostatic overload KW - general practitioners KW - recreational resources KW - resilience ER - TY - JOUR TI - [Outpatient rehabilitation programs for COVID-19 patients] AU - Fekete, Mónika AU - Szarvas, Zsófia AU - Fazekas-Pongor, Vince AU - Kováts, Zsuzsanna AU - Müller, Veronika AU - Varga, János Tamás T2 - Orvosi Hetilap AB - Összefoglaló. A COVID-19-fertőzésen átesett betegek közül többen elhúzódó panaszokról számolnak be a felépülést követően, sokaknál tartósan fennáll a köhögés, a nehézlégzés, a mellkasi fájdalom, a légszomj attól függetlenül, hogy enyhe vagy súlyosabb tüneteket okozott a koronavírus. A betegek erőtlennek érzik magukat, erős fáradtságérzetre panaszkodnak, míg mások gyomor-bél rendszeri panaszokra, fejfájásra, depresszióra, a szaglás- és ízérzékelés elvesztésére. Számtalan kutatás leírja, hogy a fertőzés még akár hónapokkal később is hatással lehet a tüdő működésére, és korábban egészséges tüdőn is látható a koronavírus-fertőzés a gyógyulás után három hónappal készült kontroll-mellkas-CT-leleten. Éppen ezért szükség van a fertőzés lezajlását követően tüdőgyógyászati kivizsgálásra, ha a betegnek elhúzódó panaszai vannak, vagy ha a betegség tüdőgyulladást okozott. Szükség van a jelenleg működő fekvőbeteg-légzőszervi rehabilitáció mellett a kezelés ambuláns kiterjesztésére is, melynek célja újabb kórházi ápolás nélkül a teljes gyógyulás elérése a betegeknél. A COVID-19-fertőzésen átesett betegeknél a komplex rehabilitáció hatására javul a terhelhetőség, az életminőség, javulnak a légzésfunkciós értékek, csökkennek a panaszok, javul a betegek fizikai és pszichikai állapota. Összefoglaló kutatásunk célja áttekinteni, hogy milyen COVID-19 ambuláns rehabilitációs programok indultak el a koronavírus-fertőzésen átesett betegek esetében nemzetközi és hazai színtereken. Orv Hetil. 22021; 162(42): 1671-1677. Summary. Several patients with COVID-19 infection report prolonged complaints after recovery and many of them suffer from persistent cough, dyspnea, chest pain and shortness of breath regardless of whether the coronavirus caused mild or more severe symptoms. They complain of severe fatigue and weakness while others grizzle about gastrointestinal complaints, headache, depression, loss of sense of smell and taste. Numerous studies describe that the infection can affect lung function even in months and coronavirus infection can be detectable in previously healthy lungs by taking a control chest CT scan three months after recovery. Therefore, chest follow-up is required after the infection if the patient has prolonged complaints or if the disease has caused pneumonia. In addition to the currently operating inpatient respiratory rehabilitation, there is also a need for an outpatient extension of treatment to achieve complete recovery in patients without further hospitalization. For those patients who have had the COVID-19 infection complex rehabilitation can improve their workload, quality of life, improves their respiratory function values, reduces their complaints and also improves their physical and mental condition. The aim of our summary research is to review what COVID-19 outpatient rehabilitation programs have been initiated for patients who went through coronavirus infection on international and domestic scenes. Orv Hetil. 2021; 162(42): 1671-1677. DA - 2021/10/17/ PY - 2021 DO - 10.1556/650.2021.32332 DP - PubMed VL - 162 IS - 42 SP - 1671 EP - 1677 J2 - Orv Hetil LA - hun SN - 1788-6120 L2 - http://www.ncbi.nlm.nih.gov/pubmed/34656999 KW - Humans KW - COVID-19 KW - SARS-CoV-2 KW - Outpatients KW - Hospitalization KW - COVID–19 KW - ambuláns rehabilitáció KW - outpatient rehabilitation KW - programok KW - programs KW - Quality of Life ER - TY - JOUR TI - Can cost-effectiveness principles be ignored in urgent times? AU - Kaló, Zoltán AU - Németh, Bertalan AU - Zemplényi, Antal T2 - Journal of Comparative Effectiveness Research DA - 2022/01// PY - 2022 DO - 10.2217/cer-2021-0211 DP - PubMed VL - 11 IS - 1 SP - 7 EP - 9 J2 - J Comp Eff Res LA - eng SN - 2042-6313 L2 - http://www.ncbi.nlm.nih.gov/pubmed/34668766 KW - COVID-19 KW - coverage with evidence development KW - evidence-based decision-making KW - health economics KW - real-world data ER - TY - JOUR TI - [Relationship between the coronavirus epidemic and the use of complementary and alternative medicine prior to elective surgical procedures] AU - Soós, Sándor Árpád AU - Szűcs, Orsolya AU - Darvas, Katalin AU - Hoffmann, Csaba AU - Harsányi, László AU - Szijártó, Attila T2 - Orvosi Hetilap AB - Összefoglaló. Bevezetés: A 2019 végén Vuhanból kiinduló, SARS-CoV-2 okozta koronavírus-járvány jelentős hatást gyakorolt életünkre. Specifikus terápia hiányában az emberek egy része alternatív gyógymódokhoz fordult. Célkitűzés: Vizsgálatunk célja annak feltárása volt, milyen hatást gyakorolt a koronavírus-járvány a betegek komplementer gyógymódokhoz való viszonyulására elektív sebészeti műtétek előtt. Módszer: Egy magyarországi klinika és egy városi kórház elektív sebészeti műtétre váró betegei körében végeztünk anonim kérdőíves felmérést 2020. augusztus 3. és december 18. között. 279 kérdőívet dolgoztunk fel, a válaszadási arány 69,7% volt. Eredmények: A koronavírus-járvány hatására a válaszadók 91,4%-ának nem változott meg a véleménye a nem konvencionális kezelésekről, 8,2%-a bizakodóbban tekintett ezekre. A komplementer terápia betegségmegelőző hatása iránt a kitöltők 16,8%-a volt bizakodó, 25,4%-a elutasító, 57,7%-a nem formált véleményt. A válaszadók 24,7%-a vett igénybe élete során alternatív módszereket, a koronavírus-fertőzés megelőzésére csak a nyilatkozók 10%-a alkalmazna ilyen gyógymódokat. Kizárólag a pandémia hatására senki nem kezdett el komplementer gyógymódokat használni. A kérdőívet kitöltők 55,6%-a használt gyógynövénykészítményt élete során. A járvány ideje alatt a válaszadók 27,5%-a vett igénybe gyógynövénykészítményeket; a gyógymód alkalmazása és a vizsgált szociodemográfiai tényezők között nem találtunk összefüggést. A gyógynövények alkalmazása alacsonyabb mértékű volt a daganatos és a thromboemboliás betegek között. Következtetés: Vizsgálatunk alapján a komplementer gyógymódok használata feltehetően a járvány miatt elrendelt korlátozásokból adódóan csökkent, a gyógynövények alkalmazása azonban nem változott lényegesen. A válaszadók tizede használt komplementer gyógymódot a koronavírus-fertőzés megelőzésére. Orv Hetil. 2021; 162(42): 1678-1686. SUMMARY: INTRODUCTION: The coronavirus epidemic caused by SARS-CoV-2 from Wuhan at the end of 2019 had considerable impact on our lives. In the absence of specific therapy, some people have resorted to alternative therapies. OBJECTIVE: The aim of our study was to explore the effect of the coronavirus epidemic on the patients' attitudes toward complementary and alternative medicine. METHOD: We have performed anonymous questionnaire survey among patients of a Hungarian university hospital and a city hospital waiting for elective surgery between August 3, 2020 and December 18, 2020. We received 279 questionnaires, the response rate was 69.7%. RESULTS: As a result of the coronavirus epidemic, 91.4% of the respondents did not change their opinion about complementary and alternative treatments, 8.2% were more optimistic about them. 16.8% of respondents were optimistic, 25.4% rejected, and 57.7% did not form an opinion about the disease-preventing effect of complementary therapy. A quarter of respondents (24.7%) had used complementary therapies in their lifetime, with only 10% of respondents using such therapies to prevent coronavirus infection. As a result of the pandemic, no one started using complementary therapies. 55.6% of the respondents used a herbal preparation during their lifetime. In the course of the epidemic, a high proportion of respondents (27.5%) used herbal preparations; no correlation was found between the use of the treatment and the socio-demographic factors examined. The use of herbs was lower among cancer and thromboembolic patients. CONCLUSION: Based on our study, the use of complementary therapies presumably decreased due to the restrictions imposed in the epidemic, however, the use of herbs did not change significantly. One-tenth of the respondents used naturopathic cure to prevent coronavirus infection. Orv Hetil. 2021; 162(42): 1678-1686. DA - 2021/10/17/ PY - 2021 DO - 10.1556/650.2021.32327 DP - PubMed VL - 162 IS - 42 SP - 1678 EP - 1686 J2 - Orv Hetil LA - hun SN - 1788-6120 L2 - http://www.ncbi.nlm.nih.gov/pubmed/34656998 KW - Humans KW - COVID-19 KW - SARS-CoV-2 KW - Pandemics KW - Elective Surgical Procedures KW - Hungary KW - COVID–19 KW - anaesthesia KW - anesztézia KW - complementary therapies KW - gyógynövény-terápia KW - herbal medicine KW - komplementer terápiás gyógymódok KW - perioperatív ellátás KW - perioperative care ER - TY - JOUR TI - COVID-19 Infection Alters the Microbiome: Elite Athletes and Sedentary Patients Have Similar Bacterial Flora AU - Babszky, Gergely AU - Torma, Ferenc AU - Aczel, Dora AU - Bakonyi, Peter AU - Gombos, Zoltan AU - Feher, Janos AU - Szabó, Dóra AU - Ligeti, Balázs AU - Pongor, Sándor AU - Balogh, Laszlo AU - Pósa, Anikó AU - Radak, Zsolt T2 - Genes AB - Regular exercise can upgrade the efficiency of the immune system and beneficially alter the composition of the gastro-intestinal microbiome. We tested the hypothesis that active athletes have a more diverse microbiome than sedentary subjects, which could provide better protection against COVID-19 during infection. Twenty active competing athletes (CA) (16 male and 4 females of the national first and second leagues), aged 24.15 ± 4.7 years, and 20 sedentary subjects (SED) (15 male and 5 females), aged 27.75 ± 7.5 years, who had been diagnosed as positive for COVID-19 by a PCR test, served as subjects for the study. Fecal samples collected five to eight days after diagnosis and three weeks after a negative COVID-19 PCR test were used for microbiome analysis. Except for two individuals, all subjects reported very mild and/or mild symptoms of COVID-19 and stayed at home under quarantine. Significant differences were not found in the bacterial flora of trained and untrained subjects. On the other hand, during COVID-19 infection, at the phylum level, the relative abundance of Bacteroidetes was elevated during COVID-19 compared to the level measured three weeks after a negative PCR test (p < 0.05) when all subjects were included in the statistical analysis. Since it is known that Bacteroidetes can suppress toll-like receptor 4 and ACE2-dependent signaling, thus enhancing resistance against pro-inflammatory cytokines, it is suggested that Bacteroidetes provide protection against severe COVID-19 infection. There is no difference in the microbiome bacterial flora of trained and untrained subjects during and after a mild level of COVID-19 infection. DA - 2021/10/04/ PY - 2021 DO - 10.3390/genes12101577 DP - PubMed VL - 12 IS - 10 SP - 1577 J2 - Genes (Basel) LA - eng SN - 2073-4425 ST - COVID-19 Infection Alters the Microbiome L1 - https://www.mdpi.com/2073-4425/12/10/1577/pdf L2 - http://www.ncbi.nlm.nih.gov/pubmed/34680972 KW - Adult KW - Female KW - Humans KW - Male KW - Gastrointestinal Microbiome KW - microbiome KW - COVID-19 KW - SARS-CoV-2 KW - Sedentary Behavior KW - inflammation KW - Athletes KW - Bacteroidetes KW - exercise ER - TY - JOUR TI - Changes in the SARS-CoV-2 cellular receptor ACE2 levels in cardiovascular patients: a potential biomarker for the stratification of COVID-19 patients AU - Fagyas, Miklós AU - Bánhegyi, Viktor AU - Úri, Katalin AU - Enyedi, Attila AU - Lizanecz, Erzsébet AU - Mányiné, Ivetta Siket AU - Mártha, Lilla AU - Fülöp, Gábor Áron AU - Radovits, Tamás AU - Pólos, Miklós AU - Merkely, Béla AU - Kovács, Árpád AU - Szilvássy, Zoltán AU - Ungvári, Zoltán AU - Édes, István AU - Csanádi, Zoltán AU - Boczán, Judit AU - Takács, István AU - Szabó, Gábor AU - Balla, József AU - Balla, György AU - Seferovic, Petar AU - Papp, Zoltán AU - Tóth, Attila T2 - GeroScience AB - Angiotensin-converting enzyme 2 (ACE2) is essential for SARS-CoV-2 cellular entry. Here we studied the effects of common comorbidities in severe COVID-19 on ACE2 expression. ACE2 levels (by enzyme activity and ELISA measurements) were determined in human serum, heart and lung samples from patients with hypertension (n = 540), heart transplantation (289) and thoracic surgery (n = 49). Healthy individuals (n = 46) represented the controls. Serum ACE2 activity was increased in hypertensive subjects (132%) and substantially elevated in end-stage heart failure patients (689%) and showed a strong negative correlation with the left ventricular ejection fraction. Serum ACE2 activity was higher in male (147%), overweight (122%), obese (126%) and elderly (115%) hypertensive patients. Primary lung cancer resulted in higher circulating ACE2 activity, without affecting ACE2 levels in the surrounding lung tissue. Male sex resulted in elevated serum ACE2 activities in patients with heart transplantation or thoracic surgery (146% and 150%, respectively). Left ventricular (tissular) ACE2 activity was unaffected by sex and was lower in overweight (67%), obese (62%) and older (73%) patients with end-stage heart failure. There was no correlation between serum and tissular (left ventricular or lung) ACE2 activities. Neither serum nor tissue (left ventricle or lung) ACE2 levels were affected by RAS inhibitory medications. Abandoning of ACEi treatment (non-compliance) resulted in elevated blood pressure without effects on circulating ACE2 activities. ACE2 levels associate with the severity of cardiovascular diseases, suggestive for a role of ACE2 in the pathomechanisms of cardiovascular diseases and providing a potential explanation for the higher mortality of COVID-19 among cardiovascular patients. Abandoning RAS inhibitory medication worsens the cardiovascular status without affecting circulating or tissue ACE2 levels. DA - 2021/10//undefined PY - 2021 DO - 10.1007/s11357-021-00467-2 DP - PubMed VL - 43 IS - 5 SP - 2289 EP - 2304 J2 - Geroscience LA - eng SN - 2509-2723 ST - Changes in the SARS-CoV-2 cellular receptor ACE2 levels in cardiovascular patients L1 - https://link.springer.com/content/pdf/10.1007/s11357-021-00467-2.pdf L2 - http://www.ncbi.nlm.nih.gov/pubmed/34674152 KW - SARS-CoV-2 KW - Angiotensin converting enzyme 2 (ACE2) KW - Cardiovascular disease KW - Heart failure KW - Hypertension KW - RAAS inhibitors KW - Renin-angiotensin-aldosterone system (RAAS) ER - TY - JOUR TI - [Impact of the epidemiological instructions due to the COVID-19 pandemic on general surgical care at the Bajcsy-Zsilinszky Hospital in Budapest] AU - Benedek, Zsófia AU - Molnár-Gallatz, Zsolt T2 - Orvosi Hetilap AB - Összefoglaló. Bevezetés: 2020 első negyedévében a koronavírus gyors terjedése, az általa okozott betegségek súlyos következményei miatt világszerte, így hazánkban is megváltozott az egészségügyi ellátás. Közleményünkben bemutatjuk, hogyan befolyásolták egy fővárosi kórház hasi sebészeti osztályának betegellátását, az ellátott esetek számát és összetételét a járvány első, 2020-as tavaszi hulláma idején bevezetett járványügyi korlátozó intézkedések. Célkitűzés: Célunk az volt, hogy adatokkal összehasonlítsuk 2021., 2020. és 2019. április sebészeti fekvőbeteg-ellátásának jellemzőit osztályunkon. Módszer: A 2019. április 1. és 30., 2020. április 1. és 30. és 2021. április 1. és 30. közötti időszakokban a fővárosi Bajcsy-Zsilinszky Kórház Sebészeti, Érsebészeti és Mellkassebészeti Osztályán az általános sebészeti fekvőbeteg-ellátás keretében végzett hasi sebészeti műtéti beavatkozások adatait hasonlítottuk össze. Az adatokat MS Excel és SPSS (25. verzió) programokkal vizsgáltuk, és statisztikai elemzéseket végeztünk. Eredmények: A bevonási kritériumoknak 197 eset felelt meg 2019 áprilisában, 77 eset 2020 áprilisában és 95 eset 2021 áprilisában. Az osztályos ápolási idő 2019-ben átlagosan 4,51 nap, míg 2020-ban 6,31 nap és 2021-ben 6,29 nap volt. 2019-ben napi átlagban 2,54 akut és 6,2 tervezett műtét, 2020-ban napi 2 akut és 1 tervezett műtét, míg 2021-ben napi 2,8 akut és 0,9 tervezett műtét történt. Az 1 főre jutó kísérő betegségek száma a tervezett műtétek esetében 2019-ben 1,69 volt, míg 2020-ban 2,97, 2021-ben pedig 2,74. Az akut műtétre került betegek kísérő betegségeinek eloszlása szignifikánsan eltért, 1 betegre 2019-ben átlagosan 2,5, 2020-ban 3,75, míg 2021-ben 3,25 kísérő betegség jutott. Az akut sebészeti ellátáson átesett betegek halálozása 2019-ben 11,8%, 2020-ban 13,33%, 2021-ben 15,66% volt. Következtetés: A COVID-19-járvány miatt bevezetett járványügyi intézkedések velejárója volt, hogy hasi sebészeti osztályunkon lényegesen kevesebb elektív műtétet végeztünk. A sürgősséggel ellátott páciensek kísérő betegségeinek száma szignifikánsan emelkedett, valószínűleg ezzel magyarázható a halálesetek számának párhuzamos emelkedése. Orv Hetil. 2021; 162(44): 1761-1768. SUMMARY: INTRODUCTION: Due to the rapid spread of the coronavirus and the serious consequences of the diseases, the organization of healthcare worldwide changed in the first quarter of 2020. We show effects of restriction due to protection against the first (April 2020) wave of coronavirus in our surgery care. OBJECTIVE: The aim of this study was to compare characteristics of general surgical inpatient care in April 2020 and April 2021 with April 2019 by the hospital database. METHOD: We compared general surgical data of April 2021, 2020, and 2019 from the medical informatic system at the General, Vascular and Thoracal Surgery Department of the Bajcsy-Zsilinszky Hospital in Budapest. The data were analyzed with MS Excel and SPSS (version 25) programs. RESULTS: Study inclusion criteria met with 197 cases from April 2019, 77 cases from April 2020, and 95 cases from April 2021. Length of stay at surgical department was average 4.51 days in 2019, 6.31 days in 2020, and 6.29 days in 2021. In 2019, average 2.54 urgent and 6.2 planned operations were done, in 2020 these numbers were average 2 and 1 per day and in 2021, 2.8 urgent and 0.9 planned surgical procedures were performed. The number of co-morbidities per capita in elective cases was 1.69 in 2019, 2.97 in 2020, and 2.74 in 2021. Distribution of coded co-morbidities in the case of patients with urgent surgery was significantly different between the groups, in 2019 it was 2.5, in 2020 3.75, and in 2021 3.25 per capita. Postoperative mortality at the same care of patients after urgent surgery was 11.8% in 2019, 13.33% in 2020, and 15.66% in 2021. CONCLUSION: Due to the government instructions because of COVID-19 pandemic, less elective general surgery procedures were performed in our department. Co-morbidities of patients with urgent surgery significantly increased, probably this is responsible for the increase of postoperative mortality. Orv Hetil. 2021; 162(44): 1761-1768. DA - 2021/10/31/ PY - 2021 DO - 10.1556/650.2021.32308 DP - PubMed VL - 162 IS - 44 SP - 1761 EP - 1768 J2 - Orv Hetil LA - hun SN - 1788-6120 UR - https://akjournals.com/view/journals/650/162/44/article-p1761.xml L2 - http://www.ncbi.nlm.nih.gov/pubmed/34718228 KW - Humans KW - COVID-19 KW - SARS-CoV-2 KW - Pandemics KW - Elective Surgical Procedures KW - Hungary KW - COVID-19 pandemic KW - Hospitals KW - COVID–19-járvány KW - elective and urgent surgical procedures KW - general surgery KW - hasi sebészet KW - tervezett és sürgős sebészi beavatkozások ER - TY - JOUR TI - The impact of the COVID-19 pandemic on autoimmune diagnostics in Europe: A lesson to be learned AU - Nagy, Eszter AU - Infantino, Maria AU - Bizzaro, Nicola AU - Andreeva, Hristina AU - Bontkes, Hetty J. AU - Bossuyt, Xavier AU - Fabien, Nicole AU - Fischer, Katarzyna AU - Heijnen, Ingmar A. F. M. AU - Herold, Manfred AU - Kozmar, Ana AU - Kuhi, Liisa AU - López-Hoyos, Marcos AU - Pullerits, Rille AU - Sousa, Maria José Rego AU - Tsirogianni, Alexandra AU - Damoiseaux, Jan AU - European Autoimmunity Standardisation Initiative T2 - Autoimmunity Reviews AB - INTRODUCTION: The first wave of COVID-19 pandemic has disrupted almost all areas of the health care services to some extent throughout the world. Although the negative impact of COVID-19 on patients with autoimmune diseases has also been recognized, available data in this regard are limited. In the current study of the European Autoimmunity Standardisation Initiative (EASI) we aimed to provide reliable data on the extent of the impact of COVID-19 pandemic on test requests for different autoantibodies in European countries. METHODS: Data on test numbers and on the number of positive results were collected in 97 clinical laboratories from 15 European countries on a monthly basis for the year before (2019) and the year during (2020) the COVID-19 pandemic. RESULTS: A reduction in the number of autoantibody tests was observed in all European countries in the year 2020 compared to 2019. The reduction affected all autoantibody tests with an overall decrease of 13%, ranging from 1.4% (Switzerland) to 25.5% (Greece). In all countries, the decrease was most pronounced during the first wave of the pandemic (March-May 2020) with an overall decrease in those three months of 45.2%. The most affected autoantibodies were those commonly requested by general practitioners (anti-tTG IgA (-71%), RF IgM (-66%) and ACPA (-61%)). In the second wave of the pandemic (October-December 2020) the decrease was less pronounced (6.8%). With respect to the rate of positive results, subtle differences were observed for distinct autoantibodies during the pandemic, but the total rate of positive results was similar in both years. CONCLUSIONS: Our study demonstrated a strong decrease in autoantibody requests during the first wave of the COVID-19 pandemic in 15 European countries. The second wave was characterized by a less pronounced impact, with some participating countries hardly affected, while some other countries experienced a second decline. The decrease was clearly associated with the level of lock-down and with the required adjustments in the health care systems in different countries, supporting the importance of an effective strategy for the coordination of autoimmune testing in challenging situations as the COVID-19 pandemic. DA - 2021/12// PY - 2021 DO - 10.1016/j.autrev.2021.102985 DP - PubMed VL - 20 IS - 12 SP - 102985 J2 - Autoimmun Rev LA - eng SN - 1873-0183 ST - The impact of the COVID-19 pandemic on autoimmune diagnostics in Europe L2 - http://www.ncbi.nlm.nih.gov/pubmed/34718167 KW - Autoantibody testing KW - Autoimmune diseases KW - Covid-19 pandemic ER - TY - JOUR TI - Tracking development assistance for health and for COVID-19: a review of development assistance, government, out-of-pocket, and other private spending on health for 204 countries and territories, 1990–2050 AU - Micah, Angela E AU - Cogswell, Ian E AU - Cunningham, Brandon AU - Ezoe, Satoshi AU - Harle, Anton C AU - Maddison, Emilie R AU - McCracken, Darrah AU - Nomura, Shuhei AU - Simpson, Kyle E AU - Stutzman, Hayley N AU - Tsakalos, Golsum AU - Wallace, Lindsey E AU - Zhao, Yingxi AU - Zende, Rahul R AU - Abbafati, Cristiana AU - Abdelmasseh, Michael AU - Abedi, Aidin AU - Abegaz, Kedir Hussein AU - Abhilash, E S AU - Abolhassani, Hassan AU - Abrigo, Michael R M AU - Adhikari, Tara Ballav AU - Afzal, Saira AU - Ahinkorah, Bright Opoku AU - Ahmadi, Sepideh AU - Ahmed, Haroon AU - Ahmed, Muktar Beshir AU - Ahmed Rashid, Tarik AU - Ajami, Marjan AU - Aji, Budi AU - Akalu, Yonas AU - Akunna, Chisom Joyqueenet AU - Al Hamad, Hanadi AU - Alam, Khurshid AU - Alanezi, Fahad Mashhour AU - Alanzi, Turki M AU - Alemayehu, Yosef AU - Alhassan, Robert Kaba AU - Alinia, Cyrus AU - Aljunid, Syed Mohamed AU - Almustanyir, Sami Almustanyir AU - Alvis-Guzman, Nelson AU - Alvis-Zakzuk, Nelson J AU - Amini, Saeed AU - Amini-Rarani, Mostafa AU - Amu, Hubert AU - Ancuceanu, Robert AU - Andrei, Catalina Liliana AU - Andrei, Tudorel AU - Angell, Blake AU - Anjomshoa, Mina AU - Antonio, Carl Abelardo T AU - Antony, Catherine M AU - Aqeel, Muhammad AU - Arabloo, Jalal AU - Arab-Zozani, Morteza AU - Aripov, Timur AU - Arrigo, Alessandro AU - Ashraf, Tahira AU - Atnafu, Desta Debalkie AU - Ausloos, Marcel AU - Avila-Burgos, Leticia AU - Awan, Asma Tahir AU - Ayano, Getinet AU - Ayanore, Martin Amogre AU - Azari, Samad AU - Azhar, Gulrez Shah AU - Babalola, Tesleem Kayode AU - Bahrami, Mohammad Amin AU - Baig, Atif Amin AU - Banach, Maciej AU - Barati, Nastaran AU - Bärnighausen, Till Winfried AU - Barrow, Amadou AU - Basu, Sanjay AU - Baune, Bernhard T AU - Bayati, Mohsen AU - Benzian, Habib AU - Berman, Adam E AU - Bhagavathula, Akshaya Srikanth AU - Bhardwaj, Nikha AU - Bhardwaj, Pankaj AU - Bhaskar, Sonu AU - Bibi, Sadia AU - Bijani, Ali AU - Bodolica, Virginia AU - Bragazzi, Nicola Luigi AU - Braithwaite, Dejana AU - Breitborde, Nicholas J K AU - Breusov, Alexey V AU - Briko, Nikolay Ivanovich AU - Busse, Reinhard AU - Cahuana-Hurtado, Lucero AU - Callander, Emily Joy AU - Cámera, Luis Alberto AU - Castañeda-Orjuela, Carlos A AU - Catalá-López, Ferrán AU - Charan, Jaykaran AU - Chatterjee, Souranshu AU - Chattu, Soosanna Kumary AU - Chattu, Vijay Kumar AU - Chen, Simiao AU - Cicero, Arrigo Francesco Giuseppe AU - Dadras, Omid AU - Dahlawi, Saad M A AU - Dai, Xiaochen AU - Dalal, Koustuv AU - Dandona, Lalit AU - Dandona, Rakhi AU - Davitoiu, Dragos Virgil AU - De Neve, Jan-Walter AU - de Sá-Junior, Antonio Reis AU - Denova-Gutiérrez, Edgar AU - Dhamnetiya, Deepak AU - Dharmaratne, Samath Dhamminda AU - Doshmangir, Leila AU - Dube, John AU - Ehsani-Chimeh, Elham AU - El Sayed Zaki, Maysaa AU - El Tantawi, Maha AU - Eskandarieh, Sharareh AU - Farzadfar, Farshad AU - Ferede, Tomas Y AU - Fischer, Florian AU - Foigt, Nataliya A AU - Freitas, Alberto AU - Friedman, Sara D AU - Fukumoto, Takeshi AU - Fullman, Nancy AU - Gaal, Peter Andras AU - Gad, Mohamed M AU - Garcia-Gordillo, Ma AU - Garg, Tushar AU - Ghafourifard, Mansour AU - Ghashghaee, Ahmad AU - Gholamian, Asadollah AU - Gholamrezanezhad, Ali AU - Ghozali, Ghozali AU - Gilani, Syed Amir AU - Glăvan, Ionela-Roxana AU - Glushkova, Ekaterina Vladimirovna AU - Goharinezhad, Salime AU - Golechha, Mahaveer AU - Goli, Srinivas AU - Guha, Avirup AU - Gupta, Veer Bala AU - Gupta, Vivek Kumar AU - Haakenstad, Annie AU - Haider, Mohammad Rifat AU - Hailu, Alemayehu AU - Hamidi, Samer AU - Hanif, Asif AU - Harapan, Harapan AU - Hartono, Risky Kusuma AU - Hasaballah, Ahmed I AU - Hassan, Shoaib AU - Hassanein, Mohamed H AU - Hayat, Khezar AU - Hegazy, Mohamed I AU - Heidari, Golnaz AU - Hendrie, Delia AU - Heredia-Pi, Ileana AU - Herteliu, Claudiu AU - Hezam, Kamal AU - Holla, Ramesh AU - Hossain, Sheikh Jamal AU - Hosseinzadeh, Mehdi AU - Hostiuc, Sorin AU - Huda, Tanvir M AU - Hwang, Bing-Fang AU - Iavicoli, Ivo AU - Idrisov, Bulat AU - Ilesanmi, Olayinka Stephen AU - Irvani, Seyed Sina Naghibi AU - Islam, Sheikh Mohammed Shariful AU - Ismail, Nahlah Elkudssiah AU - Isola, Gaetano AU - Jahani, Mohammad Ali AU - Jahanmehr, Nader AU - Jakovljevic, Mihajlo AU - Janodia, Manthan Dilipkumar AU - Javaheri, Tahereh AU - Jayapal, Sathish Kumar AU - Jayawardena, Ranil AU - Jazayeri, Seyed Behzad AU - Jha, Ravi Prakash AU - Jonas, Jost B AU - Joo, Tamas AU - Joukar, Farahnaz AU - Jürisson, Mikk AU - Kaambwa, Billingsley AU - Kalhor, Rohollah AU - Kanchan, Tanuj AU - Kandel, Himal AU - Karami Matin, Behzad AU - Karimi, Salah Eddin AU - Kassahun, Getinet AU - Kayode, Gbenga A AU - Kazemi Karyani, Ali AU - Keikavoosi-Arani, Leila AU - Khader, Yousef Saleh AU - Khajuria, Himanshu AU - Khalilov, Rovshan AU - Khammarnia, Mohammad AU - Khan, Junaid AU - Khubchandani, Jagdish AU - Kianipour, Neda AU - Kim, Gyu Ri AU - Kim, Yun Jin AU - Kisa, Adnan AU - Kisa, Sezer AU - Kohler, Stefan AU - Kosen, Soewarta AU - Koteeswaran, Rajasekaran AU - Koulmane Laxminarayana, Sindhura Lakshmi AU - Koyanagi, Ai AU - Krishan, Kewal AU - Kumar, G Anil AU - Kusuma, Dian AU - Lamnisos, Demetris AU - Lansingh, Van Charles AU - Larsson, Anders O AU - Lasrado, Savita AU - Le, Long Khanh Dao AU - Lee, Shaun Wen Huey AU - Lee, Yeong Yeh AU - Lim, Stephen S AU - Lobo, Stany W AU - Lozano, Rafael AU - Magdy Abd El Razek, Hassan AU - Magdy Abd El Razek, Muhammed AU - Mahdavi, Mokhtar Mahdavi AU - Majeed, Azeem AU - Makki, Alaa AU - Maleki, Afshin AU - Malekzadeh, Reza AU - Manda, Ana Laura AU - Mansour-Ghanaei, Fariborz AU - Mansournia, Mohammad Ali AU - Marrugo Arnedo, Carlos Alberto AU - Martinez-Valle, Adolfo AU - Masoumi, Seyedeh Zahra AU - Maude, Richard James AU - McKee, Martin AU - Medina-Solís, Carlo Eduardo AU - Menezes, Ritesh G AU - Meretoja, Atte AU - Meretoja, Tuomo J AU - Mesregah, Mohamed Kamal AU - Mestrovic, Tomislav AU - Milevska Kostova, Neda AU - Miller, Ted R AU - Mini, Gk AU - Mirica, Andreea AU - Mirrakhimov, Erkin M AU - Mohajer, Bahram AU - Mohamed, Teroj Abdulrahman AU - Mohammadi, Mokhtar AU - Mohammadian-Hafshejani, Abdollah AU - Mohammed, Shafiu AU - Moitra, Modhurima AU - Mokdad, Ali H AU - Molokhia, Mariam AU - Moni, Mohammad Ali AU - Moradi, Yousef AU - Morze, Jakub AU - Mousavi, Seyyed Meysam AU - Mpundu-Kaambwa, Christine AU - Muriithi, Moses K AU - Muthupandian, Saravanan AU - Nagarajan, Ahamarshan Jayaraman AU - Naimzada, Mukhammad David AU - Nangia, Vinay AU - Naqvi, Atta Abbas AU - Narayana, Aparna Ichalangod AU - Nascimento, Bruno Ramos AU - Naveed, Muhammad AU - Nayak, Biswa Prakash AU - Nazari, Javad AU - Ndejjo, Rawlance AU - Negoi, Ionut AU - Neupane Kandel, Sandhya AU - Nguyen, Trang Huyen AU - Nonvignon, Justice AU - Noubiap, Jean Jacques AU - Nwatah, Vincent Ebuka AU - Oancea, Bogdan AU - Ojelabi, Foluke Adetola Ogunyemi AU - Olagunju, Andrew T AU - Olakunde, Babayemi Oluwaseun AU - Olgiati, Stefano AU - Olusanya, Jacob Olusegun AU - Onwujekwe, Obinna E AU - Otoiu, Adrian AU - Otstavnov, Nikita AU - Otstavnov, Stanislav S AU - Owolabi, Mayowa O AU - Padubidri, Jagadish Rao AU - Palladino, Raffaele AU - Panda-Jonas, Songhomitra AU - Park, Eun-Cheol AU - Pashazadeh Kan, Fatemeh AU - Pawar, Shrikant AU - Pazoki Toroudi, Hamidreza AU - Pereira, David M AU - Perianayagam, Arokiasamy AU - Pesudovs, Konrad AU - Piccinelli, Cristiano AU - Postma, Maarten J AU - Prada, Sergio I AU - Rabiee, Mohammad AU - Rabiee, Navid AU - Rahim, Fakher AU - Rahimi-Movaghar, Vafa AU - Rahman, Mohammad Hifz Ur AU - Rahman, Mosiur AU - Rahmani, Amir Masoud AU - Ram, Usha AU - Ranabhat, Chhabi Lal AU - Ranasinghe, Priyanga AU - Rao, Chythra R AU - Rathi, Priya AU - Rawaf, David Laith AU - Rawaf, Salman AU - Rawal, Lal AU - Rawassizadeh, Reza AU - Reiner Jr, Robert C AU - Renzaho, Andre M N AU - Reshmi, Bhageerathy AU - Riaz, Mavra A AU - Ripon, Rezaul Karim AU - Saad, Anas M AU - Sahraian, Mohammad Ali AU - Sahu, Maitreyi AU - Salama, Joseph S AU - Salehi, Sana AU - Samy, Abdallah M AU - Sanabria, Juan AU - Sanmarchi, Francesco AU - Santos, João Vasco AU - Santric-Milicevic, Milena M AU - Sathian, Brijesh AU - Savic, Miloje AU - Saxena, Deepak AU - Sayyah, Mehdi AU - Schwendicke, Falk AU - Senthilkumaran, Subramanian AU - Sepanlou, Sadaf G AU - Seylani, Allen AU - Shahabi, Saeed AU - Shaikh, Masood Ali AU - Sheikh, Aziz AU - Shetty, Adithi AU - Shetty, Pavanchand H AU - Shibuya, Kenji AU - Shrime, Mark G AU - Shuja, Kanwar Hamza AU - Singh, Jasvinder A AU - Skryabin, Valentin Yurievich AU - Skryabina, Anna Aleksandrovna AU - Soltani, Shahin AU - Soofi, Moslem AU - Spurlock, Emma Elizabeth AU - Stefan, Simona Cătălina AU - Szerencsés, Viktória AU - Szócska, Miklós AU - Tabarés-Seisdedos, Rafael AU - Taddele, Biruk Wogayehu AU - Tefera, Yonas Getaye AU - Thavamani, Aravind AU - Tobe-Gai, Ruoyan AU - Topor-Madry, Roman AU - Tovani-Palone, Marcos Roberto AU - Tran, Bach Xuan AU - Tudor Car, Lorainne AU - Ullah, Anayat AU - Ullah, Saif AU - Umar, Nasir AU - Undurraga, Eduardo A AU - Valdez, Pascual R AU - Vasankari, Tommi Juhani AU - Villafañe, Jorge Hugo AU - Violante, Francesco S AU - Vlassov, Vasily AU - Vo, Bay AU - Vollmer, Sebastian AU - Vos, Theo AU - Vu, Giang Thu AU - Vu, Linh Gia AU - Wamai, Richard G AU - Werdecker, Andrea AU - Woldekidan, Mesfin Agachew AU - Wubishet, Befikadu Legesse AU - Xu, Gelin AU - Yaya, Sanni AU - Yazdi-Feyzabadi, Vahid AU - Yiğit, Vahit AU - Yip, Paul AU - Yirdaw, Birhanu Wubale AU - Yonemoto, Naohiro AU - Younis, Mustafa Z AU - Yu, Chuanhua AU - Yunusa, Ismaeel AU - Zahirian Moghadam, Telma AU - Zandian, Hamed AU - Zastrozhin, Mikhail Sergeevich AU - Zastrozhina, Anasthasia AU - Zhang, Zhi-Jiang AU - Ziapour, Arash AU - Zuniga, Yves Miel H AU - Hay, Simon I AU - Murray, Christopher J L AU - Dieleman, Joseph L T2 - The Lancet DA - 2021/10// PY - 2021 DO - 10.1016/S0140-6736(21)01258-7 DP - DOI.org (Crossref) VL - 398 IS - 10308 SP - 1317 EP - 1343 J2 - The Lancet LA - en SN - 0140-6736 ST - Tracking development assistance for health and for COVID-19 UR - https://linkinghub.elsevier.com/retrieve/pii/S0140673621012587 Y2 - 2021/11/05/09:38:20 L1 - https://www.thelancet.com/article/S0140673621012587/pdf ER - TY - JOUR TI - Impact of the first wave of COVID-19 pandemic on the Hungarian university students' social and health behaviour AU - Csépe, Péter AU - Dinya, Elek AU - Balázs, Péter AU - Hosseini, Shahrokh Mirza AU - Küzdy, Gábor AU - Rosivall, László T2 - Zeitschrift Fur Gesundheitswissenschaften = Journal of Public Health AB - Background: The COVID-19 pandemic brought quick, severe and unexpected changes to our everyday life and also changed the traditional education pattern of Semmelweis University in the middle of academic year 2019-2020. We explored adaptive changes in Hungarian students' behaviour and their time-budget in order to determine whether quarantine and/or fear of infection were responsible for these changes. Methods: A self-administered online questionnaire was distributed to all students in the Hungarian language program (N = 7436) of Semmelweis University. Information was collected on basic demographic data, knowledge and attitude about COVID-19, methods of prevention as well as the students' behaviour before, during and after the first wave of the pandemic. Statistical analyses were processed using the IBM-SPSS 25.0 software package. Results: The overall response rate was 11% (N = 816). Only complete responses were processed (55%, N = 447). Among these responders, 83% did not fear the pandemic. Those who greatly feared COVID-19 infection strictly kept all regulations. The number of non-smokers increased by the end of the first wave. The nutrition of 100 students (21%) became healthier and the lockdown reduced the level of physical activity. Conclusion: Social and health-related behaviour of medical students changed basically during the first wave of the pandemic and some changes remained after it in tobacco smoking, nutrition and sleeping habits. Time-budget of students changed significantly during the pandemic and did not return to the baseline values. Results of this study justify future multiple systematic research to analyse and better understand the short- and long-term effects of the current crisis. DA - 2021/10/28/ PY - 2021 DO - 10.1007/s10389-021-01660-5 DP - PubMed J2 - Z Gesundh Wiss LA - eng SN - 2198-1833 L1 - https://link.springer.com/content/pdf/10.1007/s10389-021-01660-5.pdf L2 - http://www.ncbi.nlm.nih.gov/pubmed/34725631 KW - COVID-19 KW - Hungary KW - Lockdown KW - Social and health-related behaviour KW - University students ER - TY - JOUR TI - Natural Apocarotenoids and Their Synthetic Glycopeptide Conjugates Inhibit SARS-CoV-2 Replication AU - Bereczki, Ilona AU - Papp, Henrietta AU - Kuczmog, Anett AU - Madai, Mónika AU - Nagy, Veronika AU - Agócs, Attila AU - Batta, Gyula AU - Milánkovits, Márton AU - Ostorházi, Eszter AU - Mitrović, Ana AU - Kos, Janko AU - Zsigmond, Áron AU - Hajdú, István AU - Lőrincz, Zsolt AU - Bajusz, Dávid AU - Keserű, György Miklós AU - Hodek, Jan AU - Weber, Jan AU - Jakab, Ferenc AU - Herczegh, Pál AU - Borbás, Anikó T2 - Pharmaceuticals AB - The protracted global COVID-19 pandemic urges the development of new drugs against the causative agent SARS-CoV-2. The clinically used glycopeptide antibiotic, teicoplanin, emerged as a potential antiviral, and its efficacy was improved with lipophilic modifications. This prompted us to prepare new lipophilic apocarotenoid conjugates of teicoplanin, its pseudoaglycone and the related ristocetin aglycone. Their antiviral effect was tested against SARS-CoV-2 in Vero E6 cells, using a cell viability assay and quantitative PCR of the viral RNA, confirming their micromolar inhibitory activity against viral replication. Interestingly, two of the parent apocarotenoids, bixin and β-apo-8′carotenoic acid, exerted remarkable anti-SARS-CoV-2 activity. Mechanistic studies involved cathepsin L and B, as well as the main protease 3CLPro, and the results were rationalized by computational studies. Glycopeptide conjugates show dual inhibitory action, while apocarotenoids have mostly cathepsin B and L affinity. Since teicoplanin is a marketed antibiotic and the natural bixin is an approved, cheap and widely used red colorant food additive, these readily available compounds and their conjugates as potential antivirals are worthy of further exploration. DA - 2021/10/30/ PY - 2021 DO - 10.3390/ph14111111 DP - DOI.org (Crossref) VL - 14 IS - 11 SP - 1111 J2 - Pharmaceuticals LA - en SN - 1424-8247 UR - https://www.mdpi.com/1424-8247/14/11/1111 Y2 - 2021/11/11/07:14:32 L1 - https://www.mdpi.com/1424-8247/14/11/1111/pdf ER - TY - JOUR TI - Results of the COVID-19 mental health international for the general population (COMET-G) study AU - Fountoulakis, Konstantinos N. AU - Karakatsoulis, Grigorios AU - Abraham, Seri AU - Adorjan, Kristina AU - Ahmed, Helal Uddin AU - Alarcón, Renato D. AU - Arai, Kiyomi AU - Auwal, Sani Salihu AU - Berk, Michael AU - Bjedov, Sarah AU - Bobes, Julio AU - Bobes-Bascaran, Teresa AU - Bourgin-Duchesnay, Julie AU - Bredicean, Cristina Ana AU - Bukelskis, Laurynas AU - Burkadze, Akaki AU - Abud, Indira Indiana Cabrera AU - Castilla-Puentes, Ruby AU - Cetkovich, Marcelo AU - Colon-Rivera, Hector AU - Corral, Ricardo AU - Cortez-Vergara, Carla AU - Crepin, Piirika AU - De Berardis, Domenico AU - Zamora Delgado, Sergio AU - De Lucena, David AU - De Sousa, Avinash AU - Stefano, Ramona Di AU - Dodd, Seetal AU - Elek, Livia Priyanka AU - Elissa, Anna AU - Erdelyi-Hamza, Berta AU - Erzin, Gamze AU - Etchevers, Martin J. AU - Falkai, Peter AU - Farcas, Adriana AU - Fedotov, Ilya AU - Filatova, Viktoriia AU - Fountoulakis, Nikolaos K. AU - Frankova, Iryna AU - Franza, Francesco AU - Frias, Pedro AU - Galako, Tatiana AU - Garay, Cristian J. AU - Garcia-Álvarez, Leticia AU - García-Portilla, Maria Paz AU - Gonda, Xenia AU - Gondek, Tomasz M. AU - González, Daniela Morera AU - Gould, Hilary AU - Grandinetti, Paolo AU - Grau, Arturo AU - Groudeva, Violeta AU - Hagin, Michal AU - Harada, Takayuki AU - Hasan, Tasdik M. AU - Hashim, Nurul Azreen AU - Hilbig, Jan AU - Hossain, Sahadat AU - Iakimova, Rossitza AU - Ibrahim, Mona AU - Iftene, Felicia AU - Ignatenko, Yulia AU - Irarrazaval, Matias AU - Ismail, Zaliha AU - Ismayilova, Jamila AU - Jakobs, Asaf AU - Jakovljević, Miro AU - Jakšić, Nenad AU - Javed, Afzal AU - Kafali, Helin Yilmaz AU - Karia, Sagar AU - Kazakova, Olga AU - Khalifa, Doaa AU - Khaustova, Olena AU - Koh, Steve AU - Kopishinskaia, Svetlana AU - Kosenko, Korneliia AU - Koupidis, Sotirios A. AU - Kovacs, Illes AU - Kulig, Barbara AU - Lalljee, Alisha AU - Liewig, Justine AU - Majid, Abdul AU - Malashonkova, Evgeniia AU - Malik, Khamelia AU - Malik, Najma Iqbal AU - Mammadzada, Gulay AU - Mandalia, Bilvesh AU - Marazziti, Donatella AU - Marčinko, Darko AU - Martinez, Stephanie AU - Matiekus, Eimantas AU - Mejia, Gabriela AU - Memon, Roha Saeed AU - Martínez, Xarah Elenne Meza AU - Mickevičiūtė, Dalia AU - Milev, Roumen AU - Mohammed, Muftau AU - Molina-López, Alejandro AU - Morozov, Petr AU - Muhammad, Nuru Suleiman AU - Mustač, Filip AU - Naor, Mika S. AU - Nassieb, Amira AU - Navickas, Alvydas AU - Okasha, Tarek AU - Pandova, Milena AU - Panfil, Anca-Livia AU - Panteleeva, Liliya AU - Papava, Ion AU - Patsali, Mikaella E. AU - Pavlichenko, Alexey AU - Pejuskovic, Bojana AU - Pinto Da Costa, Mariana AU - Popkov, Mikhail AU - Popovic, Dina AU - Raduan, Nor Jannah Nasution AU - Ramírez, Francisca Vargas AU - Rancans, Elmars AU - Razali, Salmi AU - Rebok, Federico AU - Rewekant, Anna AU - Flores, Elena Ninoska Reyes AU - Rivera-Encinas, María Teresa AU - Saiz, Pilar AU - de Carmona, Manuel Sánchez AU - Martínez, David Saucedo AU - Saw, Jo Anne AU - Saygili, Görkem AU - Schneidereit, Patricia AU - Shah, Bhumika AU - Shirasaka, Tomohiro AU - Silagadze, Ketevan AU - Sitanggang, Satti AU - Skugarevsky, Oleg AU - Spikina, Anna AU - Mahalingappa, Sridevi Sira AU - Stoyanova, Maria AU - Szczegielniak, Anna AU - Tamasan, Simona Claudia AU - Tavormina, Giuseppe AU - Tavormina, Maurilio Giuseppe Maria AU - Theodorakis, Pavlos N. AU - Tohen, Mauricio AU - Tsapakis, Eva Maria AU - Tukhvatullina, Dina AU - Ullah, Irfan AU - Vaidya, Ratnaraj AU - Vega-Dienstmaier, Johann M. AU - Vrublevska, Jelena AU - Vukovic, Olivera AU - Vysotska, Olga AU - Widiasih, Natalia AU - Yashikhina, Anna AU - Prezerakos, Panagiotis E. AU - Smirnova, Daria T2 - European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology AB - INTRODUCTION: There are few published empirical data on the effects of COVID-19 on mental health, and until now, there is no large international study. MATERIAL AND METHODS: During the COVID-19 pandemic, an online questionnaire gathered data from 55,589 participants from 40 countries (64.85% females aged 35.80 ± 13.61; 34.05% males aged 34.90±13.29 and 1.10% other aged 31.64±13.15). Distress and probable depression were identified with the use of a previously developed cut-off and algorithm respectively. STATISTICAL ANALYSIS: Descriptive statistics were calculated. Chi-square tests, multiple forward stepwise linear regression analyses and Factorial Analysis of Variance (ANOVA) tested relations among variables. RESULTS: Probable depression was detected in 17.80% and distress in 16.71%. A significant percentage reported a deterioration in mental state, family dynamics and everyday lifestyle. Persons with a history of mental disorders had higher rates of current depression (31.82% vs. 13.07%). At least half of participants were accepting (at least to a moderate degree) a non-bizarre conspiracy. The highest Relative Risk (RR) to develop depression was associated with history of Bipolar disorder and self-harm/attempts (RR = 5.88). Suicidality was not increased in persons without a history of any mental disorder. Based on these results a model was developed. CONCLUSIONS: The final model revealed multiple vulnerabilities and an interplay leading from simple anxiety to probable depression and suicidality through distress. This could be of practical utility since many of these factors are modifiable. Future research and interventions should specifically focus on them. DA - 2022/01// PY - 2022 DO - 10.1016/j.euroneuro.2021.10.004 DP - PubMed VL - 54 SP - 21 EP - 40 J2 - Eur Neuropsychopharmacol LA - eng SN - 1873-7862 L2 - http://www.ncbi.nlm.nih.gov/pubmed/34758422 KW - COVID-19 KW - Mental health KW - Anxiety KW - Conspiracy theories KW - Depression KW - Mental disorders KW - Psychiatry KW - Suicidality ER - TY - JOUR TI - Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Risk Factors and Medications AU - Targownik, Laura E. AU - Bernstein, Charles N. AU - Lakatos, Peter L. AU - Murthy, Sanjay K. AU - Benchimol, Eric I. AU - Bitton, Alain AU - Huang, James Guoxian AU - Kuenzig, M. Ellen AU - Jones, Jennifer L. AU - Kaplan, Gilaad G. AU - Lee, Kate AU - Mukhtar, Mariam S. AU - Tandon, Parul AU - Windsor, Joseph W. AU - Panaccione, Remo T2 - Journal of the Canadian Association of Gastroenterology AB - Inflammatory bowel disease (IBD) is a disease that results from dysregulation of the immune system and frequently requires medications that can affect the immune response to infections; therefore, it was imperative to quickly understand the risk of coronavirus disease 2019 (COVID-19) infection on persons living with IBD and how that risk may be increased by commonly used IBD medications. The IBD research community in Canada and beyond quickly established collaborative efforts to better understand the specific risk posed by COVID-19 on persons with IBD. We learned that IBD itself was not a risk factor for death or serious complications of COVID-19, and that most commonly used drug classes (with the notable exception of corticosteroids) do not increase the risk of COVID-19-related adverse outcomes. The risk factors for serious complications and death from COVID-19 appear to be similar to those identified in the wider population; those being advanced age, having pre-existing heart or lung disease, and smoking. We recommend that persons with IBD do not alter their course of therapy to avoid complications of COVID-19, though the indiscriminate use of corticosteroids should be avoided. Persons with IBD should follow the same public health recommendations as the general population to reduce their personal risk of acquiring COVID-19. DA - 2021/// PY - 2021 DO - 10.1093/jcag/gwab032 DP - PubMed VL - 4 IS - Suppl 2 SP - S40 EP - S45 J2 - J Can Assoc Gastroenterol LA - eng SN - 2515-2092 ST - Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada L1 - https://academic.oup.com/jcag/article-pdf/4/Supplement_2/S40/41090861/gwab032.pdf L2 - http://www.ncbi.nlm.nih.gov/pubmed/34755038 KW - Inflammatory bowel disease KW - COVID-19 KW - Biologics KW - Risk factors ER - TY - JOUR TI - Crohn's and Colitis Canada's 2021 Impact of COVID-19 & Inflammatory Bowel Disease in Canada: A Knowledge Translation Strategy AU - Kaplan, Gilaad G. AU - Windsor, Joseph W. AU - Crain, Janet AU - Barrett, Lisa AU - Bernstein, Charles N. AU - Bitton, Alain AU - Chauhan, Usha AU - Coward, Stephanie AU - Fowler, Sharyle AU - Ghia, Jean-Eric AU - Gibson, Deanna L. AU - Griffiths, Anne M. AU - Jones, Jennifer L. AU - Khanna, Reena AU - Kuenzig, M. Ellen AU - Lakatos, Peter L. AU - Lee, Kate AU - Mack, David R. AU - Marshall, John K. AU - Mawani, Mina AU - Murthy, Sanjay K. AU - Panaccione, Remo AU - Seow, Cynthia H. AU - Targownik, Laura E. AU - Zelinsky, Sandra AU - Benchimol, Eric I. T2 - Journal of the Canadian Association of Gastroenterology AB - The prevalence of inflammatory bowel diseases (IBD), Crohn's disease and ulcerative colitis, in Canada, is over 0.75% in 2021. Many individuals with IBD are immunocompromised. Consequently, the World Health Organization's declaration of a global pandemic uniquely impacted those with IBD. Crohn's and Colitis Canada (CCC) formed the COVID-19 and IBD Taskforce to provide evidence-based guidance during the pandemic to individuals with IBD and their families. The Taskforce met regularly through the course of the pandemic, synthesizing available information on the impact of COVID-19 on IBD. At first, the information was extrapolated from expert consensus guidelines, but eventually, recommendations were adapted for an international registry of worldwide cases of COVID-19 in people with IBD. The task force launched a knowledge translation initiative consisting of a webinar series and online resources to communicate information directly to the IBD community. Taskforce recommendations were posted to CCC's website and included guidance such as risk stratification, management of immunosuppressant medications, physical distancing, and mental health. A weekly webinar series communicated critical information directly to the IBD community. During the pandemic, traffic to CCC's website increased with 484,755 unique views of the COVID-19 webpages and 126,187 views of the 23 webinars, including their video clips. CCC's COVID-19 and IBD Taskforce provided critical guidance to the IBD community as the pandemic emerged, the nation underwent a lockdown, the economy reopened, and the second wave ensued. By integrating public health guidance through the unique prism of a vulnerable population, CCC's knowledge translation platform informed and protected the IBD community. DA - 2021/// PY - 2021 DO - 10.1093/jcag/gwab028 DP - PubMed VL - 4 IS - Suppl 2 SP - S10 EP - S19 J2 - J Can Assoc Gastroenterol LA - eng SN - 2515-2092 ST - Crohn's and Colitis Canada's 2021 Impact of COVID-19 & Inflammatory Bowel Disease in Canada L1 - https://academic.oup.com/jcag/article-pdf/4/Supplement_2/S10/41090869/gwab028.pdf L2 - http://www.ncbi.nlm.nih.gov/pubmed/34755034 KW - Ulcerative colitis KW - Crohn’s disease KW - SARS-CoV-2 KW - Coronavirus ER - TY - JOUR TI - Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Executive Summary AU - Ellen Kuenzig, M. AU - Windsor, Joseph W. AU - Barrett, Lisa AU - Bernstein, Charles N. AU - Bitton, Alain AU - Carroll, Matthew W. AU - Chauhan, Usha AU - Coward, Stephanie AU - Fowler, Sharyle AU - Ghia, Jean-Eric AU - Geist, Rose AU - Gibson, Deanna L. AU - Graff, Lesley A. AU - Griffiths, Anne M. AU - Guoxian Huang, James AU - Jones, Jennifer L. AU - Khanna, Reena AU - Lakatos, Peter L. AU - Lee, Kate AU - Mack, David R. AU - Marshall, John K. AU - Mukhtar, Mariam S. AU - Murthy, Sanjay K. AU - Nguyen, Geoffrey C. AU - Panaccione, Remo AU - Seow, Cynthia H. AU - Singh, Harminder AU - Tandon, Parul AU - Targownik, Laura E. AU - Zelinsky, Sandra AU - Benchimol, Eric I. AU - Kaplan, Gilaad G. T2 - Journal of the Canadian Association of Gastroenterology AB - Persons with inflammatory bowel disease (IBD) make up more than 0.75% of the Canadian population in 2021. Early in the COVID-19 pandemic, individuals with IBD, particularly those on immunosuppressive therapies, were concerned that their health status may place them at higher risk of contracting COVID-19 or experiencing more severe disease course if infected with SARS-CoV-2. In response, Crohn's and Colitis Canada developed the COVID-19 and IBD Taskforce in March 2020 to rapidly synthesize the evolving knowledge of COVID-19 as relevant to Canadians with IBD. The Taskforce communicated expert information directly to the Canadian IBD community through online tools and a webinar series. In order to understand the full impact of COVID-19 on the IBD community, Crohn's and Colitis Canada commissioned a policy report that was informed through a systematic literature review and synthesized across working groups along the following domains: Epidemiology, Children and Expectant Mothers with IBD, Seniors with IBD, Mental Health, Risk Factors and Medications, Vaccines, and Healthcare Delivery during the Pandemic and the Future Model of IBD Care. This report from Canadian physicians, researchers, and IBD community representatives highlights the physical, mental, and health systems impact of COVID-19 on the entire spectrum of the IBD community, including children, adolescents, adults, seniors, and pregnant people with IBD. This executive summary provides an overview of the crucial information from each of the chapters of the policy report, supplemented with additional information made available through Crohn's and Colitis Canada's webinar-based knowledge translation platform. DA - 2021/// PY - 2021 DO - 10.1093/jcag/gwab027 DP - PubMed VL - 4 IS - Suppl 2 SP - S1 EP - S9 J2 - J Can Assoc Gastroenterol LA - eng SN - 2515-2092 ST - Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada L1 - https://academic.oup.com/jcag/article-pdf/4/Supplement_2/S1/41090857/gwab027.pdf L2 - http://www.ncbi.nlm.nih.gov/pubmed/34755033 KW - Ulcerative colitis KW - Crohn’s disease KW - SARS-CoV-2 KW - Coronavirus ER - TY - JOUR TI - [The impact of the SARS-CoV-2 pandemic on out-of-hospital and in-hospital cardiac arrest] AU - Fekete-Győr, Alexandra AU - Kovács, Enikő AU - Kiss, Boldizsár AU - Zima, Endre T2 - Orvosi Hetilap AB - Összefoglaló. A koronavírus-betegség (COVID-19) okozta közvetlen mortalitáson túl, a járvány közvetett úton is hatással lehet a hirtelen szívhalálra. Egyre növekvő számú közlemény foglalkozik a járványnak a hirtelen szívhalálra kifejtett közvetett hatásával. A kijárási korlátozások és az egészségügyi rendszerek átszervezése hozzájárulhatott ahhoz, hogy a járvány alatt mind a kórházon kívüli, mind a kórházon belüli szívhalál előfordulása megemelkedett. Közegészségügyi intézkedések, mint a korlátozások és a kórházak átszervezése, megváltoztathatják az egészségügyi szolgáltatásokhoz való hozzáférést, ezért hozzájárulhattak az elmúlt évben tapasztalt emelkedett számú szívmegálláshoz. Közleményünk célja a SARS-CoV-2-járvány hirtelen szívhalálra kifejtett hatására vonatkozó, a nemzetközi irodalomban jelenleg megtalálható tanulmányok összefoglalása, melyek a kórházon kívüli szívmegállás előfordulásának háromszoros emelkedéséről számoltak be a járványt megelőző évhez képest. Általánosságban elmondható, hogy a kórházon kívüli szívmegállás a járvány ideje alatt nagyobb gyakorisággal járt nem sokkolandó ritmussal, hosszabb idő telt el a mentők kiérkezéséig, alacsonyabb volt a szemtanú által megkezdett újraélesztés, a spontán keringés visszatérésének, valamint a kórházi elbocsátásnak a gyakorisága. A járványnak a kórházon belüli szívmegállásra kifejtett hatása kevésbé vizsgált az irodalomban. Míg a hirtelen szívhalált követő mortalitás néhány kutatásban jelentős emelkedést mutatott, addig máshol nem volt különbség a járványt megelőző időszakhoz képest. A COVID-19-pandémia ideje alatt jelentősen megnövekedett kórházon kívüli és belüli szívmegállás hátterében a járványnak közvetett úton is szerepe lehet, a fertőzés közvetlen hatása mellett. A túlélési lánc megbomlását számos helyen tapasztalták, ami hozzájárulhatott a kedvezőtlen kimenetelhez. Mind a prehospitális, mind pedig a hospitális ellátás gyakorlatában bekövetkező jelentős változások magyarázhatják a világ különböző pontjain megfigyelt eltéréseket. Orv Hetil. 2021; 162(46): 1831-1841. Summary. The direct effect of COVID-19 on mortality through acute respiratory failure is well-established. However, there are a growing number of publications suggesting that the prevalence and outcome of sudden cardiac death may also be indirectly affected by the pandemic. Public health measures, such as lockdowns and reorganisation of hospitals, can alter the access to healthcare services and therefore might have contributed to the excess number of cardiac arrests which were seen over the last year. Our aim was to review the currently available publications regarding the impact of the COVID-19 pandemic on out-of-hospital and in-hospital cardiac arrests. A recent study reported a 3-fold growth in the incidence of out-of-hospital cardiac arrests during the 2020 COVID-19 period compared to the year before. In general, the number of non-shockable rhythms increased, bystander-witnessed cases and bystander-initiated cardiopulmonary resuscitation were reduced and ambulance response times were significantly delayed during the pandemic. Return of spontaneous circulation and survival to discharge substantially decreased compared to the time before the pandemic. The difference between the rate of mortality following in-hospital cardiac arrest during and before the pandemic is controversial according to published data. The incidence of out-of-hospital and in-hospital cardiac arrests significantly increased during the pandemic compared to previous years suggesting direct effects of COVID-19 infection and indirect effects from new public health measures. The disruption of the chain of survival could have contributed to the increased mortality following out-of-hospital cardiac arrest. Orv Hetil. 2021; 162(46): 1831-1841. DA - 2021/11/14/ PY - 2021 DO - 10.1556/650.2021.32381 DP - PubMed VL - 162 IS - 46 SP - 1831 EP - 1841 J2 - Orv Hetil LA - hun SN - 1788-6120 UR - https://akjournals.com/view/journals/650/162/46/article-p1831.xml L2 - http://www.ncbi.nlm.nih.gov/pubmed/34775368 KW - Humans KW - COVID-19 KW - SARS-CoV-2 KW - Pandemics KW - Hungary KW - Hospitals KW - Communicable Disease Control KW - COVID–19 KW - Heart Arrest KW - in-hospital cardiac arrest KW - kimenetel KW - kórházon belüli szívmegállás KW - kórházon kívüli szívmegállás KW - out-of-hospital cardiac arrest KW - outcome ER - TY - JOUR TI - A reversal of fortune: Comparison of health system responses to COVID-19 in the Visegrad group during the early phases of the pandemic AU - Sagan, Anna AU - Bryndova, Lucie AU - Kowalska-Bobko, Iwona AU - Smatana, Martin AU - Spranger, Anne AU - Szerencses, Viktoria AU - Webb, Erin AU - Gaal, Peter T2 - Health Policy (Amsterdam, Netherlands) AB - This paper analyses the health policy response to the COVID-19 pandemic in the four Visegrad countries - Czechia, Hungary, Poland, and Slovakia - in spring and summer 2020. The four countries implemented harsh transmission prevention measures at the beginning of the pandemic and managed to effectively avoid the first wave of infections during spring. Likewise, all four relaxed most of these measures during the summer and experienced uncontrolled growth of cases since September 2020. Along the way, there has been an erosion of public support for the government measures. This was mainly due to economic considerations taking precedent but also likely due to diminished trust in the government. All four countries have been overly reliant on their relatively high bed capacity, which they managed to further increase at the cost of elective treatments, but this could not always be supported with sufficient health workforce capacity. Finally, none of the four countries developed effective find, test, trace, isolate and support systems over the summer despite having relaxed most of the transmission protection measures since late spring. This left the countries ill-prepared for the rise in the number of COVID-19 infections they have been experiencing since autumn 2020. DA - 2021/10/20/ PY - 2021 DO - 10.1016/j.healthpol.2021.10.009 DP - PubMed SP - S0168 EP - 8510(21)00267-0 J2 - Health Policy LA - eng SN - 1872-6054 ST - A reversal of fortune L1 - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8527640/pdf/main.pdf L2 - http://www.ncbi.nlm.nih.gov/pubmed/34789401 ER - TY - JOUR TI - Early Transfusion of Convalescent Plasma Improves the Clinical Outcome in Severe SARS-CoV2 Infection AU - Fodor, Eszter AU - Müller, Veronika AU - Iványi, Zsolt AU - Berki, Tímea AU - Kuten Pella, Olga AU - Hornyák, István AU - Ambrus, Mira AU - Sárkány, Ágnes AU - Skázel, Árpád AU - Madár, Ágnes AU - Kardos, Dorottya AU - Kemenesi, Gábor AU - Földes, Fanni AU - Nagy, Sándor AU - Matusovits, Andrea AU - János, Nacsa AU - Tordai, Attila AU - Jakab, Ferenc AU - Lacza, Zsombor T2 - Infectious Diseases and Therapy AB - INTRODUCTION: Plasma harvested from convalescent COVID-19 patients (CCP) has been applied as first-line therapy in the early phase of the SARS-CoV2 pandemic through clinical studies using various protocols. METHODS: We present data from a cohort of 267 hospitalized severe COVID-19 patients who received CCP. No transfusion-related complications were reported, indicating the overall safety of CCP therapy. RESULTS: Patients who eventually died from COVID-19 received CCP significantly later (3.95 versus 5.22 days after hospital admission) and had higher interleukin 6 (IL-6) levels (28.9 pg/ml versus 102.5 pg/ml) than those who survived. In addition, CCP transfusion caused a significant reduction in the overall inflammatory status of the patients regardless of the severity of disease or outcome, as evidenced by decreasing C-reactive protein, IL6 and ferritin levels. CONCLUSION: We conclude that CCP transfusion is a safe and effective supplementary treatment modality for hospitalized COVID-19 patients characterized by better expected outcome if applied as early as possible. We also observed that IL-6 may be a suitable laboratory parameter for patient selection and monitoring of CCP therapy effectiveness. DA - 2021/// PY - 2021 DO - 10.1007/s40121-021-00514-7 DP - PubMed J2 - Infect Dis Ther LA - eng SN - 2193-8229 L1 - https://link.springer.com/content/pdf/10.1007/s40121-021-00514-7.pdf L2 - http://www.ncbi.nlm.nih.gov/pubmed/34817840 KW - COVID-19 KW - Interleukin-6 KW - Convalescent plasma KW - SARS2-CoV ER - TY - JOUR TI - ESCMID COVID-19 Living guidelines: drug treatment and clinical management AU - Bartoletti, Michele AU - Azap, Ozlem AU - Barac, Aleksandra AU - Bussini, Linda AU - Ergonul, Onder AU - Krause, Robert AU - Paño-Pardo, José Ramón AU - Power, Nicholas R. AU - Sibani, Marcella AU - Szabo, Balint Gergely AU - Tsiodras, Sotirios AU - Verweij, Paul E. AU - Zollner-Schwetz, Ines AU - Rodríguez-Baño, Jesús T2 - Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases AB - SCOPE: In January 2021, the ESCMID Executive Committee (EC) decided to launch a new initiative to develop ESCMID guidelines on several COVID19-related issues, including treatment of COVID-19. METHODS: An ESCMID COVID-19 guidelines task force was established by the ESCMID Executive Committee. A small group was established, half appointed by the chair, and the remaining selected with an open call. Each panel met virtually once a week. For all decisions, a simple majority vote was used. A long list of clinical questions using the PICO (population, intervention, comparison, outcome) format was developed at the beginning of the process. For each PICO, two panel members performed a literature search with a third panelist involved in case of inconsistent results. Voting was based on the GRADE approach. QUESTIONS ADDRESSED BY THE GUIDELINE AND RECOMMENDATIONS: A synthesis of the available evidence and recommendations are provided for each of the 15 PICOs, which cover use of hydroxychloroquine, bamlanivimab alone or in combination with etesevimab, casirivimab combined with imdevimab, ivermectin, azithromycin and empirical antibiotics, colchicine, corticosteroids, convalescent plasma, favipiravir, remdesivir, tocilizumab, and interferon β-1a, as well as the utility of antifungal prophylaxis and enoxaparin. In general, the panel recommended against the use of hydroxychloroquine, ivermectin, azithromycin, colchicine, and interferon β-1a. Conditional recommendations were given for the use of monoclonal antibodies in high-risk outpatients with mild-moderate COVID-19, and remdesivir. There was insufficient evidence to make a recommendation for use of favipiravir and antifungal prophylaxis, and it was recommended that antibiotics should not be routinely prescribed in patients with COVID-19 unless bacterial coinfection or secondary infection is suspected or confirmed. Tocilizumab and corticosteroids was recommended for treatment of severe COVID-19 but not in outpatients with non-severe COVID-19. DA - 2022/02// PY - 2022 DO - 10.1016/j.cmi.2021.11.007 DP - PubMed VL - 28 IS - 2 SP - 222 EP - 238 J2 - Clin Microbiol Infect LA - eng SN - 1469-0691 ST - ESCMID COVID-19 Living guidelines L1 - https://www.clinicalmicrobiologyandinfection.com/article/S1198743X21006340/pdf L2 - http://www.ncbi.nlm.nih.gov/pubmed/34823008 ER - TY - JOUR TI - Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary - The HUN-VE study AU - Vokó, Zoltán AU - Kiss, Zoltán AU - Surján, György AU - Surján, Orsolya AU - Barcza, Zsófia AU - Pályi, Bernadett AU - Formanek-Balku, Eszter AU - Molnár, Gergő Attila AU - Herczeg, Róbert AU - Gyenesei, Attila AU - Miseta, Attila AU - Kollár, Lajos AU - Wittmann, István AU - Müller, Cecília AU - Kásler, Miklós T2 - Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases AB - OBJECTIVES: The Hungarian vaccination campaign was conducted with five different vaccines during the third wave of the Covid-19 pandemic in 2021. This observational study (HUN-VE: Hungarian Vaccine Effectiveness) estimated vaccine effectiveness against SARS-CoV-2 infection and Covid-19 related mortality in 3.7 million vaccinated individuals. METHODS: Incidence rates of SARS-CoV-2 infection and Covid-19 related mortality were calculated using data from the National Public Health Center (NPHC) surveillance database. Estimated vaccine effectiveness was calculated as 1 - incidence rate ratio (IRR) ≥7 days after the second dose for each available vaccine vs. an unvaccinated control group using mixed effect negative binomial regression controlling for age, sex and calendar day. RESULTS: Between 22 January 2021 and 10 June 2021, 3,740,066 Hungarian individuals received two doses of the BNT162b2 (Pfizer-BioNTech), HB02 (Sinopharm), Gam-COVID-Vac (Sputnik-V), AZD1222 (AstraZeneca), or mRNA-1273 (Moderna) vaccines. Incidence rates of SARS-CoV2 infection and Covid-19 related death were 1.73-9.3/100,000 person-days and 0.04-0.65/100.000 person-days in the fully vaccinated population, respectively. Estimated adjusted effectiveness varied between 68.7% (95% CI 67.2-70.1%) and 88.7% (95% CI: 86.6-90.4%) against SARS-CoV-2 infection, and between 87.8% (95% CI: 86.1-89.5%) and 97.5% (95% CI: 95.6-98.6%) against Covid-19 related death, with 100% effectiveness in individuals aged 16-44 years for all vaccines. CONCLUSIONS: Our observational study demonstrated the high or very high effectiveness of five different vaccines in the prevention SARS-CoV-2 infection and Covid-19 related death. DA - 2022/03// PY - 2022 DO - 10.1016/j.cmi.2021.11.011 DP - PubMed VL - 28 IS - 3 SP - 398 EP - 404 J2 - Clin Microbiol Infect LA - eng SN - 1469-0691 L2 - http://www.ncbi.nlm.nih.gov/pubmed/34838783 ER - TY - JOUR TI - COVID-19 vaccinations: The unknowns, challenges, and hopes AU - Mohamed, Kawthar AU - Rzymski, Piotr AU - Islam, Md Shahidul AU - Makuku, Rangarirai AU - Mushtaq, Ayesha AU - Khan, Amjad AU - Ivanovska, Mariya AU - Makka, Sara A. AU - Hashem, Fareeda AU - Marquez, Leander AU - Cseprekal, Orsolya AU - Mickael, Essouma AU - Ling, Irene AU - Arero, Amanuel Godana AU - Cuschieri, Sarah AU - Minakova, Kseniia AU - Rodríguez-Román, Eduardo AU - Abarikwu, Sunny O. AU - Faten, Attig-Bahar AU - Grancini, Giulia AU - Rezaei, Nima T2 - Journal of Medical Virology AB - The entire world has been suffering from the COVID-19 pandemic since 11 March, 2020. More than a year later, the COVID-19 vaccination brought hope to control this viral pandemic. Here, we review the unknowns of the COVID-19 vaccination, such as its longevity, asymptomatic spread, long-term side effects, and its efficacy on immunocompromised patients. In addition, we discuss challenges associated with the COVID-19 vaccination, such as the global access and distribution of vaccine doses, adherence to hygiene guidelines after vaccination, the emergence of novel SARS-CoV-2 variants, and vaccine resistance. Despite all these challenges and the fact that the end of the COVID-19 pandemic is still unclear, vaccines have brought great hope for the world, with several reports indicating a significant decline in the risk of COVID19-related infection and hospitalizations. This article is protected by copyright. All rights reserved. DA - 2022/04// PY - 2022 DO - 10.1002/jmv.27487 DP - PubMed VL - 94 IS - 4 SP - 1336 EP - 1349 J2 - J Med Virol LA - eng SN - 1096-9071 ST - COVID-19 vaccinations L2 - http://www.ncbi.nlm.nih.gov/pubmed/34845731 KW - COVID-19 KW - SARS-CoV-2 KW - COVID-19 Vaccination KW - Global Assessment KW - Global Challenges KW - Herd Immunity ER - TY - JOUR TI - Admission criteria in critically ill COVID-19 patients: A physiology-based approach AU - Ceruti, Samuele AU - Glotta, Andrea AU - Biggiogero, Maira AU - Maida, Pier Andrea AU - Marzano, Martino AU - Urso, Patrizia AU - Bona, Giovanni AU - Garzoni, Christian AU - Molnar, Zsolt T2 - PloS One AB - INTRODUCTION: The COVID-19 pandemic required careful management of intensive care unit (ICU) admissions, to reduce ICU overload while facing limitations in resources. We implemented a standardized, physiology-based, ICU admission criteria and analyzed the mortality rate of patients refused from the ICU. MATERIALS AND METHODS: In this retrospective observational study, COVID-19 patients proposed for ICU admission were consecutively analyzed; Do-Not-Resuscitate patients were excluded. Patients presenting an oxygen peripheral saturation (SpO2) lower than 85% and/or dyspnea and/or mental confusion resulted eligible for ICU admission; patients not presenting these criteria remained in the ward with an intensive monitoring protocol. Primary outcome was both groups' survival rate. Secondary outcome was a sub analysis correlating SpO2 cutoff with ICU admission. RESULTS: From March 2020 to January 2021, 1623 patients were admitted to our Center; 208 DNR patients were excluded; 97 patients were evaluated. The ICU-admitted group (n = 63) mortality rate resulted 15.9% at 28 days and 27% at 40 days; the ICU-refused group (n = 34) mortality rate resulted 0% at both intervals (p < 0.001). With a SpO2 cut-off of 85%, a significant correlation was found (p = 0.009), but with a 92% a cut-off there was no correlation with ICU admission (p = 0.26). A similar correlation was also found with dyspnea (p = 0.0002). CONCLUSION: In COVID-19 patients, standardized ICU admission criteria appeared to safely reduce ICU overload. In the absence of dyspnea and/or confusion, a SpO2 cutoff up to 85% for ICU admission was not burdened by negative outcomes. In a pandemic context, the SpO2 cutoff of 92%, as a threshold for ICU admission, needs critical re-evaluation. DA - 2021/// PY - 2021 DO - 10.1371/journal.pone.0260318 DP - PubMed VL - 16 IS - 11 SP - e0260318 J2 - PLoS One LA - eng SN - 1932-6203 ST - Admission criteria in critically ill COVID-19 patients L1 - https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0260318&type=printable L2 - http://www.ncbi.nlm.nih.gov/pubmed/34843531 ER - TY - JOUR TI - Evaluation of a novel, rapid antigen detection test for the diagnosis of SARS-CoV-2 AU - Thell, Rainer AU - Kallab, Verena AU - Weinhappel, Wolfgang AU - Mueckstein, Wolfgang AU - Heschl, Lukas AU - Heschl, Martina AU - Korsatko, Stefan AU - Toedling, Franz AU - Blaschke, Amelie AU - Herzog, Theresa AU - Klicpera, Anna AU - Koeller, Clara AU - Haugk, Moritz AU - Kreil, Anna AU - Spiel, Alexander AU - Kreuzer, Philipp AU - Krause, Robert AU - Sebesta, Christian AU - Winkler, Stefan AU - Laky, Brenda AU - Szell, Marton T2 - PloS One AB - BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19) is currently finally determined in laboratory settings by real-time reverse-transcription polymerase-chain-reaction (rt-PCR). However, simple testing with immediately available results are crucial to gain control over COVID-19. The aim was to evaluate such a point-of-care antigen rapid test (AG-rt) device in its performance compared to laboratory-based rt-PCR testing in COVID-19 suspected, symptomatic patients. METHODS: For this prospective study, two specimens each of 541 symptomatic female (54.7%) and male (45.3%) patients aged between 18 and 95 years tested at five emergency departments (ED, n = 296) and four primary healthcare centres (PHC, n = 245), were compared, using AG-rt (positive/negative/invalid) and rt-PCR (positive/negative and cycle threshold, Ct) to diagnose SARS-CoV-2. Diagnostic accuracy, sensitivity, specificity, positive predictive values (PPV), negative predictive value (NPV), and likelihood ratios (LR+/-) of the AG-rt were assessed. RESULTS: Differences between ED and PHC were detected regarding gender, age, symptoms, disease prevalence, and diagnostic performance. Overall, 174 (32.2%) were tested positive on AG-rt and 213 (39.4%) on rt-PCR. AG correctly classified 91.7% of all rt-PCR positive cases with a sensitivity of 80.3%, specificity of 99.1%, PPV of 98.3, NPV of 88.6%, LR(+) of 87.8, and LR(-) of 0.20. The highest sensitivities and specificities of AG-rt were detected in PHC (sensitivity: 84.4%, specificity: 100.0%), when using Ct of 30 as cut-off (sensitivity: 92.5%, specificity: 97.8%), and when symptom onset was within the first three days (sensitivity: 82.9%, specificity: 99.6%). CONCLUSIONS: The highest sensitivity was detected with a high viral load. Our findings suggest that AG-rt are comparable to rt-PCR to diagnose SARS-CoV-2 in COVID-19 suspected symptomatic patients presenting both at emergency departments and primary health care centres. DA - 2021/// PY - 2021 DO - 10.1371/journal.pone.0259527 DP - PubMed VL - 16 IS - 11 SP - e0259527 J2 - PLoS One LA - eng SN - 1932-6203 L1 - https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0259527&type=printable L2 - http://www.ncbi.nlm.nih.gov/pubmed/34843505 ER - TY - JOUR TI - The Predictive Role of Artificial Intelligence-Based Chest CT Quantification in Patients with COVID-19 Pneumonia AU - Szabó, István Viktor AU - Simon, Judit AU - Nardocci, Chiara AU - Kardos, Anna Sára AU - Nagy, Norbert AU - Abdelrahman, Renad-Heyam AU - Zsarnóczay, Emese AU - Fejér, Bence AU - Futácsi, Balázs AU - Müller, Veronika AU - Merkely, Béla AU - Maurovich-Horvat, Pál T2 - Tomography (Ann Arbor, Mich.) AB - We sought to analyze the prognostic value of laboratory and clinical data, and an artificial intelligence (AI)-based algorithm for Coronavirus disease 2019 (COVID-19) severity scoring, on CT-scans of patients hospitalized with COVID-19. Moreover, we aimed to determine personalized probabilities of clinical deterioration. Data of symptomatic patients with COVID-19 who underwent chest-CT-examination at the time of hospital admission between April and November 2020 were analyzed. COVID-19 severity score was automatically quantified for each pulmonary lobe as the percentage of affected lung parenchyma with the AI-based algorithm. Clinical deterioration was defined as a composite of admission to the intensive care unit, need for invasive mechanical ventilation, use of vasopressors or in-hospital mortality. In total 326 consecutive patients were included in the analysis (mean age 66.7 ± 15.3 years, 52.1% male) of whom 85 (26.1%) experienced clinical deterioration. In the multivariable regression analysis prior myocardial infarction (OR = 2.81, 95% CI = 1.12-7.04, p = 0.027), immunodeficiency (OR = 2.08, 95% CI = 1.02-4.25, p = 0.043), C-reactive protein (OR = 1.73, 95% CI = 1.32-2.33, p < 0.001) and AI-based COVID-19 severity score (OR = 1.08; 95% CI = 1.02-1.15, p = 0.013) appeared to be independent predictors of clinical deterioration. Personalized probability values were determined. AI-based COVID-19 severity score assessed at hospital admission can provide additional information about the prognosis of COVID-19, possibly serving as a useful tool for individualized risk-stratification. DA - 2021/11/01/ PY - 2021 DO - 10.3390/tomography7040058 DP - PubMed VL - 7 IS - 4 SP - 697 EP - 710 J2 - Tomography LA - eng SN - 2379-139X L1 - https://www.mdpi.com/2379-139X/7/4/58/pdf L2 - http://www.ncbi.nlm.nih.gov/pubmed/34842822 KW - COVID-19 KW - artificial intelligence KW - computed tomography ER - TY - JOUR TI - Is cardiac involvement prevalent in highly trained athletes after SARS-CoV-2 infection? A cardiac magnetic resonance study using sex-matched and age-matched controls AU - Szabó, Liliána AU - Juhász, Vencel AU - Dohy, Zsófia AU - Fogarasi, Csenge AU - Kovács, Attila AU - Lakatos, Bálint Károly AU - Kiss, Orsolya AU - Sydó, Nóra AU - Csulak, Emese AU - Suhai, Ferenc Imre AU - Hirschberg, Kristóf AU - Becker, Dávid AU - Merkely, Béla AU - Vágó, Hajnalka T2 - British Journal of Sports Medicine AB - OBJECTIVES: To investigate the cardiovascular consequences of SARS-CoV-2 infection in highly trained, otherwise healthy athletes using cardiac magnetic resonance (CMR) imaging and to compare our results with sex-matched and age-matched athletes and less active controls. METHODS: SARS-CoV-2 infection was diagnosed by PCR on swab tests or serum immunoglobulin G antibody tests prior to a comprehensive CMR examination. The CMR protocol contained sequences to assess structural, functional and tissue-specific data. RESULTS: One hundred forty-seven athletes (94 male, median 23, IQR 20-28 years) after SARS-CoV-2 infection were included. Overall, 4.7% (n=7) of the athletes had alterations in their CMR as follows: late gadolinium enhancement (LGE) showing a non-ischaemic pattern with or without T2 elevation (n=3), slightly elevated native T1 values with or without elevated T2 values without pathological LGE (n=3) and pericardial involvement (n=1). Only two (1.4%) athletes presented with definite signs of myocarditis. We found pronounced sport adaptation in both athletes after SARS-CoV-2 infection and athlete controls. There was no difference between CMR parameters, including native T1 and T2 mapping, between athletes after SARS-CoV-2 infection and the matched athletic groups. Comparing athletes with different symptom severities showed that athletes with moderate symptoms had slightly greater T1 values than athletes with asymptomatic and mildly symptomatic infections (p<0.05). However, T1 mapping values remained below the cut-off point for most patients. CONCLUSION: Among 147 highly trained athletes after SARS-CoV-2 infection, cardiac involvement on CMR showed a modest frequency (4.7%), with definite signs of myocarditis present in only 1.4%. Comparing athletes after SARS-CoV-2 infection and healthy sex-matched and age-matched athletes showed no difference between CMR parameters, including native T1 and T2 values. DA - 2021/// PY - 2021 DO - 10.1136/bjsports-2021-104576 DP - PubMed SP - bjsports EP - 2021-104576 J2 - Br J Sports Med LA - eng SN - 1473-0480 ST - Is cardiac involvement prevalent in highly trained athletes after SARS-CoV-2 infection? L1 - https://bjsm.bmj.com/content/bjsports/early/2021/11/29/bjsports-2021-104576.full.pdf L2 - http://www.ncbi.nlm.nih.gov/pubmed/34848398 KW - COVID-19 KW - athletes KW - heart ER - TY - JOUR TI - [Relationships between COVID-19 disease, nutritional status, and dysphagia, particularly in stroke patients] AU - Kovács, Andrea AU - Szabó, Tamás Pál AU - Folyovich, András T2 - Ideggyogyaszati Szemle AB - The new coronavirus, SARS-CoV-2, which causes the COVID-19 disease can lead to severe acute respiratory distress syndrome (ARDS). It poses a serious challenge to the health care system, especially intensive care. Neurological patients, usually of advanced age and with a myriad of comorbidities, are at particular risk through the impact of the new coronavirus on their condition and nutritional capacity. Stroke is a leader in morbidity and mortality data, with a focus on dysphagia and its complications due to COVID-19 disease and acute cerebrovascular accident. In the acute phase of stroke, 30-50% of patients suffer from dysphagia, which still shows a prevalence of 10% six months later. Dysphagia results in decreased or insufficient fluid and nutrient uptake, supp-lemented by inactivity, leading to malnutrition and sarcopenia, which worsens overall condition, outcome, and rehabilitation efficiency. Screening and early detection of swallowing disorders is a fundamental issue in order to develop a personalized and timely-initiated nutritional therapy strategy. Nutritional therapy plays a key role in frequent intensive care due to COVID-19 disease, where it increases the chances of recovery and reduces the length of stay in the intensive care unit and mortality. This is especially true in critically ill patients requiring prolonged ventilation. In COVID-19 diagnosed patients, screening for dysphagia, bedside assessment, and instrumental examination, followed by swallowing rehabilitation, are of paramount importance. Stroke can also be a complication of the COVID-19 infection. Care for cerebrovascular patients has also adapted to the pandemic, "triazination" has become systemic, and dysphagia screening for stroke patients and nutritional therapy adapted to it have also shed new light. DA - 2021/11/30/ PY - 2021 DO - 10.18071/isz.74.0367 DP - PubMed VL - 74 IS - 11-12 SP - 367 EP - 378 J2 - Ideggyogy Sz LA - hun SN - 0019-1442 L2 - http://www.ncbi.nlm.nih.gov/pubmed/34856087 KW - COVID-19 KW - dysphagia KW - malnutrition KW - stroke ER - TY - JOUR TI - Fluoxetine use is associated with improved survival of patients with COVID-19 pneumonia: A retrospective case-control study AU - Németh, Zsófia Klára AU - Szűcs, Anna AU - Vitrai, József AU - Juhász, Dóra AU - Németh, János Pál AU - Holló, András T2 - Ideggyogyaszati Szemle AB - Background and purpose: We aimed to investigate the association between fluoxetine use and the survival of hospitalised coronavirus disease (COVID-19) pneumonia patients. Methods: This retrospective case-control study used data extracted from the medical records of adult patients hospitalised with moderate or severe COVID-19 pneumonia at the Uzsoki Teaching Hospital of the Semmelweis University in Budapest, Hungary between 17 March and 22 April 2021. As a part of standard medical treatment, patients received anti-COVID-19 therapies as favipiravir, remdesivir, baricitinib or a combination of these drugs; and 110 of them received 20 mg fluoxetine capsules once daily as an adjuvant medication. Multivariable logistic regression was used to evaluate the association between fluoxetine use and mortality. For excluding a fluoxetine-selection bias potentially influencing our results, we compared baseline prognostic markers in the two groups treated versus not treated with fluoxetine. Results: Out of the 269 participants, 205 (76.2%) survived and 64 (23.8%) died between days 2 and 28 after hospitalisation. Greater age (OR [95% CI] 1.08 [1.05-1.11], p<0.001), radiographic severity based on chest X-ray (OR [95% CI] 2.03 [1.27-3.25], p=0.003) and higher score of shortened National Early Warning Score (sNEWS) (OR [95% CI] 1.20 [1.01-1.43], p=0.04) were associated with higher mortality. Fluoxetine use was associated with an important (70%) decrease of mortality (OR [95% CI] 0.33 [0.16-0.68], p=0.002) compared to the non-fluoxetine group. Age, gender, LDH, CRP, and D-dimer levels, sNEWS, Chest X-ray score did not show statistical difference between the fluoxetine and non-fluoxetine groups supporting the reliability of our finding. Conclusion: Provisional to confirmation in randomised controlled studies, fluoxetine may be a potent treatment increasing the survival for COVID-19 pneumonia. DA - 2021/11/30/ PY - 2021 DO - 10.18071/isz.74.0389 DP - PubMed VL - 74 IS - 11-12 SP - 389 EP - 396 J2 - Ideggyogy Sz LA - eng SN - 0019-1442 ST - Fluoxetine use is associated with improved survival of patients with COVID-19 pneumonia L1 - https://elitmed.hu/en/publications/clinical-neuroscience/fluoxetine-use-is-associated-with-improved-survival-of-patients-with-covid-19-pneumonia-a-retrospective-case-control-study/pdf-download L2 - http://www.ncbi.nlm.nih.gov/pubmed/34856085 KW - COVID-19 KW - SARS-CoV-2 KW - mortality KW - pneumonia KW - fluoxetine KW - survival ER - TY - JOUR TI - Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease AU - Wetwittayakhlang, Panu AU - Albader, Farah AU - Golovics, Petra A. AU - Hahn, Gustavo Drügg AU - Bessissow, Talat AU - Bitton, Alain AU - Afif, Waqqas AU - Wild, Gary AU - Lakatos, Peter L. T2 - Canadian Journal of Gastroenterology & Hepatology AB - Background and Aims: The impact of COVID-19 has been of great concern in patients with inflammatory bowel disease (IBD) worldwide, including an increased risk of severe outcomes and/or possible flare of IBD. This study aims to evaluate prevalence, outcomes, the impact of COVID-19 in patients with IBD, and risk factors associated with severe COVID-19 or flare of IBD activity. Methods: A consecutive cohort of IBD patients who were diagnosed with COVID-19 infection and followed up at the McGill University Health Care Centre was obtained between March 1, 2020, and April 30, 2021. Demographics, comorbidities, IBD (type, treatments, pre- and post-COVID-19 clinical activity, biomarkers, and endoscopic activity), and COVID-19-related outcomes (pneumonia, hospitalization, death, and flare of IBD disease) were analyzed. Results: A cohort of 3,516 IBD patients was included. 82 patients (2.3%) were diagnosed with COVID-19 infection (median age: 39.0 (IQR 27.8-48.0), 77% with Crohn's disease, 50% were female). The prevalence of COVID-19 infection in IBD patients was significantly lower compared to the general population in Canada and Quebec (3.5% versus 4.3%, p < 0.001). Severe COVID-19 occurred in 6 patients (7.3%); 2 patients (2.4%) died. A flare of IBD post-COVID-19 infection was reported in 8 patients (9.8%) within 3 months. Biologic therapy was held during active COVID-19 infection in 37% of patients. Age ≥55 years (odds ratio (OR): 11.1, 95% CI: 1.8-68.0), systemic corticosteroid use (OR: 4.6, 95% CI: 0.7-30.1), active IBD (OR: 3.8, 95% CI: 0.7-20.8), and comorbidity (OR: 4.9, 95% CI: 0.8-28.6) were factors associated with severe COVID-19. After initial infection, 61% of IBD patients received COVID-19 vaccinations. Conclusion: The prevalence of COVID-19 infection among patients with IBD was lower than that in the general population in Canada. Severe COVID-19, mortality, and flare of IBD were relatively rare, while a large proportion of patients received COVID-19 vaccination. Older age, comorbidities, active IBD disease, and systemic corticosteroid, but not immunosuppressive or biological therapy, were associated with severe COVID-19 infection. DA - 2021/// PY - 2021 DO - 10.1155/2021/7591141 DP - PubMed VL - 2021 SP - 7591141 J2 - Can J Gastroenterol Hepatol LA - eng SN - 2291-2797 L1 - https://downloads.hindawi.com/journals/cjgh/2021/7591141.pdf L2 - http://www.ncbi.nlm.nih.gov/pubmed/34858891 ER - TY - JOUR TI - Simultaneous effective treatment of critical COVID-19 disease and newly diagnosed high-risk multiple myeloma with thalidomide, methylprednisolone, tocilizumab and baricitinib: is it clinically feasible? AU - Szabo, Balint G. AU - Lorinczi, Csaba AU - Szanka, Judit AU - Lakatos, Botond AU - Sinko, Janos AU - Szlavik, Janos AU - Mikala, Gabor T2 - Minerva Medica DA - 2021/// PY - 2021 DO - 10.23736/S0026-4806.20.07050-0 DP - PubMed J2 - Minerva Med LA - eng SN - 1827-1669 ST - Simultaneous effective treatment of critical COVID-19 disease and newly diagnosed high-risk multiple myeloma with thalidomide, methylprednisolone, tocilizumab and baricitinib L2 - http://www.ncbi.nlm.nih.gov/pubmed/34856779 ER - TY - JOUR TI - Extracorporeal Cytokine Removal in Critically Ill COVID-19 Patients: A Case Series AU - Virág, Marcell AU - Rottler, Máté AU - Ocskay, Klementina AU - Leiner, Tamás AU - Horváth, Balázs AU - Blanco, Daniel Adam AU - Vasquez, Alexa AU - Bucsi, László AU - Sárkány, Ágnes AU - Molnár, Zsolt T2 - Frontiers in Medicine AB - Introduction: Extracorporeal hemoadsorption (HA) is a potential adjunctive therapy in severe cases of COVID-19 associated pneumonia. In this retrospective study we report data from critically ill patients treated with HA during the first and second wave of the pandemic. Patients and Methods: All patients, who received HA therapy with CytoSorb within the first 96 h of intensive care unit (ICU) admission without hospital-acquired bacterial superinfection, were included. Clinical and laboratory data were collected: on admission, before (TB) and after (TA) HA therapy. Results: Out of the 367 COVID-19 cases, 13 patients were treated with CytoSorb, also requiring mechanical ventilation and renal replacement therapy. All patients were alive at the end of HA, but only 3 survived hospital stay. From TB-TA there was a tendency of decreasing norepinephrine requirement: 193.7 [IQR: 34.8-270.4] to 50.2 [6.5-243.5] ug/kg/day and increasing PaO2/FiO2 ratio 127.8 (95% CI: 96.0-159.6) to 155.0 (115.3-194.6) mmHg but they did not reach statistical significance (p = 0.14 and 0.58, respectively). Treatment related adverse events were not reported. Conclusion: The treatment was well-tolerated, and there was a tendency toward an improvement in vasopressor need and oxygenation during the course of HA. These observations render the need for prospective randomized trials. DA - 2021/// PY - 2021 DO - 10.3389/fmed.2021.760435 DP - PubMed VL - 8 SP - 760435 J2 - Front Med (Lausanne) LA - eng SN - 2296-858X ST - Extracorporeal Cytokine Removal in Critically Ill COVID-19 Patients L1 - https://www.frontiersin.org/articles/10.3389/fmed.2021.760435/pdf L2 - http://www.ncbi.nlm.nih.gov/pubmed/34869464 KW - COVID-19 KW - cytokine storm KW - ARDS KW - CRRT KW - Cytosorb KW - hemoadsorption ER - TY - JOUR TI - A házi gondozók kihívásai a Covid19 első hulláma alatt AU - Patyán, László AU - Széman, Zsuzsa AU - Kostyál, László Árpád AU - Almási, Virág Erzsébet AU - Asztalos, Bernadett T2 - Esély AB - Jelen tanulmány azt vizsgálja, hogy milyen kihívásokkal szembesültek a házi gondozók a Covid19 világjárvány első hulláma alatt. A vizsgálat alapját egy online kérdőíves kutatás képezte, melyet 551 házi gondozó töltött ki. A cikkben a járványügyi szigorítások gondozókra gyakorolt hatását a változásra fókuszálva elemezzük a következő kutatási kérdések mentén: Milyen változásokat érzékeltek a gondozók feladataikban és gondozottjaik létszámában a járványügyi intézkedések bevezetése előtt és az azt követő hónap között? Milyen változást tapasztaltak a gondozáshoz kapott segítségben a pandémia kitörése előtt és a járvány első hulláma alatt? Hogyan változott a gondozók szubjektív leterheltsége és stressz-szintje? A vizsgálat főbb megállapításai: a gondozók több mint fele számolt be az ellátotti létszám csökkenéséről (27%) vagy növekedéséről (25%). A megkérdezettek 75%-a érezte úgy, hogy a járvány kitörése óta többlettevékenysége keletkezett, leginkább a szociális segítés (50%), a mentális támogatás (42%) és a gondozási tevékenységek (30%) területén. A gondozók több mint kétharmada jelentős stressz-szintemelkedést érzékelt a veszélyhelyzet kihirdetése előttihez képest. Feladataik ellátáshoz a veszélyhelyzet kihirdetése előtt és utána is a legtöbb segítséget a kollégáiktól (80%) és a gondozottak családjaitól (50% körül) kapták a válaszadók. DA - 2021/// PY - 2021 DO - 10.48007/esely.2021.3.4 VL - 32 IS - 3 SP - 59 EP - 74 LA - magyar SN - 0865-0810 KW - járvány KW - koronavírus ER - TY - JOUR TI - The diagnostic performance of deep-learning-based CT severity score to identify COVID-19 pneumonia AU - Kardos, Anna Sára AU - Simon, Judit AU - Nardocci, Chiara AU - Szabó, István Viktor AU - Nagy, Norbert AU - Abdelrahman, Renad Heyam AU - Zsarnóczay, Emese AU - Fejér, Bence AU - Futácsi, Balázs AU - Müller, Veronika AU - Merkely, Béla AU - Maurovich-Horvat, Pál T2 - The British Journal of Radiology AB - Objective: To determine the diagnostic accuracy of a deep-learning (DL)-based algorithm using chest computed tomography (CT) scans for the rapid diagnosis of coronavirus disease 2019 (COVID-19), as compared to the reference standard reverse-transcription polymerase chain reaction (RT-PCR) test. Methods: In this retrospective analysis, data of COVID-19 suspected patients who underwent RT-PCR and chest CT examination for the diagnosis of COVID-19 were assessed. By quantifying the affected area of the lung parenchyma, severity score was evaluated for each lobe of the lung with the DL-based algorithm. The diagnosis was based on the total lung severity score ranging from 0 to 25. The data were randomly split into a 40% training set and a 60% test set. Optimal cut-off value was determined using Youden-index method on the training cohort. Results: A total of 1259 patients were enrolled in this study. The prevalence of RT-PCR positivity in the overall investigated period was 51.5%. As compared to RT-PCR, sensitivity, specificity, positive predictive value, negative predictive value and accuracy on the test cohort were 39.0%, 80.2%, 68.0%, 55.0% and 58.9%, respectively. Regarding the whole data set, when adding those with positive RT-PCR test at any time during hospital stay or “COVID-19 without virus detection”, as final diagnosis to the true positive cases, specificity increased from 80.3% to 88.1% and the positive predictive value increased from 68.4% to 81.7%. Conclusion: DL-based CT severity score was found to have a good specificity and positive predictive value, as compared to RT-PCR. This standardized scoring system can aid rapid diagnosis and clinical decision making. Advances in knowledge: DL-based CT severity score can detect COVID-19-related lung alterations even at early stages, when RT-PCR is not yet positive. DA - 2022/01/01/ PY - 2022 DO - 10.1259/bjr.20210759 DP - DOI.org (Crossref) VL - 95 IS - 1129 SP - 20210759 J2 - BJR LA - en SN - 0007-1285, 1748-880X UR - https://www.birpublications.org/doi/10.1259/bjr.20210759 Y2 - 2021/12/11/12:05:24 ER - TY - JOUR TI - A poszt-COVID-szindróma gasztroenterológiai vonatkozásai AU - Csontos, Ágnes Anna T2 - Central European Journal of Gastroenterology and Hepatology AB - A SARS-CoV-2-fertőzés gyakran érinti a gasztrointesztinális traktust. A szisztémás és emésztőrendszeri tünetek (étvágytalanság, hányás, hasmenés) fokozott rizikót jelentenek a malnutríció, sarcopenia kialakulására, amelyek akár döntően befolyásolhatják a betegség lefolyását. A fertőzés kezdetétől számított négy hétnél tovább elhúzódó maradványtüneteket poszt-COVID-szindrómának nevezzük. A gyomor-bél rendszeri tünetek háttere máig nem teljesen feltérképezett, kihívást jelent a beteg és az egészségügyi rendszer számára. DA - 2021/// PY - 2021 VL - 7 IS - 3 SP - 128 EP - 130 LA - magyar SN - 2415-9107 KW - járvány KW - koronavírus ER - TY - JOUR TI - A COVID-19-fertőzések lehetséges szövődményei AU - Nagy, Zoltán Zsolt T2 - Szemészet DA - 2021/// PY - 2021 VL - 158 IS - 3 SP - 149 EP - 151 LA - magyar SN - 0039-8101 KW - járvány KW - koronavírus ER - TY - JOUR TI - Molecular interactions in remdesivir-cyclodextrin systems AU - Várnai, Bianka AU - Malanga, Milo AU - Sohajda, Tamás AU - Béni, Szabolcs T2 - Journal of Pharmaceutical and Biomedical Analysis AB - Remdesivir (REM) is the first antiviral drug (Veklury™) approved by the Food and Drug Administration for the therapy of COVID-19. Due to its poor water solubility, the preparation of Veklury™ requires a suitable solubilizing excipient at pH 2 conditions. For this purpose, the final formulation contains the randomly substituted sulfobutylether-β-cyclodextrin (SBEβCD) as a complexing agent. Herein, extensive NMR spectroscopic study with various cyclodextrin (CD) derivatives were conducted to understand the interactions in SBEβCD - REM systems at the molecular level. The pKa value of REM has been determined experimentally for the first time, as the protonation state of the aminopyrrolo-triazine moiety can play a key role in CD-REM inclusion complex formation as SBEβCD has permanent negative charges. The UV-pH titration experiments yielded a pKa of 3.56, thus the majority of REM bears a positive charge at pH 2.0. NMR experiments were performed on β- and γCD derivatives to determine complex stabilities, stoichiometries and structures. The stability constants were determined by nonlinear curve fitting based on 1H NMR titrations at pH 2.0, while Job's method was used to determine the stoichiometries. βCD complexes were one order of magnitude more stable than their γCD counterparts. Sulfobutylation resulted in a significant increase in stability and the single isomer derivatives showed unexpectedly high stability values (logK = 4.35 for REM - per-6-SBEβCD). In the case of βCDs, the ethylbutyl-moiety plays a key role in complexation immersing into the βCD cavity, while the phenoxy-moiety overtakes and drives the inclusion of REM in the case of γCDs. This is the first comprehensive study of REM-CD complexation, allowing the design of new CD derivatives with tailored stabilities, thereby aiding the formulation or production and even the analytical characterization of REM. DA - 2022/02/05/ PY - 2022 DO - 10.1016/j.jpba.2021.114482 DP - PubMed VL - 209 SP - 114482 J2 - J Pharm Biomed Anal LA - eng SN - 1873-264X L2 - http://www.ncbi.nlm.nih.gov/pubmed/34856493 KW - Complexation KW - NMR KW - pK(a) value KW - Stability constant KW - Sulfobutylated-cyclodextrin KW - Veklury ER - TY - JOUR TI - Natural Compounds as Target Biomolecules in Cellular Adhesion and Migration: From Biomolecular Stimulation to Label-Free Discovery and Bioactivity-Based Isolation AU - Péter, Beatrix AU - Boldizsár, Imre AU - Kovács, Gábor M. AU - Erdei, Anna AU - Bajtay, Zsuzsa AU - Vörös, Alexandra AU - Ramsden, Jeremy J. AU - Szabó, Ildikó AU - Bősze, Szilvia AU - Horvath, Robert T2 - Biomedicines AB - Plants and fungi can be used for medical applications because of their accumulation of special bioactive metabolites. These substances might be beneficial to human health, exerting also anti-inflammatory and anticancer (antiproliferative) effects. We propose that they are mediated by influencing cellular adhesion and migration via various signaling pathways and by directly inactivating key cell adhesion surface receptor sites. The evidence for this proposition is reviewed (by summarizing the natural metabolites and their effects influencing cellular adhesion and migration), along with the classical measuring techniques used to gain such evidence. We systematize existing knowledge concerning the mechanisms of how natural metabolites affect adhesion and movement, and their role in gene expression as well. We conclude by highlighting the possibilities to screen natural compounds faster and more easily by applying new label-free methods, which also enable a far greater degree of quantification than the conventional methods used hitherto. We have systematically classified recent studies regarding the effects of natural compounds on cellular adhesion and movement, characterizing the active substances according to their organismal origin (plants, animals or fungi). Finally, we also summarize the results of recent studies and experiments on SARS-CoV-2 treatments by natural extracts affecting mainly the adhesion and entry of the virus. DA - 2021/11/26/ PY - 2021 DO - 10.3390/biomedicines9121781 DP - DOI.org (Crossref) VL - 9 IS - 12 SP - 1781 J2 - Biomedicines LA - en SN - 2227-9059 ST - Natural Compounds as Target Biomolecules in Cellular Adhesion and Migration UR - https://www.mdpi.com/2227-9059/9/12/1781 Y2 - 2021/12/11/13:30:41 L1 - https://www.mdpi.com/2227-9059/9/12/1781/pdf ER - TY - JOUR TI - Telefonos krízisintervenció Covid-19-világjárvány idején AU - Tóth, Mónika Ditta T2 - Lege Artis Medicinae DA - 2021/// PY - 2021 DO - 10.33616/lam.31.032 DP - DOI.org (Crossref) VL - 31 IS - 10 SP - 433 EP - 438 J2 - LAM SN - 08664811, 20634161 UR - https://elitmed.hu/en/publications/lege-artis-medicinae/telephone-hotline-crisis-intervention-during-the-covid-19-pandemic Y2 - 2021/12/22/09:57:31 ER - TY - JOUR TI - Mental Health and Adherence to COVID-19 Protective Behaviors among Cancer Patients during the COVID-19 Pandemic: An International, Multinational Cross-Sectional Study AU - Kassianos, Angelos P. AU - Georgiou, Alexandros AU - Kyprianidou, Maria AU - Lamnisos, Demetris AU - Ļubenko, Jeļena AU - Presti, Giovambattista AU - Squatrito, Valeria AU - Constantinou, Marios AU - Nicolaou, Christiana AU - Papacostas, Savvas AU - Aydin, Gökçen AU - Chong, Yuen Yu AU - Chien, Wai Tong AU - Cheng, Ho Yu AU - Ruiz, Francisco J. AU - Garcia-Martin, Maria B. AU - Obando, Diana AU - Segura-Vargas, Miguel A. AU - Vasiliou, Vasilis S. AU - McHugh, Louise AU - Höfer, Stefan AU - Baban, Adriana AU - Neto, David Dias AU - Silva, Ana Nunes da AU - Monestès, Jean-Louis AU - Alvarez-Galvez, Javier AU - Blarrina, Marisa Paez AU - Montesinos, Francisco AU - Salas, Sonsoles Valdivia AU - Őri, Dorottya AU - Kleszcz, Bartosz AU - Lappalainen, Raimo AU - Ivanović, Iva AU - Gosar, David AU - Dionne, Frederick AU - Merwin, Rhonda M. AU - Chatzittofis, Andreas AU - Konstantinou, Evangelia AU - Economidou, Sofia AU - Gloster, Andrew T. AU - Karekla, Maria AU - Constantinidou, Anastasia T2 - Cancers AB - A population-based cross-sectional study was conducted during the first COVID-19 wave, to examine the impact of COVID-19 on mental health using an anonymous online survey, enrolling 9565 individuals in 78 countries. The current sub-study examined the impact of the pandemic and the associated lockdown measures on the mental health, and protective behaviors of cancer patients in comparison to non-cancer participants. Furthermore, 264 participants from 30 different countries reported being cancer patients. The median age was 51.5 years, 79.9% were female, and 28% had breast cancer. Cancer participants reported higher self-efficacy to follow recommended national guidelines regarding COVID-19 protective behaviors compared to non-cancer participants (p < 0.01). They were less stressed (p < 0.01), more psychologically flexible (p < 0.01), and had higher levels of positive affect compared to non-cancer participants. Amongst cancer participants, the majority (80.3%) reported COVID-19, not their cancer, as their priority during the first wave of the pandemic and females reported higher levels of stress compared to males. In conclusion, cancer participants appeared to have handled the unpredictable nature of the first wave of the pandemic efficiently, with a positive attitude towards an unknown and otherwise frightening situation. Larger, cancer population specific and longitudinal studies are warranted to ensure adequate medical and psychological care for cancer patients. DA - 2021/12/15/ PY - 2021 DO - 10.3390/cancers13246294 DP - DOI.org (Crossref) VL - 13 IS - 24 SP - 6294 J2 - Cancers LA - en SN - 2072-6694 ST - Mental Health and Adherence to COVID-19 Protective Behaviors among Cancer Patients during the COVID-19 Pandemic UR - https://www.mdpi.com/2072-6694/13/24/6294 Y2 - 2021/12/22/10:00:30 L1 - https://www.mdpi.com/2072-6694/13/24/6294/pdf ER - TY - JOUR TI - To PEGylate or not to PEGylate: Immunological properties of nanomedicine's most popular component, polyethylene glycol and its alternatives AU - Shi, Da AU - Beasock, Damian AU - Fessler, Adam AU - Szebeni, Janos AU - Ljubimova, Julia Y. AU - Afonin, Kirill A. AU - Dobrovolskaia, Marina A. T2 - Advanced Drug Delivery Reviews AB - Polyethylene glycol or PEG has a long history of use in medicine. Many conventional formulations utilize PEG as either an active ingredient or an excipient. PEG found its use in biotechnology therapeutics as a tool to slow down drug clearance and shield protein therapeutics from undesirable immunogenicity. Nanotechnology field applies PEG to create stealth drug carriers with prolonged circulation time and decreased recognition and clearance by the mononuclear phagocyte system (MPS). Most nanomedicines approved for clinical use and experimental nanotherapeutics contain PEG. Among the most recent successful examples are two mRNA-based COVID-19 vaccines that are delivered by PEGylated lipid nanoparticles. The breadth of PEG use in a wide variety of over the counter (OTC) medications as well as in drug products and vaccines stimulated research which uncovered that PEG is not as immunologically inert as it was initially expected. Herein, we review the current understanding of PEG's immunological properties and discuss them in the context of synthesis, biodistribution, safety, efficacy, and characterization of PEGylated nanomedicines. We also review the current knowledge about immunological compatibility of other polymers that are being actively investigated as PEG alternatives. DA - 2022/01// PY - 2022 DO - 10.1016/j.addr.2021.114079 DP - PubMed VL - 180 SP - 114079 J2 - Adv Drug Deliv Rev LA - eng SN - 1872-8294 ST - To PEGylate or not to PEGylate L2 - http://www.ncbi.nlm.nih.gov/pubmed/34902516 KW - Poly(ethylene)glycol, PEG, immunogenicity, immunology, nanomedicine, toxicity, anti-PEG antibodies, hypersensitivity, synthesis, drug delivery, biotherapeutics ER - TY - JOUR TI - Az izraeli Dietetikai Szövetség ajánlásának magyar adaptációja: a kritikus állapotú, gépi lélegeztetett betegek táplálásáról a COVID-19 világjárvány alatt : Táplálási Ajánlások Dietetikusok részére : 1. rész AU - Kovács, Andrea AU - Veresné Bálint, Márta T2 - Új Diéta DA - 2021/// PY - 2021 VL - 30 IS - 4 SP - 2 EP - 5 LA - magyar SN - 1587-169X KW - járvány KW - koronavírus ER - TY - JOUR TI - Hyperinflammatio és modulációja kritikus állapotú Covid-betegekben AU - Zádori, Noémi AU - Molnár, Zsolt T2 - Lege Artis Medicinae DA - 2021/// PY - 2021 DO - 10.33616/lam.31.031 DP - DOI.org (Crossref) VL - 31 IS - 10 SP - 423 EP - 431 J2 - LAM SN - 08664811, 20634161 UR - https://elitmed.hu/en/publications/lege-artis-medicinae/hyperinflammation-and-its-modulation-in-critically-ill-covid-19-patients Y2 - 2022/01/07/09:01:05 ER - TY - JOUR TI - Challenges posed by COVID-19 in cancer patients: A narrative review AU - Mohseni Afshar, Zeinab AU - Hosseinzadeh, Rezvan AU - Barary, Mohammad AU - Ebrahimpour, Soheil AU - Alijanpour, Amirmasoud AU - Sayad, Babak AU - Hosseinzadeh, Dariush AU - Miri, Seyed Rouhollah AU - Sio, Terence T. AU - Sullman, Mark J. M. AU - Carson-Chahhoud, Kristin AU - Babazadeh, Arefeh T2 - Cancer Medicine AB - A novel coronavirus, or severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was identified as the causative agent of coronavirus disease 2019 (COVID-19). In early 2020, the World Health Organization declared COVID-19 the sixth public health emergency of international concern. The COVID-19 pandemic has substantially affected many groups within the general population, but particularly those with extant clinical conditions, such as having or being treated for cancer. Cancer patients are at a higher risk of developing severe COVID-19 since the malignancy and chemotherapy may negatively affect the immune system, and their immunocompromised condition also increases the risk of infection. Substantial international efforts are currently underway to develop specific methods for diagnosing and treating COVID-19. However, cancer patients' risk profiles, management, and outcomes are not well understood. Thus, the main objective of this review is to discuss the relevant evidence to understand the prognosis of COVID-19 infections in cancer patients more clearly, as well as helping to improve the clinical management of these patients. DA - 2022/02// PY - 2022 DO - 10.1002/cam4.4519 DP - PubMed VL - 11 IS - 4 SP - 1119 EP - 1135 J2 - Cancer Med LA - eng SN - 2045-7634 ST - Challenges posed by COVID-19 in cancer patients L1 - https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cam4.4519 L2 - http://www.ncbi.nlm.nih.gov/pubmed/34951152 KW - COVID-19 KW - SARS-CoV-2 KW - cancer KW - immunodeficiency ER - TY - JOUR TI - The collaborative outcomes study on health and functioning during infection times in adults (COH-FIT-Adults): Design and methods of an international online survey targeting physical and mental health effects of the COVID-19 pandemic AU - Solmi, Marco AU - Estradé, Andrés AU - Thompson, Trevor AU - Agorastos, Agorastos AU - Radua, Joaquim AU - Cortese, Samuele AU - Dragioti, Elena AU - Leisch, Friedrich AU - Vancampfort, Davy AU - Thygesen, Lau Caspar AU - Aschauer, Harald AU - Schloegelhofer, Monika AU - Akimova, Elena AU - Schneeberger, Andres AU - Huber, Christian G. AU - Hasler, Gregor AU - Conus, Philippe AU - Cuénod, Kim Q. Do AU - von Känel, Roland AU - Arrondo, Gonzalo AU - Fusar-Poli, Paolo AU - Gorwood, Philip AU - Llorca, Pierre-Michel AU - Krebs, Marie-Odile AU - Scanferla, Elisabetta AU - Kishimoto, Taishiro AU - Rabbani, Golam AU - Skonieczna-Żydecka, Karolina AU - Brambilla, Paolo AU - Favaro, Angela AU - Takamiya, Akihiro AU - Zoccante, Leonardo AU - Colizzi, Marco AU - Bourgin, Julie AU - Kamiński, Karol AU - Moghadasin, Maryam AU - Seedat, Soraya AU - Matthews, Evan AU - Wells, John AU - Vassilopoulou, Emilia AU - Gadelha, Ary AU - Su, Kuan-Pin AU - Kwon, Jun Soo AU - Kim, Minah AU - Lee, Tae Young AU - Papsuev, Oleg AU - Manková, Denisa AU - Boscutti, Andrea AU - Gerunda, Cristiano AU - Saccon, Diego AU - Righi, Elena AU - Monaco, Francesco AU - Croatto, Giovanni AU - Cereda, Guido AU - Demurtas, Jacopo AU - Brondino, Natascia AU - Veronese, Nicola AU - Enrico, Paolo AU - Politi, Pierluigi AU - Ciappolino, Valentina AU - Pfennig, Andrea AU - Bechdolf, Andreas AU - Meyer-Lindenberg, Andreas AU - Kahl, Kai G. AU - Domschke, Katharina AU - Bauer, Michael AU - Koutsouleris, Nikolaos AU - Winter, Sibylle AU - Borgwardt, Stefan AU - Bitter, Istvan AU - Balazs, Judit AU - Czobor, Pal AU - Unoka, Zsolt AU - Mavridis, Dimitris AU - Tsamakis, Konstantinos AU - Bozikas, Vasilios P. AU - Tunvirachaisakul, Chavit AU - Maes, Michael AU - Rungnirundorn, Teerayuth AU - Supasitthumrong, Thitiporn AU - Haque, Ariful AU - Brunoni, Andre R. AU - Costardi, Carlos Gustavo AU - Schuch, Felipe Barreto AU - Polanczyk, Guilherme AU - Luiz, Jhoanne Merlyn AU - Fonseca, Lais AU - Aparicio, Luana V. AU - Valvassori, Samira S. AU - Nordentoft, Merete AU - Vendsborg, Per AU - Hoffmann, Sofie Have AU - Sehli, Jihed AU - Sartorius, Norman AU - Heuss, Sabina AU - Guinart, Daniel AU - Hamilton, Jane AU - Kane, John AU - Rubio, Jose AU - Sand, Michael AU - Koyanagi, Ai AU - Solanes, Aleix AU - Andreu-Bernabeu, Alvaro AU - Cáceres, Antonia San José AU - Arango, Celso AU - Díaz-Caneja, Covadonga M. AU - Hidalgo-Mazzei, Diego AU - Vieta, Eduard AU - Gonzalez-Peñas, Javier AU - Fortea, Lydia AU - Parellada, Mara AU - Fullana, Miquel A. AU - Verdolini, Norma AU - Fárková, Eva AU - Janků, Karolina AU - Millan, Mark AU - Honciuc, Mihaela AU - Moniuszko-Malinowska, Anna AU - Łoniewski, Igor AU - Samochowiec, Jerzy AU - Kiszkiel, Łukasz AU - Marlicz, Maria AU - Sowa, Paweł AU - Marlicz, Wojciech AU - Spies, Georgina AU - Stubbs, Brendon AU - Firth, Joseph AU - Sullivan, Sarah AU - Darcin, Asli Enez AU - Aksu, Hatice AU - Dilbaz, Nesrin AU - Noyan, Onur AU - Kitazawa, Momoko AU - Kurokawa, Shunya AU - Tazawa, Yuki AU - Anselmi, Alejandro AU - Cracco, Cecilia AU - Machado, Ana Inés AU - Estrade, Natalia AU - De Leo, Diego AU - Curtis, Jackie AU - Berk, Michael AU - Ward, Philip AU - Teasdale, Scott AU - Rosenbaum, Simon AU - Marx, Wolfgang AU - Horodnic, Adrian Vasile AU - Oprea, Liviu AU - Alexinschi, Ovidiu AU - Ifteni, Petru AU - Turliuc, Serban AU - Ciuhodaru, Tudor AU - Bolos, Alexandra AU - Matei, Valentin AU - Nieman, Dorien H. AU - Sommer, Iris AU - van Os, Jim AU - van Amelsvoort, Therese AU - Sun, Ching-Fang AU - Guu, Ta-Wei AU - Jiao, Can AU - Zhang, Jieting AU - Fan, Jialin AU - Zou, Liye AU - Yu, Xin AU - Chi, Xinli AU - de Timary, Philippe AU - van Winke, Ruud AU - Ng, Bernardo AU - Pena, Edilberto AU - Arellano, Ramon AU - Roman, Raquel AU - Sanchez, Thelma AU - Movina, Larisa AU - Morgado, Pedro AU - Brissos, Sofia AU - Aizberg, Oleg AU - Mosina, Anna AU - Krinitski, Damir AU - Mugisha, James AU - Sadeghi-Bahmani, Dena AU - Sadeghi, Masoud AU - Hadi, Samira AU - Brand, Serge AU - Errazuriz, Antonia AU - Crossley, Nicolas AU - Ristic, Dragana Ignjatovic AU - López-Jaramillo, Carlos AU - Efthymiou, Dimitris AU - Kuttichira, Praveenlal AU - Kallivayalil, Roy Abraham AU - Javed, Afzal AU - Afridi, Muhammad Iqbal AU - James, Bawo AU - Seb-Akahomen, Omonefe Joy AU - Fiedorowicz, Jess AU - Carvalho, Andre F. AU - Daskalakis, Jeff AU - Yatham, Lakshmi N. AU - Yang, Lin AU - Okasha, Tarek AU - Dahdouh, Aïcha AU - Gerdle, Björn AU - Tiihonen, Jari AU - Shin, Jae Il AU - Lee, Jinhee AU - Mhalla, Ahmed AU - Gaha, Lotfi AU - Brahim, Takoua AU - Altynbekov, Kuanysh AU - Negay, Nikolay AU - Nurmagambetova, Saltanat AU - Jamei, Yasser Abu AU - Weiser, Mark AU - Correll, Christoph U. T2 - Journal of Affective Disorders AB - BACKGROUND: . High-quality comprehensive data on short-/long-term physical/mental health effects of the COVID-19 pandemic are needed. METHODS: . The Collaborative Outcomes study on Health and Functioning during Infection Times (COH-FIT) is an international, multi-language (n=30) project involving >230 investigators from 49 countries/territories/regions, endorsed by national/international professional associations. COH-FIT is a multi-wave, on-line anonymous, cross-sectional survey [wave 1: 04/2020 until the end of the pandemic, 12 months waves 2/3 starting 6/24 months threreafter] for adults, adolescents (14-17), and children (6-13), utilizing non-probability/snowball and representative sampling. COH-FIT aims to identify non-modifiable/modifiable risk factors/treatment targets to inform prevention/intervention programs to improve social/health outcomes in the general population/vulnerable subgrous during/after COVID-19. In adults, co-primary outcomes are change from pre-COVID-19 to intra-COVID-19 in well-being (WHO-5) and a composite psychopathology P-Score. Key secondary outcomes are a P-extended score, global mental and physical health. Secondary outcomes include health-service utilization/functioning, treatment adherence, functioning, symptoms/behaviors/emotions, substance use, violence, among others. RESULTS: . Starting 04/26/2020, up to 14/07/2021 >151,000 people from 155 countries/territories/regions and six continents have participated. Representative samples of ≥1,000 adults have been collected in 15 countries. Overall, 43.0% had prior physical disorders, 16.3% had prior mental disorders, 26.5% were health care workers, 8.2% were aged ≥65 years, 19.3% were exposed to someone infected with COVID-19, 76.1% had been in quarantine, and 2.1% had been COVID 19-positive. LIMITATIONS: . Cross-sectional survey, preponderance of non-representative participants. CONCLUSIONS: . Results from COH-FIT will comprehensively quantify the impact of COVID-19, seeking to identify high-risk groups in need for acute and long-term intervention, and inform evidence-based health policies/strategies during this/future pandemics. DA - 2022/02// PY - 2022 DO - 10.1016/j.jad.2021.07.048 DP - PubMed VL - 299 SP - 393 EP - 407 J2 - J Affect Disord LA - eng SN - 1573-2517 ST - The collaborative outcomes study on health and functioning during infection times in adults (COH-FIT-Adults) L1 - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8288233/pdf/main.pdf L2 - http://www.ncbi.nlm.nih.gov/pubmed/34949568 KW - COVID-19 KW - depression KW - children KW - survey KW - mental health KW - resilience KW - adolescents KW - adults KW - anxiety KW - COH-FIT KW - functioning KW - international KW - physical health KW - post-traumatic KW - psychiatry KW - representative KW - well-being ER - TY - JOUR TI - Comparison of hesitancy between COVID-19 and seasonal influenza vaccinations within the general Hungarian population: a cross-sectional study AU - Dombrádi, Viktor AU - Joó, Tamás AU - Palla, Gergely AU - Pollner, Péter AU - Belicza, Éva T2 - BMC public health AB - BACKGROUND: The willingness to get COVID-19 or seasonal influenza vaccines has not yet been thoroughly investigated together, thus, this study aims to explore this notion within the general adult population. METHODS: The responses of 840 Hungarian participants were analysed who took part in a nationwide computer-assisted telephone interviewing. During the survey questions concerning various demographic characteristics, perceived financial status, and willingness to get the two types of vaccines were asked. Descriptive statistics, comparative statistics and word co-occurrence network analysis were conducted. RESULTS: 48.2% of participants were willing to get a COVID-19 vaccine, while this ratio for the seasonal influenza was only 25.7%. The difference was significant. Regardless of how the participants were grouped, based on demographic data or perceived financial status, the significant difference always persisted. Being older than 59 years significantly increased the willingness to get both vaccines when compared to the middle-aged groups, but not when compared to the younger ones. Having higher education significantly elevated the acceptance of COVID-19 vaccination in comparison to secondary education. The willingness of getting any type of COVID-19 vaccine correlated with the willingness to get both influenza and COVID-19. Finally, those who were willing to get either vaccine coupled similar words together to describe their thoughts about a COVID-19 vaccination. CONCLUSION: The overall results show a clear preference for a COVID-19 vaccine and there are several similarities between the nature of willingness to get either type of vaccine. DA - 2021/12/23/ PY - 2021 DO - 10.1186/s12889-021-12386-0 DP - PubMed VL - 21 IS - 1 SP - 2317 J2 - BMC Public Health LA - eng SN - 1471-2458 ST - Comparison of hesitancy between COVID-19 and seasonal influenza vaccinations within the general Hungarian population L1 - https://bmcpublichealth.biomedcentral.com/track/pdf/10.1186/s12889-021-12386-0 L2 - http://www.ncbi.nlm.nih.gov/pubmed/34949176 KW - Adult KW - Humans KW - COVID-19 KW - SARS-CoV-2 KW - Middle Aged KW - Cross-Sectional Studies KW - COVID-19 Vaccines KW - Vaccination KW - Hungary KW - Hesitancy KW - Influenza KW - Influenza Vaccines KW - Influenza, Human KW - Population KW - Seasons ER - TY - JOUR TI - Physical and mental health impact of COVID-19 on children, adolescents, and their families: The Collaborative Outcomes study on Health and Functioning during Infection Times - Children and Adolescents (COH-FIT-C&A) AU - Solmi, Marco AU - Estradé, Andrés AU - Thompson, Trevor AU - Agorastos, Agorastos AU - Radua, Joaquim AU - Cortese, Samuele AU - Dragioti, Elena AU - Leisch, Friedrich AU - Vancampfort, Davy AU - Thygesen, Lau Caspar AU - Aschauer, Harald AU - Schloegelhofer, Monika AU - Akimova, Elena AU - Schneeberger, Andres AU - Huber, Christian G. AU - Hasler, Gregor AU - Conus, Philippe AU - Cuénod, Kim Q. Do AU - von Känel, Roland AU - Arrondo, Gonzalo AU - Fusar-Poli, Paolo AU - Gorwood, Philip AU - Llorca, Pierre-Michel AU - Krebs, Marie-Odile AU - Scanferla, Elisabetta AU - Kishimoto, Taishiro AU - Rabbani, Golam AU - Skonieczna-Żydecka, Karolina AU - Brambilla, Paolo AU - Favaro, Angela AU - Takamiya, Akihiro AU - Zoccante, Leonardo AU - Colizzi, Marco AU - Bourgin, Julie AU - Kamiński, Karol AU - Moghadasin, Maryam AU - Seedat, Soraya AU - Matthews, Evan AU - Wells, John AU - Vassilopoulou, Emilia AU - Gadelha, Ary AU - Su, Kuan-Pin AU - Kwon, Jun Soo AU - Kim, Minah AU - Lee, Tae Young AU - Papsuev, Oleg AU - Manková, Denisa AU - Boscutti, Andrea AU - Gerunda, Cristiano AU - Saccon, Diego AU - Righi, Elena AU - Monaco, Francesco AU - Croatto, Giovanni AU - Cereda, Guido AU - Demurtas, Jacopo AU - Brondino, Natascia AU - Veronese, Nicola AU - Enrico, Paolo AU - Politi, Pierluigi AU - Ciappolino, Valentina AU - Pfennig, Andrea AU - Bechdolf, Andreas AU - Meyer-Lindenberg, Andreas AU - Kahl, Kai G. AU - Domschke, Katharina AU - Bauer, Michael AU - Koutsouleris, Nikolaos AU - Winter, Sibylle AU - Borgwardt, Stefan AU - Bitter, Istvan AU - Balazs, Judit AU - Czobor, Pal AU - Unoka, Zsolt AU - Mavridis, Dimitris AU - Tsamakis, Konstantinos AU - Bozikas, Vasilios P. AU - Tunvirachaisakul, Chavit AU - Maes, Michael AU - Rungnirundorn, Teerayuth AU - Supasitthumrong, Thitiporn AU - Haque, Ariful AU - Brunoni, Andre R. AU - Costardi, Carlos Gustavo AU - Schuch, Felipe Barreto AU - Polanczyk, Guilherme AU - Luiz, Jhoanne Merlyn AU - Fonseca, Lais AU - Aparicio, Luana V. AU - Valvassori, Samira S. AU - Nordentoft, Merete AU - Vendsborg, Per AU - Hoffmann, Sofie Have AU - Sehli, Jihed AU - Sartorius, Norman AU - Heuss, Sabina AU - Guinart, Daniel AU - Hamilton, Jane AU - Kane, John AU - Rubio, Jose AU - Sand, Michael AU - Koyanagi, Ai AU - Solanes, Aleix AU - Andreu-Bernabeu, Alvaro AU - Cáceres, Antonia San José AU - Arango, Celso AU - Díaz-Caneja, Covadonga M. AU - Hidalgo-Mazzei, Diego AU - Vieta, Eduard AU - Gonzalez-Peñas, Javier AU - Fortea, Lydia AU - Parellada, Mara AU - Fullana, Miquel A. AU - Verdolini, Norma AU - Fárková, Eva AU - Janků, Karolina AU - Millan, Mark AU - Honciuc, Mihaela AU - Moniuszko-Malinowska, Anna AU - Łoniewski, Igor AU - Samochowiec, Jerzy AU - Kiszkiel, Łukasz AU - Marlicz, Maria AU - Sowa, Paweł AU - Marlicz, Wojciech AU - Spies, Georgina AU - Stubbs, Brendon AU - Firth, Joseph AU - Sullivan, Sarah AU - Darcin, Asli Enez AU - Aksu, Hatice AU - Dilbaz, Nesrin AU - Noyan, Onur AU - Kitazawa, Momoko AU - Kurokawa, Shunya AU - Tazawa, Yuki AU - Anselmi, Alejandro AU - Cracco, Cecilia AU - Machado, Ana Inés AU - Estrade, Natalia AU - De Leo, Diego AU - Curtis, Jackie AU - Berk, Michael AU - Ward, Philip AU - Teasdale, Scott AU - Rosenbaum, Simon AU - Marx, Wolfgang AU - Horodnic, Adrian Vasile AU - Oprea, Liviu AU - Alexinschi, Ovidiu AU - Ifteni, Petru AU - Turliuc, Serban AU - Ciuhodaru, Tudor AU - Bolos, Alexandra AU - Matei, Valentin AU - Nieman, Dorien H. AU - Sommer, Iris AU - van Os, Jim AU - van Amelsvoort, Therese AU - Sun, Ching-Fang AU - Guu, Ta-wei AU - Jiao, Can AU - Zhang, Jieting AU - Fan, Jialin AU - Zou, Liye AU - Yu, Xin AU - Chi, Xinli AU - de Timary, Philippe AU - van Winke, Ruud AU - Ng, Bernardo AU - Pena, Edilberto AU - Arellano, Ramon AU - Roman, Raquel AU - Sanchez, Thelma AU - Movina, Larisa AU - Morgado, Pedro AU - Brissos, Sofia AU - Aizberg, Oleg AU - Mosina, Anna AU - Krinitski, Damir AU - Mugisha, James AU - Sadeghi-Bahmani, Dena AU - Sadeghi, Masoud AU - Hadi, Samira AU - Brand, Serge AU - Errazuriz, Antonia AU - Crossley, Nicolas AU - Ristic, Dragana Ignjatovic AU - López-Jaramillo, Carlos AU - Efthymiou, Dimitris AU - Kuttichira, Praveenlal AU - Kallivayalil, Roy Abraham AU - Javed, Afzal AU - Afridi, Muhammad Iqbal AU - James, Bawo AU - Seb-Akahomen, Omonefe Joy AU - Fiedorowicz, Jess AU - Carvalho, Andre F. AU - Daskalakis, Jeff AU - Yatham, Lakshmi N. AU - Yang, Lin AU - Okasha, Tarek AU - Dahdouh, Aïcha AU - Gerdle, Björn AU - Tiihonen, Jari AU - Shin, Jae Il AU - Lee, Jinhee AU - Mhalla, Ahmed AU - Gaha, Lotfi AU - Brahim, Takoua AU - Altynbekov, Kuanysh AU - Negay, Nikolay AU - Nurmagambetova, Saltanat AU - Jamei, Yasser Abu AU - Weiser, Mark AU - Correll, Christoph U. T2 - Journal of Affective Disorders DA - 2022/02// PY - 2022 DO - 10.1016/j.jad.2021.09.090 DP - DOI.org (Crossref) VL - 299 SP - 367 EP - 376 J2 - Journal of Affective Disorders LA - en SN - 01650327 ST - Physical and mental health impact of COVID-19 on children, adolescents, and their families UR - https://linkinghub.elsevier.com/retrieve/pii/S0165032721010491 Y2 - 2022/01/07/09:16:10 L1 - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8486586/pdf/main.pdf ER - TY - JOUR TI - Diabetes and COVID-19: What 2 Years of the Pandemic Has Taught Us AU - Stoian, Anca Pantea AU - Kempler, Peter AU - Stulnig, Thomas AU - Rizvi, Ali A. AU - Rizzo, Manfredi T2 - Metabolic Syndrome and Related Disorders AB - As the world enters its third year of the COVID-19 pandemic, individuals with diabetes have faced particular challenges from the virus. A deleterious bidirectional relationship exists between the two disorders, with heightened inflammatory, immunologic, and cellular mechanisms leading to a more severe illness and increased morbidity and mortality. Tight glucose control, though necessary, is hampered by physical restrictions and difficulty accessing health care. Novel glucose-lowering medications may provide unique benefits in this regard. It is imperative that multi-pronged efforts be prioritized in order to reduce adverse outcomes in patients with diabetes at risk for COVID-19. DA - 2021/// PY - 2021 DO - 10.1089/met.2021.0133 DP - PubMed J2 - Metab Syndr Relat Disord LA - eng SN - 1557-8518 ST - Diabetes and COVID-19 L2 - http://www.ncbi.nlm.nih.gov/pubmed/34967689 KW - COVID-19 KW - cardiometabolic risk KW - complications KW - diabetes KW - obesity KW - treatment ER - TY - JOUR TI - Microsimulation based quantitative analysis of COVID-19 management strategies AU - Reguly, István Z. AU - Csercsik, Dávid AU - Juhász, János AU - Tornai, Kálmán AU - Bujtár, Zsófia AU - Horváth, Gergely AU - Keömley-Horváth, Bence AU - Kós, Tamás AU - Cserey, György AU - Iván, Kristóf AU - Pongor, Sándor AU - Szederkényi, Gábor AU - Röst, Gergely AU - Csikász-Nagy, Attila T2 - PLoS computational biology AB - Pandemic management requires reliable and efficient dynamical simulation to predict and control disease spreading. The COVID-19 (SARS-CoV-2) pandemic is mitigated by several non-pharmaceutical interventions, but it is hard to predict which of these are the most effective for a given population. We developed the computationally effective and scalable, agent-based microsimulation framework PanSim, allowing us to test control measures in multiple infection waves caused by the spread of a new virus variant in a city-sized societal environment using a unified framework fitted to realistic data. We show that vaccination strategies prioritising occupational risk groups minimise the number of infections but allow higher mortality while prioritising vulnerable groups minimises mortality but implies an increased infection rate. We also found that intensive vaccination along with non-pharmaceutical interventions can substantially suppress the spread of the virus, while low levels of vaccination, premature reopening may easily revert the epidemic to an uncontrolled state. Our analysis highlights that while vaccination protects the elderly from COVID-19, a large percentage of children will contract the virus, and we also show the benefits and limitations of various quarantine and testing scenarios. The uniquely detailed spatio-temporal resolution of PanSim allows the design and testing of complex, specifically targeted interventions with a large number of agents under dynamically changing conditions. DA - 2022/// PY - 2022 DO - 10.1371/journal.pcbi.1009693 DP - PubMed VL - 18 IS - 1 SP - e1009693 J2 - PLoS Comput Biol LA - eng SN - 1553-7358 L1 - https://journals.plos.org/ploscompbiol/article/file?id=10.1371/journal.pcbi.1009693&type=printable L2 - http://www.ncbi.nlm.nih.gov/pubmed/34982766 ER - TY - JOUR TI - Acute SARS-CoV-2 infection and seropositivity among healthcare workers and medical students in summer 2020, Hungary AU - Kosztin, Annamária AU - Merkely, Béla AU - Szabó, Attila J. AU - Blaha, Béla AU - Varga, Péter AU - Vásárhelyi, Barna AU - Vokó, Zoltán T2 - International Journal of Occupational Medicine and Environmental Health AB - OBJECTIVES: The aim was to compare the prevalence of acute infection and seropositivity of SARS-CoV-2 among healthcare workers (HCWs) and medical students. MATERIAL AND METHODS: A high-volume, single-center analysis was conducted in the period of July 1‒August 1, 2020, at the Semmelweis University. Naso- and oropharyngeal samples were collected for polymerase chain reaction (PCR), and blood samples for anti-SARS-CoV-2 IgG. A questionnaire was also administered about the infection symptoms and the obtained results were assessed by profession and site of care delivery. RESULTS: From the total cohort (N = 7948), 4478 (56%) and 3470 (44%) were health professionals and medical students, respectively. They were mainly female (67%), and the mean age of HCWs and students was 40 and 25 years, respectively. By profession, physicians (1.5%) and other HCWs (1.8%) showed a comparable SARS-CoV-2 exposure. International students had the highest (2.1%), whereas Hungarian students had the lowest (0.6%) prevalence of seropositivity. The highest prevalence was detected among the staff of COVID-19 wards (12.1%). By PCR, medical students showed the lowest occurrence of active infection with a prevalence of 0.17%, while physicians and other HCWs had a higher prevalence (1.46% and 1.71%, respectively). By site of care delivery, positive test results were the most frequent at COVID-19 wards (3.8%). CONCLUSIONS: Physicians and other HCWs showed comparable SARS-CoV-2 seropositivity prevalence, approximately twice as high as in the general population of Budapest. Hungarian students had lower prevalence of seropositivity than this reference. High prevalence among international students suggests that they had imported the infection. The very high prevalence of documented exposure among staff members at COVID-19 wards urges for improving the safety measures. DA - 2022/04/11/ PY - 2022 DO - 10.13075/ijomeh.1896.01804 DP - PubMed VL - 35 IS - 2 SP - 209 EP - 216 J2 - Int J Occup Med Environ Health LA - eng SN - 1896-494X L1 - http://ijomeh.eu/pdf-141614-70530?filename=Acute SARS_CoV_2.pdf L2 - http://www.ncbi.nlm.nih.gov/pubmed/34981793 KW - COVID-19 KW - healthcare workers KW - medical students KW - polymerase chain reaction KW - SARS-CoV-2 KW - seropositivity ER - TY - JOUR TI - Modeling of nursing care-associated airborne transmission of SARS-CoV-2 in a real-world hospital setting AU - Nagy, Attila AU - Horváth, Alpár AU - Farkas, Árpád AU - Füri, Péter AU - Erdélyi, Tamás AU - Madas, Balázs G. AU - Czitrovszky, Aladár AU - Merkely, Béla AU - Szabó, Attila AU - Ungvári, Zoltán AU - Müller, Veronika T2 - GeroScience AB - Respiratory transmission of SARS-CoV-2 from one older patient to another by airborne mechanisms in hospital and nursing home settings represents an important health challenge during the COVID-19 pandemic. However, the factors that influence the concentration of respiratory droplets and aerosols that potentially contribute to hospital- and nursing care-associated transmission of SARS-CoV-2 are not well understood. To assess the effect of health care professional (HCP) and patient activity on size and concentration of airborne particles, an optical particle counter was placed (for 24 h) in the head position of an empty bed in the hospital room of a patient admitted from the nursing home with confirmed COVID-19. The type and duration of the activity, as well as the number of HCPs providing patient care, were recorded. Concentration changes associated with specific activities were determined, and airway deposition modeling was performed using these data. Thirty-one activities were recorded, and six representative ones were selected for deposition modeling, including patient's activities (coughing, movements, etc.), diagnostic and therapeutic interventions (e.g., diagnostic tests and drug administration), as well as nursing patient care (e.g., bedding and hygiene). The increase in particle concentration of all sizes was sensitive to the type of activity. Increases in supermicron particle concentration were associated with the number of HCPs (r = 0.66; p < 0.05) and the duration of activity (r = 0.82; p < 0.05), while submicron particles increased with all activities, mainly during the daytime. Based on simulations, the number of particles deposited in unit time was the highest in the acinar region, while deposition density rate (number/cm2/min) was the highest in the upper airways. In conclusion, even short periods of HCP-patient interaction and minimal patient activity in a hospital room or nursing home bedroom may significantly increase the concentration of submicron particles mainly depositing in the acinar regions, while mainly nursing activities increase the concentration of supermicron particles depositing in larger airways of the adjacent bed patient. Our data emphasize the need for effective interventions to limit hospital- and nursing care-associated transmission of SARS-CoV-2 and other respiratory pathogens (including viral pathogens, such as rhinoviruses, respiratory syncytial virus, influenza virus, parainfluenza virus and adenoviruses, and bacterial and fungal pathogens). DA - 2022/// PY - 2022 DO - 10.1007/s11357-021-00512-0 DP - PubMed J2 - Geroscience LA - eng SN - 2509-2723 L1 - https://link.springer.com/content/pdf/10.1007/s11357-021-00512-0.pdf L2 - http://www.ncbi.nlm.nih.gov/pubmed/34985588 KW - SARS-CoV-2 KW - Aerosol dispersion KW - Aerosol measurement KW - Airborne transmission KW - Elderly KW - Lung deposition KW - Nursing ER - TY - JOUR TI - CytoSorb Therapy in COVID-19 (CTC) Patients Requiring Extracorporeal Membrane Oxygenation: A Multicenter, Retrospective Registry AU - Song, Tae AU - Hayanga, Jeremiah AU - Durham, Lucian AU - Garrison, Lawrence AU - McCarthy, Paul AU - Barksdale, Andy AU - Smith, Deane AU - Bartlett, Robert AU - Jaros, Mark AU - Nelson, Peter AU - Molnar, Zsolt AU - Deliargyris, Efthymios AU - Moazami, Nader T2 - Frontiers in Medicine AB - Introduction: CytoSorb extracorporeal blood purification therapy received FDA Emergency Use Authorization (EUA) to suppress hyperinflammation in critically ill COVID-19 patients. The multicenter CTC Registry was established to systematically collect patient-level data, outcomes, and utilization patterns of CytoSorb under the EUA. Methods: Patient-level data was entered retrospectively at participating centers. The primary outcome of the registry was ICU mortality. Patient disposition of death, continuing ICU care, or ICU discharge was analyzed up to Day 90 after start of CytoSorb therapy. Demographics, comorbidities, COVID-19 medications, inflammatory biomarkers, and details on CytoSorb use were compared between survivors and non-survivors in the veno-venous extracorporeal membrane oxygenation (ECMO) cohort. Results: Between April 2020 and April 2021, 52 patients received veno-venous ECMO plus CytoSorb therapy at 5 U.S. centers. ICU mortality was 17.3% (9/52) on day 30, 26.9% (14/52) on day 90, and 30.8% (16/52) at final follow-up of 153 days. Survivors had a trend toward lower baseline D-Dimer levels (2.3 ± 2.5 vs. 19.8 ± 32.2 μg/mL, p = 0.056) compared to non-survivors. A logistic regression analysis suggested a borderline association between baseline D-Dimer levels and mortality with a 32% increase in the risk of death per 1 μg/mL increase (p = 0.055). CytoSorb was well-tolerated without any device-related adverse events reported. Conclusions: CytoSorb therapy for critically ill COVID-19 patients on ECMO was associated with high survival rates suggesting potential therapeutic benefit. Elevated baseline D-Dimer levels may suggest increased risk of mortality. Prospective controlled studies are warranted to substantiate these results. Clinical Trial Registration: https://clinicaltrials.gov/ct2/show/NCT0439192, identifier: NCT04391920. DA - 2021/// PY - 2021 DO - 10.3389/fmed.2021.773461 DP - PubMed VL - 8 SP - 773461 J2 - Front Med (Lausanne) LA - eng SN - 2296-858X ST - CytoSorb Therapy in COVID-19 (CTC) Patients Requiring Extracorporeal Membrane Oxygenation L1 - https://www.frontiersin.org/articles/10.3389/fmed.2021.773461/pdf L2 - http://www.ncbi.nlm.nih.gov/pubmed/34988092 KW - mortality KW - inflammation KW - coronavirus–COVID-19 KW - CytoSorb KW - ECMO–extracorporeal membrane oxygenation KW - hemoabsorption KW - hemoperfusion KW - ICU–intensive care unit ER - TY - JOUR TI - COVID-19: a trigger for severe thrombotic microangiopathy in a patient with complement gene variant AU - Pinte, Larisa AU - Sorohan, Bogdan Marian AU - Prohászka, Zoltán AU - Gherghiceanu, Mihaela AU - Băicuş, Cristian T2 - Romanian Journal of Internal Medicine = Revue Roumaine De Medecine Interne AB - The evidence regarding thrombotic microangiopathy (TMA) related to Coronavirus Infectious Disease 2019 (COVID-19) in patients with complement gene mutations as a cause of acute kidney injury (AKI) are limited. We presented a case of a 23-year-old male patient admitted with an asymptomatic form of COVID-19, but with uncontrolled hypertension and AKI. Kidney biopsy showed severe lesions of TMA. In evolution patient had persistent microangiopathic hemolytic anemia, decreased level of haptoglobin and increased LDH level. Decreased complement C3 level and the presence of schistocytes were found for the first time after biopsy. Kidney function progressively decreased and the patient remained hemodialysis dependent. Complement work-up showed a heterozygous variant with unknown significance in complement factor I (CFI) c.-13G>A, affecting the 5' UTR region of the gene. In addition, the patient was found to be heterozygous for the complement factor H (CFH) H3 haplotype (involving the rare alleles of c.-331C>T, Q672Q and E936D polymorphisms) reported as a risk factor of atypical hemolytic uremic syndrome. This case of AKI associated with severe TMA and secondary hemolytic uremic syndrome highlights the importance of genetic risk modifiers in the alternative pathway dysregulation of the complement in the setting of COVID-19, even in asymptomatic forms. DA - 2022/// PY - 2022 DO - 10.2478/rjim-2021-0040 DP - PubMed J2 - Rom J Intern Med LA - eng SN - 2501-062X ST - COVID-19 L2 - http://www.ncbi.nlm.nih.gov/pubmed/34997957 KW - COVID-19 KW - acute kidney injury KW - complement KW - thrombotic microangiopathy ER - TY - JOUR TI - Promoting a Syndemic Approach for Cardiometabolic Disease Management During COVID-19: The CAPISCO International Expert Panel AU - Al Mahmeed, Wael AU - Al-Rasadi, Khalid AU - Banerjee, Yajnavalka AU - Ceriello, Antonio AU - Cosentino, Francesco AU - Galia, Massimo AU - Goh, Su-Yen AU - Kempler, Peter AU - Lessan, Nader AU - Papanas, Nikolaos AU - Rizvi, Ali A. AU - Santos, Raul D. AU - Stoian, Anca P. AU - Toth, Peter P. AU - Rizzo, Manfredi AU - CArdiometabolic Panel of International experts on Syndemic COvid-19 (CAPISCO) T2 - Frontiers in Cardiovascular Medicine AB - Efforts in the fight against COVID-19 are achieving success in many parts of the world, although progress remains slow in other regions. We believe that a syndemic approach needs to be adopted to address this pandemic given the strong apparent interplay between COVID-19, its related complications, and the socio-structural environment. We have assembled an international, multidisciplinary group of researchers and clinical practitioners to promote a novel syndemic approach to COVID-19: the CArdiometabolic Panel of International experts on Syndemic COvid-19 (CAPISCO). This geographically diverse group aims to facilitate collaborative-networking and scientific exchanges between researchers and clinicians facing a multitude of challenges on different continents during the pandemic. In the present article we present our "manifesto", with the intent to provide evidence-based guidance to the global medical and scientific community for better management of patients both during and after the current pandemic. DA - 2021/// PY - 2021 DO - 10.3389/fcvm.2021.787761 DP - PubMed VL - 8 SP - 787761 J2 - Front Cardiovasc Med LA - eng SN - 2297-055X ST - Promoting a Syndemic Approach for Cardiometabolic Disease Management During COVID-19 L1 - https://www.frontiersin.org/articles/10.3389/fcvm.2021.787761/pdf L2 - http://www.ncbi.nlm.nih.gov/pubmed/34977193 KW - COVID-19 KW - pandemic KW - complications KW - diabetes KW - cardiovascular diseases KW - syndemic ER - TY - JOUR TI - Impact of COVID-19 Lockdown in Eating Disorders: A Multicentre Collaborative International Study AU - Baenas, Isabel AU - Etxandi, Mikel AU - Munguía, Lucero AU - Granero, Roser AU - Mestre-Bach, Gemma AU - Sánchez, Isabel AU - Ortega, Emilio AU - Andreu, Alba AU - Moize, Violeta L. AU - Fernández-Real, Jose-Manuel AU - Tinahones, Francisco J. AU - Diéguez, Carlos AU - Frühbeck, Gema AU - Le Grange, Daniel AU - Tchanturia, Kate AU - Karwautz, Andreas AU - Zeiler, Michael AU - Imgart, Hartmut AU - Zanko, Annika AU - Favaro, Angela AU - Claes, Laurence AU - Shekriladze, Ia AU - Serrano-Troncoso, Eduardo AU - Cecilia-Costa, Raquel AU - Rangil, Teresa AU - Loran-Meler, Maria Eulalia AU - Soriano-Pacheco, José AU - Carceller-Sindreu, Mar AU - Navarrete, Rosa AU - Lozano, Meritxell AU - Linares, Raquel AU - Gudiol, Carlota AU - Carratala, Jordi AU - Plana, Maria T. AU - Graell, Montserrat AU - González-Parra, David AU - Gómez-Del Barrio, José A. AU - Sepúlveda, Ana R. AU - Sánchez-González, Jéssica AU - Machado, Paulo P. P. AU - Håkansson, Anders AU - Túry, Ferenc AU - Pászthy, Bea AU - Stein, Daniel AU - Papezová, Hana AU - Gricova, Jana AU - Bax, Brigita AU - Borisenkov, Mikhail F. AU - Popov, Sergey V. AU - Gubin, Denis G. AU - Petrov, Ivan M. AU - Isakova, Dilara AU - Mustafina, Svetlana V. AU - Kim, Youl-Ri AU - Nakazato, Michiko AU - Godart, Nathalie AU - van Voren, Robert AU - Ilnytska, Tetiana AU - Chen, Jue AU - Rowlands, Katie AU - Voderholzer, Ulrich AU - Monteleone, Alessio M. AU - Treasure, Janet AU - Jiménez-Murcia, Susana AU - Fernández-Aranda, Fernando T2 - Nutrients AB - BACKGROUND: The COVID-19 lockdown has had a significant impact on mental health. Patients with eating disorders (ED) have been particularly vulnerable. AIMS: (1) To explore changes in eating-related symptoms and general psychopathology during lockdown in patients with an ED from various European and Asian countries; and (2) to assess differences related to diagnostic ED subtypes, age, and geography. METHODS: The sample comprised 829 participants, diagnosed with an ED according to DSM-5 criteria from specialized ED units in Europe and Asia. Participants were assessed using the COVID-19 Isolation Scale (CIES). RESULTS: Patients with binge eating disorder (BED) experienced the highest impact on weight and ED symptoms in comparison with other ED subtypes during lockdown, whereas individuals with other specified feeding and eating disorders (OFSED) had greater deterioration in general psychological functioning than subjects with other ED subtypes. Finally, Asian and younger individuals appeared to be more resilient. CONCLUSIONS: The psychopathological changes in ED patients during the COVID-19 lockdown varied by cultural context and individual variation in age and ED diagnosis. Clinical services may need to target preventive measures and adapt therapeutic approaches for the most vulnerable patients. DA - 2022/01// PY - 2022 DO - 10.3390/nu14010100 DP - PubMed VL - 14 IS - 1 SP - 100 J2 - Nutrients LA - eng SN - 2072-6643 ST - Impact of COVID-19 Lockdown in Eating Disorders L1 - https://www.mdpi.com/2072-6643/14/1/100/pdf L2 - http://www.ncbi.nlm.nih.gov/pubmed/35010974 KW - Adult KW - Child KW - Female KW - Humans KW - Male KW - Adolescent KW - COVID-19 KW - SARS-CoV-2 KW - Young Adult KW - Longitudinal Studies KW - Quarantine KW - Europe KW - eating disorders KW - Feeding and Eating Disorders KW - Internationality KW - Asia KW - COVID-19 Isolation Eating Scale (CIES) KW - COVID-19 lockdown KW - eating symptoms KW - psychological impact KW - Social Isolation ER - TY - JOUR TI - Case Study: Effects of the COVID-19 Lockdown Restrictions on Eight Mongolian Single Mothers AU - Amarsanaa, Khongorzul AU - Rácz, József AU - Kovács, Mónika T2 - Journal of International Women's Studies AB - This article discusses a comparative case study of eight single mothers' lockdown experiences during COVID-19 in Mongolia. The case study investigated single mothers' experiences and the psychological impact of the lockdown. Semi-structured interviews were conducted with eight single mothers, four of whom were survivors of intimate partner violence. All interviews were carried out online. Thematic analysis identified patterns and themes regarding lockdown experiences. The four months (from late January to early May 2020) of lockdown had both positive and negative psychological consequences for these single mothers. For both survivor and non-survivor single mothers, uncertainty was the primary psychological state reported, followed by other adverse effects such as worry, anxiety, insecurity, and frustration. Lockdown and the government's uncertain policies have added more workload on women. They have been looking after the children, household chores, and managing their paid workload. Their relationships (both official and family) have also been affected. An extra burden on women is the loss of income and employment because of the lockdown. Positive psychological outcomes were increased creativity, newly acquired life skills, community care, and a reminder of values. DA - 2021/11/23/ PY - 2021 VL - 22 IS - 12 SP - 82 EP - 97 SN - 1539-8706 ST - Case Study UR - https://vc.bridgew.edu/jiws/vol22/iss12/5 ER - TY - JOUR TI - Production of Scientific Articles on COVID-19 in Student Research Committees of Medical Universities AU - Pezeshgi, Pourya AU - Akbari Soufiani, Mehdi AU - Tarahomi, Arian T2 - Iranian Journal of Medical Microbiology DA - 2021/12/01/ PY - 2021 DO - 10.30699/ijmm.15.6.708 DP - DOI.org (Crossref) VL - 15 IS - 6 SP - 708 EP - 710 J2 - Iran J Med Microbiol LA - en SN - 1735-8612, 2345-4342 UR - https://ijmm.ir/article-1-1448-en.html Y2 - 2022/03/25/13:14:21 L1 - https://ijmm.ir/files/site1/user_files_418104/pourya_pezeshgi-A-10-1695-1-63d2906.pdf ER - TY - JOUR TI - EACVI survey on burnout amongst cardiac imaging specialists during the 2019 coronavirus disease pandemic AU - Joshi, Shruti S. AU - Stankovic, Ivan AU - Demirkiran, Ahmet AU - Haugaa, Kristina AU - Maurovich-Horvat, Pal AU - Popescu, Bogdan A. AU - Cosyns, Bernard AU - Edvardsen, Thor AU - Petersen, Steffen E. AU - Carvalho, Ricardo Fontes AU - Cameli, Matteo AU - Dweck, Marc R. T2 - European Heart Journal. Cardiovascular Imaging AB - AIMS: The European Association of Cardiovascular Imaging Scientific Initiatives Committee conducted a global survey to evaluate the impact of the 2019 coronavirus disease (COVID-19) pandemic on the mental well-being of cardiac imaging specialists. METHODS AND RESULTS: In a prospective international survey performed between 23 July 2021 and 31 August 2021, we assessed the mental well-being of cardiac imaging specialists ∼18 months into the COVID-19 pandemic. One-hundred-and-twenty-five cardiac imaging specialists from 34 countries responded to the survey. More than half described feeling anxious during the pandemic, 34% felt melancholic, 27% felt fearful, and 23% respondents felt lonely. A quarter of respondents had increased their alcohol intake and more than half reported difficulties in sleeping. Two-thirds of respondents described worsening features of burnout during the past 18 months, 44% considered quitting their job. One in twenty respondents had experienced suicidal ideation during the pandemic. Despite these important issues, the majority of participants (57%) reported having no access to any formal mental health support at work. CONCLUSION: The survey has highlighted important issues regarding the mental well-being of cardiac imaging specialists during the COVID-19 pandemic. This is a major issue in our sub-specialty, which requires urgent action and prioritization so that we can improve the mental health of cardiovascular imaging specialists. DA - 2022/03/22/ PY - 2022 DO - 10.1093/ehjci/jeac002 DP - PubMed VL - 23 IS - 4 SP - 441 EP - 446 J2 - Eur Heart J Cardiovasc Imaging LA - eng SN - 2047-2412 L1 - https://academic.oup.com/ehjcimaging/advance-article-pdf/doi/10.1093/ehjci/jeac002/42257465/jeac002.pdf L2 - http://www.ncbi.nlm.nih.gov/pubmed/35061874 KW - COVID-19 KW - Burnout ER - TY - JOUR TI - Case Report: A Case of COVID Vaccine-Induced Thrombotic Thrombocytopenia Manifested as Pulmonary Embolism and Hemorrhagia. A First Reported Case From Slovakia AU - Ihnatko, Martin AU - Truchla, Ivana AU - Ihnatková, L'udmila AU - Prohászka, Zoltán AU - Lazúrová, Ivica T2 - Frontiers in Medicine AB - COVID-19 vaccine-induced thrombotic thrombocytopenia (VITT) is a rare complication of adenoviral vector (ChAdOx1 nCoV-19) vaccine administration. It is presented as thrombocytopenia and thrombotic manifestations in various sites, especially in cerebral veins. Pulmonary emboli have been reported rarely. We present a case of a young male patient who developed severe thrombocytopenia and pulmonary embolism 12 days after the first dose of the vaccine. Severe thrombocytopenia, skin hematomas, and segmental pulmonary emboli were detected. Anti-platelet factor 4 (aPF-4) antibody was highly positive supporting the diagnosis of VITT. Prompt treatment with fondaparinux, intravenous immunoglobulin, and prednisone led to a marked improvement of clinical condition and thrombocytes count. We report the first known case of VITT in Slovakia. DA - 2022/01/04/ PY - 2022 DO - 10.3389/fmed.2021.789972 DP - PubMed VL - 8 SP - 789972 J2 - Front Med (Lausanne) LA - eng SN - 2296-858X ST - Case Report L1 - https://www.frontiersin.org/articles/10.3389/fmed.2021.789972/pdf L2 - http://www.ncbi.nlm.nih.gov/pubmed/35059416 KW - COVID-19 KW - adenoviral vector vaccine KW - hemorrhagia KW - pulmonary embolism KW - vaccine-induced thrombotic thrombocytopenia ER - TY - JOUR TI - Association between COVID-19 morbidity, mortality, and gross domestic product, overweight/ obesity, non-communicable diseases, vaccination rate: A cross-sectional study AU - Oshakbayev, Kuat AU - Zhankalova, Zulfiya AU - Gazaliyeva, Meruyert AU - Mustafin, Khalit AU - Bedelbayeva, Gulnara AU - Dukenbayeva, Bibazhar AU - Otarbayev, Nurzhan AU - Tordai, Attila T2 - Journal of Infection and Public Health AB - BACKGROUND: The spread of COVID-19 depends on a lot of social and economic factors. THE AIM: to study the influence of country's gross domestic product, population prevalence of overweight/ obesity, NCD mortality, and vaccination on COVID-19 morbidity and mortality rates. METHODS: A cross-sectional study with two phases: correlation-regression interrelations in 1) all world countries; 2) all world non-island countries. The study includes the following data from 218 world countries: COVID-19 morbidity/mortality rates, GDP per capita, the prevalence of overweight/ obesity, NCD mortality among adults (both sexes), people fully vaccinated against COVID-19. RESULTS: An average percentage of the prevalence of overweight among adults in world countries by 2019 was 47.31 ± 15.99%, obesity 18.34 ± 9.64%, while the prevalence by 2016 were 39% and 13%, respectively. Overweight and obesity among adults during three years grew by 21.2% and 40.8%, respectively. Data from the world countries provide significant correlations (p < 0.0001) between COVID-19 morbidity, and: GDP (r = 0.517), overweight (r = 0.54), obesity (r = 0.528), NCD mortality (r = 0.537); COVID-19 mortality, and: GDP (r = 0.344), overweight (r = 0.514), obesity (r = 0.489), NCD mortality (r = 0.611); GDP, and: overweight (r = 0.507), obesity (r = 0.523), NCD mortality (r = 0.35), fully vaccinated people (r = 0.754). An increase in fully vaccinated people, from 3% to 30% of world population, decreases new confirmed COVID-19 cases, although the dependence was not significant (p = 0.07). Data from non-island world countries provides more highly significant correlations (p < 0.0001) between COVID-19 morbidity, and: GDP (r = 0.616), overweight (r = 0.581), obesity (r = 0.583); COVID-19 mortality, and: GDP (r = 0.43), overweight (r = 0.556), obesity (r = 0.539); GDP, and: overweight (r = 0.601), obesity (r = 0.633). The differences of correlation coefficients between data of 176 world countries and data of 143 world non-island countries were not significant (Z-scores<1.29; p > 0.05). CONCLUSION: The study provides evidence of a significant impact of overweight/obesity prevalence on the increase in COVID-19 morbidity/mortality. Countries with higher GDP have a high overweight/obesity prevalence and possibility to get vaccinated. DA - 2022/02// PY - 2022 DO - 10.1016/j.jiph.2022.01.009 DP - PubMed VL - 15 IS - 2 SP - 255 EP - 260 J2 - J Infect Public Health LA - eng SN - 1876-035X ST - Association between COVID-19 morbidity, mortality, and gross domestic product, overweight/ obesity, non-communicable diseases, vaccination rate L1 - https://www.sciencedirect.com/science/article/pii/S1876034122000119/pdfft?md5=85f773d223b67f544b1175e115da8f47&pid=1-s2.0-S1876034122000119-main.pdf&isDTMRedir=Y L2 - http://www.ncbi.nlm.nih.gov/pubmed/35065358 KW - Adult KW - Female KW - Humans KW - Male KW - COVID-19 KW - SARS-CoV-2 KW - Cross-Sectional Studies KW - Prevalence KW - Global Health KW - Obesity KW - Overweight KW - Vaccination KW - Noncommunicable Diseases KW - Non-communicable diseases KW - A cross-sectional study KW - COVID-19 mortality/morbidity KW - Gross domestic product KW - Gross Domestic Product KW - Overweight/obesity ER - TY - JOUR TI - Frequent Constriction-Like Echocardiographic Findings in Elite Athletes Following Mild COVID-19: A Propensity Score-Matched Analysis AU - Lakatos, Bálint Károly AU - Tokodi, Márton AU - Fábián, Alexandra AU - Ladányi, Zsuzsanna AU - Vágó, Hajnalka AU - Szabó, Liliána AU - Sydó, Nóra AU - Csulak, Emese AU - Kiss, Orsolya AU - Babity, Máté AU - Kiss, Anna Réka AU - Gregor, Zsófia AU - Szűcs, Andrea AU - Merkely, Béla AU - Kovács, Attila T2 - Frontiers in Cardiovascular Medicine AB - Background: The cardiovascular effects of SARS-CoV-2 in elite athletes are still a matter of debate. Accordingly, we sought to perform a comprehensive echocardiographic characterization of post-COVID athletes by comparing them to a non-COVID athlete cohort. Methods: 107 elite athletes with COVID-19 were prospectively enrolled (P-CA; 23 ± 6 years, 23% female) 107 healthy athletes were selected as a control group using propensity score matching (N-CA). All athletes underwent 2D and 3D echocardiography. Left (LV) and right ventricular (RV) end-diastolic volumes (EDVi) and ejection fractions (EF) were quantified. To characterize LV longitudinal deformation, 2D global longitudinal strain (GLS) and the ratio of free wall vs. septal longitudinal strain (FWLS/SLS) were also measured. To describe septal flattening (SF-frequently seen in P-CA), LV eccentricity index (EI) was calculated. Results: P-CA and N-CA athletes had comparable LV and RVEDVi (P-CA vs. N-CA; 77 ± 12 vs. 78 ± 13mL/m2; 79 ± 16 vs. 80 ± 14mL/m2). P-CA had significantly higher LVEF (58 ± 4 vs. 56 ± 4%, p < 0.001), while LVGLS values did not differ between P-CA and N-CA (-19.0 ± 1.9 vs. -18.8 ± 2.2%). EI was significantly higher in P-CA (1.13 ± 0.16 vs. 1.01 ± 0.05, p < 0.001), which was attributable to a distinct subgroup of P-CA with a prominent SF (n = 35, 33%), further provoked by inspiration. In this subgroup, the EI was markedly higher compared to the rest of the P-CA (1.29 ± 0.15 vs. 1.04 ± 0.08, p < 0.001), LVEDVi was also significantly higher (80 ± 14 vs. 75 ± 11 mL/m2, p < 0.001), while RVEDVi did not differ (82 ± 16 vs. 78 ± 15mL/m2). Moreover, the FWLS/SLS ratio was significantly lower in the SF subgroup (91.7 ± 8.6 vs. 97.3 ± 8.2, p < 0.01). P-CA with SF experienced symptoms less frequently (1.4 ± 1.3 vs. 2.1 ± 1.5 symptom during the infection, p = 0.01). Conclusions: Elite athletes following COVID-19 showed distinct morphological and functional cardiac changes compared to a propensity score-matched control athlete group. These results are mainly driven by a subgroup, which presented with some echocardiographic features characteristic of constrictive pericarditis. DA - 2022/01/05/ PY - 2022 DO - 10.3389/fcvm.2021.760651 DP - PubMed VL - 8 SP - 760651 J2 - Front Cardiovasc Med LA - eng SN - 2297-055X ST - Frequent Constriction-Like Echocardiographic Findings in Elite Athletes Following Mild COVID-19 L1 - https://www.frontiersin.org/articles/10.3389/fcvm.2021.760651/pdf L2 - http://www.ncbi.nlm.nih.gov/pubmed/35071343 KW - COVID-19 KW - 3D echocardiography KW - athlete's heart KW - constrictive pericaditis KW - speckle-tracking analysis ER - TY - JOUR TI - RBD-specific antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine AU - Ferenci, Tamás AU - Sarkadi, Balázs T2 - BMC infectious diseases AB - BACKGROUND: Limited information is available on the effectiveness of the BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine, especially in the elderly, despite the fact that it is approved in more than 50 countries. METHODS: RBD-specific antibody titres, as a rapidly available and highly predictive surrogate marker, were measured after two doses of the BBIBP-CorV vaccine in 450 subjects. Results were analyzed in a multivariable model accounting for age, sex and time since the administration of the second dose of the vaccine. RESULTS: Sex and time since the second dose had little association with the antibody titres. Age, however, was highly relevant: measurable antibody levels were present in about 90% of individuals below the age of 50, but antibody production after BBIBP-CorV vaccination was strongly reduced with increasing age. A large number of elderly subjects, reaching 25% at 60 years, and up to 50% at ages over 80, were found not to produce any protective antibody. CONCLUSIONS: RBD-specific antibody titre, as a correlate of protection for COVID-19 disease susceptibility, should help to evaluate the effectiveness of the BBIBP-CorV vaccine. Results suggest that proper measures should be undertaken to prevent a potential outbreak of COVID-19 in BBIBP-CorV vaccinated but eventually unprotected elderly individuals. DA - 2022/01/24/ PY - 2022 DO - 10.1186/s12879-022-07069-z DP - PubMed VL - 22 IS - 1 SP - 87 J2 - BMC Infect Dis LA - eng SN - 1471-2334 L1 - https://bmcinfectdis.biomedcentral.com/track/pdf/10.1186/s12879-022-07069-z L2 - http://www.ncbi.nlm.nih.gov/pubmed/35073866 KW - Humans KW - COVID-19 KW - SARS-CoV-2 KW - Aged KW - Vaccination KW - Vaccine KW - Antibody response KW - Antibody Formation KW - BBIBP-CorV KW - Beijing ER - TY - JOUR TI - Developing Immunity Testing for SARS-CoV-2 and Other Novel Vaccines—Correlates of Immunogenicity Parameters with Protection AU - Vajo, Zoltan T2 - Viruses AB - During the assessment and licensing of novel vaccines, as well as post licensure follow up, it is critical to have reliable immunogenicity testing methods that relate well to real life protection [...] DA - 2022/01/20/ PY - 2022 DO - 10.3390/v14020196 DP - DOI.org (Crossref) VL - 14 IS - 2 SP - 196 J2 - Viruses LA - en SN - 1999-4915 UR - https://www.mdpi.com/1999-4915/14/2/196 Y2 - 2022/03/25/13:43:04 L1 - https://www.mdpi.com/1999-4915/14/2/196/pdf ER - TY - JOUR TI - [COVID-19 in patients with primary immunodeficiency] AU - Maródi, László T2 - Orvosi Hetilap AB - Összefoglaló. Az új típusú koronavírus (SARS-CoV-2) okozta pandémia súlyos terhet és nagy kihívást jelent a fertőzésekkel szemben általában is fogékony, szerteágazó immunológiai és genetikai hátterű, primer immundeficiens (PID-) betegek számára. Az eddigi megfigyelések arra utalnak, hogy a SARS-CoV-2-fertőzés és a súlyos COVID-19 mortalitása nem elsősorban az immunológiai alapbetegséggel, hanem sokkal inkább egyéb, a PID talaján megelőzően kialakult (például bronchiectasia, asthma, autoimmun betegség stb.) vagy attól független krónikus társbetegséggel (például diabetes, krónikus szív- és érrendszeri vagy vesebetegség) és szervi károsodással függ össze. A betegek egy kis csoportjában az I. típusú interferon-immunitás zavarát okozhatják génmutációk vagy autoantitestek termelése. A közleményben az eddig közölt adatok alapján beszámolunk a SARS-CoV-2-fertőzés és a COVID-19 lefolyásáról és mortalitásáról PID-betegekben. Orv Hetil. 2022; 163(5): 166-170. Summary. The pandemic caused by the novel coronavirus (SARS-CoV-2) has resulted in tremendous challenges to the management of patients with primary immunodeficiencies (PIDs) representing a wide range of immunological and genetic entities. Preliminary data suggest that patients with PID would be at increased risk of severe disease and mortality from this newly emerged coronavirus. However, morbidity and mortality by SARS-CoV-2 may depend only partly on specific defect of immunity. Most of disease morbidity and mortality has been published to be related to previous damage of organs and tissues that had developed on the bases of PID before contracting SARS-CoV-2 or other, PID-independent disorders. In a small fraction of patients, impaired type I interferon immunity was found to predispose PID patients to severe coronavirus disease. In this review, we provide an update on published data about SARS-CoV-2 infections and COVID-19 in various PIDs. Orv Hetil. 2022; 163(5): 166-170. DA - 2022/01/30/ PY - 2022 DO - 10.1556/650.2022.32395 DP - PubMed VL - 163 IS - 5 SP - 166 EP - 170 J2 - Orv Hetil LA - hun SN - 1788-6120 UR - https://akjournals.com/view/journals/650/163/5/article-p166.xml L2 - http://www.ncbi.nlm.nih.gov/pubmed/35093927 KW - Antiviral Agents KW - coronavirus disease 2019 KW - COVID-19 KW - Humans KW - I. típusú interferon KW - Interferons KW - koronavírus-2 KW - koronavírus-betegség 2019 KW - primary immunodeficiency KW - primer immundefektus KW - SARS-CoV-2 KW - severe acute respiratory syndrome coronavirus 2 KW - súlyos akut respiratorikus szindróma KW - type I interferon ER - TY - CHAP TI - Psychological Perspectives on COVID-19 AU - Hosseini-Nezhad, Sara AU - Safdar, Saba AU - Hosseini-Nezhad, Pegah AU - Luu, Lan Anh Nguyen T2 - Socioeconomic Dynamics of the COVID-19 Crisis A2 - Faghih, Nezameddin A2 - Forouharfar, Amir T3 - Contributions to Economics AB - Background: A considerable quantity of research supports the findings that the COVID-19 pandemic has significantly influenced individuals’ psychological wellbeing and behaviours. Purpose: This chapter aims to provide an overview of some of the current studies examining psychological responses of various groups across cultures in relation to the COVID-19 pandemic employing the behavioural immune system (BIS) framework and terror management theory (TMT) as a theoretical lens. Methodology: Online databases are used to conduct a literature review of some of the studies carried out during the global pandemic between 2019 and 2021. Results: The pandemic has had an overall detrimental effect on everyone to some extent, with a disproportionate impact on more vulnerable populations. Conclusion and Recommendation: People continue to cope with the death anxiety from the perspective of the TMT and are driven to avoid pathogens from the BIS viewpoint in the face of the COVID-19 pandemic; however, given the disproportionate impact of the pandemic on vulnerable groups, it is recommended that societies prioritize equity-oriented public health measures to ensure the population’s future wellbeing. CY - Cham DA - 2022/// PY - 2022 DP - DOI.org (Crossref) SP - 291 EP - 325 LA - en PB - Springer International Publishing SN - 978-3-030-89995-0 978-3-030-89996-7 UR - https://link.springer.com/10.1007/978-3-030-89996-7_14 Y2 - 2022/03/25/13:56:16 ER - TY - JOUR TI - SARS-CoV-2-related and Covid-19 vaccine-induced thromboembolic events: A comparative review AU - Afshar, Zeinab Mohseni AU - Barary, Mohammad AU - Babazadeh, Arefeh AU - Hosseinzadeh, Rezvan AU - Alijanpour, Amirmasoud AU - Miri, Seyed Rouhollah AU - Sio, Terence T. AU - Sullman, Mark J. M. AU - Carson-Chahhoud, Kristin AU - Langer, Florian AU - Ebrahimpour, Soheil T2 - Reviews in Medical Virology AB - Since the start of the pandemic, thrombotic events have been a well-known and severe complication associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Nevertheless, the initiation of vaccination programs brought another rare yet highly fatal thrombotic event, vaccine-induced immune thrombotic thrombocytopaenia, which has caused extensive debate regarding the safety of vaccines. This review defines the thromboembolic events following infection and vaccination, identifies their risk factors, describes their pathophysiology, and discusses their management, treatment, and prevention. DA - 2022/02/03/ PY - 2022 DO - 10.1002/rmv.2327 DP - PubMed SP - e2327 J2 - Rev Med Virol LA - eng SN - 1099-1654 ST - SARS-CoV-2-related and Covid-19 vaccine-induced thromboembolic events L1 - https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/rmv.2327 L2 - http://www.ncbi.nlm.nih.gov/pubmed/35112763 KW - SARS-CoV-2 KW - Covid-19 KW - thrombosis KW - VITT ER - TY - JOUR TI - The impact of the COVID-19 pandemic on the European Union’s public health policy AU - Virág, Attila AU - Túri, Gergő T2 - Politics in Central Europe AB - Abstract In the spring of 2020 the COVID-19 pandemic emerged as one of the most complex and most serious challenges of the European Union, threatening the lives and quality of life of European citizens and the economy and healthcare systems of EU Member States. The fight against the pandemic required the collaboration of many different disciplines and sectors, and over time it had become clear that co-operation between EU Member States and EU organisations is essential for successful crisis management. This cross-border healthcare emergency has seriously tested the mechanisms set by EU treaties and legislations, as well as the organisations responsible for shaping and implementing the European Union’s public health policy. Over the past year we have gained valuable data on how the system of rules and task sharing mechanisms have supported the fight against the pandemic and its effects. By reviewing and examining our findings, we may find answers about the impact of the COVID-19 pandemic on the European Union’s public health policy and how it can be further developed. DA - 2021/12/01/ PY - 2021 DO - 10.2478/pce-2021-0035 DP - DOI.org (Crossref) VL - 17 IS - 4 SP - 651 EP - 674 LA - en SN - 1801-3422 UR - https://www.sciendo.com/article/10.2478/pce-2021-0035 Y2 - 2022/03/25/14:04:50 L1 - https://www.sciendo.com/pdf/10.2478/pce-2021-0035 ER - TY - JOUR TI - [The gastrointestinal effects of COVID–19 infection during childhood and among the children affected with inflammatory bowel disease] AU - Tóbi, Luca AU - Prehoda, Bence AU - Balogh, Anna AU - Dezsőfi-Gottl, Antal AU - Cseh, Áron T2 - Orvosi Hetilap AB - Összefoglaló. A SARS-CoV-2-infekció változatos kórlefolyású, a gyermekpopulációban növekvő incidenciát mutató fertőzés. Ebben a korcsoportban a felnőttekkel szemben sokkal gyakrabban tapasztalhatók gasztroenterológiai tünetek a betegség során, 18-32%-ban jelentkezik legalább egy szimptóma. Ezek nem specifikusak, gyakran megegyezhetnek a virális enteritisek, a gyulladásos bélbetegségek vagy a vakbélgyulladás tüneteivel. A gyermekkori SARS-CoV-2-infekciónak egy viszonylag ritkán megjelenő, de súlyos, akár életveszélyes szövődménye a gyermekkori sokszervi gyulladásos szindróma (multisystem inflammatory syndrome in children, MIS-C). Ilyenkor a gastrointestinalis tünetek gyakorisága 60-100%-ra nő, sok esetben akut has benyomását keltve. A jelenlegi kutatások eredményei alapján a gyulladásos bélbeteg gyerekek az alapbetegségük miatt nincsenek nagyobb veszélynek kitéve az átlagpopulációhoz képest a COVID-19-fertőzés szempontjából. A terápiájukban alkalmazott gyógyszereik közül a nagy dózisú szteroidkezelés okoz nagyobb kockázatot a megfertőződésre, illetve ebben az esetben a súlyosabb kórlefolyásra. Az éppen remisszióban lévő gyulladásos bélbetegek fenntartó terápiájának módosítások nélküli folytatása javasolt, kiemelt figyelmet fordítva a biológiai terápiák időben történő, megszakítás nélküli alkalmazására. Törekedni kell a személyes vizitek számának csökkentésére a pandémia idején, ezek telemedicinával történő helyettesítése javasolt. A halasztható endoszkópos vizsgálatok noninvazív vizsgálómódszerekkel történő átmeneti kiváltása részesítendő előnyben a betegség aktivitásának, a terápia hatékonyságának megítélésére. A gyulladásos bélbetegségben szenvedő gyermekek COVID-19 elleni védőoltása javasolt, jelenleg minden elérhető oltóanyag alkalmazható náluk (az élő ágenst tartalmazó vakcinák ellenjavalltak). Immunmoduláns, szteroid- vagy anti-tumornekrózisfaktor (TNF)-alfa-terápia esetén az oltás lehetséges csökkent hatékonyságával kell számolni. Orv Hetil. 2022; 163(6): 214-221. Summary. The SARS-CoV-2 infection is showing high variety in the disease course, with a constantly increasing incidence among the pediatric population. In this age group, at least one gastrointestinal symptom appears in 18-32% of the cases, showing a significant difference compared to the adult population. The gastrointestinal signs of COVID-19 are not specific, can mimic the symptoms of viral enteritis, inflammatory bowel diseases or acute appendicitis. The multisystem inflammatory syndrome in children (MIS-C) is a rather rare, but serious complication of the pediatric COVID-19 disease: in these cases, the incidence of the gastrointestinal symptoms is increased up to 60-100%, often observed as acute abdomen. Based on recent researches, patients with inflammatory bowel diseases (IBD) are shown to have the same risk in developing COVID-19 infection compared to the normal population: in their medications, the high dose steroid treatment is proved to increase the risk of infection or to make the disease course more serious. The treatment of patients with IBD should be continued without any changes (when the disease is in remission). The use of biologics should be done with special care, with more attention keeping the schedule and the continuity. It is advised to minimise the number of personal visits during the pandemic, they should be substituted with telemedicine. The postponable endoscopic examinations should be temporarily redeemed by non-invasive methods for screening the disease activity and the efficacy of the treatment. The vaccination against COVID-19 is advised in the population with IBD. All vaccines currently available are usable in this patient group (the use of vaccines containing live agents are contraindicated). In the case of patients treated with immunmodulators, steroids or anti-tumor necrosis factor (TNF) alpha, a possible lower efficacy can be expected after the vaccination. Orv Hetil. 2022; 163(6): 214-221. DA - 2022/02/06/ PY - 2022 DO - 10.1556/650.2022.32443 DP - PubMed VL - 163 IS - 6 SP - 214 EP - 221 J2 - Orv Hetil LA - hun SN - 1788-6120 L1 - https://akjournals.com/downloadpdf/journals/650/163/6/article-p214.pdf L2 - http://www.ncbi.nlm.nih.gov/pubmed/35124570 KW - Adult KW - Child KW - Humans KW - COVID-19 KW - SARS-CoV-2 KW - inflammatory bowel disease KW - coronavirus KW - koronavírus KW - COVID–19 KW - IBD KW - Colitis KW - gastrointestinal KW - gastrointestinalis KW - gyulladásos bélbetegség KW - Inflammatory Bowel Diseases KW - Systemic Inflammatory Response Syndrome ER - TY - JOUR TI - Associations between the von Willebrand Factor-ADAMTS13 Axis, Complement Activation, and COVID-19 Severity and Mortality AU - Sinkovits, György AU - Réti, Marienn AU - Müller, Veronika AU - Iványi, Zsolt AU - Gál, János AU - Gopcsa, László AU - Reményi, Péter AU - Szathmáry, Beáta AU - Lakatos, Botond AU - Szlávik, János AU - Bobek, Ilona AU - Prohászka, Zita Z. AU - Förhécz, Zsolt AU - Mező, Blanka AU - Csuka, Dorottya AU - Hurler, Lisa AU - Kajdácsi, Erika AU - Cervenak, László AU - Kiszel, Petra AU - Masszi, Tamás AU - Vályi-Nagy, István AU - Prohászka, Zoltán T2 - Thrombosis and Haemostasis AB - BACKGROUND: Endothelial and complement activation were both associated with immunothrombosis, a key determinant of COVID-19 severity, but their interrelation has not yet been investigated. OBJECTIVES: We aimed to determine von Willebrand factor (VWF) antigen (VWF:Ag) concentration, VWF collagen binding activity (VWF:CBA), a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) activity (ADAMTS13:Ac), and their ratios in hospitalized COVID-19 patients, and to investigate how these parameters and their constellation with complement activation relate to disease severity and in-hospital mortality in COVID-19. METHODS: Samples of 102 hospitalized patients with polymerase chain reaction-confirmed severe acute respiratory syndrome coronavirus 2 positivity were included in our observational cohort study. Patients were stratified according to the peak severity of COVID-19 disease in agreement with the World Health Organization ordinal scale. Twenty-six convalescent plasma donors with previous COVID-19 disease formed the control group. VWF:Ag concentration and VWF:CBA were determined by enzyme-linked immunosorbent assay (ELISA); ADAMTS13:Ac was determined by fluorescence resonance energy transfer. Complement C3 and C3a were measured by turbidimetry and ELISA, respectively. Clinical covariates and markers of inflammation were extracted from hospital records. RESULTS: VWF:Ag and VWF:CBA were elevated in all groups of hospitalized COVID-19 patients and increased in parallel with disease severity. ADAMTS13:Ac was decreased in patients with severe COVID-19, with the lowest values in nonsurvivors. High (> 300%) VWF:Ag concentrations or decreased (< 67%) ADAMTS13:Ac were associated with higher risk of severe COVID-19 disease or in-hospital mortality. The concomitant presence of decreased ADAMTS13:Ac and increased C3a/C3 ratio-indicating complement overactivation and consumption-was a strong independent predictor of in-hospital mortality. CONCLUSION: Our results suggest that an interaction between the VWF-ADAMTS13 axis and complement overactivation and consumption plays an important role in the pathogenesis of COVID-19. DA - 2022/02// PY - 2022 DO - 10.1055/s-0041-1740182 DP - PubMed VL - 122 IS - 2 SP - 240 EP - 256 J2 - Thromb Haemost LA - eng SN - 2567-689X L1 - https://www.thieme-connect.de/products/ejournals/pdf/10.1055/s-0041-1740182.pdf L2 - http://www.ncbi.nlm.nih.gov/pubmed/35062036 KW - Adult KW - Female KW - Humans KW - Male KW - COVID-19 KW - SARS-CoV-2 KW - Middle Aged KW - Aged KW - Severity of Illness Index KW - Survival Analysis KW - Hungary KW - Hospitalization KW - ADAMTS13 Protein KW - Complement Activation KW - Complement C3 KW - Convalescence KW - Nephelometry and Turbidimetry KW - von Willebrand Factor ER - TY - JOUR TI - A naturally hypersensitive porcine model may help understand the mechanism of COVID-19 mRNA vaccine-induced rare (pseudo) allergic reactions: complement activation as a possible contributing factor AU - Dézsi, László AU - Mészáros, Tamás AU - Kozma, Gergely AU - H-Velkei, Mária AU - Oláh, Csaba Zs AU - Szabó, Miklós AU - Patkó, Zsófia AU - Fülöp, Tamás AU - Hennies, Mark AU - Szebeni, Miklós AU - Barta, Bálint András AU - Merkely, Béla AU - Radovits, Tamás AU - Szebeni, János T2 - GeroScience AB - A tiny fraction of people immunized with lipid nanoparticle (LNP)-enclosed mRNA (LNP-mRNA) vaccines develop allergic symptoms following their first or subsequent vaccinations, including anaphylaxis. These reactions resemble complement (C) activation-related pseudoallergy (CARPA) to i.v. administered liposomes, for which pigs provide a naturally oversensitive model. Using this model, we injected i.v. the human vaccination dose (HVD) of BNT162b2 (Comirnaty, CMT) or its 2-fold (2x) or 5-fold (5x) amounts and measured the hemodynamic changes and other parameters of CARPA. We observed in 6 of 14 pigs transient pulmonary hypertension along with thromboxane A2 release into the blood and other hemodynamic and blood cell changes, including hypertension, granulocytosis, lymphopenia, and thrombocytopenia. One pig injected with 5x CMT developed an anaphylactic shock requiring resuscitation, while a repeat dose failed to induce the reaction, implying tachyphylaxis. These typical CARPA symptoms could not be linked to animal age, sex, prior immune stimulation with zymosan, immunization of animals with Comirnaty i.v., or i.m. 2 weeks before the vaccine challenge, and anti-PEG IgM levels in Comirnaty-immunized pigs. Nevertheless, IgM binding to the whole vaccine, used as antigen in an ELISA, was significantly higher in reactive animals compared to non-reactive ones. Incubation of Comirnaty with pig serum in vitro showed significant elevations of C3a anaphylatoxin and sC5b-9, the C-terminal complex. These data raise the possibility that C activation plays a causal or contributing role in the rare HSRs to Comirnaty and other vaccines with similar side effects. Further studies are needed to uncover the factors controlling these vaccine reactions in pigs and to understand their translational value to humans. DA - 2022/02/11/ PY - 2022 DO - 10.1007/s11357-021-00495-y DP - PubMed J2 - Geroscience LA - eng SN - 2509-2723 ST - A naturally hypersensitive porcine model may help understand the mechanism of COVID-19 mRNA vaccine-induced rare (pseudo) allergic reactions L1 - https://link.springer.com/content/pdf/10.1007/s11357-021-00495-y.pdf L2 - http://www.ncbi.nlm.nih.gov/pubmed/35146583 KW - COVID-19 KW - Anaphylatoxins KW - CARPA KW - Complement KW - Hemodynamic changes KW - Pigs KW - Pseudoallergy KW - Shock ER - TY - JOUR TI - Evaluating the field performance of multiple SARS-Cov-2 antigen rapid tests using nasopharyngeal swab samples AU - Magyar, Nóra AU - Déri, Dániel AU - Veres, Dániel Sándor AU - Kis, Zoltán AU - Barcsay, Erzsébet AU - Pályi, Bernadett T2 - PloS One AB - The SARS-CoV-2 pandemic, which started in December 2019, has been posing significant challenges to the health care system worldwide. As the pandemic spreads with rapidly increasing number of positive cases, early diagnosis of infected patients is crucial to successfully limit the spread of the virus. Although the real-time reverse-transcription polymerase chain reaction (RT-qPCR) is the recommended laboratory method to diagnose COVID-19 infection, many factors such as availability of laboratory equipment, reagents and trained personnel affect the use of time-consuming molecular techniques. To facilitate on-the-spot diagnosis of COVID-19, SARS-CoV-2 rapid antigen tests were developed by several different manufacturers. The evaluation of such rapid tests is particularly important due to the recent unanimous agreement by the European Commission Member States on a recommendation setting out a framework for the use of antigen rapid tests that contains a list of the mutually recognized assays and the basis of independent validation protocols. To evaluate the on-field performance of ten commercially available SARS-CoV-2 antigen rapid tests (CLINITEST Rapid COVID-19 Antigen Test, GenBody COVID-19 Antigen Test, GENEDIA W COVID-19 Ag Test, Healgen Coronavirus Antigen Rapid Test, Humasis COVID-19 Ag Test, VivaDiag SARS-CoV-2 Ag Rapid Test, Helix i-SARS-CoV-2 Ag Rapid Test, Roche SARS-CoV-2 Rapid Antigen Test, Abbot COVID-19 Ag Rapid Test and Vazyme SARS-CoV-2 Antigen Detection Kit) and compare with RT-qPCR as a reference method, the Hungarian National Public Health Center provided 1,597 antigen rapid tests to the National Ambulance Service, COVID-testing trucks and two hospitals treating COVID-19 patients. Sensitivity, specificity and accuracy were determined by performing the rapid test directly from nasopharyngeal swab samples of symptomatic individuals. For strongly positive samples (Ct < 25) sensitivities ranged between 66.7% and 100%, while for positive samples (Ct < 30) they gave a maximum sensitivity of 87.5%. The specificity of the tests was ranging between 79% to 100%. The results presented here are of high importance to the European Commission and also help governmental decision-making regarding the application of the proper rapid tests for screening different at-risk populations. Nonetheless, SARS-Cov-2 rapid tests play an important role in early and on-the-spot diagnosis of potentially infected individuals. DA - 2022/// PY - 2022 DO - 10.1371/journal.pone.0262399 DP - PubMed VL - 17 IS - 2 SP - e0262399 J2 - PLoS One LA - eng SN - 1932-6203 L1 - https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0262399&type=printable L2 - http://www.ncbi.nlm.nih.gov/pubmed/35157700 KW - Adult KW - Female KW - Humans KW - Male KW - Adolescent KW - Child, Preschool KW - SARS-CoV-2 KW - Middle Aged KW - Young Adult KW - Aged KW - Antigens, Viral KW - Nasopharynx KW - Sensitivity and Specificity KW - Specimen Handling KW - Real-Time Polymerase Chain Reaction KW - COVID-19 Serological Testing KW - Probability ER - TY - JOUR TI - Clinical Frailty Scale (CFS) indicated frailty is associated with increased in-hospital and 30-day mortality in COVID-19 patients: a systematic review and meta-analysis AU - Rottler, Máté AU - Ocskay, Klementina AU - Sipos, Zoltán AU - Görbe, Anikó AU - Virág, Marcell AU - Hegyi, Péter AU - Molnár, Tihamér AU - Erőss, Bálint AU - Leiner, Tamás AU - Molnár, Zsolt T2 - Annals of Intensive Care AB - BACKGROUND: The concept of frailty provides an age-independent, easy-to-use tool for risk stratification. We aimed to summarize the evidence on the efficacy of frailty tools in risk assessment in COVID-19 patients. METHODS: The protocol was registered (CRD42021241544). Studies reporting on frailty in COVID-19 patients were eligible. The main outcomes were mortality, length of hospital stay (LOH) and intensive care unit (ICU) admission in frail and non-frail COVID-19 patients. Frailty was also compared in survivors and non-survivors. Five databases were searched up to 24th September 2021. The QUIPS tool was used for the risk of bias assessment. Odds ratios (OR) and weighted mean differences (WMD) were calculated with 95% confidence intervals (CI) using a random effect model. Heterogeneity was assessed using the I2 and χ2 tests. RESULTS: From 3640 records identified, 54 were included in the qualitative and 42 in the quantitative synthesis. Clinical Frailty Scale (CFS) was used in 46 studies, the Hospital Frailty Risk Score (HFRS) by 4, the Multidimensional Prognostic Index (MPI) by 3 and three studies used other scores. We found that patients with frailty (CFS 4-9 or HFRS ≥ 5) have a higher risk of mortality (CFS: OR: 3.12; CI 2.56-3.81; HFRS OR: 1.98; CI 1.89-2.07). Patients with frailty (CFS 4-9) were less likely to be admitted to ICU (OR 0.28, CI 0.12-0.64). Quantitative synthesis for LOH was not feasible. Most studies carried a high risk of bias. CONCLUSIONS: As determined by CFS, frailty is strongly associated with mortality; hence, frailty-based patient management should be included in international COVID-19 treatment guidelines. Future studies investigating the role of frailty assessment on deciding ICU admission are strongly warranted. DA - 2022/02/20/ PY - 2022 DO - 10.1186/s13613-021-00977-4 DP - PubMed VL - 12 IS - 1 SP - 17 J2 - Ann Intensive Care LA - eng SN - 2110-5820 ST - Clinical Frailty Scale (CFS) indicated frailty is associated with increased in-hospital and 30-day mortality in COVID-19 patients L1 - https://annalsofintensivecare.springeropen.com/track/pdf/10.1186/s13613-021-00977-4 L2 - http://www.ncbi.nlm.nih.gov/pubmed/35184215 KW - Ceiling of care KW - Clinical Frailty Scale KW - Geriatric KW - Hospital Frailty Risk Score KW - Intensive care ER - TY - JOUR TI - Decreased circulating dipeptidyl peptidase-4 enzyme activity is prognostic for severe outcomes in COVID-19 inpatients AU - Nádasdi, Ákos AU - Sinkovits, György AU - Bobek, Ilona AU - Lakatos, Botond AU - Förhécz, Zsolt AU - Prohászka, Zita Z. AU - Réti, Marienn AU - Arató, Miklós AU - Cseh, Gellért AU - Masszi, Tamás AU - Merkely, Béla AU - Ferdinandy, Péter AU - Vályi-Nagy, István AU - Prohászka, Zoltán AU - Firneisz, Gábor T2 - Biomarkers in Medicine AB - Aim: To investigate the serum circulating DPP4 activity in patients with COVID-19 disease. Materials & methods: Serum samples from 102 hospitalized COVID-19 patients and 43 post-COVID-19 plasma donors and 39 SARS-CoV-2 naive controls and their medical data were used. Circulating DPP4 activities according to different COVID-19 disease peak severity (WHO) groups at sampling and at peak were assessed. Results: A significant decrease (p < 0.0001) in serum DPP4 activity was found in study groups of higher disease severity. When the circulating DPP4 activity was assessed as a prognostic marker, the logistic regression (p = 0.0023) indicated that the enzyme activity is a predictor of mortality (median 9.5 days before death) with receiver operating characteristic area under the curves of 73.33% (p[area = 0.5] < 0.0001) as single predictor and 83.45% (p[area = 0.5] < 0.0001) in combination with age among hospitalized patients with COVID-19. Conclusion: Decreased circulating DPP4 activity is associated with severe COVID-19 disease and is a strong prognostic biomarker of mortality. DA - 2022/04// PY - 2022 DO - 10.2217/bmm-2021-0717 DP - PubMed VL - 16 IS - 5 SP - 317 EP - 330 J2 - Biomark Med LA - eng SN - 1752-0371 L2 - http://www.ncbi.nlm.nih.gov/pubmed/35195023 KW - COVID-19 KW - SARS-CoV-2 KW - mortality KW - disease severity KW - circulating DPP4 activity KW - DPP4 KW - prognostic biomarker KW - T2DM ER - TY - JOUR TI - Short- and long-term outcome and predictors in an international cohort of patients with neuro-COVID-19 AU - Beghi, Ettore AU - Helbok, Raimund AU - Ozturk, Serefnur AU - Karadas, Omer AU - Lisnic, Vitalie AU - Grosu, Oxana AU - Kovács, Tibor AU - Dobronyi, Levente AU - Bereczki, Daniel AU - Cotelli, Maria Sofia AU - Turla, Marinella AU - Davidescu, Eugenia Irene AU - Popescu, Bogdan Ovidiu AU - Valzania, Franco AU - Cavallieri, Francesco AU - Ulmer, Hanno AU - Maia, Luis F. AU - Amodt, Anne Hege AU - Armon, Carmel AU - Brola, Waldemer AU - Victoria, Gryb AU - Riahi, Anis AU - Krehan, Ingomar AU - von Oertzen, Tim AU - Azab, Mohammed A. AU - Crean, Michael AU - Lolich, Maria AU - Lima, Maria João AU - Sellner, Johann AU - Perneczky, Julian AU - Jenkins, Tom AU - Meoni, Sara AU - Bianchi, Elisa AU - Moro, Elena AU - Bassetti, Claudio L. A. AU - ENERGY Study Group T2 - European Journal of Neurology AB - BACKGROUND AND PURPOSE: Despite the increasing number of reports on the spectrum of neurological manifestations of COVID-19 (neuro-COVID), few studies have assessed short- and long-term outcome of the disease. METHODS: This is a cohort study enrolling adult patients with neuro-COVID seen in neurological consultation. Data were collected prospectively or retrospectively in the European Academy of Neurology NEuro-covid ReGistrY ((ENERGY). The outcome at discharge was measured using the modified Rankin Scale and defined as 'stable/improved' if the modified Rankin Scale score was equal to or lower than the pre-morbid score, 'worse' if the score was higher than the pre-morbid score. Status at 6 months was also recorded. Demographic and clinical variables were assessed as predictors of outcome at discharge and 6 months. RESULTS: From July 2020 to March 2021, 971 patients from 19 countries were included. 810 (83.4%) were hospitalized. 432 (53.3%) were discharged with worse functional status. Older age, stupor/coma, stroke and intensive care unit (ICU) admission were predictors of worse outcome at discharge. 132 (16.3%) died in hospital. Older age, cancer, cardiovascular complications, refractory shock, stupor/coma and ICU admission were associated with death. 262 were followed for 6 months. Acute stroke or ataxia, ICU admission and degree of functional impairment at discharge were predictors of worse outcome. 65/221 hospitalized patients (29.4%) and 10/32 non-hospitalized patients (24.4%) experienced persisting neurological symptoms/signs. 10/262 patients (3.8%) developed new neurological complaints during the 6 months of follow-up. CONCLUSIONS: Neuro-COVID is a severe disease associated with worse functional status at discharge, particularly in older subjects and those with comorbidities and acute complications of infection. DA - 2022/02/23/ PY - 2022 DO - 10.1111/ene.15293 DP - PubMed J2 - Eur J Neurol LA - eng SN - 1468-1331 L1 - https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ene.15293 L2 - http://www.ncbi.nlm.nih.gov/pubmed/35194889 KW - COVID-19 KW - SARS-CoV-2 KW - outcome KW - neurological disorders KW - predictors ER - TY - JOUR TI - Co-infections in COVID-19 patients and correlation with mortality rate. Minireview AU - Fehér, Ágnes AU - Szarvas, Zsófia AU - Lehoczki, Andrea AU - Fekete, Mónika AU - Fazekas-Pongor, Vince T2 - Physiology International AB - Purpose: The goal of our review was to gather information on the most important community-acquired and hospital-acquired co-infections among coronavirus disease 2019 (COVID-19) patients, and to examine not only the effect of these co-infections on disease outcomes but also to identify the possible risk factors that predispose COVID-19 patients to co-infections. Methods: Medline (PubMed) and Google Scholar were searched for relevant articles published between January 1st, 2020, and September 31st, 2021, on the topic of co-infections among COVID-19 patients. Results: Among community-acquired and hospital-acquired co-infections, bacterial and fungal co-infections are equally frequent, followed by viral co-infections that affected a relatively smaller portion of patients. Overall, co-infections were more frequent in the hospital than at the community level. Risk factors for acquiring co-infections include male gender, longer length of hospital stay, presence of supportive treatment, such as ventilation, the admission to intensive care units, the administration of medications, such as steroids or antibiotics, and certain blood parameters, such as high C-reactive protein or lymphopenia. The presence of co-infections could aggravate the COVID-19 disease severity, prolong the healing time of patients, and lead to worse disease outcomes overall. Conclusion: Co-infections may increase the mortality of COVID-19 patients, especially in the hospital setting. Paying closer attention to hygiene, adhering to diagnostic and therapeutic protocols, implementing antimicrobial stewardship programs could decrease the occurrence of co-infections and lead to improved outcomes for COVID-19 patients. DA - 2022/03/10/ PY - 2022 DO - 10.1556/2060.2022.00015 DP - PubMed VL - 109 IS - 1 SP - 1 EP - 8 J2 - Physiol Int LA - eng SN - 2498-602X L1 - https://akjournals.com/downloadpdf/journals/2060/aop/article-10.1556-2060.2022.00015/article-10.1556-2060.2022.00015.pdf L2 - http://www.ncbi.nlm.nih.gov/pubmed/35218335 KW - co-infection KW - community-acquired KW - COVID-19 disease KW - death rate KW - healthcare-associated ER - TY - JOUR TI - Seroconversion after anti-SARS-CoV-2 mRNA vaccinations among moderate-to-severe psoriatic patients receiving systemic biologicals-Prospective observational cohort study AU - Piros, Éva Anna AU - Cseprekál, Orsolya AU - Görög, Anna AU - Hidvégi, Bernadett AU - Medvecz, Márta AU - Szabó, Zsófia AU - Olajos, Ferenc AU - Barabás, Eszter AU - Galajda, Noémi AU - Miheller, Pál AU - Holló, Péter T2 - Dermatologic Therapy AB - It is unclear whether biological antipsoriatic therapies affect seroconversion after messenger ribonucleic acid (mRNA)-based antisevere acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) vaccinations. To assess antibody formation and the incidence of side effects after anti-SARS-CoV-2 mRNA vaccinations in psoriatic patients receiving different biologicals compared to healthy controls. 102 moderate-to-severe psoriatic patients (56.2 [±13.5] years) and 55 age-matched healthy (56.4 ± 13.6 years) volunteers were included in our study. Ten to 21 days after the administration of the second dosage of BNT162b2 or mRNA-1273 vaccine, antibody levels specific to the SARS-CoV-2 spike (S) protein receptor binding domain were monitored. The incidence of postvaccination side effects was recorded and compared to real-life data in the literature. Of the 102 patients, 57 (55.88%) received tumor necrosis factor (TNF), 28 (27.45%) received interleukin (IL)-12/23, 16 (15.68%) received IL-17, and 1 (0.99%) received IL-23 inhibitors. No significant differences in the median serum level of anti-SARS-CoV-2S antibody were observed between the study population and the control group (median IQR range: 1681.0 U/mL (600.0-4844.0) versus 1984.0 U/mL (1000.0-3136.0; p = 0.82). The most frequent side effects of the mRNA vaccines within 7 days after the administration of both dosages were arm pain on the side of injection (23.53% and 23.53%), fatigue (9.80% and 13.72%), headache (4.9% and 5.88%), and chills or shivering (4.9% and 8.82%). Detectable antibodies against SARS-CoV-2S protein appear 10-21 days after the administration of the second dosage of BNT162b2 or mRNA-1273 vaccines in moderate-to-severe psoriatic patients receiving biologicals, similar to those of healthy controls. DA - 2022/02/26/ PY - 2022 DO - 10.1111/dth.15408 DP - PubMed SP - e15408 J2 - Dermatol Ther LA - eng SN - 1529-8019 L2 - http://www.ncbi.nlm.nih.gov/pubmed/35218276 KW - SARS-CoV-2 KW - biologic therapy KW - mRNA vaccine KW - psoriasis KW - seroconversion ER - TY - JOUR TI - [Monitoring the development of post-COVID–19 syndrome] AU - Tamasi, József AU - Kalabay, László T2 - Orvosi Hetilap AB - Összefoglaló. Bevezetés: A SARS-CoV-2-fertőzés elhúzódó tüneteit 4 héten túl poszt-COVID-19-tüneteknek nevezzük, és fennállási idő szerint csoportosítjuk. Célkitűzés: A vizsgálat célja egy háziorvosi körzet megközelítőleg állandó populációjában megfigyelni, hogy adott időintervallumon belül a SARS-CoV-2-fertőzöttek között milyen arányban, milyen jellegű poszt-COVID-19-tünetek alakulnak ki, és mennyi ideig tartanak. Módszer: 282 SARS-CoV-2-beteg tüneteit 2020. szeptember 1. és 2021. szeptember 1. között követtük, 4 hetente, 15-42 héten át - elhúzódó szaglászavar esetén 30-50 héten át -, elsősorban telefonos interjúk segítségével. Eredmények: Egy hónapon túli panaszok a betegek 67%-ában (170 fő) alakultak ki. A leggyakoribb tünet a fáradékonyság (79 fő, 29%) és a szaglászavar volt (74 fő, 27%). Az utóbbi jellemzően nem dohányzók körében lépett fel, és a COVID-19-fertőzöttek 2,5%-ában 43 héten túl is fennmaradt. A fáradékonyság panaszköre a poszt-COVID-19-betegek 46%-át érintette. Ezen betegek szignifikánsan hosszabb időt töltöttek keresőképtelenségi állományban, mint azok, akik nem voltak fáradékonyak (12,3 vs. 19,7 nap). Az enyhe SARS-CoV-2-fertőzést követő súlyos fáradékonysággal küzdő betegek a panaszaikat szindrómaszerűen írták le, melyre jellemző volt a palpitáció, a fáradékonyság, a terhelésre jelentkező légszomj, az alvászavar, a laza széklet és a posturalis panaszok. Ezek átlagosan 19 hét alatt múltak el. Megbeszélés: A poszt-COVID-19-tünetek kialakulása enyhe lefolyás mellett is gyakori, a lefolyás súlyossága sok esetben nincs arányban a poszt-COVID-19-fáradékonyság súlyosságával. A posztakut-COVID-19-fáradékony betegek kórházi kezelést nem igénylő csoportja számos tényező alapján elkülöníthető a posztakut-COVID-19-fáradékony betegek hospitalizált csoportjától. Következtetés: Az enyhe COVID-19-fertőzést is követheti elhúzódó fáradékonyság poszt-COVID-19-tünetként, mely spontán regrediál. SARS-CoV-2-fertőzést követően hosszú távon fennmaradhat szaglászavar, illetve a középsúlyos és súlyos COVID-19-eseteket követően fáradékonyság. Orv Hetil. 2022; 163(9): 335-342. SUMMARY: INTRODUCTION: Extended symptoms may develop after a SARS-CoV-2 infection. We refer to these as post-COVID-19 symptoms and they are grouped according to time duration. OBJECTIVE: The aim of the study was to follow all COVID-19 infected patients in a family practise, to observe all post-COVID-19 symptoms, symptom development rates and to document how long they last. METHOD: 282 SARS-CoV-2 patients were followed mainly through telephone interviews between 01. 09. 2020 and 01. 09. 2021. Post-COVID-19 symptoms were monitored for 15-42 weeks every 4 weeks (30-50 weeks in cases of delayed hypsomia). RESULTS: Symptoms lasting longer than a month developed in 67% of all patients (170 cases). The most frequent symptoms were fatigue (79 cases, 29%) and hyposmia (74 cases, 27%). The latter mainly developed in non-smokers, affecting 2,5% of all COVID-19 patients beyond 43 weeks. Fatigue affected 46% of all post-COVID-19 patients. Sick leave was significantly longer among these patients (19.7 vs. 12.3 days in patients with no fatigue). Severe post-COVID-19 fatigue in non-hospitalized patients presented in a sydrome-like appearance displaying palpitations, fatigue, dyspnoea, sleep disturbances, loose stools and postural complaints. These regrediated after 19 weeks. DISCUSSION: Post-COVID-19 symptoms often develop after a mild COVID-19 infection. Severity of COVID-19 infection and severity of post-COVID-19 symptoms often do not correlate. Groups of hospitalized and non-hospitalized post-acute COVID patients with fatigue can be distinguished by many attributes. CONCLUSION: Mild COVID-19 infections may also be followed up by severe fatigue, but it spontenaously regrediates. Long-term effects of COVID-19 are permanent hyposmia and fatigue (the latter affect some hospitalized COVID-19 patients). Orv Hetil. 2022; 163(9): 335-342. DA - 2022/02/27/ PY - 2022 DO - 10.1556/650.2022.32432 DP - PubMed VL - 163 IS - 9 SP - 335 EP - 342 J2 - Orv Hetil LA - hun SN - 1788-6120 UR - https://akjournals.com/view/journals/650/163/9/article-p335.xml L2 - http://www.ncbi.nlm.nih.gov/pubmed/35220274 KW - Humans KW - COVID-19 KW - SARS-CoV-2 KW - Fatigue KW - Hungary KW - SARS-CoV-2 infection KW - fáradékonyság KW - fatigue KW - olfactorian disorders KW - post-acute COVID–19 syndrome KW - poszt-COVID-szindróma KW - SARS-CoV-2-fertőzés KW - Syndrome KW - szaglászavar ER - TY - JOUR TI - Cyber victimization during the COVID-19 pandemic: A syndemic looming large AU - Shoib, Sheikh AU - Philip, Sharad AU - Bista, Seema AU - Saeed, Fahimeh AU - Javed, Sana AU - Ori, Dorottya AU - Bashir, Adil AU - Chandradasa, Miyuru T2 - Health Science Reports DA - 2022/03// PY - 2022 DO - 10.1002/hsr2.528 DP - PubMed VL - 5 IS - 2 SP - e528 J2 - Health Sci Rep LA - eng SN - 2398-8835 ST - Cyber victimization during the COVID-19 pandemic L1 - https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/hsr2.528 L2 - http://www.ncbi.nlm.nih.gov/pubmed/35224224 ER - TY - JOUR TI - To Help or Not to Help? Prosocial Behavior, Its Association With Well-Being, and Predictors of Prosocial Behavior During the Coronavirus Disease Pandemic AU - Haller, Elisa AU - Lubenko, Jelena AU - Presti, Giovambattista AU - Squatrito, Valeria AU - Constantinou, Marios AU - Nicolaou, Christiana AU - Papacostas, Savvas AU - Aydın, Gökçen AU - Chong, Yuen Yu AU - Chien, Wai Tong AU - Cheng, Ho Yu AU - Ruiz, Francisco J. AU - García-Martín, María B. AU - Obando-Posada, Diana P. AU - Segura-Vargas, Miguel A. AU - Vasiliou, Vasilis S. AU - McHugh, Louise AU - Höfer, Stefan AU - Baban, Adriana AU - Dias Neto, David AU - da Silva, Ana Nunes AU - Monestès, Jean-Louis AU - Alvarez-Galvez, Javier AU - Paez-Blarrina, Marisa AU - Montesinos, Francisco AU - Valdivia-Salas, Sonsoles AU - Ori, Dorottya AU - Kleszcz, Bartosz AU - Lappalainen, Raimo AU - Ivanović, Iva AU - Gosar, David AU - Dionne, Frederick AU - Merwin, Rhonda M. AU - Karekla, Maria AU - Kassianos, Angelos P. AU - Gloster, Andrew T. T2 - Frontiers in Psychology AB - The coronavirus disease (COVID-19) pandemic fundamentally disrupted humans' social life and behavior. Public health measures may have inadvertently impacted how people care for each other. This study investigated prosocial behavior, its association well-being, and predictors of prosocial behavior during the first COVID-19 pandemic lockdown and sought to understand whether region-specific differences exist. Participants (N = 9,496) from eight regions clustering multiple countries around the world responded to a cross-sectional online-survey investigating the psychological consequences of the first upsurge of lockdowns in spring 2020. Prosocial behavior was reported to occur frequently. Multiple regression analyses showed that prosocial behavior was associated with better well-being consistently across regions. With regard to predictors of prosocial behavior, high levels of perceived social support were most strongly associated with prosocial behavior, followed by high levels of perceived stress, positive affect and psychological flexibility. Sociodemographic and psychosocial predictors of prosocial behavior were similar across regions. DA - 2021/// PY - 2021 DO - 10.3389/fpsyg.2021.775032 DP - PubMed VL - 12 SP - 775032 J2 - Front Psychol LA - eng SN - 1664-1078 ST - To Help or Not to Help? L1 - https://www.frontiersin.org/articles/10.3389/fpsyg.2021.775032/pdf L2 - http://www.ncbi.nlm.nih.gov/pubmed/35222147 KW - COVID-19 pandemic KW - social support KW - well-being KW - predictors of prosocial behavior KW - prosocial behavior ER - TY - JOUR TI - COVID-19 infection in patients with chronic obstructive pulmonary disease: From pathophysiology to therapy. Mini-review AU - Fekete, Monika AU - Szarvas, Zsofia AU - Fazekas-Pongor, Vince AU - Feher, Agnes AU - Dosa, Norbert AU - Lehoczki, Andrea AU - Tarantini, Stefano AU - Varga, Janos Tamas T2 - Physiology International AB - Abstract Introduction Patients with chronic obstructive pulmonary disease (COPD) are a vulnerable group in terms of the outcome of coronavirus infection in relation to their disease or its treatment, with a higher risk of developing serious complications compared to the healthy population. Aim The aim of our summary study is to review the background and health outcomes of chronic obstructive pulmonary disease and COVID-19 infection in the presence of both diseases. Methods Review of national and international medical databases (PubMed, MEDLINE, and MOB) with keywords COPD, COVID-19, disease risk, cause, prevention, complications, and prognosis. Results Meta-analyses show that COPD is one of the most common underlying conditions in patients hospitalized for COVID-19. Such patients are five times more likely to develop a serious complication due to oxygen supply problems therefore they are more likely to be admitted to intensive care units, where they may require mechanical ventilation. In the case of underlying COPD, the usual care plan for COVID-19 infection should be followed, as well as all public health recommendations to minimize the risk of developing and transmitting COVID-19. Conclusion Coronavirus infection is especially dangerous for COPD patients, who are much more likely to become seriously ill, so increased surveillance, prevention, early detection, adequate treatment and rehabilitation of the disease group are of paramount importance. DA - 2022/03/10/ PY - 2022 DO - 10.1556/2060.2022.00172 DP - DOI.org (Crossref) VL - 109 IS - 1 SP - 9 EP - 19 J2 - PhysInt SN - 2498-602X, 2677-0164 ST - COVID-19 infection in patients with chronic obstructive pulmonary disease UR - https://akjournals.com/view/journals/2060/109/1/article-p9.xml Y2 - 2022/04/11/07:21:07 L1 - https://akjournals.com/downloadpdf/journals/2060/aop/article-10.1556-2060.2022.00172/article-10.1556-2060.2022.00172.pdf ER - TY - JOUR TI - Povidone-Iodine as a Pre-Procedural Mouthwash to Reduce the Salivary Viral Load of SARS-CoV-2: A Systematic Review of Randomized Controlled Trials AU - Garcia-Sanchez, Alvaro AU - Peña-Cardelles, Juan-Francisco AU - Ordonez-Fernandez, Esther AU - Montero-Alonso, María AU - Kewalramani, Naresh AU - Salgado-Peralvo, Angel-Orión AU - Végh, Dániel AU - Gargano, Angélica AU - Parra, Gabriela AU - Guerra-Guajardo, Lourdes-Isabela AU - Kozuma, Wataru T2 - International Journal of Environmental Research and Public Health AB - The use of pre-procedural rinses has been investigated to reduce the number of viral particles and bacteria in aerosols, potentially decreasing the risk of cross-infection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) during medical and dental procedures. This review aims to confirm whether there is evidence in the literature describing a reduction in salivary load of SARS-CoV-2 when povidone-iodine (PVP-I) is used as a pre-intervention mouthwash. An search of the MEDLINE, Embase, SCOPUS, and the Cochrane library databases was conducted. The criteria used followed the PRISMA® Statement guidelines. Randomized controlled trials investigating the reduction of salivary load of SARS-CoV-2 using PVP-I were included. Ultimately, four articles were included that met the established criteria. According to the current evidence, PVP-I is effective against SARS-CoV-2 in saliva and could be implemented as a rinse before interventions to decrease the risk of cross-infection in healthcare settings. DA - 2022/03/01/ PY - 2022 DO - 10.3390/ijerph19052877 DP - PubMed VL - 19 IS - 5 SP - 2877 J2 - Int J Environ Res Public Health LA - eng SN - 1660-4601 ST - Povidone-Iodine as a Pre-Procedural Mouthwash to Reduce the Salivary Viral Load of SARS-CoV-2 L1 - https://www.mdpi.com/1660-4601/19/5/2877/pdf L2 - http://www.ncbi.nlm.nih.gov/pubmed/35270569 KW - Humans KW - COVID-19 KW - SARS-CoV-2 KW - Viral Load KW - Randomized Controlled Trials as Topic KW - aerosols KW - cetylpiridinium chloride KW - chlorhexidine KW - colony-forming units KW - hydrogen peroxide KW - mouthrinse KW - mouthwashes KW - Mouthwashes KW - povidone-iodine KW - Povidone-Iodine ER - TY - JOUR TI - In Vitro Determination of Inhibitory Effects of Humic Substances Complexing Zn and Se on SARS-CoV-2 Virus Replication AU - Hajdrik, Polett AU - Pályi, Bernadett AU - Kis, Zoltán AU - Kovács, Noémi AU - Veres, Dániel Sándor AU - Szigeti, Krisztián AU - Budán, Ferenc AU - Hegedüs, Imre AU - Kovács, Tibor AU - Bergmann, Ralf AU - Máthé, Domokos T2 - Foods (Basel, Switzerland) AB - (1) Background: Humic substances are well-known human nutritional supplement materials and they play an important performance-enhancing role as animal feed additives. For decades, ingredients of humic substances have been proven to carry potent antiviral effects against different viruses. (2) Methods: Here, the antiviral activity of a humic substance containing ascorbic acid, Se- and Zn2+ ions intended as a nutritional supplement material was investigated against SARS-CoV-2 virus B1.1.7 Variant of Concern ("Alpha Variant") in a VeroE6 cell line. (3) Results: This combination has a significant in vitro antiviral effect at a very low concentration range of its intended active ingredients. (4) Conclusions: Even picomolar concentration ranges of humic substances, Vitamin C and Zn/Se ions in the given composition, were enough to achieve 50% viral replication inhibition in the applied SARS-CoV-2 virus inhibition test. DA - 2022/02/26/ PY - 2022 DO - 10.3390/foods11050694 DP - PubMed VL - 11 IS - 5 SP - 694 J2 - Foods LA - eng SN - 2304-8158 L1 - https://www.mdpi.com/2304-8158/11/5/694/pdf L2 - http://www.ncbi.nlm.nih.gov/pubmed/35267328 KW - SARS-CoV-2 KW - antiviral activity KW - fulvic acid KW - humic acid KW - RT-PCR KW - Zn-Se-ascorbic acid complex ER - TY - JOUR TI - Differential Diagnostic Challenges in the COVID-19 Pandemic: Renal Abscess After SARS-CoV-2 Infection in a Young Adolescent AU - Martonosi, Ágnes Rita AU - Pázmány, Piroska AU - Fukász, Ádám AU - Rudolf, Judit AU - Kovács, Éva AU - Szakács, Zsolt AU - Szabó, László T2 - The American Journal of Case Reports AB - BACKGROUND Prolonged fever in pediatric patients is often a diagnostic challenge. Clinicians tend to associate prolonged fever with COVID-19-related diseases in patients with a history of SARS-CoV-2 infection. Here we present a patient who was admitted with a clinical suspicion of multi-inflammatory syndrome in children (MIS-C) and was finally diagnosed with a renal abscess. CASE REPORT A 16-year-old girl with prolonged fever, bilateral non-purulent conjunctivitis, weight loss, muscle pain, general malaise, cough, and yellow sputum was admitted to Heim Pál National Pediatric Institute, Budapest, Hungary. She had proven SARS-CoV-2 infection 3 weeks prior to admission. Although inflammatory markers were elevated, repeated urine analyses, aerobic and anaerobic urine cultures, hemoculture, chest X-ray, and otorhinolaryngology examinations were negative. Based on clinical and laboratory criteria, the diagnosis of MIS-C was eventually ruled out. Abdominal ultrasound revealed a 17×20×15 mm simplex cyst at the edge of the parenchyma in the upper third of the left kidney. Magnetic resonance imaging was performed, showing a multi-compartment, septated, thick-walled parenchymal lesion of 50×40×52 mm in the upper pole of the right kidney, which showed signal characteristics of an abscess, and 20×16 mm and 8 mm lesions in the upper pole of the left kidney, which appeared to be cysts. After being unresponsive to intravenous wide-spectrum antibiotic therapy (meropenem 2 g tid for 5 days), surgical intervention was needed to remove the abscess. CONCLUSIONS This case demonstrates that during the COVID-19 pandemic, besides the obvious post-COVID etiology, other life-threatening conditions should be investigated in the first line. DA - 2022/03/13/ PY - 2022 DO - 10.12659/AJCR.935190 DP - PubMed VL - 23 SP - e935190 J2 - Am J Case Rep LA - eng SN - 1941-5923 ST - Differential Diagnostic Challenges in the COVID-19 Pandemic L2 - http://www.ncbi.nlm.nih.gov/pubmed/35279666 KW - Child KW - Female KW - Humans KW - Adolescent KW - COVID-19 KW - SARS-CoV-2 KW - Pandemics KW - Abscess KW - Systemic Inflammatory Response Syndrome ER - TY - JOUR TI - [SARS-CoV-2 infection and its prevention in pediatric autoimmune diseases] AU - Constantin, Tamás AU - Kulcsár, Andrea AU - Krivácsy, Péter AU - Mészner, Zsófia AU - Ponyi, Andrea AU - Tóth, Attila AU - Ónozó, Beáta AU - Szekanecz, Zoltán T2 - Orvosi Hetilap AB - Összefoglaló. A krónikus autoimmun betegségben szenvedőkben a súlyos COVID-19 kialakulásának kockázata magasabb, a SARS-CoV-2-fertőzés pedig a krónikus alapbetegség progressziójához, fellángolásához vezethet. A COVID-19 elkerülésének legbiztonságosabb, legköltséghatékonyabb módszere a vakcináció, illetve az emellett alkalmazott higiénés szabályok betartása, a megfelelő maszk viselése. A hiedelemmel ellentétben önmagában az autoimmun megbetegedés nem jelent oltási ellenjavallatot, sőt a rizikóállapot miatt ezek a betegek az elsők között oltandók. A COVID-19 elleni vakcina alkalmazásának egyetlen egyértelmű kontraindikációja az anamnézisben szereplő súlyos allergiás reakció (anafilaxia) a vakcina valamelyik alkotórészével szemben. A betegek olthatóságát többek között befolyásolja az aktuális betegségaktivitás és az alkalmazott kezelés. Az immunizáció idejét a legbiztonságosabban a gondozó orvos tervezheti meg. Az autoimmun betegek immunizációja során észlelhető oltási reakciók és szövődmények incidenciája megegyezik az egészséges populációban is tapasztalt előfordulási gyakorisággal. Orv Hetil. 2022; 163(11): 414-423. Summary. The risk of developing severe COVID-19 is higher in patients with autoimmune diseases, and SARS-CoV-2 infection can lead to progression and exacerbation of the underlying chronic disease. The safest and most cost-effective way to avoid COVID-19 is to be vaccinated, to follow the hygiene rules and to wear an appropriate mask. Contrary to belief, autoimmune disease alone is not a contraindication to vaccination and, in fact, patients should be among the first to be vaccinated because of the risk. The only clear contraindication to the use of COVID-19 vaccine is a history of severe allergic reaction (anaphylaxis) to any of the components of the vaccine. Indication of vaccination migh be influenced by, among other things, the current disease activity and the treatment applied. The timing of immunization can be the most safely planned by the attending physician. The incidence of vaccination reactions and complications during immunization in autoimmune patients is similar to that seen in the healthy population. Orv Hetil. 2022; 163(11): 414-423. DA - 2022/03/13/ PY - 2022 DO - 10.1556/650.2022.32448 DP - PubMed VL - 163 IS - 11 SP - 414 EP - 423 J2 - Orv Hetil LA - hun SN - 1788-6120 UR - https://akjournals.com/view/journals/650/163/11/article-p414.xml L2 - http://www.ncbi.nlm.nih.gov/pubmed/35279647 KW - Autoimmune Diseases KW - Child KW - children KW - COVID-19 KW - COVID-19 Vaccines KW - COVID–19 KW - gyermekek KW - Humans KW - reumatológia KW - rheumatology KW - SARS-CoV-2 KW - vaccination KW - védőoltás KW - Viral Vaccines ER - TY - JOUR TI - Virucidal Activity of Different Mouthwashes against the Salivary Load of SARS-CoV-2: A Narrative Review AU - Garcia-Sanchez, Alvaro AU - Peña-Cardelles, Juan-Francisco AU - Salgado-Peralvo, Angel-Orión AU - Robles, Flor AU - Ordonez-Fernandez, Esther AU - Ruiz, Steve AU - Végh, Dániel T2 - Healthcare AB - The saliva of COVID-19-confirmed patients presents a high viral load of the virus. Aerosols generated during medical and dental procedures can transport the virus and are a possible causative agent of cross-infection. Since the onset of the pandemic, numerous investigations have been attempting to mitigate the risk of transmission by reducing the viral load in saliva using preprocedural mouthwashes. This study aims to review the most up-to-date in vitro and in vivo studies investigating the efficacy of different mouthwashes on reducing the salivary viral load of SARS-CoV-2, giving particular attention to the most recent randomized control trials published. DA - 2022/03/03/ PY - 2022 DO - 10.3390/healthcare10030469 DP - DOI.org (Crossref) VL - 10 IS - 3 SP - 469 J2 - Healthcare LA - en SN - 2227-9032 ST - Virucidal Activity of Different Mouthwashes against the Salivary Load of SARS-CoV-2 UR - https://www.mdpi.com/2227-9032/10/3/469 Y2 - 2022/04/11/07:58:31 L1 - https://www.mdpi.com/2227-9032/10/3/469/pdf ER - TY - JOUR TI - Breakthrough SARS-CoV-2 infections after vaccination: a critical review AU - Mohseni Afshar, Zeinab AU - Barary, Mohammad AU - Hosseinzadeh, Rezvan AU - Alijanpour, Amirmasoud AU - Hosseinzadeh, Dariush AU - Ebrahimpour, Soheil AU - Nazary, Kosar AU - Sio, Terence T. AU - Sullman, Mark J. M. AU - Carson-Chahhoud, Kristin AU - Babazadeh, Arefeh T2 - Human Vaccines & Immunotherapeutics AB - At the beginning of the current pandemic, it was believed that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection would induce lifelong immunity and that reinfections would be unlikely. However, after several cases of reinfection were documented in previously infected patients, this was understood to be a false assumption, and this waning humoral immunity has raised significant concerns. Accordingly, long-term and durable vaccine-induced antibody protection against infection have also become a challenge, as several breakthroughs of COVID-19 infection have been identified in individuals who were fully vaccinated. This review discusses the current evidence on breakthrough COVID-19 infections occurring after vaccination. DA - 2022/03/18/ PY - 2022 DO - 10.1080/21645515.2022.2051412 DP - PubMed SP - 1 EP - 5 J2 - Hum Vaccin Immunother LA - eng SN - 2164-554X ST - Breakthrough SARS-CoV-2 infections after vaccination L1 - https://www.tandfonline.com/doi/pdf/10.1080/21645515.2022.2051412?needAccess=true L2 - http://www.ncbi.nlm.nih.gov/pubmed/35302905 KW - COVID-19 KW - SARS-CoV-2 KW - vaccination KW - breakthrough KW - immunization ER - TY - JOUR TI - COVID-19: autoimmunity, multisystemic inflammation and autoimmune rheumatic patients AU - Szekanecz, Zoltán AU - Balog, Attila AU - Constantin, Tamás AU - Czirják, László AU - Géher, Pál AU - Kovács, László AU - Kumánovics, Gábor AU - Nagy, György AU - Rákóczi, Éva AU - Szamosi, Szilvia AU - Szűcs, Gabriella AU - Vályi-Nagy, István T2 - Expert Reviews in Molecular Medicine AB - Coronavirus disease 2019 (COVID-19) is associated with autoimmunity and systemic inflammation. Patients with autoimmune rheumatic and musculoskeletal disease (RMD) may be at high risk for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In this review, based on evidence from the literature, as well as international scientific recommendations, we review the relationships between COVID-19, autoimmunity and patients with autoimmune RMDs, as well as the basics of a multisystemic inflammatory syndrome associated with COVID-19. We discuss the repurposing of pharmaceutics used to treat RMDs, the principles for the treatment of patients with autoimmune RMDs during the pandemic and the main aspects of vaccination against SARS-CoV-2 in autoimmune RMD patients. DA - 2022/03/15/ PY - 2022 DO - 10.1017/erm.2022.10 DP - PubMed VL - 24 SP - e13 J2 - Expert Rev Mol Med LA - eng SN - 1462-3994 ST - COVID-19 L1 - https://www.cambridge.org/core/services/aop-cambridge-core/content/view/7F50815BD5DC9F095AED1F90C0546C71/S1462399422000102a.pdf/div-class-title-covid-19-autoimmunity-multisystemic-inflammation-and-autoimmune-rheumatic-patients-div.pdf L2 - http://www.ncbi.nlm.nih.gov/pubmed/35311631 KW - Humans KW - COVID-19 KW - SARS-CoV-2 KW - drug repurposing KW - vaccination KW - Autoimmunity KW - Inflammation KW - multisystemic inflammatory syndrome KW - Musculoskeletal Diseases KW - rheumatic and musculoskeletal diseases ER - TY - JOUR TI - Characteristics of the Third COVID-19 Pandemic Wave with Special Focus on Socioeconomic Inequalities in Morbidity, Mortality and the Uptake of COVID-19 Vaccination in Hungary AU - Oroszi, Beatrix AU - Juhász, Attila AU - Nagy, Csilla AU - Horváth, Judit Krisztina AU - Komlós, Krisztina Eszter AU - Túri, Gergő AU - McKee, Martin AU - Ádány, Róza T2 - Journal of Personalized Medicine AB - Governments are increasingly looking to vaccination to provide a path out of the COVID-19 pandemic. Hungary offers an example to investigate whether social inequalities compromise what a successful vaccine program can achieve. COVID-19 morbidity, mortality, and vaccination coverage were characterized by calculation of indirectly standardized ratios in the Hungarian population during the third pandemic wave at the level of municipalities, classified into deprivation quintiles. Then, their association with socioeconomic deprivation was assessed using ecological regression. Compared to the national average, people living in the most deprived municipalities had a 15–24% lower relative incidence of confirmed COVID-19 cases, but a 17–37% higher relative mortality and a 38% lower vaccination coverage. At an ecological level, COVID-19 mortality showed a strong positive association with deprivation and an inverse association with vaccination coverage (RRVaccination = 0.86 (0.75–0.98)), but the latter became non-significant after adjustment for deprivation (RRVaccination = 0.95 (0.84–1.09), RRDeprivation = 1.10 (1.07–1.14)). Even what is widely viewed as one of the more successful vaccine roll outs was unable to close the gap in COVID-19 mortality during the third pandemic wave in Hungary. This is likely to be due to the challenges of reaching those living in the most deprived municipalities who experienced the highest mortality rates during the third wave. DA - 2022/03/03/ PY - 2022 DO - 10.3390/jpm12030388 DP - DOI.org (Crossref) VL - 12 IS - 3 SP - 388 J2 - JPM LA - en SN - 2075-4426 UR - https://www.mdpi.com/2075-4426/12/3/388 Y2 - 2022/04/11/08:26:08 L1 - https://www.mdpi.com/2075-4426/12/3/388/pdf ER - TY - JOUR TI - Inappropriate use of ivermectin during the COVID-19 pandemic: Primum non nocere! AU - Barac, Aleksandra AU - Bartoletti, Michele AU - Azap, Ozlem AU - Bussini, Linda AU - Ergonul, Onder AU - Krause, Robert AU - Paño-Pardo, José Ramón AU - Power, Nicholas R. AU - Rodríguez-Baño, Jesús AU - Sibani, Marcella AU - Szabo, Balint Gergely AU - Tsiodras, Sotirios AU - Verweij, Paul E. AU - Quirós, Alejandro Martín AU - Zollner-Schwetz, Ines T2 - Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases DA - 2022/03/23/ PY - 2022 DO - 10.1016/j.cmi.2022.03.022 DP - PubMed SP - S1198 EP - 743X(22)00161-6 J2 - Clin Microbiol Infect LA - eng SN - 1469-0691 ST - Inappropriate use of ivermectin during the COVID-19 pandemic L1 - https://www.clinicalmicrobiologyandinfection.com/article/S1198743X22001616/pdf L2 - http://www.ncbi.nlm.nih.gov/pubmed/35337977 KW - COVID-19 KW - clinical trial KW - treatment KW - ESCMID guidelines KW - Ivermectin ER - TY - JOUR TI - Vascular procedures during the COVID-19 pandemic in a high volume Eastern European interventional radiology department AU - Bérczi, Ákos AU - Kaposi Novák, Pál AU - Sarkadi, Hunor AU - Csongor, Péter AU - Bérczi, Viktor AU - Dósa, Edit T2 - Imaging AB - Abstract Aim To assess the impact of the COVID-19 outbreak on trends in hospital admissions and number of diagnostic and therapeutic procedures in the largest tertiary vascular center in Hungary. Patients and Methods A retrospective analysis was carried out. The first wave of the COVID-19 pandemic occurred approximately from March 15 until June 1 in Hungary. We have compared the same period of 2020 to 2019. Electronic medical records were reviewed for the clinical status of the patients and treatment-related information. Results The total number of diagnostic angiographies and therapeutic interventions in 2020 ( N = 233) decreased significantly ( P = 0.046) compared to 2019 ( N = 373). The ratio of Fontaine stage I–II cases to Fontaine stage III–IV cases for both diagnostic angiographies and therapeutic interventions was significantly lower (OR, 2.11; 95% CI, 1.26–3.59; P = 0.007 and OR, 3.22; 95% CI, 1.67–6.52; P < 0.001) in 2020 (0.36 and 0.27) than in 2019 (0.77 and 0.89). There was also a negative but not significant change in the number of supra-aortic (including internal carotid artery stenting) ( P = 0.128) and other vascular therapeutic interventions (superior vena caval stenting, hemodialysis access percutaneous transluminal angioplasty [PTA], visceral artery/vein PTA/stenting, embolization) ( P = 0.452) in 2020 ( N = 16 and N = 21) compared to 2019 ( N = 39 and N = 37). Conclusion The first wave of the COVID-19 pandemic had a negative effect on the total number of endovascular procedures in the largest tertiary vascular center in Hungary. DA - 2021/12/20/ PY - 2021 DO - 10.1556/1647.2021.00032 DP - DOI.org (Crossref) VL - 13 IS - 2 SP - 138 EP - 141 J2 - IMAGING SN - 2732-0960 UR - https://akjournals.com/view/journals/1647/13/2/article-p138.xml Y2 - 2022/04/11/09:36:47 L1 - https://akjournals.com/downloadpdf/journals/1647/13/2/article-p138.pdf ER - TY - JOUR TI - The secondary effect of the first wave of COVID-19 and its consequences on myocardial infarction care in a high volume Hungarian cardiovascular centre AU - Skoda, Réka AU - Fülöp, Gábor AU - Csulak, Emese AU - Danics, Krisztina AU - Törő, Klára AU - Bokor, Laura AU - Bárczi, György AU - Merkely, Béla AU - Becker, Dávid T2 - Cor et Vasa DA - 2021/07/20/ PY - 2021 DO - 10.33678/cor.2020.101 DP - DOI.org (Crossref) VL - 63 IS - 3 SP - 345 EP - 349 J2 - Cor Vasa SN - 00108650, 18037712 UR - http://e-coretvasa.cz/doi/10.33678/cor.2020.101.html Y2 - 2022/04/11/09:42:41 L1 - https://e-coretvasa.cz/doi/10.33678/cor.2020.101.pdf ER - TY - JOUR TI - [Can we influence the negative drug attitude? Interpretation of the rejection of COVID-19 vaccine in the light of results of a pilot study] AU - Pogány, László AU - Horváth, András A. AU - Lazáry, Judit T2 - Ideggyogyaszati Szemle AB - Background and purpose: Vaccination refusal is a serious obstacle to minimizing the spread of COVID-19. Nevertheless, the rejection of vaccine can be considered the result of a negative attitude towards medical treatment, and according to our previously published data, it can be influenced by the underlying affective state. Increased incidence of affective disorders and anxiety could be observed globally during the pandemic, which may have a significant impact on vaccination acceptance. The aim of our pilot study was to determine the association between clinical improvement of affective and neurocognitive symptoms and change of drug attitude and health control beliefs in a sample of psychiatric patients. Methods: A data set of 85 patients with psychiatric disorder has been analysed with the use of Patient's Health Belief Questionnaire on Psychiatric Treatment (PHBQPT) with 5 subscales (Negative Aspect of Medication - NA; Positive Aspect of Medication - PA; Doctor health locus of control- Doctor HLOC; Internal HLOC; Psychological Reactance - PR); Hospital Anxiety Depression Scale (HADS-Anx; HADS-Dep) and neurocognitive tests, such as the Stroop test and the Trail Making Tests. All the tests were performed before and after a 14 days treatment. Paired t-tests and generalized linear models were performed to assess the associations between the variables. Results: The baseline scores of NA and HADS-Anx correlated significantly (p=0.001) and after two weeks of treatment NA decreased (p=0.001), while Doctor HLOC and Internal HLOC increased (p=0.001 and p=0.006). The patients performance of the neurocognitive tests improved (all p<0.05). The reduction of HADS-Anx (p=0.002) and HADS-Dep (p=0.006) scores showed significant associations with the decrease of NA. Increase of the PA score was associated with reduction of HADS-Dep (p=0.028). Improvement of neurocognitive functions had no effect on PHBQPT scores. Conclusion: Important conclusions can be drawn regarding the rejection of the COVID-19 vaccine based on the associations found between the intensity of affective and anxiety symptoms and the attitude towards treatment. Our findings suggest that affective symptoms have a negative influence on the attitude towards treatment and that the improvement of these symptoms can facilitate the acceptance of the therapy, regardless of diagnosis. The modest effect of the improvement of neurocognitive functioning on the attitude towards drugs and the significant role of affective-emotional factors suggest that the accep-tance of vaccination probably cannot be facilitated solely with the aid of educational programs. Considering the increasing incidence of affective disorders during the COVID-19 pandemic, the screening of affective and anxiety symptoms and treatment of these disorders could be an important step towards the acceptance of the vaccine. Although psychiatry is not considered as a frontline care unit of the COVID cases, more attention is needed to pay on the availability of mental health services because refuse of vaccine can develop due to affective disorders too. DA - 2022/03/31/ PY - 2022 DO - 10.18071/isz.75.0111 DP - PubMed VL - 75 IS - 03-04 SP - 111 EP - 116 J2 - Ideggyogy Sz LA - hun SN - 0019-1442 ST - Can we influence the negative drug attitude? L2 - http://www.ncbi.nlm.nih.gov/pubmed/35357785 KW - Humans KW - COVID-19 KW - Pandemics KW - COVID-19 Vaccines KW - anti-vax behavior KW - Anxiety Disorders KW - drug attitude KW - health beliefs KW - Pilot Projects KW - psychological reactance KW - rejection of vaccination ER - TY - JOUR TI - [Lifelong vaccination strategy as a tool against pandemics in Hungary] AU - Ugrin, Irina AU - Dombrádi, Viktor AU - Joó, Tamás AU - Nagyjánosi, László AU - Palicz, Tamás AU - Varga, Gergely AU - Lakatos, Botond AU - Szerencsés, Viktória AU - Lám, Judit T2 - Orvosi Hetilap AB - Összefoglaló. Különböző tényezők következtében az új és újra felbukkanó fertőző betegségek megjelenésére a 21. században egyre nagyobb az esély, ezzel párhuzamosan a pandémiák kialakulása is nagyobb valószínűségű. A 2019-ben felbukkant COVID-19-járvány azt is közvetíti számunkra, hogy egyes új és újra jelentkező fertőző betegségek - az eredményes intézkedések elmaradása, késlekedése esetén - gyorsan terjedhetnek. A fertőző betegségek elleni harc egyik fő eszköze a védőoltás segítségével történő immunizáció. A jelen tanulmány célja bemutatni a védőoltások előnyeit, fókuszba helyezve az elöregedő társadalomban az élethosszan tartó immunizációs stratégiának a személyes egészségre ható, közegészségügyi, gazdasági, valamint társadalmi érdekeit. Az oltás előnyeinek minél nagyobb fokú kihasználásához egy élethosszan tartó immunizációs stratégia felállítása javasolható, amelynek aspektusait és gyakorlatba ültetésének lehetséges lépéseit foglaltuk össze közleményünkben. Orv Hetil. 2022; 163(14): 535-543. Summary. Due to various factors, the chances of infectious disease emergence or re-emergence have increased in the 21st century, thus, the likelihood of new emerging pandemics has also increased. The COVID-19 pandemic, which appeared in 2019, has highlighted that certain new and re-emerging infectious diseases - in the case of lack or delay in effective measures - can spread very rapidly. The main tool for the fight against infectious diseases is immunization through vaccination. While focusing on the personal health, public health, economic and societal benefits of a lifelong immunization strategy, especially in light of the aging society, the goal of this paper is to present the benefits of vaccines. In order to increase the added value of vaccinations it is recommended to create a lifelong immunization strategy. Our paper summarizes the relevant aspects of such a strategy, highlighting potential practical steps towards implementation. Orv Hetil. 2022; 163(14): 535-543. DA - 2022/04/03/ PY - 2022 DO - 10.1556/650.2022.32408 DP - PubMed VL - 163 IS - 14 SP - 535 EP - 543 J2 - Orv Hetil LA - eng SN - 1788-6120 UR - https://akjournals.com/view/journals/650/163/14/article-p535.xml L2 - http://www.ncbi.nlm.nih.gov/pubmed/35377853 KW - Humans KW - COVID-19 KW - Pandemics KW - Vaccination KW - primary prevention KW - pandemic KW - COVID–19 KW - vaccination KW - egészséges öregedés KW - healthy aging KW - immunizációs program KW - immunization program KW - Mentha KW - pandémia KW - primer prevenció KW - Vaccines KW - vakcináció ER - TY - JOUR TI - The effect of the Covid-19 pandemic on the mental health of students and teaching staff AU - Sipeki, I. AU - Vissi, T. AU - Túri, I. T2 - Heliyon AB - In the past decade, mental health is embedded in the concept of health and teachers' mental health has become the focus of surveys. In this study we examined the mental health of special educator-students compared to their lecturers and inspectors at the University Semmelweis Pető András Faculty. We used the validated Hungarian language Mental Health Test (MHT) to assess the mental health. The MHT is linked to the concept of physical and mental wellbeing, it is ability-based approach, and examines 5 areas: wellbeing, savoring, creative-executive efficiency self-regulation resilience. Altogether 237 questionnaires had been returned that were suitable for evaluation (19 lecturers, 16 instructors and 202 students). Students' mean values are lower than the instructors' and lecturers' mean values, and students presented significant lower scores in three scales: self-regulation, creative-executive efficiency, and resilience subscales. In the wellbeing scale we found significant correlation with the existence of the separate room to learn/work during the home-office. These results point to the need for the university to pay attention to the mental health of students, who will be able to consciously monitor their mental health, and who are able to provide effective support to their students. DA - 2022/03/28/ PY - 2022 DO - 10.1016/j.heliyon.2022.e09185 DP - PubMed VL - 8 IS - 4 SP - e09185 J2 - Heliyon LA - eng SN - 2405-8440 L1 - https://www.cell.com/article/S240584402200473X/pdf L2 - http://www.ncbi.nlm.nih.gov/pubmed/35372705 KW - Mental health KW - Covid-19 KW - Higher education ER - TY - JOUR TI - ESCMID COVID-19 living guidelines: drug treatment and clinical management: author's reply AU - Bartoletti, Michele AU - Azap, Ozlem AU - Barac, Aleksandra AU - Bussini, Linda AU - Ergonul, Onder AU - Krause, Robert AU - Martín-Quirós, Alejandro AU - Paño-Pardo, José Ramon AU - Power, Nicholas AU - Sibani, Marcella AU - Szabo, Balint AU - Tsiodras, Sotirios AU - Zollner-Schwetz, Ines AU - Rodriguez-Baño, Jesús AU - ESCMID COVID-19 Treatment Guidelines Panel T2 - Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases DA - 2022/04// PY - 2022 DO - 10.1016/j.cmi.2021.12.025 DP - PubMed VL - 28 IS - 4 SP - 617 EP - 618 J2 - Clin Microbiol Infect LA - eng SN - 1469-0691 ST - ESCMID COVID-19 living guidelines L1 - https://www.clinicalmicrobiologyandinfection.com/article/S1198743X21007333/pdf L2 - http://www.ncbi.nlm.nih.gov/pubmed/35026374 KW - Humans KW - COVID-19 KW - SARS-CoV-2 ER - TY - JOUR TI - SARS-CoV-2 entry sites are present in all structural elements of the human glossopharyngeal and vagal nerves: Clinical implications AU - Vitale-Cross, Lynn AU - Szalayova, Ildiko AU - Scoggins, Aiden AU - Palkovits, Miklos AU - Mezey, Eva T2 - eBioMedicine AB - BACKGROUND: Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infections result in the temporary loss of smell and taste in about one third of confirmed cases. METHODS: We used immunohistochemistry to confirm the presence of ACE2, NRP1 and TMPRSS2 in two cranial nerves (IX and X) that mediate taste where they leave/join the medulla. Samples from three (two paraffin embedded and one frozen) postmortem samples were studied (facial (VII) nerve was not available). We also performed immunohistochemistry using the same antibodies in two human cell lines (oligodendrocytes and fibroblasts), and we isolated RNA from one nerve and performed PCR to confirm the presence of the mRNAs that encode the proteins visualized. FINDINGS: All three of the proteins (ACE-2, NRP1 and TMPRSS2) required for SARS-CoV-2 infections appear to be present in all cellular components (Schwann cells, axons, vascular endothelium, and connective tissue) of the human IXth and Xth nerves near the medulla. We also found their mRNAs in the nerve and in human oligodendrocytes and fibroblasts which were stained by antibodies directed at the three proteins examined. INTERPRETATION: Infection of the IXth and Xth nerves by the SARS-CoV-2 virus is likely to cause the loss of taste experienced by many Covid patients. Migration of the virus from the oral cavity through these nerves to brainstem respiratory centers might contribute to the problems that patients experience. FUNDING: This study was supported by the Intramural Research Program of the National Institute of Dental and Craniofacial Research (NIDCR), NIH (intramural project no. ZDE000755-01), and the Human Brain Tissue Bank, Semmelweis University, Budapest, Hungary from the Hungarian Brain Research Program (2017-1.2.1-NKP-2017-00002). DA - 2022/04/04/ PY - 2022 DO - 10.1016/j.ebiom.2022.103981 DP - PubMed VL - 78 SP - 103981 J2 - eBioMedicine LA - eng SN - 2352-3964 ST - SARS-CoV-2 entry sites are present in all structural elements of the human glossopharyngeal and vagal nerves L1 - https://www.thelancet.com/article/S2352396422001657/pdf L2 - http://www.ncbi.nlm.nih.gov/pubmed/35390636 KW - ACE2 KW - Brainstem respiratory centers KW - Human cranial nerves IX and X KW - SARS-Cov-2 entry sites ER - TY - JOUR TI - Chloroquine and COVID-19-A systems biology model uncovers the drug's detrimental effect on autophagy and explains its failure AU - Kapuy, Orsolya AU - Korcsmáros, Tamás T2 - PloS One AB - The COVID-19 pandemic caused by SARS-CoV-2 has resulted in an urgent need for identifying potential therapeutic drugs. In the first half of 2020 tropic antimalarial drugs, such as chloroquine (CQ) or hydroxochloroquine (HCQ) were the focus of tremendous public attention. In the initial periods of the pandemic, many scientific results pointed out that CQ/HCQ could be very effective for patients with severe COVID. While CQ and HCQ have successfully been used against several diseases (such as malaria, autoimmune disease and rheumatic illnesses); long term use of these agents are associated with serious adverse effects (i.e. inducing acute kidney injury, among many others) due to their role in blocking autophagy-dependent self-degradation. Recent experimental and clinical trial data also confirmed that there is no sufficient evidence about the efficient usage of CQ/HCQ against COVID-19. By using systems biology techniques, here we show that the cellular effect of CQ/HCQ on autophagy during endoplasmic reticulum (ER) stress or following SARS-CoV-2 infection results in upregulation of ER stress. By presenting a simple mathematical model, we claim that although CQ/HCQ might be able to ameliorate virus infection, the permanent inhibition of autophagy by CQ/HCQ has serious negative effects on the cell. Since CQ/HCQ promotes apoptotic cell death, here we confirm that addition of CQ/HCQ cannot be really effective even in severe cases. Only a transient treatment seemed to be able to avoid apoptotic cell death, but this type of therapy could not limit virus replication in the infected host. The presented theoretical analysis clearly points out the utility and applicability of systems biology modelling to test the cellular effect of a drug targeting key major processes, such as autophagy and apoptosis. Applying these approaches could decrease the cost of pre-clinical studies and facilitate the selection of promising clinical trials in a timely fashion. DA - 2022/// PY - 2022 DO - 10.1371/journal.pone.0266337 DP - PubMed VL - 17 IS - 4 SP - e0266337 J2 - PLoS One LA - eng SN - 1932-6203 L2 - http://www.ncbi.nlm.nih.gov/pubmed/35390060 ER - TY - JOUR TI - Applying lessons learned from nanomedicines to understand rare hypersensitivity reactions to mRNA-based SARS-CoV-2 vaccines AU - Szebeni, Janos AU - Storm, Gert AU - Ljubimova, Julia Y. AU - Castells, Mariana AU - Phillips, Elizabeth J. AU - Turjeman, Keren AU - Barenholz, Yechezkel AU - Crommelin, Daan J. A. AU - Dobrovolskaia, Marina A. T2 - Nature Nanotechnology AB - After over a billion of vaccinations with messenger RNA-lipid nanoparticle (mRNA-LNP) based SARS-CoV-2 vaccines, anaphylaxis and other manifestations of hypersensitivity can be considered as very rare adverse events. Although current recommendations include avoiding a second dose in those with first-dose anaphylaxis, the underlying mechanisms are unknown; therefore, the risk of a future reaction cannot be predicted. Given how important new mRNA constructs will be to address the emergence of new viral variants and viruses, there is an urgent need for clinical approaches that would allow a safe repeated immunization of high-risk individuals and for reliable predictive tools of adverse reactions to mRNA vaccines. In many aspects, anaphylaxis symptoms experienced by the affected vaccine recipients resemble those of infusion reactions to nanomedicines. Here we share lessons learned over a decade of nanomedicine research and discuss the current knowledge about several factors that individually or collectively contribute to infusion reactions to nanomedicines. We aim to use this knowledge to inform the SARS-CoV-2 lipid-nanoparticle-based mRNA vaccine field. DA - 2022/04/07/ PY - 2022 DO - 10.1038/s41565-022-01071-x DP - PubMed J2 - Nat Nanotechnol LA - eng SN - 1748-3395 L2 - http://www.ncbi.nlm.nih.gov/pubmed/35393599 ER - TY - JOUR TI - Potential Role of the Antidepressants Fluoxetine and Fluvoxamine in the Treatment of COVID-19 AU - Mahdi, Mohamed AU - Hermán, Levente AU - Réthelyi, János M. AU - Bálint, Bálint László T2 - International Journal of Molecular Sciences AB - Mapping non-canonical cellular pathways affected by approved medications can accelerate drug repurposing efforts, which are crucial in situations with a global impact such as the COVID-19 pandemic. Fluoxetine and fluvoxamine are well-established and widely-used antidepressive agents that act as serotonin reuptake inhibitors (SSRI-s). Interestingly, these drugs have been reported earlier to act as lysosomotropic agents, inhibitors of acid sphingomyelinase in the lysosomes, and as ligands of sigma-1 receptors, mechanisms that might be used to fight severe outcomes of COVID-19. In certain cases, these drugs were administered for selected COVID-19 patients because of their antidepressive effects, while in other cases, clinical studies were performed to assess the effect of these drugs on treating COVID-19 patients. Clinical studies produced promising data that encourage the further investigation of fluoxetine and fluvoxamine regarding their use in COVID-19. In this review, we summarize experimental data and the results of the performed clinical studies. We also provide an overview of previous knowledge on the tissue distribution of these drugs and by integrating this information with the published experimental results, we highlight the real opportunity of using these drugs in our fight against COVID-19. DA - 2022/03/30/ PY - 2022 DO - 10.3390/ijms23073812 DP - DOI.org (Crossref) VL - 23 IS - 7 SP - 3812 J2 - IJMS LA - en SN - 1422-0067 UR - https://www.mdpi.com/1422-0067/23/7/3812 Y2 - 2022/04/11/12:35:18 L1 - https://www.mdpi.com/1422-0067/23/7/3812/pdf ER - TY - JOUR TI - Associations of lockdown stringency and duration with Google searches for mental health terms during the COVID-19 pandemic: A nine-country study AU - de la Rosa, Pedro A. AU - Cowden, Richard G. AU - de Filippis, Renato AU - Jerotic, Stefan AU - Nahidi, Mahsa AU - Ori, Dorottya AU - Orsolini, Laura AU - Nagendrappa, Sachin AU - Pinto da Costa, Mariana AU - Ransing, Ramdas AU - Saeed, Fahimeh AU - Shoib, Sheikh AU - Turan, Serkan AU - Ullah, Irfan AU - Vadivel, Ramyadarshni AU - Ramalho, Rodrigo T2 - Journal of Psychiatric Research AB - OBJECTIVES: We examined the associations of lockdown stringency and duration with Google searches for four mental health concepts (i.e., "Anxiety," "Depression," "Suicide," "Mental Health") in nine countries (i.e., Hungary, India, Iran, Italy, Paraguay, Serbia, South Africa, Spain, Turkey) during the COVID-19 pandemic. METHODS: We retrieved national-level data for each country from Google Trends and the Global Panel Database of Pandemic Policies. In our primary analysis, we used data from all countries to estimate a set of multilevel regression models examining associations of overall lockdown stringency and lockdown duration with relative search volumes for each mental health term. We repeated the models after replacing overall lockdown stringency with each of the lockdown stringency components. RESULTS: A negative association was found between overall lockdown stringency and "Depression." Lockdown duration and the most stringent stay-at-home requirements were negatively associated with "Anxiety." Policies that recommended or required the cancelation of public events evidenced negative associations with "Depression," whereas associations between policies that required some or all levels of schooling to close and "Depression" were positive. Policies that recommended or required workplaces to close and those that enforced quarantines on non-citizens arriving from high-risk regions or closed borders entirely were negatively associated with "Suicide." CONCLUSIONS: Lockdown duration and some lockdown policies during the COVID-19 pandemic were generally associated with significantly lower, rather than higher, Google searches for selected mental health terms. These findings could be used alongside other evidence to develop future lockdown strategies that are sensitive to mental health issues during public health crises. DA - 2022/04/01/ PY - 2022 DO - 10.1016/j.jpsychires.2022.03.026 DP - PubMed VL - 150 SP - 237 EP - 245 J2 - J Psychiatr Res LA - eng SN - 1879-1379 ST - Associations of lockdown stringency and duration with Google searches for mental health terms during the COVID-19 pandemic L2 - http://www.ncbi.nlm.nih.gov/pubmed/35398667 KW - COVID-19 KW - Mental health KW - Lockdown KW - Google trends KW - Internet behavior ER - TY - JOUR TI - Computational drug repurposing against SARS-CoV-2 reveals plasma membrane cholesterol depletion as key factor of antiviral drug activity AU - Barsi, Szilvia AU - Papp, Henrietta AU - Valdeolivas, Alberto AU - Tóth, Dániel J. AU - Kuczmog, Anett AU - Madai, Mónika AU - Hunyady, László AU - Várnai, Péter AU - Saez-Rodriguez, Julio AU - Jakab, Ferenc AU - Szalai, Bence T2 - PLoS computational biology AB - Comparing SARS-CoV-2 infection-induced gene expression signatures to drug treatment-induced gene expression signatures is a promising bioinformatic tool to repurpose existing drugs against SARS-CoV-2. The general hypothesis of signature-based drug repurposing is that drugs with inverse similarity to a disease signature can reverse disease phenotype and thus be effective against it. However, in the case of viral infection diseases, like SARS-CoV-2, infected cells also activate adaptive, antiviral pathways, so that the relationship between effective drug and disease signature can be more ambiguous. To address this question, we analysed gene expression data from in vitro SARS-CoV-2 infected cell lines, and gene expression signatures of drugs showing anti-SARS-CoV-2 activity. Our extensive functional genomic analysis showed that both infection and treatment with in vitro effective drugs leads to activation of antiviral pathways like NFkB and JAK-STAT. Based on the similarity-and not inverse similarity-between drug and infection-induced gene expression signatures, we were able to predict the in vitro antiviral activity of drugs. We also identified SREBF1/2, key regulators of lipid metabolising enzymes, as the most activated transcription factors by several in vitro effective antiviral drugs. Using a fluorescently labeled cholesterol sensor, we showed that these drugs decrease the cholesterol levels of plasma-membrane. Supplementing drug-treated cells with cholesterol reversed the in vitro antiviral effect, suggesting the depleting plasma-membrane cholesterol plays a key role in virus inhibitory mechanism. Our results can help to more effectively repurpose approved drugs against SARS-CoV-2, and also highlights key mechanisms behind their antiviral effect. DA - 2022/04/11/ PY - 2022 DO - 10.1371/journal.pcbi.1010021 DP - PubMed VL - 18 IS - 4 SP - e1010021 J2 - PLoS Comput Biol LA - eng SN - 1553-7358 L2 - http://www.ncbi.nlm.nih.gov/pubmed/35404937 ER - TY - JOUR TI - A rare case of COVID-19 vaccine-induced myopericarditis in a young adult AU - Sharbatdaran, Arman AU - Chahal, Yasmeen AU - Molaei, Mirsadra AU - Bhavsar, Dishang T2 - Radiology Case Reports AB - Although extremely rare, the COVID-19 mRNA vaccine can induce myopericarditis without left ventricular dysfunction, and there have been rare reports of such incidents. However, these prior cases either did not have pericardial effusion without reduced left ventricular ejection fraction or had a more typical presentation of vaccine-induced myopericarditis such as shortness of breath or tactile temperature. We present a rare case of a 25-year-old man who developed myopericarditis following administration of the second dose of COVID-19 mRNA Vaccine. As vaccination plays a significant role in the fight against the COVID-19 pandemic, it is essential to highlight the physical manifestations of the vaccine's potential adverse effects and risk factors to increase the general population's awareness regarding the importance of emergent medical care. DA - 2022/06// PY - 2022 DO - 10.1016/j.radcr.2022.03.039 DP - PubMed VL - 17 IS - 6 SP - 1916 EP - 1920 J2 - Radiol Case Rep LA - eng SN - 1930-0433 L2 - http://www.ncbi.nlm.nih.gov/pubmed/35401904 KW - COVID-19 KW - Myocarditis KW - Myopericarditis KW - Pericardial effusion KW - Pericarditis KW - Vaccine ER -